{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    " # Multi-Step Agentic RAG with Azure AI Services\n",
    " \n",
    " This notebook demonstrates a Multi-Step Agentic RAG (Retrieval Augmented Generation) system that provides a cardiology-focused AI assistant with access to multiple data sources:\n",
    "\n",
    " 1. **Structured Data** (Azure SQL Database) - Patient medical records and information\n",
    " 2. **Unstructured Data** (Azure AI Search) - Medical guidelines from the American College of Cardiology\n",
    " 3. **Web Data** (Azure AI Agent Service with Bing Grounding Tool) - Real-time web information\n",
    " \n",
    " The system uses Azure OpenAI's function/tool calling capabilities to orchestrate the retrieval process and generate comprehensive responses to medical queries."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "!pip install -r requirements.txt"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## 1. Import Libraries and Set Up Environment\n",
    " We'll start by importing the necessary libraries and loading environment variables.\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "import json\n",
    "import pandas as pd\n",
    "import pyodbc\n",
    "import sqlalchemy\n",
    "from azure.ai.projects import AIProjectClient\n",
    "from azure.ai.projects.models import BingGroundingTool\n",
    "from azure.core.credentials import AzureKeyCredential\n",
    "from azure.identity import DefaultAzureCredential\n",
    "from azure.search.documents import SearchClient\n",
    "from azure.search.documents.models import VectorizableTextQuery\n",
    "from dotenv import load_dotenv\n",
    "from openai import AzureOpenAI\n",
    "from rich.console import Console\n",
    "from rich.panel import Panel\n",
    "\n",
    "load_dotenv()\n",
    "console = Console()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## 2. Configure Azure Services\n",
    "\n",
    "Next, we set up all the necessary configurations for the Azure services we'll be using.\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Azure OpenAI configuration\n",
    "AZURE_OPENAI_API_KEY = os.getenv(\"AZURE_OPENAI_API_KEY\", \"your-azure-openai-api-key\")\n",
    "AZURE_OPENAI_API_VERSION = os.getenv(\"AZURE_OPENAI_API_VERSION\", \"2024-10-21\")\n",
    "AZURE_OPENAI_ENDPOINT = os.getenv(\"AZURE_OPENAI_ENDPOINT\", \"https://your-azure-openai-endpoint.openai.azure.com/\")\n",
    "AZURE_OPENAI_CHAT_COMPLETION_DEPLOYED_MODEL_NAME = os.getenv(\"AZURE_OPENAI_CHAT_COMPLETION_DEPLOYED_MODEL_NAME\", \"gpt-4o\")\n",
    "\n",
    "# Azure AI Search configuration\n",
    "AZURE_SEARCH_ENDPOINT = os.getenv(\"AZURE_SEARCH_SERVICE_ENDPOINT\", \"https://your-search-service.search.windows.net\")\n",
    "AZURE_SEARCH_KEY = os.getenv(\"AZURE_SEARCH_ADMIN_KEY\", \"your-azure-search-key\")\n",
    "SEARCH_INDEX_NAME = \"acc-guidelines-index\"\n",
    "\n",
    "# Azure AI Project configuration for Bing Grounding\n",
    "AZURE_CONNECTION_STRING = os.getenv(\"AZURE_CONNECTION_STRING\", \"your-azure-connection-string\")\n",
    "BING_CONNECTION_NAME = os.getenv(\"BING_CONNECTION_NAME\", \"fsunavalabinggrounding\")\n",
    "\n",
    "# Azure SQL connection details (for patient data)\n",
    "server = os.getenv(\"AZURE_SQL_SERVER_NAME\")\n",
    "database = os.getenv(\"AZURE_SQL_DATABASE_NAME\")\n",
    "username = os.getenv(\"AZURE_SQL_USER_NAME\")\n",
    "password = os.getenv(\"AZURE_SQL_PASSWORD\")\n",
    "driver = '{ODBC Driver 17 for SQL Server}'\n",
    "\n",
    "# Create an Azure SQL connection string\n",
    "AZURE_SQL_CONNECTION_STRING = f\"DRIVER={driver};SERVER={server};DATABASE={database};UID={username};PWD={password}\"\n",
    "\n",
    "# Initialize the Azure OpenAI client\n",
    "openai_client = AzureOpenAI(\n",
    "    api_key=AZURE_OPENAI_API_KEY,\n",
    "    api_version=AZURE_OPENAI_API_VERSION,\n",
    "    azure_endpoint=AZURE_OPENAI_ENDPOINT,\n",
    ")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## 3. Define Tool Functions\n",
    "\n",
    "Now we'll implement the three tool functions that our agent will use to access different data sources.\n",
    "\n",
    "### 3.1 Unstructured Data Tool: ACC Guidelines Search via Azure AI Search\n",
    "\n",
    "This tool retrieves relevant American College of Cardiology guidelines using Azure AI Search with semantic and vector search capabilities.\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "def search_acc_guidelines(query: str) -> str:\n",
    "    \"\"\"\n",
    "    Searches the Azure AI Search index 'acc-guidelines-index' \n",
    "    for relevant American College of Cardiology (ACC) guidelines.\n",
    "    \"\"\"\n",
    "    credential = AzureKeyCredential(AZURE_SEARCH_KEY)\n",
    "    client = SearchClient(\n",
    "        endpoint=AZURE_SEARCH_ENDPOINT,\n",
    "        index_name=SEARCH_INDEX_NAME,\n",
    "        credential=credential,\n",
    "    )\n",
    "    \n",
    "    results = client.search(\n",
    "        search_text=query,\n",
    "        vector_queries=[\n",
    "            VectorizableTextQuery(\n",
    "                text=query,\n",
    "                k_nearest_neighbors=10,   # Adjust as needed\n",
    "                fields=\"embedding\"   # Adjust based on your index schema\n",
    "            )\n",
    "        ],\n",
    "        query_type=\"semantic\",\n",
    "        semantic_configuration_name=\"default\",\n",
    "        search_fields=[\"chunk\"],\n",
    "        top=10,\n",
    "        include_total_count=True\n",
    "    )\n",
    "    \n",
    "    retrieved_texts = []\n",
    "    for result in results:\n",
    "        content_chunk = result.get(\"chunk\", \"\")\n",
    "        retrieved_texts.append(content_chunk)\n",
    "    \n",
    "    context_str = \"\\n\".join(retrieved_texts) if retrieved_texts else \"No relevant guidelines found.\"\n",
    "    \n",
    "    console.print(\n",
    "        Panel(\n",
    "            f\"Tool Invoked: ACC Guidelines Search\\nQuery: {query}\",\n",
    "            style=\"bold yellow\"\n",
    "        )\n",
    "    )\n",
    "    return context_str"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    " ### 3.2 Web Data Tool: Bing Web Grounding via Azure AI Agent Service\n",
    " \n",
    " This tool uses the Azure AI Agent Service with the Bing Web Grounding Tool to search for real-time information from the web. This is a significant improvement over direct Bing Search API calls, as it leverages Azure's AI Agent framework for better context and grounding and remains compliant with Bing's Terms of Use."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 74,
   "metadata": {},
   "outputs": [],
   "source": [
    "def search_bing_grounding(query: str):\n",
    "    \"\"\"\n",
    "    Uses the Azure AI Projects client to perform a Bing search with grounding.\n",
    "\n",
    "    Args:\n",
    "        query (str): The search query\n",
    "\n",
    "    Returns:\n",
    "        str: The search results\n",
    "    \"\"\"\n",
    "    try:\n",
    "        # Create or get a project client\n",
    "        project_client = AIProjectClient.from_connection_string(\n",
    "            credential=DefaultAzureCredential(),\n",
    "            conn_str=AZURE_CONNECTION_STRING,\n",
    "        )\n",
    "\n",
    "        # Set up the Bing grounding tool\n",
    "        bing_connection = project_client.connections.get(\n",
    "            connection_name=BING_CONNECTION_NAME\n",
    "        )\n",
    "        conn_id = bing_connection.id\n",
    "        bing = BingGroundingTool(connection_id=conn_id)\n",
    "\n",
    "        # Create a temporary agent with the Bing tool\n",
    "        with project_client:\n",
    "            agent = project_client.agents.create_agent(\n",
    "                model=\"gpt-4o\",\n",
    "                name=\"temp-bing-agent\",\n",
    "                instructions=\"Perform a search and return the results directly without additional commentary\",\n",
    "                tools=bing.definitions,\n",
    "                headers={\"x-ms-enable-preview\": \"true\"},\n",
    "            )\n",
    "\n",
    "            # Create thread and message\n",
    "            thread = project_client.agents.create_thread()\n",
    "            message = project_client.agents.create_message(\n",
    "                thread_id=thread.id,\n",
    "                role=\"user\",\n",
    "                content=query,\n",
    "            )\n",
    "\n",
    "            # Run the agent\n",
    "            run = project_client.agents.create_and_process_run(\n",
    "                thread_id=thread.id, assistant_id=agent.id\n",
    "            )\n",
    "\n",
    "            # Get the results\n",
    "            if run.status == \"completed\":\n",
    "                # Get the assistant's response\n",
    "                messages = project_client.agents.list_messages(thread_id=thread.id)\n",
    "\n",
    "                # Extract the actual message text from the response\n",
    "                for msg in reversed(\n",
    "                    messages.data\n",
    "                ):  # Use .data to access the list of messages\n",
    "                    if msg.role == \"assistant\" and msg.content:\n",
    "                        # Extract the text value from the content\n",
    "                        for content_item in msg.content:\n",
    "                            if content_item.type == \"text\":\n",
    "                                return content_item.text.value  # Return the actual text\n",
    "\n",
    "                return \"No specific weather information found.\"\n",
    "\n",
    "            # Clean up\n",
    "            project_client.agents.delete_agent(agent.id)\n",
    "\n",
    "            # If we couldn't get a response\n",
    "            if run.status == \"failed\":\n",
    "                return f\"Search failed: {run.last_error}\"\n",
    "\n",
    "            return \"No results found.\"\n",
    "\n",
    "    except Exception as e:\n",
    "        return f\"Error performing Bing search: {str(e)}\""
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### 3.3 Structured Data Tool: Patient Data Query via Azure SQL\n",
    "\n",
    "This tool queries a SQL database containing patient medical data, transforming natural language questions into SQL queries.\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 65,
   "metadata": {},
   "outputs": [],
   "source": [
    "def lookup_patient_data(query: str) -> str:\n",
    "    \"\"\"\n",
    "    Queries the 'PatientMedicalData' table in Azure SQL and returns the results as a string.\n",
    "    'query' should be a valid SQL statement.\n",
    "    This version uses SQLAlchemy to create an engine, which is fully supported by pandas.read_sql.\n",
    "    \"\"\"\n",
    "    try:\n",
    "        # Construct the connection URI for SQLAlchemy\n",
    "        connection_uri = (\n",
    "            f\"mssql+pyodbc://{username}:{password}@{server}/{database}\"\n",
    "            \"?driver=ODBC+Driver+17+for+SQL+Server\"\n",
    "        )\n",
    "        engine = sqlalchemy.create_engine(connection_uri)\n",
    "        \n",
    "        # Use the engine in pandas.read_sql, which avoids the warning\n",
    "        df = pd.read_sql(query, engine)\n",
    "        if df.empty:\n",
    "            return \"No rows found.\"\n",
    "        return df.to_string(index=False)\n",
    "    except Exception as e:\n",
    "        return f\"Database error: {str(e)}\""
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    " ## 4. Define Tools for OpenAI Function Calling\n",
    " Now we'll configure these tools to work with OpenAI's function calling feature, which allows the LLM to dynamically select and use these tools during conversation.\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 75,
   "metadata": {},
   "outputs": [],
   "source": [
    "tools = [\n",
    "    {\n",
    "        \"type\": \"function\",\n",
    "        \"function\": {\n",
    "            \"name\": \"search_acc_guidelines\",\n",
    "            \"description\": \"Query the ACC guidelines for official cardiology recommendations. Use keywords related to cardiology conditions, treatments, or guidelines.\",\n",
    "            \"parameters\": {\n",
    "                \"type\": \"object\",\n",
    "                \"properties\": {\n",
    "                    \"query\": {\n",
    "                        \"type\": \"string\",\n",
    "                        \"description\": \"Keywords or specific question related to cardiology guidelines.\"\n",
    "                    }\n",
    "                },\n",
    "                \"required\": [\"query\"]\n",
    "            }\n",
    "        }\n",
    "    },\n",
    "    {\n",
    "        \"type\": \"function\",\n",
    "        \"function\": {\n",
    "            \"name\": \"search_bing_grounding\",\n",
    "            \"description\": \"Perform a public web search for real-time or external information using Bing Grounding. For example, 'FDA new hyperlipidemia drugs', 'recent hypertension medication approvals'.\",\n",
    "            \"parameters\": {\n",
    "                \"type\": \"object\",\n",
    "                \"properties\": {\n",
    "                    \"query\": {\n",
    "                        \"type\": \"string\",\n",
    "                        \"description\": \"General query to retrieve public data.\"\n",
    "                    }\n",
    "                },\n",
    "                \"required\": [\"query\"]\n",
    "            }\n",
    "        }\n",
    "    },\n",
    "    {\n",
    "        \"type\": \"function\",\n",
    "        \"function\": {\n",
    "            \"name\": \"lookup_patient_data\",\n",
    "            \"description\": (\n",
    "                \"Query Azure SQL PatientMedicalData table. Schema: \"\n",
    "                \"PatientID: INT (PK, Identity), FirstName: VARCHAR(100), LastName: VARCHAR(100), \"\n",
    "                \"DateOfBirth: DATE, Gender: VARCHAR(20), ContactNumber: VARCHAR(100), EmailAddress: VARCHAR(100), \"\n",
    "                \"Address: VARCHAR(255), City: VARCHAR(100), PostalCode: VARCHAR(20), Country: VARCHAR(100), \"\n",
    "                \"MedicalCondition: VARCHAR(255), Medications: VARCHAR(255), Allergies: VARCHAR(255), BloodType: VARCHAR(10), \"\n",
    "                \"LastVisitDate: DATE, SmokingStatus: VARCHAR(50), AlcoholConsumption: VARCHAR(50), ExerciseFrequency: VARCHAR(50), \"\n",
    "                \"Occupation: VARCHAR(100), Height_cm: DECIMAL(5,2), Weight_kg: DECIMAL(5,2), BloodPressure: VARCHAR(20), \"\n",
    "                \"HeartRate_bpm: INT, Temperature_C: DECIMAL(3,1), Notes: VARCHAR(MAX). Use SQL to retrieve patient data.\"\n",
    "            ),\n",
    "            \"parameters\": {\n",
    "                \"type\": \"object\",\n",
    "                \"properties\": {\n",
    "                    \"query\": {\n",
    "                        \"type\": \"string\",\n",
    "                        \"description\": \"Valid SQL query for PatientMedicalData table to get patient information.\"\n",
    "                    }\n",
    "                },\n",
    "                \"required\": [\"query\"]\n",
    "            }\n",
    "        }\n",
    "    }\n",
    "]\n",
    "\n",
    "# Map the tool names to the actual function implementations\n",
    "tool_implementations = {\n",
    "    \"search_acc_guidelines\": search_acc_guidelines,\n",
    "    \"search_bing_grounding\": search_bing_grounding,\n",
    "    \"lookup_patient_data\": lookup_patient_data,\n",
    "}"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## 5. Define System Prompt for the Agent\n",
    "\n",
    "The system prompt sets the context and instructions for the Agent, defining its role and capabilities.\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 68,
   "metadata": {},
   "outputs": [],
   "source": [
    "# ----------------------------\n",
    "# System Prompt for the Agent\n",
    "# ----------------------------\n",
    "SYSTEM_PROMPT = (\n",
    "    \"You are a cardiology-focused AI assistant with access to three tools:\\n\"\n",
    "    \"1) 'lookup_patient_data' for querying patient records from Azure SQL.\\n\"\n",
    "    \"2) 'search_acc_guidelines' for official ACC guidelines.\\n\"\n",
    "    \"3) 'search_bing_grounding' for real-time public information.\\n\\n\"\n",
    "    \"You can call these tools in any order, multiple times if needed, to gather all the context.\\n\"\n",
    "    \"Stop calling tools only when you have enough information to provide a final, cohesive answer.\\n\"\n",
    "    \"Then output your final answer to the user.\"\n",
    ")\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## 6. Implement the Multi-Step Agent\n",
    "\n",
    " Now we'll create the agent that orchestrates the entire process. This agent will:\n",
    "\n",
    "1.  Receive a user query\n",
    "2.  Decide which tools to call and in what order\n",
    "3.  Parse the results from each tool\n",
    "4.  Synthesize a comprehensive answer\n",
    "\n",
    "The agent can make multiple calls to different tools before providing a final answer, allowing for complex, multi-step reasoning.\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 80,
   "metadata": {},
   "outputs": [],
   "source": [
    "def run_multi_step_agent(user_query: str, max_steps: int = 3):\n",
    "    \"\"\"\n",
    "    A multi-step agent that orchestrates tool selection and execution.\n",
    "    \"\"\"\n",
    "    messages = [\n",
    "        {\"role\": \"system\", \"content\": SYSTEM_PROMPT},\n",
    "        {\"role\": \"user\", \"content\": user_query}\n",
    "    ]\n",
    "\n",
    "    for step in range(max_steps):\n",
    "        console.print(Panel(f\"**Step {step+1}**: Starting step {step+1}\", title=\"Step Start\", style=\"bold cyan\"))\n",
    "        \n",
    "        try:\n",
    "            # Log current message state for debugging\n",
    "            console.print(Panel(f\"Messages before API call:\\n{json.dumps(messages, indent=2)}\", title=\"Current Messages\", style=\"dim\"))\n",
    "            \n",
    "            # Make API call to OpenAI\n",
    "            response = openai_client.chat.completions.create(\n",
    "                model=AZURE_OPENAI_CHAT_COMPLETION_DEPLOYED_MODEL_NAME,\n",
    "                messages=messages,\n",
    "                tools=tools,\n",
    "                tool_choice=\"auto\",\n",
    "                max_tokens=8000,\n",
    "            )\n",
    "            response_message = response.choices[0].message\n",
    "            \n",
    "            # Debug the raw response\n",
    "            console.print(Panel(f\"Raw response message:\\n{response_message}\", title=\"Raw Response\", style=\"dim\"))\n",
    "            \n",
    "            # Check if the response contains tool calls\n",
    "            if response_message.tool_calls:\n",
    "                # Create a properly structured assistant message with tool_calls\n",
    "                messages.append({\n",
    "                    \"role\": \"assistant\",\n",
    "                    \"content\": response_message.content,  # This might be None when tool_calls are present\n",
    "                    \"tool_calls\": [\n",
    "                        {\n",
    "                            \"id\": tool_call.id,\n",
    "                            \"type\": \"function\",\n",
    "                            \"function\": {\n",
    "                                \"name\": tool_call.function.name,\n",
    "                                \"arguments\": tool_call.function.arguments\n",
    "                            }\n",
    "                        } for tool_call in response_message.tool_calls\n",
    "                    ]\n",
    "                })\n",
    "                \n",
    "                # Now handle each tool call separately\n",
    "                for tool_call in response_message.tool_calls:\n",
    "                    function_name = tool_call.function.name\n",
    "                    tool_call_id = tool_call.id  # Extract the exact tool_call_id\n",
    "                    arguments_str = tool_call.function.arguments\n",
    "                    \n",
    "                    try:\n",
    "                        function_args = json.loads(arguments_str) if arguments_str.strip() else {}\n",
    "                    except json.JSONDecodeError:\n",
    "                        function_args = {}\n",
    "                        console.print(Panel(\"Warning: Could not decode tool call arguments\", title=\"JSONDecodeError\", style=\"bold red\"))\n",
    "                    \n",
    "                    # Ensure the 'query' key is present\n",
    "                    if \"query\" not in function_args or not function_args[\"query\"]:\n",
    "                        function_args[\"query\"] = user_query\n",
    "                    \n",
    "                    console.print(Panel(\n",
    "                        f\"**Step {step+1}**: LLM calls tool [bold]{function_name}[/bold]\\n\\n\"\n",
    "                        f\"**Arguments**:\\n{json.dumps(function_args, indent=2)}\",\n",
    "                        title=\"Tool Call\",\n",
    "                        style=\"bold blue\"\n",
    "                    ))\n",
    "                    \n",
    "                    # Call the appropriate tool function\n",
    "                    tool_fn = tool_implementations.get(function_name)\n",
    "                    if tool_fn is None:\n",
    "                        tool_output = f\"[Error] No implementation for tool '{function_name}'.\"\n",
    "                    else:\n",
    "                        tool_output = tool_fn(**function_args)\n",
    "                    \n",
    "                    # Add the tool response with EXACTLY the same tool_call_id \n",
    "                    messages.append({\n",
    "                        \"role\": \"tool\",\n",
    "                        \"tool_call_id\": tool_call_id,  # CRITICAL: Use exactly the same ID\n",
    "                        \"name\": function_name,\n",
    "                        \"content\": str(tool_output)\n",
    "                    })\n",
    "                    \n",
    "                    console.print(Panel(f\"Tool output added to messages:\\n{str(tool_output)}\", title=\"Tool Response Added\", style=\"green\"))\n",
    "            else:\n",
    "                # No tool calls, just add the assistant's message and return the final answer\n",
    "                messages.append({\n",
    "                    \"role\": \"assistant\",\n",
    "                    \"content\": response_message.content\n",
    "                })\n",
    "                \n",
    "                # Display the final answer\n",
    "                final_answer = response_message.content\n",
    "                console.print(Panel(final_answer, title=\"Final Answer\", style=\"bold green\", border_style=\"yellow\"))\n",
    "                return  # Successfully received final answer\n",
    "        \n",
    "        except Exception as e:\n",
    "            console.print(Panel(f\"Error during step {step+1}: {str(e)}\", title=\"Error\", style=\"bold red\"))\n",
    "            # Print the current message structure to help with debugging\n",
    "            console.print(Panel(f\"Current message structure:\\n{json.dumps(messages, indent=2)}\", title=\"Message Structure at Error\", style=\"red\"))\n",
    "            raise  # Re-raise the exception for further debugging\n",
    "\n",
    "    # If we reach the maximum steps without a final answer, show a warning\n",
    "    console.print(Panel(\"Max steps reached without a final answer. Stopping.\", title=\"Warning\", style=\"bold red\"))\n",
    "    return"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    " ## 7. Execute the Agent with a Sample Query\n",
    " \n",
    " Now let's run the agent with a cardiology-related question to see how it works. The agent will decide which tools to use and in what order to provide the most comprehensive answer."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 81,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╭──────────────────────────────────────────────────</span> Step Start <span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">───────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">│ **Step 1**: Starting step 1                                                                                     │</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;36m╭─\u001b[0m\u001b[1;36m─────────────────────────────────────────────────\u001b[0m Step Start \u001b[1;36m──────────────────────────────────────────────────\u001b[0m\u001b[1;36m─╮\u001b[0m\n",
       "\u001b[1;36m│\u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m**Step 1**: Starting step 1\u001b[0m\u001b[1;36m                                                                                    \u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m│\u001b[0m\n",
       "\u001b[1;36m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╭───────────────────────────────────────────────</span> Current Messages <span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Messages before API call:                                                                                       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ [                                                                                                               │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   {                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"role\": \"system\",                                                                                           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"content\": \"You are a cardiology-focused AI assistant with access to three tools:\\n1) 'lookup_patient_data' │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ for querying patient records from Azure SQL.\\n2) 'search_acc_guidelines' for official ACC guidelines.\\n3)       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ 'search_bing_grounding' for real-time public information.\\n\\nYou can call these tools in any order, multiple    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ times if needed, to gather all the context.\\nStop calling tools only when you have enough information to        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ provide a final, cohesive answer.\\nThen output your final answer to the user.\"                                  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   },                                                                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   {                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"role\": \"user\",                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"content\": \"What does the ACC recommend as first-line therapy for hypertension in elderly patients?\"        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   }                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ ]                                                                                                               │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[2m╭─\u001b[0m\u001b[2m──────────────────────────────────────────────\u001b[0m Current Messages \u001b[2m───────────────────────────────────────────────\u001b[0m\u001b[2m─╮\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mMessages before API call:\u001b[0m\u001b[2m                                                                                      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m[\u001b[0m\u001b[2m                                                                                                              \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  {\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"role\": \"system\",\u001b[0m\u001b[2m                                                                                          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"content\": \"You are a cardiology-focused AI assistant with access to three tools:\\n1) 'lookup_patient_data'\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfor querying patient records from Azure SQL.\\n2) 'search_acc_guidelines' for official ACC guidelines.\\n3) \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m'search_bing_grounding' for real-time public information.\\n\\nYou can call these tools in any order, multiple \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtimes if needed, to gather all the context.\\nStop calling tools only when you have enough information to \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mprovide a final, cohesive answer.\\nThen output your final answer to the user.\"\u001b[0m\u001b[2m                                 \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  },\u001b[0m\u001b[2m                                                                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  {\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"role\": \"user\",\u001b[0m\u001b[2m                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"content\": \"What does the ACC recommend as first-line therapy for hypertension in elderly patients?\"\u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  }\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m]\u001b[0m\u001b[2m                                                                                                              \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╭─────────────────────────────────────────────────</span> Raw Response <span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Raw response message:                                                                                           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ ChatCompletionMessage(content=None, refusal=None, role='assistant', audio=None, function_call=None,             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ tool_calls=[ChatCompletionMessageToolCall(id='call_LoqOLIqpc2dATUfTY5LY3UcV',                                   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ function=Function(arguments='{\"query\":\"first-line therapy for hypertension in elderly patients\"}',              │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ name='search_acc_guidelines'), type='function')])                                                               │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[2m╭─\u001b[0m\u001b[2m────────────────────────────────────────────────\u001b[0m Raw Response \u001b[2m─────────────────────────────────────────────────\u001b[0m\u001b[2m─╮\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mRaw response message:\u001b[0m\u001b[2m                                                                                          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mChatCompletionMessage(content=None, refusal=None, role='assistant', audio=None, function_call=None, \u001b[0m\u001b[2m           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtool_calls=[ChatCompletionMessageToolCall(id='call_LoqOLIqpc2dATUfTY5LY3UcV', \u001b[0m\u001b[2m                                 \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfunction=Function(arguments='{\"query\":\"first-line therapy for hypertension in elderly patients\"}', \u001b[0m\u001b[2m            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mname='search_acc_guidelines'), type='function')])\u001b[0m\u001b[2m                                                              \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">╭───────────────────────────────────────────────────</span> Tool Call <span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">───────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ **Step 1**: LLM calls tool search_acc_guidelines                                                                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ **Arguments**:                                                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ {                                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│   \"query\": \"first-line therapy for hypertension in elderly patients\"                                            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ }                                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;34m╭─\u001b[0m\u001b[1;34m──────────────────────────────────────────────────\u001b[0m Tool Call \u001b[1;34m──────────────────────────────────────────────────\u001b[0m\u001b[1;34m─╮\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m**Step 1**: LLM calls tool \u001b[0m\u001b[1;34msearch_acc_guidelines\u001b[0m\u001b[1;34m                                                               \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m                                                                                                               \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m**Arguments**:\u001b[0m\u001b[1;34m                                                                                                 \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m{\u001b[0m\u001b[1;34m                                                                                                              \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m  \"query\": \"first-line therapy for hypertension in elderly patients\"\u001b[0m\u001b[1;34m                                           \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m}\u001b[0m\u001b[1;34m                                                                                                              \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">╭─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│ Tool Invoked: ACC Guidelines Search                                                                             │</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│ Query: first-line therapy for hypertension in elderly patients                                                  │</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;33m╭─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╮\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;33m \u001b[0m\u001b[1;33mTool Invoked: ACC Guidelines Search\u001b[0m\u001b[1;33m                                                                            \u001b[0m\u001b[1;33m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;33m \u001b[0m\u001b[1;33mQuery: first-line therapy for hypertension in elderly patients\u001b[0m\u001b[1;33m                                                 \u001b[0m\u001b[1;33m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008000; text-decoration-color: #008000\">╭──────────────────────────────────────────────</span> Tool Response Added <span style=\"color: #008000; text-decoration-color: #008000\">──────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Tool output added to messages:                                                                                  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # Whelton et al.                                                                                                │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # 2017 High Blood Pressure Clinical Practice Guideline                                                          │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # MAY 15, 2018: e127–248                                                                                        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 2. The treatment of patients with hypertension without elevated risk has been systematically understudied       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ because lower-risk groups would require prolonged follow-up to have a sufficient number of clinical events to   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ provide useful information. Although there is clinical trial evidence that both drug and nondrug therapy will   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ interrupt the progressive course of hypertension (S8.1.5-6), there is no trial evidence that this treatment     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ decreases CVD morbidity and mortality. The clinical trial evidence is strongest for a target BP of 140/90 mm Hg │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ in this population. However, observational studies suggest that these individuals often have a high lifetime    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ risk and would benefit from BP control earlier in life (S8.1.5-19, S8.1.5-20).                                  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # 8.1.6. Choice of Initial Medication                                                                           │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # Recommendation for Choice of Initial Medication                                                               │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ References that support the recommendation are summarized in Online Data Supplement 27 and Systematic Review    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Report.                                                                                                         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |COR|LOE|RECOMMENDATION|                                                                                        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |---|---|---|                                                                                                   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |I|ASR|For initiation of antihypertensive drug therapy, first-line agents include thiazide diuretics, CCBs, and │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ ACE inhibitors or ARBs. (S8.1.6-1, S8.1.6-2)|                                                                   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # Synopsis                                                                                                      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ The overwhelming majority of persons with BP sufficiently elevated to warrant pharmacological therapy may be    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ best treated initially with 2 agents (see Section 8.1.6.1). When initiation of pharmacological therapy with a   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ single medication is appropriate, primary consideration should be given to comorbid conditions (e.g., HF, CKD)  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ for which specific classes of BP-lowering medication are indicated (see Section 9) (S8.1.6-1). In the largest   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ head-to-head comparison of first-step drug therapy for hypertension (S8.1.6-3), the thiazide-type diuretic      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ chlorthalidone was superior to the CCB amlodipine and the ACE inhibitor lisinopril in preventing HF, a          │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ BP-related outcome of increasing importance in the growing population of older persons with hypertension        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ (S8.1.6-4—S8.1.6-7). Additionally, ACE inhibitors were less effective than thiazide diuretics and CCBs in       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ lowering BP and in prevention of stroke. For black patients, ACE inhibitors were also notably less effective    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ than CCBs in preventing HF (S8.1.6-8) and in the prevention of stroke (S8.1.6-9) (see Section 10.1). ARBs may   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ be better tolerated than ACE inhibitors in black patients, with less cough and angioedema, but according to the │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ limited available experience they offer no proven advantage over ACE inhibitors in preventing stroke or CVD in  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ this population, making thiazide diuretics (especially chlorthalidone) or CCBs the best initial choice for      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ single-drug therapy. For stroke, in the general population, beta blockers were less effective than CCBs (36%    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ lower risk) and thiazide diuretics (30% lower risk). CCBs have been shown to be as effective as diuretics for   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ reducing all CVD events other than HF, and CCBs are a good alternative choice for initial therapy when thiazide │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ diuretics are not tolerated. Alpha blockers are not used as first-line therapy for hypertension because they    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ are less effective for prevention of CVD than other first-step agents, such as thiazide diuretics (S8.1.6-3,    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ S8.1.6-10).                                                                                                     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # Recommendation-Specific Supportive Text                                                                       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 1. The overall goal of treatment should be reduction in BP, in the context of underlying CVD risk. Five drug    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ classes have been shown, in high-quality RCTs, to prevent CVD as compared with placebo (diuretics, ACE          │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ inhibitors, ARBs, CCBs, and beta blockers) (S8.1.6-11, S8.1.6-12). In head-to-head comparisons of first-step    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ therapy, different drug classes have been reported to provide somewhat divergent capacity to prevent specific   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ CVD events. Interpretation of meta-analyses comparing agents from different drug classes is challenging because │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ the relevant RCTs were conducted in different time periods, during which concurrent antihypertensive therapy    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ was less or more common, and the efficacy of agents from certain drug classes may have                          │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # J A C C V O L . 71, N O . 1 9, 2 0 1 8                                                                        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # Whelton et al. e169                                                                                           │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # M A Y 1 5, 2 0 1 8 : e 1 2 7 – 2 4 8                                                                          │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # 2017 High Blood Pressure Clinical Practice Guideline                                                          │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ significantly better than CCBs for prevention of HF. There were some other nonsignificant differences between   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ diuretics, ACE inhibitors, ARBs, and CCBs, but the general pattern was for similarity in effect. As indicated   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ in Section 8.1.6.1, most adults with hypertension require &gt;1 drug to control their BP. As recommended in        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Section 10.1, for black adults with hypertension (without HF or CKD), initial antihypertensive treatment should │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ include a thiazide diuretic or CCB.                                                                             │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # 8.1.6.1. Choice of Initial Monotherapy Versus Initial Combination Drug Therapy                                │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |COR|LOE|RECOMMENDATIONS|                                                                                       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |---|---|---|                                                                                                   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |I|C-EO|Initiation of antihypertensive drug therapy with 2 first-line agents of different classes, either as    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ separate agents or in a fixed-dose combination, is recommended in adults with stage 2 hypertension and an       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ average BP more than 20/10 mm Hg above their BP target.|                                                        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |IIa|C-EO|Initiation of antihypertensive drug therapy with a single antihypertensive drug is reasonable in      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ adults with stage 1 hypertension and BP goal &lt;130/80 mm Hg with dosage titration and sequential addition of     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ other agents to achieve the BP target.|                                                                         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ *Fixed-dose combination antihypertensive medications are listed in Online Data Supplement D.                    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # Synopsis                                                                                                      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Systematic review of the evidence comparing the initiation of antihypertensive treatment with monotherapy and   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ sequential (stepped-care) titration of additional agents versus initiation of treatment with combination        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ therapy (including fixed-dose combinations) did not identify any RCTs meeting the systematic review questions   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ posed in the PICOTS format (P¼population, I¼intervention, C¼comparator, O¼outcome, T¼timing, S¼setting).        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ However, in both ACCORD and SPRINT, 2-drug therapy was recommended for most participants in the intensive- but  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ not standard-therapy groups.                                                                                    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # Recommendation-Specific Supportive Text                                                                       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 1. Because most patients with hypertension require multiple agents for control of their BP and those with       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ higher BPs are at greater risk, more rapid titration of antihypertensive medications began to be recommended in │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ patients with BP &gt;20/10 mm Hg above their target, beginning with the JNC 7 report (S8.1.6.1-1). In these        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ patients, initiation of antihypertensive therapy with 2 agents is recommended. Evidence favoring this approach  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ comes mostly from studies using fixed-dose combination products showing greater BP lowering with fixed-dose     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ combination agents than with single agents, as well as better adherence to therapy (S8.1.6.1-2,S8.1.6.1-3). The │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ safety and efficacy of this strategy have been demonstrated in adults to reduce BPs to &lt;140/90 mm Hg though not │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ compared with other strategies (S8.1.6.1-4—S8.1.6.1-6). In general, this approach is reasonable in older        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ adults, those at high CVD risk, or those who have a history of hypotension or drug-associated side effects.     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ However, caution is advised in initiating antihypertensive pharmacotherapy with 2 drugs in older patients       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ because hypotension or orthostatic hypotension may develop in some patients; BP should be carefully monitored.  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 2. The stepped-care approach defined by the initiation of antihypertensive drug therapy with a single agent     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ followed by the sequential titration of the dose and addition of other agents has been the recommended          │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ treatment strategy since the first report of the National High Blood Pressure Education Program (S8.1.6.1-7).   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ This approach is also reasonable in older adults or those at risk or who have a history of hypotension or       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ drug-associated side effects. This strategy has been used successfully in nearly all hypertension treatment     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ trials but has not been formally tested against other antihypertensive drug treatment strategies for            │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ effectiveness in achieving BP control or in preventing adverse outcomes.                                        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # 8.2. Achieving BP Control in Individual Patients                                                              │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Recommendations for lifestyle modifications and drug selection are specified in                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # JACC VOL. 79, NO. 17, 2022                                                                                    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # Heidenreich et al e329                                                                                        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # MAY 3, 2022: e263 – e421                                                                                      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # 2022 AHA/ACC/HFSA Heart Failure Guideline                                                                     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Extrapolated from those for treatment of patients with hypertension in general (26). However, the optimal blood │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ pressure goal and antihypertensive regimens are not known for patients with HFpEF. RAAS antagonists including   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ ACEi, ARB, MRA, and possibly ARNi, could be first-line agents given experience with their use in HFpEF trials   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ (8,10,16,20,27,28). Beta blockers may be used to treat hypertension in patients with a history of MI (27),      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ symptomatic CAD, or AF with rapid ventricular response. These effects need to be balanced with the potential    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ contribution of chronotropic incompetence to exercise intolerance in some patients (29).                        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # 1. EMPEROR-Preserved                                                                                          │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ (Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Preserved Ejection Fraction) showed a  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ significant benefit of the SGLT2i, empagliflozin, in symptomatic patients with HF with LVEF &gt;40% and elevated   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ natriuretic peptides (30). The 21% reduction in the primary composite endpoint of time to HF hospitalization or │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ cardiovascular death was driven mostly by a significant 29% reduction in time to HF hospitalization             │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ (nonsignificant lower cardiovascular death [HR, 0.91; 95% CI, 0.76-1.0]), with no benefit on all-cause          │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ mortality. Empagliflozin also resulted in a significant reduction in total HF hospitalizations, decrease in the │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ slope of the eGFR decline, and a modest improvement in QOL at 52 weeks. Of note, the benefit was similar        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ irrespective of the presence or absence of diabetes at baseline. Although the benefit in the primary endpoint   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ did not have a significant interaction by LVEF subgroups (&lt;50%, 50%–&lt;60%, and &gt;60%) (30), in a subgroup         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ analysis by EF, there was a signal for lower benefit on the primary composite endpoint, first and recurrent HF  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ hospitalizations at higher LVEFs &gt;62.5% (31).                                                                   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # 2. Atrial Fibrillation Management                                                                             │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Large, randomized clinical trial data are unavailable to specifically guide therapy in patients with HFpEF and  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ AF. Currently, the comprehensive care of AF can be extrapolated from the clinical practice guidelines for AF,   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ with individualization of strategies for rate or rhythm control in patients with HFpEF (see also Section 10.2,  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ “Management of Atrial Fibrillation (AF) in HF,” for HF specific recommendations for AF). Although beta blockers │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ and nondihydropyridine calcium channel blockers are often considered as first-line agents for heart rate        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ control in patients with HFpEF, a recent smaller open-label trial, RATE-AF in elderly patients with AF and      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ symptoms of HF (most with preserved LVEF), compared the use of the beta blocker, bisoprolol, to digoxin (32).   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ At 6 months, the primary endpoint of QOL was similar between the 2 groups. However, several secondary QOL       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ endpoints, functional capacity, and reduction in NT-proBNP favored digoxin at 12 months. There was a similar    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ heart rate reduction in both groups. Of note, more adverse events such as higher rates of dizziness, lethargy,  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ and hypotension occurred with beta blockers than digoxin. The comprehensive care of AF is beyond the scope of   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ these guidelines. AF-specific care recommendations can be found in separate ACC/AHA clinical practice           │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ guidelines (33,34).                                                                                             │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # 3. MRAs and Diastolic Function                                                                                │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ MRAs improve diastolic function in patients with HFpEF (35). The TOPCAT trial investigated the effects of       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ spironolactone in patients with HFpEF. The small reduction (HR, 0.89) in the composite of death, aborted        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ cardiac death, and HF hospitalization was not statistically significant, although HF hospitalization was        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ reduced (HR, 0.83); adverse effects of hyperkalemia and increasing creatinine levels were more common in the    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ treatment group (5). A post hoc analysis (6) showed efficacy in the Americas (HR 0.83) but not in               │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Russia-Georgia (HR 1.10). A sample of the Russia-Georgia population in the active treatment arm had             │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ non-detectable levels of a spironolactone metabolite. Post hoc analyses have limitations, but they suggest a    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ possibility of benefit in appropriately selected patients with symptomatic HFpEF                                │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ therapy should be assessed within 3 to 6 months.                                                                │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 2. Nonpharmacological therapy can help reduce BP in patients with stage 1 hypertension with an estimated        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 10-year ASCVD risk of ≥10% and should be used in addition to pharmacological therapy as first-line therapy in   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ such patients (see Section 6.2).                                                                                │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 3. Prompt evaluation and treatment of patients with stage 2 hypertension with a combination of drug and         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ non-pharmacological therapy are important because of the elevated risk of CVD events in this subgroup,          │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ especially those with multiple ASCVD risk factors or target organ damage (S8.1.3-1,S8.1.3-2).                   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 4. Prompt management of very high BP is important to reduce the risk of target organ damage (see Section 11.2). │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ The rapidity of the treatment needed is dependent on the patient’s clinical presentation (presence of new or    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ worsening target organ damage) and presence or absence of CVD complications, but treatment should be initiated  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ within at least 1 week.                                                                                         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # J A C C V O L . 74, N O . 1 0 , 2 0 1 9                                                                       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease                                    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 1. Adults who are 40 to 75 years of age and are being evaluated for cardiovascular disease prevention should    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ undergo 10-year atherosclerotic cardiovascular disease (ASCVD) risk estimation and have a clinician–patient     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ risk discussion before starting on pharmacological therapy, such as antihypertensive therapy, a statin, or      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ aspirin. In addition, assessing for other risk-enhancing factors can help guide decisions about preventive      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ interventions in select individuals, as can coronary artery calcium scanning.                                   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 2. All adults should consume a healthy diet that emphasizes the intake of vegetables, fruits, nuts, whole       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ grains, lean vegetable or animal protein, and fish and minimizes the intake of trans fats, red meat and         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ processed red meats, refined carbohydrates, and sweetened beverages. For adults with overweight and obesity,    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ counseling and caloric restriction are recommended for achieving and maintaining weight loss.                   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 3. Adults should engage in at least 150 minutes per week of accumulated moderate-intensity physical activity or │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 75 minutes per week of vigorous-intensity physical activity.                                                    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 4. For adults with type 2 diabetes mellitus, lifestyle changes, such as improving dietary habits and achieving  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ exercise recommendations, are crucial. If medication is indicated, metformin is first-line therapy, followed by │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ consideration of a sodium-glucose cotransporter 2 inhibitor or a glucagon-like peptide-1 receptor agonist.      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 5. All adults should be assessed at every healthcare visit for tobacco use, and those who use tobacco should be │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ assisted and strongly advised to quit.                                                                          │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 6. Aspirin should be used infrequently in the routine primary prevention of ASCVD because of lack of net        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ benefit.                                                                                                        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 7. Statin therapy is first-line treatment for primary prevention of ASCVD in patients with elevated low-density │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ lipoprotein cholesterol levels (≥190 mg/dL), those with diabetes mellitus, who are 40 to 75 years of age, and   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ those determined to be at sufficient ASCVD risk after a clinician–patient risk discussion.                      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 8. Nonpharmacological interventions are recommended for all adults with elevated blood pressure or              │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ hypertension. For those requiring pharmacological therapy, the target blood pressure should generally be        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ &lt;130/80 mm Hg.                                                                                                  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # PREAMBLE                                                                                                      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Since 1980, the American College of Cardiology (ACC) and American Heart Association (AHA) have translated       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ scientific evidence into clinical practice guidelines with recommendations to improve cardiovascular health.    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ These guidelines, which are based on systematic methods to evaluate and classify evidence, provide a foundation │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ for the delivery of quality cardiovascular care. The ACC and AHA sponsor the development and publication of     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ clinical practice guidelines without commercial support, and members volunteer their time to the writing and    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ review efforts.                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Clinical practice guidelines provide recommendations applicable to patients with or at risk of developing       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ cardiovascular disease (CVD). The focus is on medical practice in the United States, but these guidelines are   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ relevant to patients throughout the world. Although guidelines may be used to inform regulatory or payer        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ decisions, the goals are to improve quality of care and align with patients’ interests. Guidelines are intended │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ to define practices meeting the needs of patients in most but not all circumstances and should not replace      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ clinical judgment.                                                                                              │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Recommendations for guideline-directed management and therapy, which encompasses clinical evaluation,           │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ diagnostic testing, and both pharmacological and procedural treatments, are effective only when adopted by both │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ practitioners and patients. Adherence to recommendations can be enhanced by shared decision-making between      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ clinicians and patients, with patient engagement in selecting interventions on the basis of individual values,  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ preferences, and associated conditions and comorbidities.                                                       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ The ACC/AHA Task Force on Clinical Practice Guidelines strives to ensure that the guideline writing committee   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ includes requisite expertise and is representative of the broader medical community by selecting experts from a │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ broad array of backgrounds, representing different geographic regions, sexes, races, ethnicities, intellectual  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ perspectives/biases, and scopes of clinical practice. The ACC and AHA have rigorous policies and methods to     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ ensure that documents are developed without bias or improper influence. The complete policy on relationships    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ with industry and other entities (RWI) can be found online.                                                     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Beginning in 2017, numerous modifications to the guidelines have been and continue to be implemented to make    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ guidelines shorter and enhance “user friendliness.” Guidelines are written and presented in a modular knowledge │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ chunk format, in which each chunk includes a table of recommendations, a brief synopsis,                        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ recommendation-specific supportive text and, when appropriate, flow diagrams or additional tables. Hyperlinked  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ references are provided for each modular.                                                                       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # Whelton et al.                                                                                                │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # 2017 High Blood Pressure Clinical Practice Guideline                                                          │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # MAY 15, 2018: e127–248                                                                                        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # TABLE 19                                                                                                      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # Intravenous Antihypertensive Drugs for Treatment of Hypertensive Emergencies                                  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |Class|Drug(s)|Usual Dose Range|Comments|                                                                       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |---|---|---|---|                                                                                               │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |CCB—dihydropyridines|Nicardipine|Initial 5 mg/h, increasing every 5 min by 2.5 mg/h to maximum 15              │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ mg/h.|Contraindicated in advanced aortic stenosis; no dose adjustment needed for elderly.|                      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ | |Clevidipine|Initial 1–2 mg/h, doubling every 90 s until BP approaches target, then increasing by less than   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ double every 5–10 min; maximum dose 32 mg/h; maximum duration 72 h.|Contraindicated in patients with soybean,   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ soy product, egg, and egg product allergy and in patients with defective lipid metabolism (e.g., pathological   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ hyperlipidemia, lipoid nephrosis or acute pancreatitis). Use low-end dose range for elderly patients.|          │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |Vasodilators—Nitric-oxide dependent|Sodium nitroprusside|Initial 0.3–0.5 mcg/kg/min; increase in increments of │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 0.5 mcg/kg/min to achieve BP target; maximum dose 10 mcg/kg/min; duration of treatment as short as possible.    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ For infusion rates ≥4–10 mcg/kg/min or duration &gt;30 min, thiosulfate can be coadministered to prevent cyanide   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ toxicity.|Intra-arterial BP monitoring recommended to prevent “overshoot.” Lower dosing adjustment required for │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ elderly. Tachyphylaxis common with extended use. Cyanide toxicity with prolonged use can result in irreversible │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ neurological changes and cardiac arrest.|                                                                       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ | |Nitroglycerin|Initial 5 mcg/min; increase in increments of 5 mcg/min every 3–5 min to a maximum of 20        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ mcg/min.|Use only in patients with acute coronary syndrome and/or acute pulmonary edema. Do not use in          │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ volume-depleted patients.|                                                                                      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |Vasodilators—direct|Hydralazine|Initial 10 mg via slow IV infusion (maximum initial dose 20 mg); repeat every  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 4–6 h as needed.|BP begins to decrease within 10–30 min, and the fall lasts 2–4 h. Unpredictability of response │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ and prolonged duration of action do not make hydralazine a desirable first-line agent for acute treatment in    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ most patients.|                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |Adrenergic blockers—beta1 receptor selective antagonist|Esmolol|Loading dose 500–1000 mcg/kg/min over 1 min    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ followed by a 50-mcg/kg/min infusion. For additional dosing, the bolus dose is repeated and the infusion        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ increased in 50-mcg/kg/min increments as needed to a maximum of 200 mcg/kg/min.|Contraindicated in patients     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ with concurrent beta-blocker therapy, bradycardia, or decompensated HF. Monitor for bradycardia. May worsen HF. │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Higher doses may block beta2 receptors and impact lung function in reactive airway disease.|                    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |Adrenergic blockers—combined alpha1 and nonselective beta receptor antagonist|Labetalol|Initial 0.3–1.0-mg/kg  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ dose (maximum 20 mg) slow IV injection every 10 min or 0.4–1.0-mg/kg/h IV infusion up to 3 mg/kg/h. Adjust rate │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ up to total cumulative dose of 300 mg. This dose can be repeated every 4–6 h.|Contraindicated in reactive       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ airways disease or chronic obstructive pulmonary disease. Especially useful in hyperadrenergic syndromes. May   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ worsen HF and should not be given in patients with second- or third-degree heart block or bradycardia.|         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |Adrenergic blockers—nonselective alpha receptor antagonist|Phentolamine|IV bolus dose 5 mg. Additional bolus   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ doses every 10 min as needed to lower BP to target.|Used in hypertensive emergencies induced by catecholamine   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ excess (pheochromocytoma, interactions between monoamine oxidase inhibitors and other drugs or food, cocaine    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ toxicity, amphetamine overdose, or clonidine withdrawal).|                                                      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |Dopamine-receptor1 selective agonist|Fenoldopam|Initial 0.1–0.3                                                │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8                                                                     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # Whelton et al. e173                                                                                           │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # M A Y 1 5 , 2 0 1 8 : e 1 2 7 – 2 4 8                                                                         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # 2017 High Blood Pressure Clinical Practice Guideline                                                          │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Compelling indications for treatment of SIHD, these drugs are recommended as a first-line therapy in the        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ treatment of hypertension when it occurs in patients with SIHD. GDMT beta blockers for SIHD that are also       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ effective in lowering BP include carvedilol, metoprolol tartrate, metoprolol succinate, nadolol, bisoprolol,    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ propranolol, and timolol. Atenolol is not as effective as other antihypertensive drugs in the treatment of      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ hypertension (S9.1-23).                                                                                         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Dihydropyridine CCBs are effective antianginal drugs that can lower BP and relieve angina pectoris when added   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ to beta blockers in patients in whom hypertension is present and angina pectoris persists despite beta-blocker  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ therapy (S9.1-8,S9.1-17,S9.1-19—S9.1-22,S9.1-24,S9.1-25). GDMT beta blockers for SIHD that are also effective   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ in lowering BP include carvedilol, metoprolol tartrate, metoprolol succinate, nadolol, bisoprolol, propranolol, │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ and timolol.                                                                                                    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ In randomized long-term trials, use of beta blockers after MI reduced all-cause mortality by 23% (S9.1-13).     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Given the established efficacy of beta blockers for treating hypertension and SIHD, their use for treatment     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ continuing beyond 3 years after MI is reasonable (S9.1-6,S9.1-25).                                              │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ GDMT beta blockers and CCBs are effective antihypertensive and antianginal agents. CCBs include dihydropyridine │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ and nondihydropyridine agents. CCBs can be used separately or together with beta blockers beginning 3 years     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ after MI in patients with CAD who have both hypertension and angina.                                            │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # 9.2. Heart Failure                                                                                            │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # Recommendation for Prevention of HF in Adults With Hypertension                                               │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ References that support the recommendation are summarized in Online Data Supplement 33.                         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |COR|LOE|RECOMMENDATION|                                                                                        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |---|---|---|                                                                                                   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |SBP: B-R|I|In adults at increased risk of HF, the optimal BP in those with hypertension should be less than    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 130/80 mm Hg (S9.2-1—S9.2-3).|                                                                                  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |DBP: C-EO| | |                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # Synopsis                                                                                                      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Antecedent hypertension is present in 75% of patients with chronic HF (S9.2-4). In the Cardiovascular Health    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Study (S9.2-5) and the Health, Aging and Body Composition Study (S9.2-6), 11.2% of 4408 persons (53.1% women,   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ with a mean age of 72.8 years, living in the community, and not receiving antihypertensive drugs at baseline)   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ developed HF over 10 years (S9.2-7). Compared with those with an average SBP &lt;120 mm Hg, the adjusted incidence │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ of HF was increased 1.6, 2.2, and 2.6 times in those with average SBPs between 120 and 139 mm Hg, between 140   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ and 159 mm Hg, and ≥160 mm Hg, respectively (S9.2-7).                                                           │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ No RCTs are available that compare one BP-lowering agent to another for the management of patients with HF. The │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ following recommendations for treatment of hypertension in HF are based on use of drugs that lower BP and also  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ have compelling indications for management of HF (with HFrEF or HFpEF) as recommended in current ACC/AHA        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ guidelines (S9.2-4,S9.2-8).                                                                                     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # Recommendation-Specific Supportive Text                                                                       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 1. In adults with hypertension (SBP ≥130 mm Hg or DBP ≥80 mm Hg) and a high risk of CVD, a strong               │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ recommendation for BP lowering (&lt;130 mm Hg) is higher than that used in SPRINT.                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8                                                                     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # Whelton et al. e163                                                                                           │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # M A Y 1 5 , 2 0 1 8 : e 1 2 7 – 2 4 8                                                                         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # 2017 High Blood Pressure Clinical Practice Guideline                                                          │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ risk of CVD (S8.1.2-12,S8.1.2-13). Indirect support is also provided by evidence from trials using BP-lowering  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ medications to reduce the risk of developing higher levels of BP (S8.1.2-59—S8.1.2-61) and, in one case, to     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ achieve a reduction in LV mass (S8.1.2-62). In the HOPE-3 (Heart Outcomes Prevention Evaluation-3) BP Trial,    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ there was no evidence of short-term benefit during treatment of adults (average age 66 years) with a relatively │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ low risk of CVD (3.8% CVD event rate during 5.6 years of follow-up). However, subgroup analysis suggested       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ benefit in those with an average SBP approximately &gt;140 mm Hg (and a CVD risk of 6.5% during the 5.6 years of   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ follow-up) (S8.1.2-63). We acknowledge the importance of excluding white coat hypertension before initiating    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ pharmacological therapy in hypertensive patients with low ASCVD risk. This may be accomplished (as described in │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Section 4) by HBPM or ABPM as appropriate.                                                                      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # 8.1.3. Follow-Up After Initial BP Evaluation                                                                  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # Recommendations for Follow-Up After Initial BP Evaluation                                                     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ References that support recommendations are summarized in Online Data Supplement 24.                            │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |COR|LOE|RECOMMENDATIONS|                                                                                       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |---|---|---|                                                                                                   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |I|B-R|Adults with an elevated BP or stage 1 hypertension who have an estimated 10-year ASCVD risk less than    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 10% should be managed with nonpharmacological therapy and have a repeat BP evaluation within 3 to 6 months      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ (S8.1.3-1,S8.1.3-2).|                                                                                           │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |I|B-R|Adults with stage 1 hypertension who have an estimated 10-year ASCVD risk of 10% or higher should be     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ managed initially with a combination of nonpharmacological and antihypertensive drug therapy and have a repeat  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ BP evaluation in 1 month (S8.1.3-1,S8.1.3-2).|                                                                  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |I|B-R|Adults with stage 2 hypertension should be evaluated by or referred to a primary care provider within 1  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ month of the initial diagnosis, have a combination of nonpharmacological and antihypertensive drug therapy      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ (with 2 agents of different classes) initiated, and have a repeat BP evaluation in 1 month                      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ (S8.1.3-1,S8.1.3-2).|                                                                                           │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |I|B-R|For adults with a very high average BP (e.g., SBP ≥180 mm Hg or DBP ≥110 mm Hg), evaluation followed by  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ prompt antihypertensive drug treatment is recommended (S8.1.3-1,S8.1.3-2).|                                     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |IIa|C-EO|For adults with a normal BP, repeat evaluation every year is reasonable.|                             │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # Synopsis                                                                                                      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ An important component of BP management in hypertensive patients is follow-up. Different periods of time for    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ follow-up are recommended depending on the stage of hypertension, the presence or absence of target organ       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ damage, treatment with antihypertensive medications, and the level of BP control. Recommendations for follow-up │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ are summarized in Figure 4.                                                                                     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # Recommendation-Specific Supportive Text                                                                       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 1. Nonpharmacological therapy (see Section 6.2) is the preferred therapy for adults with elevated BP and an     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ appropriate first-line therapy for adults with stage 1 hypertension who have an estimated 10-year ASCVD risk of │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ &lt;10%. Adherence to and impact of non-pharmacological therapy should be assessed within 3 to 6 months.           │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 2. Nonpharmacological therapy can help reduce BP in patients with stage 1 hypertension with an estimated        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 10-year ASCVD risk of ≥10% and should be used in addition to pharmacological therapy as first-line therapy in   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ such patients (see Section 6.2).                                                                                │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 3. Prompt evaluation and treatment of patients with stage 2 hypertension with a combination of drug and         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ non-pharmacological therapy are important because of the elevated risk of CVD                                   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ \"first-line\" medication choices|                                                                                │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |ACE inhibitor intolerant| |                                                                                    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |Yes|ARB *|                                                                                                     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |No|ACF inhibitor|                                                                                              │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Colors correspond to Class of Recommendation in Table 1. *CKD stage 3 or higher or stage 1 or 2 with            │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ albuminuria ≥300 mg/d or ≥300 mg/g creatinine. ACE indicates angiotensin-converting enzyme; ARB, angiotensin    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ receptor blocker; BP blood pressure; and CKD, chronic kidney disease.                                           │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ An ACE inhibitor (or an ARB, in case of ACE inhibitor intolerance) is a preferred drug for treatment of         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ hypertension if albuminuria (≥300 mg/day or ≥300 mg/g creatinine by first morning void) is present, although    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ the evidence is mixed (S9.3-10,S9.3-11) (Figure 6). In the course of reducing intraglomerular pressure and      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ thereby reducing albuminuria, serum creatinine may increase up to 30% because of concurrent reduction in GFR    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ (S9.3-32). Further GFR decline should be investigated and may be related to other factors, including volume     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ contraction, use of nephrotoxic agents, or renovascular disease (S9.3-33). The combination of an ACE inhibitor  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ and an ARB should be avoided because of reported harms demonstrated in several large cardiology trials          │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ (S9.3-34,S9.3-35) and in 1 diabetic nephropathy trial (S9.3-36). Because of the greater risk of hyperkalemia    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ and hypotension and lack of...                                                                                  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # Whelton et al.                                                                                                │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8                                                                     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # 2017 High Blood Pressure Clinical Practice Guideline                                                          │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # M A Y  1 5 , 2 0 1 8 : e 1 2 7 – 2 4 8                                                                        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # 9.1. Stable Ischemic Heart Disease                                                                            │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # Recommendations for Treatment of Hypertension in Patients With Stable Ischemic Heart Disease (SIHD)           │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ References that support recommendations are summarized in Online Data Supplements 30-32.                        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |COR|LOE|RECOMMENDATIONS|                                                                                       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |---|---|---|                                                                                                   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |SBP: B-R|I|1. In adults with SIHD and hypertension, a BP target of less than 130/80 mm Hg is recommended       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ (S9.1-1—S9.1-5).|                                                                                               │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |DBP: C-EO| | |                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |SBP: B-R|I|2. Adults with SIHD and hypertension (BP ≥130/80 mm Hg) should be treated with medications (e.g.,   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ GDMT beta blockers, ACE inhibitors, or ARBs) for compelling indications (e.g., previous MI, stable angina) as   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ first-line therapy, with the addition of other drugs (e.g., dihydropyridine CCBs, thiazide diuretics, and/or    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ mineralocorticoid receptor antagonists) as needed to further control hypertension (S9.1-6) (S9.1-7—S9.1-10).|   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ | |B-NR|3. In adults with SIHD with angina and persistent uncontrolled hypertension, the addition of            │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ dihydropyridine CCBs to GDMT (S9.1-6) beta blockers is recommended (S9.1-8,S9.1-11,S9.1-12).|                   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ | |IIa|4. In adults who have had a MI or acute coronary syndrome, it is reasonable to continue GDMT (S9.1-6)    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ beta blockers beyond 3 years as long-term therapy for hypertension (S9.1-13,S9.1-14).|                          │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ | |IIb|5. Beta blockers and/or CCBs might be considered to control hypertension in patients with CAD (without   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ HFrEF) who had an MI more than 3 years ago and have angina.|                                                    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # Synopsis                                                                                                      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Hypertension is a major risk factor for ischemic heart disease. Numerous RCTs have demonstrated the benefits of │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ antihypertensive drug therapy in reducing the risk of ischemic heart disease. The following recommendations     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ apply only to management of hypertension in patients with SIHD without HF. See Section 9.2 for recommendations  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ for the treatment of patients with SIHD and HF.                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Figure 5 is an algorithm on management of hypertension in patients with SIHD.                                   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # Recommendation-Specific Supportive Text                                                                       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 1. In patients with increased cardiovascular risk, reduction of SBP to &lt;130/80 mm Hg has been shown to reduce   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ CVD complications by 25% and all-cause mortality by 27% (S9.1-1).                                               │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 2. After 5 years of randomized therapy in high-CVD-risk patients, ramipril produced a 22% reduction in MI,      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ stroke, or CVD compared with placebo (S9.1-10). No added benefit on CVD outcomes was seen when compared with    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ CCBs and diuretics (S9.1-15,S9.1-16). After 4.2 years of randomized therapy in patients with SIHD, perindopril  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ reduced CVD death, MI, or cardiac arrest by 20% compared with placebo (S9.1-7). Beta blockers are effective     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ drugs for preventing angina pectoris, improving exercise time until the onset of angina pectoris, reducing      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ exercise-induced ischemic ST-segment depression, and preventing coronary events (S9.1-8,S9.1-17—S9.1-22).       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # F I G U R E 5 Management of Hypertension in Patients With SIHD                                                │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Hypertension With SIHD                                                                                          │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Reduce BP to &lt;130/80 mm Hg with GDMT beta blockers, ACE inhibitor, or ARBs (Class I)                            │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ BP goal not met                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Angina pectoris                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ No                                                                                                              │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Add dihydropyridine CCBs if needed (Class I)                                                                    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Add dihydropyridine CCBs; thiazide-type                                                                         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[32m╭─\u001b[0m\u001b[32m─────────────────────────────────────────────\u001b[0m Tool Response Added \u001b[32m─────────────────────────────────────────────\u001b[0m\u001b[32m─╮\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mTool output added to messages:\u001b[0m\u001b[32m                                                                                 \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# Whelton et al.\u001b[0m\u001b[32m                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# 2017 High Blood Pressure Clinical Practice Guideline\u001b[0m\u001b[32m                                                         \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# MAY 15, 2018: e127–248\u001b[0m\u001b[32m                                                                                       \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m2. The treatment of patients with hypertension without elevated risk has been systematically understudied \u001b[0m\u001b[32m     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mbecause lower-risk groups would require prolonged follow-up to have a sufficient number of clinical events to \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mprovide useful information. Although there is clinical trial evidence that both drug and nondrug therapy will \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32minterrupt the progressive course of hypertension (S8.1.5-6), there is no trial evidence that this treatment \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mdecreases CVD morbidity and mortality. The clinical trial evidence is strongest for a target BP of 140/90 mm Hg\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32min this population. However, observational studies suggest that these individuals often have a high lifetime \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mrisk and would benefit from BP control earlier in life (S8.1.5-19, S8.1.5-20).\u001b[0m\u001b[32m                                 \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# 8.1.6. Choice of Initial Medication\u001b[0m\u001b[32m                                                                          \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# Recommendation for Choice of Initial Medication\u001b[0m\u001b[32m                                                              \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mReferences that support the recommendation are summarized in Online Data Supplement 27 and Systematic Review \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mReport.\u001b[0m\u001b[32m                                                                                                        \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|COR|LOE|RECOMMENDATION|\u001b[0m\u001b[32m                                                                                       \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|---|---|---|\u001b[0m\u001b[32m                                                                                                  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|I|ASR|For initiation of antihypertensive drug therapy, first-line agents include thiazide diuretics, CCBs, and\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mACE inhibitors or ARBs. (S8.1.6-1, S8.1.6-2)|\u001b[0m\u001b[32m                                                                  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# Synopsis\u001b[0m\u001b[32m                                                                                                     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mThe overwhelming majority of persons with BP sufficiently elevated to warrant pharmacological therapy may be \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mbest treated initially with 2 agents (see Section 8.1.6.1). When initiation of pharmacological therapy with a \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32msingle medication is appropriate, primary consideration should be given to comorbid conditions (e.g., HF, CKD) \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mfor which specific classes of BP-lowering medication are indicated (see Section 9) (S8.1.6-1). In the largest \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mhead-to-head comparison of first-step drug therapy for hypertension (S8.1.6-3), the thiazide-type diuretic \u001b[0m\u001b[32m    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mchlorthalidone was superior to the CCB amlodipine and the ACE inhibitor lisinopril in preventing HF, a \u001b[0m\u001b[32m        \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mBP-related outcome of increasing importance in the growing population of older persons with hypertension \u001b[0m\u001b[32m      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m(S8.1.6-4—S8.1.6-7). Additionally, ACE inhibitors were less effective than thiazide diuretics and CCBs in \u001b[0m\u001b[32m     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mlowering BP and in prevention of stroke. For black patients, ACE inhibitors were also notably less effective \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mthan CCBs in preventing HF (S8.1.6-8) and in the prevention of stroke (S8.1.6-9) (see Section 10.1). ARBs may \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mbe better tolerated than ACE inhibitors in black patients, with less cough and angioedema, but according to the\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mlimited available experience they offer no proven advantage over ACE inhibitors in preventing stroke or CVD in \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mthis population, making thiazide diuretics (especially chlorthalidone) or CCBs the best initial choice for \u001b[0m\u001b[32m    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32msingle-drug therapy. For stroke, in the general population, beta blockers were less effective than CCBs (36% \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mlower risk) and thiazide diuretics (30% lower risk). CCBs have been shown to be as effective as diuretics for \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mreducing all CVD events other than HF, and CCBs are a good alternative choice for initial therapy when thiazide\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mdiuretics are not tolerated. Alpha blockers are not used as first-line therapy for hypertension because they \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mare less effective for prevention of CVD than other first-step agents, such as thiazide diuretics (S8.1.6-3, \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mS8.1.6-10).\u001b[0m\u001b[32m                                                                                                    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# Recommendation-Specific Supportive Text\u001b[0m\u001b[32m                                                                      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m1. The overall goal of treatment should be reduction in BP, in the context of underlying CVD risk. Five drug \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mclasses have been shown, in high-quality RCTs, to prevent CVD as compared with placebo (diuretics, ACE \u001b[0m\u001b[32m        \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32minhibitors, ARBs, CCBs, and beta blockers) (S8.1.6-11, S8.1.6-12). In head-to-head comparisons of first-step \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mtherapy, different drug classes have been reported to provide somewhat divergent capacity to prevent specific \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mCVD events. Interpretation of meta-analyses comparing agents from different drug classes is challenging because\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mthe relevant RCTs were conducted in different time periods, during which concurrent antihypertensive therapy \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mwas less or more common, and the efficacy of agents from certain drug classes may have\u001b[0m\u001b[32m                         \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# J A C C V O L . 71, N O . 1 9, 2 0 1 8\u001b[0m\u001b[32m                                                                       \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# Whelton et al. e169\u001b[0m\u001b[32m                                                                                          \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# M A Y 1 5, 2 0 1 8 : e 1 2 7 – 2 4 8\u001b[0m\u001b[32m                                                                         \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# 2017 High Blood Pressure Clinical Practice Guideline\u001b[0m\u001b[32m                                                         \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32msignificantly better than CCBs for prevention of HF. There were some other nonsignificant differences between \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mdiuretics, ACE inhibitors, ARBs, and CCBs, but the general pattern was for similarity in effect. As indicated \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32min Section 8.1.6.1, most adults with hypertension require >1 drug to control their BP. As recommended in \u001b[0m\u001b[32m      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mSection 10.1, for black adults with hypertension (without HF or CKD), initial antihypertensive treatment should\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32minclude a thiazide diuretic or CCB.\u001b[0m\u001b[32m                                                                            \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# 8.1.6.1. Choice of Initial Monotherapy Versus Initial Combination Drug Therapy\u001b[0m\u001b[32m                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|COR|LOE|RECOMMENDATIONS|\u001b[0m\u001b[32m                                                                                      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|---|---|---|\u001b[0m\u001b[32m                                                                                                  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|I|C-EO|Initiation of antihypertensive drug therapy with 2 first-line agents of different classes, either as \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mseparate agents or in a fixed-dose combination, is recommended in adults with stage 2 hypertension and an \u001b[0m\u001b[32m     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32maverage BP more than 20/10 mm Hg above their BP target.|\u001b[0m\u001b[32m                                                       \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|IIa|C-EO|Initiation of antihypertensive drug therapy with a single antihypertensive drug is reasonable in \u001b[0m\u001b[32m    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32madults with stage 1 hypertension and BP goal <130/80 mm Hg with dosage titration and sequential addition of \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mother agents to achieve the BP target.|\u001b[0m\u001b[32m                                                                        \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m*Fixed-dose combination antihypertensive medications are listed in Online Data Supplement D.\u001b[0m\u001b[32m                   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# Synopsis\u001b[0m\u001b[32m                                                                                                     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mSystematic review of the evidence comparing the initiation of antihypertensive treatment with monotherapy and \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32msequential (stepped-care) titration of additional agents versus initiation of treatment with combination \u001b[0m\u001b[32m      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mtherapy (including fixed-dose combinations) did not identify any RCTs meeting the systematic review questions \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mposed in the PICOTS format (P¼population, I¼intervention, C¼comparator, O¼outcome, T¼timing, S¼setting). \u001b[0m\u001b[32m      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mHowever, in both ACCORD and SPRINT, 2-drug therapy was recommended for most participants in the intensive- but \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mnot standard-therapy groups.\u001b[0m\u001b[32m                                                                                   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# Recommendation-Specific Supportive Text\u001b[0m\u001b[32m                                                                      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m1. Because most patients with hypertension require multiple agents for control of their BP and those with \u001b[0m\u001b[32m     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mhigher BPs are at greater risk, more rapid titration of antihypertensive medications began to be recommended in\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mpatients with BP >20/10 mm Hg above their target, beginning with the JNC 7 report (S8.1.6.1-1). In these \u001b[0m\u001b[32m      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mpatients, initiation of antihypertensive therapy with 2 agents is recommended. Evidence favoring this approach \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mcomes mostly from studies using fixed-dose combination products showing greater BP lowering with fixed-dose \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mcombination agents than with single agents, as well as better adherence to therapy (S8.1.6.1-2,S8.1.6.1-3). The\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32msafety and efficacy of this strategy have been demonstrated in adults to reduce BPs to <140/90 mm Hg though not\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mcompared with other strategies (S8.1.6.1-4—S8.1.6.1-6). In general, this approach is reasonable in older \u001b[0m\u001b[32m      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32madults, those at high CVD risk, or those who have a history of hypotension or drug-associated side effects. \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mHowever, caution is advised in initiating antihypertensive pharmacotherapy with 2 drugs in older patients \u001b[0m\u001b[32m     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mbecause hypotension or orthostatic hypotension may develop in some patients; BP should be carefully monitored.\u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m2. The stepped-care approach defined by the initiation of antihypertensive drug therapy with a single agent \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mfollowed by the sequential titration of the dose and addition of other agents has been the recommended \u001b[0m\u001b[32m        \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mtreatment strategy since the first report of the National High Blood Pressure Education Program (S8.1.6.1-7). \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mThis approach is also reasonable in older adults or those at risk or who have a history of hypotension or \u001b[0m\u001b[32m     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mdrug-associated side effects. This strategy has been used successfully in nearly all hypertension treatment \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mtrials but has not been formally tested against other antihypertensive drug treatment strategies for \u001b[0m\u001b[32m          \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32meffectiveness in achieving BP control or in preventing adverse outcomes.\u001b[0m\u001b[32m                                       \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# 8.2. Achieving BP Control in Individual Patients\u001b[0m\u001b[32m                                                             \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mRecommendations for lifestyle modifications and drug selection are specified in\u001b[0m\u001b[32m                                \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# JACC VOL. 79, NO. 17, 2022\u001b[0m\u001b[32m                                                                                   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# Heidenreich et al e329\u001b[0m\u001b[32m                                                                                       \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# MAY 3, 2022: e263 – e421\u001b[0m\u001b[32m                                                                                     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# 2022 AHA/ACC/HFSA Heart Failure Guideline\u001b[0m\u001b[32m                                                                    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mExtrapolated from those for treatment of patients with hypertension in general (26). However, the optimal blood\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mpressure goal and antihypertensive regimens are not known for patients with HFpEF. RAAS antagonists including \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mACEi, ARB, MRA, and possibly ARNi, could be first-line agents given experience with their use in HFpEF trials \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m(8,10,16,20,27,28). Beta blockers may be used to treat hypertension in patients with a history of MI (27), \u001b[0m\u001b[32m    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32msymptomatic CAD, or AF with rapid ventricular response. These effects need to be balanced with the potential \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mcontribution of chronotropic incompetence to exercise intolerance in some patients (29).\u001b[0m\u001b[32m                       \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# 1. EMPEROR-Preserved\u001b[0m\u001b[32m                                                                                         \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m(Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Preserved Ejection Fraction) showed a \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32msignificant benefit of the SGLT2i, empagliflozin, in symptomatic patients with HF with LVEF >40% and elevated \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mnatriuretic peptides (30). The 21% reduction in the primary composite endpoint of time to HF hospitalization or\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mcardiovascular death was driven mostly by a significant 29% reduction in time to HF hospitalization \u001b[0m\u001b[32m           \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m(nonsignificant lower cardiovascular death [HR, 0.91; 95% CI, 0.76-1.0]), with no benefit on all-cause \u001b[0m\u001b[32m        \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mmortality. Empagliflozin also resulted in a significant reduction in total HF hospitalizations, decrease in the\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mslope of the eGFR decline, and a modest improvement in QOL at 52 weeks. Of note, the benefit was similar \u001b[0m\u001b[32m      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mirrespective of the presence or absence of diabetes at baseline. Although the benefit in the primary endpoint \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mdid not have a significant interaction by LVEF subgroups (<50%, 50%–<60%, and >60%) (30), in a subgroup \u001b[0m\u001b[32m       \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32manalysis by EF, there was a signal for lower benefit on the primary composite endpoint, first and recurrent HF \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mhospitalizations at higher LVEFs >62.5% (31).\u001b[0m\u001b[32m                                                                  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# 2. Atrial Fibrillation Management\u001b[0m\u001b[32m                                                                            \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mLarge, randomized clinical trial data are unavailable to specifically guide therapy in patients with HFpEF and \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mAF. Currently, the comprehensive care of AF can be extrapolated from the clinical practice guidelines for AF, \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mwith individualization of strategies for rate or rhythm control in patients with HFpEF (see also Section 10.2, \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m“Management of Atrial Fibrillation (AF) in HF,” for HF specific recommendations for AF). Although beta blockers\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mand nondihydropyridine calcium channel blockers are often considered as first-line agents for heart rate \u001b[0m\u001b[32m      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mcontrol in patients with HFpEF, a recent smaller open-label trial, RATE-AF in elderly patients with AF and \u001b[0m\u001b[32m    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32msymptoms of HF (most with preserved LVEF), compared the use of the beta blocker, bisoprolol, to digoxin (32). \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mAt 6 months, the primary endpoint of QOL was similar between the 2 groups. However, several secondary QOL \u001b[0m\u001b[32m     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mendpoints, functional capacity, and reduction in NT-proBNP favored digoxin at 12 months. There was a similar \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mheart rate reduction in both groups. Of note, more adverse events such as higher rates of dizziness, lethargy, \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mand hypotension occurred with beta blockers than digoxin. The comprehensive care of AF is beyond the scope of \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mthese guidelines. AF-specific care recommendations can be found in separate ACC/AHA clinical practice \u001b[0m\u001b[32m         \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mguidelines (33,34).\u001b[0m\u001b[32m                                                                                            \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# 3. MRAs and Diastolic Function\u001b[0m\u001b[32m                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mMRAs improve diastolic function in patients with HFpEF (35). The TOPCAT trial investigated the effects of \u001b[0m\u001b[32m     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mspironolactone in patients with HFpEF. The small reduction (HR, 0.89) in the composite of death, aborted \u001b[0m\u001b[32m      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mcardiac death, and HF hospitalization was not statistically significant, although HF hospitalization was \u001b[0m\u001b[32m      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mreduced (HR, 0.83); adverse effects of hyperkalemia and increasing creatinine levels were more common in the \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mtreatment group (5). A post hoc analysis (6) showed efficacy in the Americas (HR 0.83) but not in \u001b[0m\u001b[32m             \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mRussia-Georgia (HR 1.10). A sample of the Russia-Georgia population in the active treatment arm had \u001b[0m\u001b[32m           \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mnon-detectable levels of a spironolactone metabolite. Post hoc analyses have limitations, but they suggest a \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mpossibility of benefit in appropriately selected patients with symptomatic HFpEF\u001b[0m\u001b[32m                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mtherapy should be assessed within 3 to 6 months.\u001b[0m\u001b[32m                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m2. Nonpharmacological therapy can help reduce BP in patients with stage 1 hypertension with an estimated \u001b[0m\u001b[32m      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m10-year ASCVD risk of ≥10% and should be used in addition to pharmacological therapy as first-line therapy in \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32msuch patients (see Section 6.2).\u001b[0m\u001b[32m                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m3. Prompt evaluation and treatment of patients with stage 2 hypertension with a combination of drug and \u001b[0m\u001b[32m       \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mnon-pharmacological therapy are important because of the elevated risk of CVD events in this subgroup, \u001b[0m\u001b[32m        \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mespecially those with multiple ASCVD risk factors or target organ damage (S8.1.3-1,S8.1.3-2).\u001b[0m\u001b[32m                  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m4. Prompt management of very high BP is important to reduce the risk of target organ damage (see Section 11.2).\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mThe rapidity of the treatment needed is dependent on the patient’s clinical presentation (presence of new or \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mworsening target organ damage) and presence or absence of CVD complications, but treatment should be initiated \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mwithin at least 1 week.\u001b[0m\u001b[32m                                                                                        \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# J A C C V O L . 74, N O . 1 0 , 2 0 1 9\u001b[0m\u001b[32m                                                                      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease\u001b[0m\u001b[32m                                   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m1. Adults who are 40 to 75 years of age and are being evaluated for cardiovascular disease prevention should \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mundergo 10-year atherosclerotic cardiovascular disease (ASCVD) risk estimation and have a clinician–patient \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mrisk discussion before starting on pharmacological therapy, such as antihypertensive therapy, a statin, or \u001b[0m\u001b[32m    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32maspirin. In addition, assessing for other risk-enhancing factors can help guide decisions about preventive \u001b[0m\u001b[32m    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32minterventions in select individuals, as can coronary artery calcium scanning.\u001b[0m\u001b[32m                                  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m2. All adults should consume a healthy diet that emphasizes the intake of vegetables, fruits, nuts, whole \u001b[0m\u001b[32m     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mgrains, lean vegetable or animal protein, and fish and minimizes the intake of trans fats, red meat and \u001b[0m\u001b[32m       \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mprocessed red meats, refined carbohydrates, and sweetened beverages. For adults with overweight and obesity, \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mcounseling and caloric restriction are recommended for achieving and maintaining weight loss.\u001b[0m\u001b[32m                  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m3. Adults should engage in at least 150 minutes per week of accumulated moderate-intensity physical activity or\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m75 minutes per week of vigorous-intensity physical activity.\u001b[0m\u001b[32m                                                   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m4. For adults with type 2 diabetes mellitus, lifestyle changes, such as improving dietary habits and achieving \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mexercise recommendations, are crucial. If medication is indicated, metformin is first-line therapy, followed by\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mconsideration of a sodium-glucose cotransporter 2 inhibitor or a glucagon-like peptide-1 receptor agonist.\u001b[0m\u001b[32m     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m5. All adults should be assessed at every healthcare visit for tobacco use, and those who use tobacco should be\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32massisted and strongly advised to quit.\u001b[0m\u001b[32m                                                                         \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m6. Aspirin should be used infrequently in the routine primary prevention of ASCVD because of lack of net \u001b[0m\u001b[32m      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mbenefit.\u001b[0m\u001b[32m                                                                                                       \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m7. Statin therapy is first-line treatment for primary prevention of ASCVD in patients with elevated low-density\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mlipoprotein cholesterol levels (≥190 mg/dL), those with diabetes mellitus, who are 40 to 75 years of age, and \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mthose determined to be at sufficient ASCVD risk after a clinician–patient risk discussion.\u001b[0m\u001b[32m                     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m8. Nonpharmacological interventions are recommended for all adults with elevated blood pressure or \u001b[0m\u001b[32m            \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mhypertension. For those requiring pharmacological therapy, the target blood pressure should generally be \u001b[0m\u001b[32m      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m<130/80 mm Hg.\u001b[0m\u001b[32m                                                                                                 \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# PREAMBLE\u001b[0m\u001b[32m                                                                                                     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mSince 1980, the American College of Cardiology (ACC) and American Heart Association (AHA) have translated \u001b[0m\u001b[32m     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mscientific evidence into clinical practice guidelines with recommendations to improve cardiovascular health. \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mThese guidelines, which are based on systematic methods to evaluate and classify evidence, provide a foundation\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mfor the delivery of quality cardiovascular care. The ACC and AHA sponsor the development and publication of \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mclinical practice guidelines without commercial support, and members volunteer their time to the writing and \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mreview efforts.\u001b[0m\u001b[32m                                                                                                \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mClinical practice guidelines provide recommendations applicable to patients with or at risk of developing \u001b[0m\u001b[32m     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mcardiovascular disease (CVD). The focus is on medical practice in the United States, but these guidelines are \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mrelevant to patients throughout the world. Although guidelines may be used to inform regulatory or payer \u001b[0m\u001b[32m      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mdecisions, the goals are to improve quality of care and align with patients’ interests. Guidelines are intended\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mto define practices meeting the needs of patients in most but not all circumstances and should not replace \u001b[0m\u001b[32m    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mclinical judgment.\u001b[0m\u001b[32m                                                                                             \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mRecommendations for guideline-directed management and therapy, which encompasses clinical evaluation, \u001b[0m\u001b[32m         \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mdiagnostic testing, and both pharmacological and procedural treatments, are effective only when adopted by both\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mpractitioners and patients. Adherence to recommendations can be enhanced by shared decision-making between \u001b[0m\u001b[32m    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mclinicians and patients, with patient engagement in selecting interventions on the basis of individual values, \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mpreferences, and associated conditions and comorbidities.\u001b[0m\u001b[32m                                                      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mThe ACC/AHA Task Force on Clinical Practice Guidelines strives to ensure that the guideline writing committee \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mincludes requisite expertise and is representative of the broader medical community by selecting experts from a\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mbroad array of backgrounds, representing different geographic regions, sexes, races, ethnicities, intellectual \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mperspectives/biases, and scopes of clinical practice. The ACC and AHA have rigorous policies and methods to \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mensure that documents are developed without bias or improper influence. The complete policy on relationships \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mwith industry and other entities (RWI) can be found online.\u001b[0m\u001b[32m                                                    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mBeginning in 2017, numerous modifications to the guidelines have been and continue to be implemented to make \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mguidelines shorter and enhance “user friendliness.” Guidelines are written and presented in a modular knowledge\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mchunk format, in which each chunk includes a table of recommendations, a brief synopsis, \u001b[0m\u001b[32m                      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mrecommendation-specific supportive text and, when appropriate, flow diagrams or additional tables. Hyperlinked \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mreferences are provided for each modular.\u001b[0m\u001b[32m                                                                      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# Whelton et al.\u001b[0m\u001b[32m                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# 2017 High Blood Pressure Clinical Practice Guideline\u001b[0m\u001b[32m                                                         \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# MAY 15, 2018: e127–248\u001b[0m\u001b[32m                                                                                       \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# TABLE 19\u001b[0m\u001b[32m                                                                                                     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# Intravenous Antihypertensive Drugs for Treatment of Hypertensive Emergencies\u001b[0m\u001b[32m                                 \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|Class|Drug(s)|Usual Dose Range|Comments|\u001b[0m\u001b[32m                                                                      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|---|---|---|---|\u001b[0m\u001b[32m                                                                                              \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|CCB—dihydropyridines|Nicardipine|Initial 5 mg/h, increasing every 5 min by 2.5 mg/h to maximum 15 \u001b[0m\u001b[32m            \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mmg/h.|Contraindicated in advanced aortic stenosis; no dose adjustment needed for elderly.|\u001b[0m\u001b[32m                     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m| |Clevidipine|Initial 1–2 mg/h, doubling every 90 s until BP approaches target, then increasing by less than \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mdouble every 5–10 min; maximum dose 32 mg/h; maximum duration 72 h.|Contraindicated in patients with soybean, \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32msoy product, egg, and egg product allergy and in patients with defective lipid metabolism (e.g., pathological \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mhyperlipidemia, lipoid nephrosis or acute pancreatitis). Use low-end dose range for elderly patients.|\u001b[0m\u001b[32m         \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|Vasodilators—Nitric-oxide dependent|Sodium nitroprusside|Initial 0.3–0.5 mcg/kg/min; increase in increments of\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m0.5 mcg/kg/min to achieve BP target; maximum dose 10 mcg/kg/min; duration of treatment as short as possible. \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mFor infusion rates ≥4–10 mcg/kg/min or duration >30 min, thiosulfate can be coadministered to prevent cyanide \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mtoxicity.|Intra-arterial BP monitoring recommended to prevent “overshoot.” Lower dosing adjustment required for\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32melderly. Tachyphylaxis common with extended use. Cyanide toxicity with prolonged use can result in irreversible\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mneurological changes and cardiac arrest.|\u001b[0m\u001b[32m                                                                      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m| |Nitroglycerin|Initial 5 mcg/min; increase in increments of 5 mcg/min every 3–5 min to a maximum of 20 \u001b[0m\u001b[32m      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mmcg/min.|Use only in patients with acute coronary syndrome and/or acute pulmonary edema. Do not use in \u001b[0m\u001b[32m        \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mvolume-depleted patients.|\u001b[0m\u001b[32m                                                                                     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|Vasodilators—direct|Hydralazine|Initial 10 mg via slow IV infusion (maximum initial dose 20 mg); repeat every \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m4–6 h as needed.|BP begins to decrease within 10–30 min, and the fall lasts 2–4 h. Unpredictability of response\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mand prolonged duration of action do not make hydralazine a desirable first-line agent for acute treatment in \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mmost patients.|\u001b[0m\u001b[32m                                                                                                \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|Adrenergic blockers—beta1 receptor selective antagonist|Esmolol|Loading dose 500–1000 mcg/kg/min over 1 min \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mfollowed by a 50-mcg/kg/min infusion. For additional dosing, the bolus dose is repeated and the infusion \u001b[0m\u001b[32m      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mincreased in 50-mcg/kg/min increments as needed to a maximum of 200 mcg/kg/min.|Contraindicated in patients \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mwith concurrent beta-blocker therapy, bradycardia, or decompensated HF. Monitor for bradycardia. May worsen HF.\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mHigher doses may block beta2 receptors and impact lung function in reactive airway disease.|\u001b[0m\u001b[32m                   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|Adrenergic blockers—combined alpha1 and nonselective beta receptor antagonist|Labetalol|Initial 0.3–1.0-mg/kg \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mdose (maximum 20 mg) slow IV injection every 10 min or 0.4–1.0-mg/kg/h IV infusion up to 3 mg/kg/h. Adjust rate\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mup to total cumulative dose of 300 mg. This dose can be repeated every 4–6 h.|Contraindicated in reactive \u001b[0m\u001b[32m     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mairways disease or chronic obstructive pulmonary disease. Especially useful in hyperadrenergic syndromes. May \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mworsen HF and should not be given in patients with second- or third-degree heart block or bradycardia.|\u001b[0m\u001b[32m        \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|Adrenergic blockers—nonselective alpha receptor antagonist|Phentolamine|IV bolus dose 5 mg. Additional bolus \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mdoses every 10 min as needed to lower BP to target.|Used in hypertensive emergencies induced by catecholamine \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mexcess (pheochromocytoma, interactions between monoamine oxidase inhibitors and other drugs or food, cocaine \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mtoxicity, amphetamine overdose, or clonidine withdrawal).|\u001b[0m\u001b[32m                                                     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|Dopamine-receptor1 selective agonist|Fenoldopam|Initial 0.1–0.3\u001b[0m\u001b[32m                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8\u001b[0m\u001b[32m                                                                    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# Whelton et al. e173\u001b[0m\u001b[32m                                                                                          \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# M A Y 1 5 , 2 0 1 8 : e 1 2 7 – 2 4 8\u001b[0m\u001b[32m                                                                        \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# 2017 High Blood Pressure Clinical Practice Guideline\u001b[0m\u001b[32m                                                         \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mCompelling indications for treatment of SIHD, these drugs are recommended as a first-line therapy in the \u001b[0m\u001b[32m      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mtreatment of hypertension when it occurs in patients with SIHD. GDMT beta blockers for SIHD that are also \u001b[0m\u001b[32m     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32meffective in lowering BP include carvedilol, metoprolol tartrate, metoprolol succinate, nadolol, bisoprolol, \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mpropranolol, and timolol. Atenolol is not as effective as other antihypertensive drugs in the treatment of \u001b[0m\u001b[32m    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mhypertension (S9.1-23).\u001b[0m\u001b[32m                                                                                        \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mDihydropyridine CCBs are effective antianginal drugs that can lower BP and relieve angina pectoris when added \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mto beta blockers in patients in whom hypertension is present and angina pectoris persists despite beta-blocker \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mtherapy (S9.1-8,S9.1-17,S9.1-19—S9.1-22,S9.1-24,S9.1-25). GDMT beta blockers for SIHD that are also effective \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32min lowering BP include carvedilol, metoprolol tartrate, metoprolol succinate, nadolol, bisoprolol, propranolol,\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mand timolol.\u001b[0m\u001b[32m                                                                                                   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mIn randomized long-term trials, use of beta blockers after MI reduced all-cause mortality by 23% (S9.1-13). \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mGiven the established efficacy of beta blockers for treating hypertension and SIHD, their use for treatment \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mcontinuing beyond 3 years after MI is reasonable (S9.1-6,S9.1-25).\u001b[0m\u001b[32m                                             \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mGDMT beta blockers and CCBs are effective antihypertensive and antianginal agents. CCBs include dihydropyridine\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mand nondihydropyridine agents. CCBs can be used separately or together with beta blockers beginning 3 years \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mafter MI in patients with CAD who have both hypertension and angina.\u001b[0m\u001b[32m                                           \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# 9.2. Heart Failure\u001b[0m\u001b[32m                                                                                           \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# Recommendation for Prevention of HF in Adults With Hypertension\u001b[0m\u001b[32m                                              \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mReferences that support the recommendation are summarized in Online Data Supplement 33.\u001b[0m\u001b[32m                        \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|COR|LOE|RECOMMENDATION|\u001b[0m\u001b[32m                                                                                       \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|---|---|---|\u001b[0m\u001b[32m                                                                                                  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|SBP: B-R|I|In adults at increased risk of HF, the optimal BP in those with hypertension should be less than \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m130/80 mm Hg (S9.2-1—S9.2-3).|\u001b[0m\u001b[32m                                                                                 \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|DBP: C-EO| | |\u001b[0m\u001b[32m                                                                                                \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# Synopsis\u001b[0m\u001b[32m                                                                                                     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mAntecedent hypertension is present in 75% of patients with chronic HF (S9.2-4). In the Cardiovascular Health \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mStudy (S9.2-5) and the Health, Aging and Body Composition Study (S9.2-6), 11.2% of 4408 persons (53.1% women, \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mwith a mean age of 72.8 years, living in the community, and not receiving antihypertensive drugs at baseline) \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mdeveloped HF over 10 years (S9.2-7). Compared with those with an average SBP <120 mm Hg, the adjusted incidence\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mof HF was increased 1.6, 2.2, and 2.6 times in those with average SBPs between 120 and 139 mm Hg, between 140 \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mand 159 mm Hg, and ≥160 mm Hg, respectively (S9.2-7).\u001b[0m\u001b[32m                                                          \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mNo RCTs are available that compare one BP-lowering agent to another for the management of patients with HF. The\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mfollowing recommendations for treatment of hypertension in HF are based on use of drugs that lower BP and also \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mhave compelling indications for management of HF (with HFrEF or HFpEF) as recommended in current ACC/AHA \u001b[0m\u001b[32m      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mguidelines (S9.2-4,S9.2-8).\u001b[0m\u001b[32m                                                                                    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# Recommendation-Specific Supportive Text\u001b[0m\u001b[32m                                                                      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m1. In adults with hypertension (SBP ≥130 mm Hg or DBP ≥80 mm Hg) and a high risk of CVD, a strong \u001b[0m\u001b[32m             \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mrecommendation for BP lowering (<130 mm Hg) is higher than that used in SPRINT.\u001b[0m\u001b[32m                                \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8\u001b[0m\u001b[32m                                                                    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# Whelton et al. e163\u001b[0m\u001b[32m                                                                                          \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# M A Y 1 5 , 2 0 1 8 : e 1 2 7 – 2 4 8\u001b[0m\u001b[32m                                                                        \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# 2017 High Blood Pressure Clinical Practice Guideline\u001b[0m\u001b[32m                                                         \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mrisk of CVD (S8.1.2-12,S8.1.2-13). Indirect support is also provided by evidence from trials using BP-lowering \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mmedications to reduce the risk of developing higher levels of BP (S8.1.2-59—S8.1.2-61) and, in one case, to \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32machieve a reduction in LV mass (S8.1.2-62). In the HOPE-3 (Heart Outcomes Prevention Evaluation-3) BP Trial, \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mthere was no evidence of short-term benefit during treatment of adults (average age 66 years) with a relatively\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mlow risk of CVD (3.8% CVD event rate during 5.6 years of follow-up). However, subgroup analysis suggested \u001b[0m\u001b[32m     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mbenefit in those with an average SBP approximately >140 mm Hg (and a CVD risk of 6.5% during the 5.6 years of \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mfollow-up) (S8.1.2-63). We acknowledge the importance of excluding white coat hypertension before initiating \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mpharmacological therapy in hypertensive patients with low ASCVD risk. This may be accomplished (as described in\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mSection 4) by HBPM or ABPM as appropriate.\u001b[0m\u001b[32m                                                                     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# 8.1.3. Follow-Up After Initial BP Evaluation\u001b[0m\u001b[32m                                                                 \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# Recommendations for Follow-Up After Initial BP Evaluation\u001b[0m\u001b[32m                                                    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mReferences that support recommendations are summarized in Online Data Supplement 24.\u001b[0m\u001b[32m                           \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|COR|LOE|RECOMMENDATIONS|\u001b[0m\u001b[32m                                                                                      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|---|---|---|\u001b[0m\u001b[32m                                                                                                  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|I|B-R|Adults with an elevated BP or stage 1 hypertension who have an estimated 10-year ASCVD risk less than \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m10% should be managed with nonpharmacological therapy and have a repeat BP evaluation within 3 to 6 months \u001b[0m\u001b[32m    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m(S8.1.3-1,S8.1.3-2).|\u001b[0m\u001b[32m                                                                                          \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|I|B-R|Adults with stage 1 hypertension who have an estimated 10-year ASCVD risk of 10% or higher should be \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mmanaged initially with a combination of nonpharmacological and antihypertensive drug therapy and have a repeat \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mBP evaluation in 1 month (S8.1.3-1,S8.1.3-2).|\u001b[0m\u001b[32m                                                                 \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|I|B-R|Adults with stage 2 hypertension should be evaluated by or referred to a primary care provider within 1 \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mmonth of the initial diagnosis, have a combination of nonpharmacological and antihypertensive drug therapy \u001b[0m\u001b[32m    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m(with 2 agents of different classes) initiated, and have a repeat BP evaluation in 1 month \u001b[0m\u001b[32m                    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m(S8.1.3-1,S8.1.3-2).|\u001b[0m\u001b[32m                                                                                          \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|I|B-R|For adults with a very high average BP (e.g., SBP ≥180 mm Hg or DBP ≥110 mm Hg), evaluation followed by \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mprompt antihypertensive drug treatment is recommended (S8.1.3-1,S8.1.3-2).|\u001b[0m\u001b[32m                                    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|IIa|C-EO|For adults with a normal BP, repeat evaluation every year is reasonable.|\u001b[0m\u001b[32m                            \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# Synopsis\u001b[0m\u001b[32m                                                                                                     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mAn important component of BP management in hypertensive patients is follow-up. Different periods of time for \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mfollow-up are recommended depending on the stage of hypertension, the presence or absence of target organ \u001b[0m\u001b[32m     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mdamage, treatment with antihypertensive medications, and the level of BP control. Recommendations for follow-up\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mare summarized in Figure 4.\u001b[0m\u001b[32m                                                                                    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# Recommendation-Specific Supportive Text\u001b[0m\u001b[32m                                                                      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m1. Nonpharmacological therapy (see Section 6.2) is the preferred therapy for adults with elevated BP and an \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mappropriate first-line therapy for adults with stage 1 hypertension who have an estimated 10-year ASCVD risk of\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m<10%. Adherence to and impact of non-pharmacological therapy should be assessed within 3 to 6 months.\u001b[0m\u001b[32m          \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m2. Nonpharmacological therapy can help reduce BP in patients with stage 1 hypertension with an estimated \u001b[0m\u001b[32m      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m10-year ASCVD risk of ≥10% and should be used in addition to pharmacological therapy as first-line therapy in \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32msuch patients (see Section 6.2).\u001b[0m\u001b[32m                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m3. Prompt evaluation and treatment of patients with stage 2 hypertension with a combination of drug and \u001b[0m\u001b[32m       \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mnon-pharmacological therapy are important because of the elevated risk of CVD\u001b[0m\u001b[32m                                  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m\"first-line\" medication choices|\u001b[0m\u001b[32m                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|ACE inhibitor intolerant| |\u001b[0m\u001b[32m                                                                                   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|Yes|ARB *|\u001b[0m\u001b[32m                                                                                                    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|No|ACF inhibitor|\u001b[0m\u001b[32m                                                                                             \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mColors correspond to Class of Recommendation in Table 1. *CKD stage 3 or higher or stage 1 or 2 with \u001b[0m\u001b[32m          \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32malbuminuria ≥300 mg/d or ≥300 mg/g creatinine. ACE indicates angiotensin-converting enzyme; ARB, angiotensin \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mreceptor blocker; BP blood pressure; and CKD, chronic kidney disease.\u001b[0m\u001b[32m                                          \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mAn ACE inhibitor (or an ARB, in case of ACE inhibitor intolerance) is a preferred drug for treatment of \u001b[0m\u001b[32m       \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mhypertension if albuminuria (≥300 mg/day or ≥300 mg/g creatinine by first morning void) is present, although \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mthe evidence is mixed (S9.3-10,S9.3-11) (Figure 6). In the course of reducing intraglomerular pressure and \u001b[0m\u001b[32m    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mthereby reducing albuminuria, serum creatinine may increase up to 30% because of concurrent reduction in GFR \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m(S9.3-32). Further GFR decline should be investigated and may be related to other factors, including volume \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mcontraction, use of nephrotoxic agents, or renovascular disease (S9.3-33). The combination of an ACE inhibitor \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mand an ARB should be avoided because of reported harms demonstrated in several large cardiology trials \u001b[0m\u001b[32m        \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m(S9.3-34,S9.3-35) and in 1 diabetic nephropathy trial (S9.3-36). Because of the greater risk of hyperkalemia \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mand hypotension and lack of...\u001b[0m\u001b[32m                                                                                 \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# Whelton et al.\u001b[0m\u001b[32m                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8\u001b[0m\u001b[32m                                                                    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# 2017 High Blood Pressure Clinical Practice Guideline\u001b[0m\u001b[32m                                                         \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# M A Y  1 5 , 2 0 1 8 : e 1 2 7 – 2 4 8\u001b[0m\u001b[32m                                                                       \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# 9.1. Stable Ischemic Heart Disease\u001b[0m\u001b[32m                                                                           \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# Recommendations for Treatment of Hypertension in Patients With Stable Ischemic Heart Disease (SIHD)\u001b[0m\u001b[32m          \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mReferences that support recommendations are summarized in Online Data Supplements 30-32.\u001b[0m\u001b[32m                       \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|COR|LOE|RECOMMENDATIONS|\u001b[0m\u001b[32m                                                                                      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|---|---|---|\u001b[0m\u001b[32m                                                                                                  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|SBP: B-R|I|1. In adults with SIHD and hypertension, a BP target of less than 130/80 mm Hg is recommended \u001b[0m\u001b[32m     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m(S9.1-1—S9.1-5).|\u001b[0m\u001b[32m                                                                                              \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|DBP: C-EO| | |\u001b[0m\u001b[32m                                                                                                \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|SBP: B-R|I|2. Adults with SIHD and hypertension (BP ≥130/80 mm Hg) should be treated with medications (e.g., \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mGDMT beta blockers, ACE inhibitors, or ARBs) for compelling indications (e.g., previous MI, stable angina) as \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mfirst-line therapy, with the addition of other drugs (e.g., dihydropyridine CCBs, thiazide diuretics, and/or \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mmineralocorticoid receptor antagonists) as needed to further control hypertension (S9.1-6) (S9.1-7—S9.1-10).|\u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m| |B-NR|3. In adults with SIHD with angina and persistent uncontrolled hypertension, the addition of \u001b[0m\u001b[32m          \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mdihydropyridine CCBs to GDMT (S9.1-6) beta blockers is recommended (S9.1-8,S9.1-11,S9.1-12).|\u001b[0m\u001b[32m                  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m| |IIa|4. In adults who have had a MI or acute coronary syndrome, it is reasonable to continue GDMT (S9.1-6) \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mbeta blockers beyond 3 years as long-term therapy for hypertension (S9.1-13,S9.1-14).|\u001b[0m\u001b[32m                         \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m| |IIb|5. Beta blockers and/or CCBs might be considered to control hypertension in patients with CAD (without \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mHFrEF) who had an MI more than 3 years ago and have angina.|\u001b[0m\u001b[32m                                                   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# Synopsis\u001b[0m\u001b[32m                                                                                                     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mHypertension is a major risk factor for ischemic heart disease. Numerous RCTs have demonstrated the benefits of\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mantihypertensive drug therapy in reducing the risk of ischemic heart disease. The following recommendations \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mapply only to management of hypertension in patients with SIHD without HF. See Section 9.2 for recommendations \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mfor the treatment of patients with SIHD and HF.\u001b[0m\u001b[32m                                                                \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mFigure 5 is an algorithm on management of hypertension in patients with SIHD.\u001b[0m\u001b[32m                                  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# Recommendation-Specific Supportive Text\u001b[0m\u001b[32m                                                                      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m1. In patients with increased cardiovascular risk, reduction of SBP to <130/80 mm Hg has been shown to reduce \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mCVD complications by 25% and all-cause mortality by 27% (S9.1-1).\u001b[0m\u001b[32m                                              \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m2. After 5 years of randomized therapy in high-CVD-risk patients, ramipril produced a 22% reduction in MI, \u001b[0m\u001b[32m    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mstroke, or CVD compared with placebo (S9.1-10). No added benefit on CVD outcomes was seen when compared with \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mCCBs and diuretics (S9.1-15,S9.1-16). After 4.2 years of randomized therapy in patients with SIHD, perindopril \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mreduced CVD death, MI, or cardiac arrest by 20% compared with placebo (S9.1-7). Beta blockers are effective \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mdrugs for preventing angina pectoris, improving exercise time until the onset of angina pectoris, reducing \u001b[0m\u001b[32m    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mexercise-induced ischemic ST-segment depression, and preventing coronary events (S9.1-8,S9.1-17—S9.1-22).\u001b[0m\u001b[32m      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# F I G U R E 5 Management of Hypertension in Patients With SIHD\u001b[0m\u001b[32m                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mHypertension With SIHD\u001b[0m\u001b[32m                                                                                         \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mReduce BP to <130/80 mm Hg with GDMT beta blockers, ACE inhibitor, or ARBs (Class I)\u001b[0m\u001b[32m                           \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mBP goal not met\u001b[0m\u001b[32m                                                                                                \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mAngina pectoris\u001b[0m\u001b[32m                                                                                                \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mNo\u001b[0m\u001b[32m                                                                                                             \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mAdd dihydropyridine CCBs if needed (Class I)\u001b[0m\u001b[32m                                                                   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mAdd dihydropyridine CCBs; thiazide-type\u001b[0m\u001b[32m                                                                        \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╭──────────────────────────────────────────────────</span> Step Start <span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">───────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">│ **Step 2**: Starting step 2                                                                                     │</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;36m╭─\u001b[0m\u001b[1;36m─────────────────────────────────────────────────\u001b[0m Step Start \u001b[1;36m──────────────────────────────────────────────────\u001b[0m\u001b[1;36m─╮\u001b[0m\n",
       "\u001b[1;36m│\u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m**Step 2**: Starting step 2\u001b[0m\u001b[1;36m                                                                                    \u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m│\u001b[0m\n",
       "\u001b[1;36m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╭───────────────────────────────────────────────</span> Current Messages <span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Messages before API call:                                                                                       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ [                                                                                                               │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   {                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"role\": \"system\",                                                                                           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"content\": \"You are a cardiology-focused AI assistant with access to three tools:\\n1) 'lookup_patient_data' │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ for querying patient records from Azure SQL.\\n2) 'search_acc_guidelines' for official ACC guidelines.\\n3)       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ 'search_bing_grounding' for real-time public information.\\n\\nYou can call these tools in any order, multiple    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ times if needed, to gather all the context.\\nStop calling tools only when you have enough information to        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ provide a final, cohesive answer.\\nThen output your final answer to the user.\"                                  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   },                                                                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   {                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"role\": \"user\",                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"content\": \"What does the ACC recommend as first-line therapy for hypertension in elderly patients?\"        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   },                                                                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   {                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"role\": \"assistant\",                                                                                        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"content\": null,                                                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"tool_calls\": [                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│       {                                                                                                         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│         \"id\": \"call_LoqOLIqpc2dATUfTY5LY3UcV\",                                                                  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│         \"type\": \"function\",                                                                                     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│         \"function\": {                                                                                           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│           \"name\": \"search_acc_guidelines\",                                                                      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│           \"arguments\": \"{\\\"query\\\":\\\"first-line therapy for hypertension in elderly patients\\\"}\"                │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│         }                                                                                                       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│       }                                                                                                         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     ]                                                                                                           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   },                                                                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   {                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"role\": \"tool\",                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"tool_call_id\": \"call_LoqOLIqpc2dATUfTY5LY3UcV\",                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"name\": \"search_acc_guidelines\",                                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"content\": \"# Whelton et al.\\n\\n# 2017 High Blood Pressure Clinical Practice Guideline\\n\\n# MAY 15, 2018:   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ e127\\u2013248\\n\\n2. The treatment of patients with hypertension without elevated risk has been systematically   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ understudied because lower-risk groups would require prolonged follow-up to have a sufficient number of         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ clinical events to provide useful information. Although there is clinical trial evidence that both drug and     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ nondrug therapy will interrupt the progressive course of hypertension (S8.1.5-6), there is no trial evidence    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ that this treatment decreases CVD morbidity and mortality. The clinical trial evidence is strongest for a       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ target BP of 140/90 mm Hg in this population. However, observational studies suggest that these individuals     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ often have a high lifetime risk and would benefit from BP control earlier in life (S8.1.5-19, S8.1.5-20).\\n\\n#  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ 8.1.6. Choice of Initial Medication\\n\\n# Recommendation for Choice of Initial Medication\\n\\nReferences that     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ support the recommendation are summarized in Online Data Supplement 27 and Systematic Review                    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Report.\\n\\n|COR|LOE|RECOMMENDATION|\\n|---|---|---|\\n|I|ASR|For initiation of antihypertensive drug therapy,     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ first-line agents include thiazide diuretics, CCBs, and ACE inhibitors or ARBs. (S8.1.6-1, S8.1.6-2)|\\n\\n#      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Synopsis\\n\\nThe overwhelming majority of persons with BP sufficiently elevated to warrant pharmacological       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ therapy may be best treated initially with 2 agents (see Section 8.1.6.1). When initiation of pharmacological   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ therapy with a single medication is appropriate, primary consideration should be given to comorbid conditions   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (e.g., HF, CKD) for which specific classes of BP-lowering medication are indicated (see Section 9) (S8.1.6-1).  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ In the largest head-to-head comparison of first-step drug therapy for hypertension (S8.1.6-3), the              │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ thiazide-type diuretic chlorthalidone was superior to the CCB amlodipine and the ACE inhibitor lisinopril in    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ preventing HF, a BP-related outcome of increasing importance in the growing population of older persons with    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ hypertension (S8.1.6-4\\u2014S8.1.6-7). Additionally, ACE inhibitors were less effective than thiazide diuretics │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ and CCBs in lowering BP and in prevention of stroke. For black patients, ACE inhibitors were also notably less  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ effective than CCBs in preventing HF (S8.1.6-8) and in the prevention of stroke (S8.1.6-9) (see Section 10.1).  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ ARBs may be better tolerated than ACE inhibitors in black patients, with less cough and angioedema, but         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ according to the limited available experience they offer no proven advantage over ACE inhibitors in preventing  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ stroke or CVD in this population, making thiazide diuretics (especially chlorthalidone) or CCBs the best        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ initial choice for single-drug therapy. For stroke, in the general population, beta blockers were less          │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ effective than CCBs (36% lower risk) and thiazide diuretics (30% lower risk). CCBs have been shown to be as     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ effective as diuretics for reducing all CVD events other than HF, and CCBs are a good alternative choice for    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ initial therapy when thiazide diuretics are not tolerated. Alpha blockers are not used as first-line therapy    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ for hypertension because they are less effective for prevention of CVD than other first-step agents, such as    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ thiazide diuretics (S8.1.6-3, S8.1.6-10).\\n\\n# Recommendation-Specific Supportive Text\\n\\n1. The overall goal   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ of treatment should be reduction in BP, in the context of underlying CVD risk. Five drug classes have been      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ shown, in high-quality RCTs, to prevent CVD as compared with placebo (diuretics, ACE inhibitors, ARBs, CCBs,    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ and beta blockers) (S8.1.6-11, S8.1.6-12). In head-to-head comparisons of first-step therapy, different drug    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ classes have been reported to provide somewhat divergent capacity to prevent specific CVD events.               │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Interpretation of meta-analyses comparing agents from different drug classes is challenging because the         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ relevant RCTs were conducted in different time periods, during which concurrent antihypertensive therapy was    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ less or more common, and the efficacy of agents from certain drug classes may have\\n# J A C C V O L . 71, N O . │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ 1 9, 2 0 1 8\\n\\n# Whelton et al. e169\\n\\n# M A Y 1 5, 2 0 1 8 : e 1 2 7 \\u2013 2 4 8\\n\\n# 2017 High Blood       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Pressure Clinical Practice Guideline\\n\\nsignificantly better than CCBs for prevention of HF. There were some    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ other nonsignificant differences between diuretics, ACE inhibitors, ARBs, and CCBs, but the general pattern was │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ for similarity in effect. As indicated in Section 8.1.6.1, most adults with hypertension require &gt;1 drug to     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ control their BP. As recommended in Section 10.1, for black adults with hypertension (without HF or CKD),       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ initial antihypertensive treatment should include a thiazide diuretic or CCB.\\n\\n# 8.1.6.1. Choice of Initial   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Monotherapy Versus Initial Combination Drug                                                                     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Therapy\\n\\n|COR|LOE|RECOMMENDATIONS|\\n|---|---|---|\\n|I|C-EO|Initiation of antihypertensive drug therapy with 2 │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ first-line agents of different classes, either as separate agents or in a fixed-dose combination, is            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ recommended in adults with stage 2 hypertension and an average BP more than 20/10 mm Hg above their BP          │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ target.|\\n|IIa|C-EO|Initiation of antihypertensive drug therapy with a single antihypertensive drug is          │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ reasonable in adults with stage 1 hypertension and BP goal &lt;130/80 mm Hg with dosage titration and sequential   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ addition of other agents to achieve the BP target.|\\n\\n*Fixed-dose combination antihypertensive medications are │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ listed in Online Data Supplement D.\\n\\n# Synopsis\\n\\nSystematic review of the evidence comparing the initiation │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ of antihypertensive treatment with monotherapy and sequential (stepped-care) titration of additional agents     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ versus initiation of treatment with combination therapy (including fixed-dose combinations) did not identify    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ any RCTs meeting the systematic review questions posed in the PICOTS format (P\\u00bcpopulation,                 │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ I\\u00bcintervention, C\\u00bccomparator, O\\u00bcoutcome, T\\u00bctiming, S\\u00bcsetting). However, in both ACCORD │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ and SPRINT, 2-drug therapy was recommended for most participants in the intensive- but not standard-therapy     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ groups.\\n\\n# Recommendation-Specific Supportive Text\\n\\n1. Because most patients with hypertension require      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ multiple agents for control of their BP and those with higher BPs are at greater risk, more rapid titration of  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ antihypertensive medications began to be recommended in patients with BP &gt;20/10 mm Hg above their target,       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ beginning with the JNC 7 report (S8.1.6.1-1). In these patients, initiation of antihypertensive therapy with 2  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ agents is recommended. Evidence favoring this approach comes mostly from studies using fixed-dose combination   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ products showing greater BP lowering with fixed-dose combination agents than with single agents, as well as     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ better adherence to therapy (S8.1.6.1-2,S8.1.6.1-3). The safety and efficacy of this strategy have been         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ demonstrated in adults to reduce BPs to &lt;140/90 mm Hg though not compared with other strategies                 │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (S8.1.6.1-4\\u2014S8.1.6.1-6). In general, this approach is reasonable in older adults, those at high CVD risk,  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ or those who have a history of hypotension or drug-associated side effects. However, caution is advised in      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ initiating antihypertensive pharmacotherapy with 2 drugs in older patients because hypotension or orthostatic   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ hypotension may develop in some patients; BP should be carefully monitored.\\n\\n2. The stepped-care approach     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ defined by the initiation of antihypertensive drug therapy with a single agent followed by the sequential       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ titration of the dose and addition of other agents has been the recommended treatment strategy since the first  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ report of the National High Blood Pressure Education Program (S8.1.6.1-7). This approach is also reasonable in  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ older adults or those at risk or who have a history of hypotension or drug-associated side effects. This        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ strategy has been used successfully in nearly all hypertension treatment trials but has not been formally       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ tested against other antihypertensive drug treatment strategies for effectiveness in achieving BP control or in │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ preventing adverse outcomes.\\n\\n# 8.2. Achieving BP Control in Individual Patients\\n\\nRecommendations for       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ lifestyle modifications and drug selection are specified in\\n# JACC VOL. 79, NO. 17, 2022\\n\\n# Heidenreich et   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ al e329\\n\\n# MAY 3, 2022: e263 \\u2013 e421\\n\\n# 2022 AHA/ACC/HFSA Heart Failure Guideline\\n\\nExtrapolated from  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ those for treatment of patients with hypertension in general (26). However, the optimal blood pressure goal and │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ antihypertensive regimens are not known for patients with HFpEF. RAAS antagonists including ACEi, ARB, MRA, and │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ possibly ARNi, could be first-line agents given experience with their use in HFpEF trials (8,10,16,20,27,28).   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Beta blockers may be used to treat hypertension in patients with a history of MI (27), symptomatic CAD, or AF   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ with rapid ventricular response. These effects need to be balanced with the potential contribution of           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ chronotropic incompetence to exercise intolerance in some patients (29).\\n\\n# 1.                                │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ EMPEROR-Preserved\\n\\n(Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Preserved         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Ejection Fraction) showed a significant benefit of the SGLT2i, empagliflozin, in symptomatic patients with HF   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ with LVEF &gt;40% and elevated natriuretic peptides (30). The 21% reduction in the primary composite endpoint of   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ time to HF hospitalization or cardiovascular death was driven mostly by a significant 29% reduction in time to  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ HF hospitalization (nonsignificant lower cardiovascular death [HR, 0.91; 95% CI, 0.76-1.0]), with no benefit on │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ all-cause mortality. Empagliflozin also resulted in a significant reduction in total HF hospitalizations,       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ decrease in the slope of the eGFR decline, and a modest improvement in QOL at 52 weeks. Of note, the benefit    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ was similar irrespective of the presence or absence of diabetes at baseline. Although the benefit in the        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ primary endpoint did not have a significant interaction by LVEF subgroups (&lt;50%, 50%\\u2013&lt;60%, and &gt;60%) (30), │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ in a subgroup analysis by EF, there was a signal for lower benefit on the primary composite endpoint, first and │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ recurrent HF hospitalizations at higher LVEFs &gt;62.5% (31).\\n\\n# 2. Atrial Fibrillation Management\\n\\nLarge,     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ randomized clinical trial data are unavailable to specifically guide therapy in patients with HFpEF and AF.     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Currently, the comprehensive care of AF can be extrapolated from the clinical practice guidelines for AF, with  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ individualization of strategies for rate or rhythm control in patients with HFpEF (see also Section 10.2,       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ \\u201cManagement of Atrial Fibrillation (AF) in HF,\\u201d for HF specific recommendations for AF). Although     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ beta blockers and nondihydropyridine calcium channel blockers are often considered as first-line agents for     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ heart rate control in patients with HFpEF, a recent smaller open-label trial, RATE-AF in elderly patients with  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ AF and symptoms of HF (most with preserved LVEF), compared the use of the beta blocker, bisoprolol, to digoxin  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (32). At 6 months, the primary endpoint of QOL was similar between the 2 groups. However, several secondary QOL │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ endpoints, functional capacity, and reduction in NT-proBNP favored digoxin at 12 months. There was a similar    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ heart rate reduction in both groups. Of note, more adverse events such as higher rates of dizziness, lethargy,  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ and hypotension occurred with beta blockers than digoxin. The comprehensive care of AF is beyond the scope of   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ these guidelines. AF-specific care recommendations can be found in separate ACC/AHA clinical practice           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ guidelines (33,34).\\n\\n# 3. MRAs and Diastolic Function\\n\\nMRAs improve diastolic function in patients with     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ HFpEF (35). The TOPCAT trial investigated the effects of spironolactone in patients with HFpEF. The small       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ reduction (HR, 0.89) in the composite of death, aborted cardiac death, and HF hospitalization was not           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ statistically significant, although HF hospitalization was reduced (HR, 0.83); adverse effects of hyperkalemia  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ and increasing creatinine levels were more common in the treatment group (5). A post hoc analysis (6) showed    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ efficacy in the Americas (HR 0.83) but not in Russia-Georgia (HR 1.10). A sample of the Russia-Georgia          │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ population in the active treatment arm had non-detectable levels of a spironolactone metabolite. Post hoc       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ analyses have limitations, but they suggest a possibility of benefit in appropriately selected patients with    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ symptomatic HFpEF\\ntherapy should be assessed within 3 to 6 months.\\n2. Nonpharmacological therapy can help     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ reduce BP in patients with stage 1 hypertension with an estimated 10-year ASCVD risk of \\u226510% and should be │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ used in addition to pharmacological therapy as first-line therapy in such patients (see Section 6.2).\\n3.       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Prompt evaluation and treatment of patients with stage 2 hypertension with a combination of drug and            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ non-pharmacological therapy are important because of the elevated risk of CVD events in this subgroup,          │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ especially those with multiple ASCVD risk factors or target organ damage (S8.1.3-1,S8.1.3-2).\\n4. Prompt        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ management of very high BP is important to reduce the risk of target organ damage (see Section 11.2). The       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ rapidity of the treatment needed is dependent on the patient\\u2019s clinical presentation (presence of new or   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ worsening target organ damage) and presence or absence of CVD complications, but treatment should be initiated  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ within at least 1 week.\\n# J A C C V O L . 74, N O . 1 0 , 2 0 1 9\\n\\n# 2019 ACC/AHA Guideline on the Primary   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Prevention of Cardiovascular Disease\\n\\n1. Adults who are 40 to 75 years of age and are being evaluated for     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ cardiovascular disease prevention should undergo 10-year atherosclerotic cardiovascular disease (ASCVD) risk    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ estimation and have a clinician\\u2013patient risk discussion before starting on pharmacological therapy, such   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ as antihypertensive therapy, a statin, or aspirin. In addition, assessing for other risk-enhancing factors can  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ help guide decisions about preventive interventions in select individuals, as can coronary artery calcium       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ scanning.\\n2. All adults should consume a healthy diet that emphasizes the intake of vegetables, fruits, nuts,  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ whole grains, lean vegetable or animal protein, and fish and minimizes the intake of trans fats, red meat and   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ processed red meats, refined carbohydrates, and sweetened beverages. For adults with overweight and obesity,    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ counseling and caloric restriction are recommended for achieving and maintaining weight loss.\\n3. Adults should │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ engage in at least 150 minutes per week of accumulated moderate-intensity physical activity or 75 minutes per   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ week of vigorous-intensity physical activity.\\n4. For adults with type 2 diabetes mellitus, lifestyle changes,  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ such as improving dietary habits and achieving exercise recommendations, are crucial. If medication is          │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ indicated, metformin is first-line therapy, followed by consideration of a sodium-glucose cotransporter 2       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ inhibitor or a glucagon-like peptide-1 receptor agonist.\\n5. All adults should be assessed at every healthcare  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ visit for tobacco use, and those who use tobacco should be assisted and strongly advised to quit.\\n6. Aspirin   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ should be used infrequently in the routine primary prevention of ASCVD because of lack of net benefit.\\n7.      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Statin therapy is first-line treatment for primary prevention of ASCVD in patients with elevated low-density    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ lipoprotein cholesterol levels (\\u2265190 mg/dL), those with diabetes mellitus, who are 40 to 75 years of age,  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ and those determined to be at sufficient ASCVD risk after a clinician\\u2013patient risk discussion.\\n8.         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Nonpharmacological interventions are recommended for all adults with elevated blood pressure or hypertension.   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ For those requiring pharmacological therapy, the target blood pressure should generally be &lt;130/80 mm Hg.\\n\\n#  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ PREAMBLE\\n\\nSince 1980, the American College of Cardiology (ACC) and American Heart Association (AHA) have      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ translated scientific evidence into clinical practice guidelines with recommendations to improve cardiovascular │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ health. These guidelines, which are based on systematic methods to evaluate and classify evidence, provide a    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ foundation for the delivery of quality cardiovascular care. The ACC and AHA sponsor the development and         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ publication of clinical practice guidelines without commercial support, and members volunteer their time to the │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ writing and review efforts.\\n\\nClinical practice guidelines provide recommendations applicable to patients with │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ or at risk of developing cardiovascular disease (CVD). The focus is on medical practice in the United States,   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ but these guidelines are relevant to patients throughout the world. Although guidelines may be used to inform   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ regulatory or payer decisions, the goals are to improve quality of care and align with patients\\u2019           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ interests. Guidelines are intended to define practices meeting the needs of patients in most but not all        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ circumstances and should not replace clinical judgment.\\n\\nRecommendations for guideline-directed management    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ and therapy, which encompasses clinical evaluation, diagnostic testing, and both pharmacological and procedural │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ treatments, are effective only when adopted by both practitioners and patients. Adherence to recommendations    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ can be enhanced by shared decision-making between clinicians and patients, with patient engagement in selecting │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ interventions on the basis of individual values, preferences, and associated conditions and                     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ comorbidities.\\n\\nThe ACC/AHA Task Force on Clinical Practice Guidelines strives to ensure that the guideline   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ writing committee includes requisite expertise and is representative of the broader medical community by        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ selecting experts from a broad array of backgrounds, representing different geographic regions, sexes, races,   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ ethnicities, intellectual perspectives/biases, and scopes of clinical practice. The ACC and AHA have rigorous   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ policies and methods to ensure that documents are developed without bias or improper influence. The complete    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ policy on relationships with industry and other entities (RWI) can be found online.\\n\\nBeginning in 2017,       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ numerous modifications to the guidelines have been and continue to be implemented to make guidelines shorter    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ and enhance \\u201cuser friendliness.\\u201d Guidelines are written and presented in a modular knowledge chunk    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ format, in which each chunk includes a table of recommendations, a brief synopsis, recommendation-specific      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ supportive text and, when appropriate, flow diagrams or additional tables. Hyperlinked references are provided  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ for each modular.\\n# Whelton et al.\\n\\n# 2017 High Blood Pressure Clinical Practice Guideline\\n\\n# MAY 15,      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ 2018: e127\\u2013248\\n\\n# TABLE 19\\n\\n# Intravenous Antihypertensive Drugs for Treatment of Hypertensive         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Emergencies\\n\\n|Class|Drug(s)|Usual Dose                                                                        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Range|Comments|\\n|---|---|---|---|\\n|CCB\\u2014dihydropyridines|Nicardipine|Initial 5 mg/h, increasing every 5   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ min by 2.5 mg/h to maximum 15 mg/h.|Contraindicated in advanced aortic stenosis; no dose adjustment needed for  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ elderly.|\\n| |Clevidipine|Initial 1\\u20132 mg/h, doubling every 90 s until BP approaches target, then           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ increasing by less than double every 5\\u201310 min; maximum dose 32 mg/h; maximum duration 72                   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ h.|Contraindicated in patients with soybean, soy product, egg, and egg product allergy and in patients with     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ defective lipid metabolism (e.g., pathological hyperlipidemia, lipoid nephrosis or acute pancreatitis). Use     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ low-end dose range for elderly patients.|\\n|Vasodilators\\u2014Nitric-oxide dependent|Sodium                     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ nitroprusside|Initial 0.3\\u20130.5 mcg/kg/min; increase in increments of 0.5 mcg/kg/min to achieve BP target;   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ maximum dose 10 mcg/kg/min; duration of treatment as short as possible. For infusion rates \\u22654\\u201310      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ mcg/kg/min or duration &gt;30 min, thiosulfate can be coadministered to prevent cyanide toxicity.|Intra-arterial   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ BP monitoring recommended to prevent \\u201covershoot.\\u201d Lower dosing adjustment required for elderly.       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Tachyphylaxis common with extended use. Cyanide toxicity with prolonged use can result in irreversible          │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ neurological changes and cardiac arrest.|\\n| |Nitroglycerin|Initial 5 mcg/min; increase in increments of 5      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ mcg/min every 3\\u20135 min to a maximum of 20 mcg/min.|Use only in patients with acute coronary syndrome and/or │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ acute pulmonary edema. Do not use in volume-depleted patients.|\\n|Vasodilators\\u2014direct|Hydralazine|Initial  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ 10 mg via slow IV infusion (maximum initial dose 20 mg); repeat every 4\\u20136 h as needed.|BP begins to        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ decrease within 10\\u201330 min, and the fall lasts 2\\u20134 h. Unpredictability of response and prolonged       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ duration of action do not make hydralazine a desirable first-line agent for acute treatment in most             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ patients.|\\n|Adrenergic blockers\\u2014beta1 receptor selective antagonist|Esmolol|Loading dose 500\\u20131000    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ mcg/kg/min over 1 min followed by a 50-mcg/kg/min infusion. For additional dosing, the bolus dose is repeated   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ and the infusion increased in 50-mcg/kg/min increments as needed to a maximum of 200                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ mcg/kg/min.|Contraindicated in patients with concurrent beta-blocker therapy, bradycardia, or decompensated HF. │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Monitor for bradycardia. May worsen HF. Higher doses may block beta2 receptors and impact lung function in      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ reactive airway disease.|\\n|Adrenergic blockers\\u2014combined alpha1 and nonselective beta receptor             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ antagonist|Labetalol|Initial 0.3\\u20131.0-mg/kg dose (maximum 20 mg) slow IV injection every 10 min or          │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ 0.4\\u20131.0-mg/kg/h IV infusion up to 3 mg/kg/h. Adjust rate up to total cumulative dose of 300 mg. This dose  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ can be repeated every 4\\u20136 h.|Contraindicated in reactive airways disease or chronic obstructive pulmonary  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ disease. Especially useful in hyperadrenergic syndromes. May worsen HF and should not be given in patients with │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ second- or third-degree heart block or bradycardia.|\\n|Adrenergic blockers\\u2014nonselective alpha receptor     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ antagonist|Phentolamine|IV bolus dose 5 mg. Additional bolus doses every 10 min as needed to lower BP to        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ target.|Used in hypertensive emergencies induced by catecholamine excess (pheochromocytoma, interactions        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ between monoamine oxidase inhibitors and other drugs or food, cocaine toxicity, amphetamine overdose, or        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ clonidine withdrawal).|\\n|Dopamine-receptor1 selective agonist|Fenoldopam|Initial 0.1\\u20130.3\\n# J A C C V O L │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ . 7 1 , N O . 1 9 , 2 0 1 8\\n\\n# Whelton et al. e173\\n\\n# M A Y 1 5 , 2 0 1 8 : e 1 2 7 \\u2013 2 4 8\\n\\n# 2017  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ High Blood Pressure Clinical Practice Guideline\\n\\nCompelling indications for treatment of SIHD, these drugs    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ are recommended as a first-line therapy in the treatment of hypertension when it occurs in patients with SIHD.  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ GDMT beta blockers for SIHD that are also effective in lowering BP include carvedilol, metoprolol tartrate,     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ metoprolol succinate, nadolol, bisoprolol, propranolol, and timolol. Atenolol is not as effective as other      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ antihypertensive drugs in the treatment of hypertension (S9.1-23).\\n\\nDihydropyridine CCBs are effective        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ antianginal drugs that can lower BP and relieve angina pectoris when added to beta blockers in patients in whom │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ hypertension is present and angina pectoris persists despite beta-blocker therapy                               │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (S9.1-8,S9.1-17,S9.1-19\\u2014S9.1-22,S9.1-24,S9.1-25). GDMT beta blockers for SIHD that are also effective in   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ lowering BP include carvedilol, metoprolol tartrate, metoprolol succinate, nadolol, bisoprolol, propranolol,    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ and timolol.\\n\\nIn randomized long-term trials, use of beta blockers after MI reduced all-cause mortality by    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ 23% (S9.1-13). Given the established efficacy of beta blockers for treating hypertension and SIHD, their use    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ for treatment continuing beyond 3 years after MI is reasonable (S9.1-6,S9.1-25).\\n\\nGDMT beta blockers and CCBs │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ are effective antihypertensive and antianginal agents. CCBs include dihydropyridine and nondihydropyridine      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ agents. CCBs can be used separately or together with beta blockers beginning 3 years after MI in patients with  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ CAD who have both hypertension and angina.\\n\\n# 9.2. Heart Failure\\n\\n# Recommendation for Prevention of HF in  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Adults With Hypertension\\n\\nReferences that support the recommendation are summarized in Online Data Supplement │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ 33.\\n\\n|COR|LOE|RECOMMENDATION|\\n|---|---|---|\\n|SBP: B-R|I|In adults at increased risk of HF, the optimal BP   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ in those with hypertension should be less than 130/80 mm Hg (S9.2-1\\u2014S9.2-3).|\\n|DBP: C-EO| | |\\n\\n#        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Synopsis\\n\\nAntecedent hypertension is present in 75% of patients with chronic HF (S9.2-4). In the              │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Cardiovascular Health Study (S9.2-5) and the Health, Aging and Body Composition Study (S9.2-6), 11.2% of 4408   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ persons (53.1% women, with a mean age of 72.8 years, living in the community, and not receiving                 │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ antihypertensive drugs at baseline) developed HF over 10 years (S9.2-7). Compared with those with an average    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ SBP &lt;120 mm Hg, the adjusted incidence of HF was increased 1.6, 2.2, and 2.6 times in those with average SBPs   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ between 120 and 139 mm Hg, between 140 and 159 mm Hg, and \\u2265160 mm Hg, respectively (S9.2-7).\\n\\nNo RCTs    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ are available that compare one BP-lowering agent to another for the management of patients with HF. The         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ following recommendations for treatment of hypertension in HF are based on use of drugs that lower BP and also  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ have compelling indications for management of HF (with HFrEF or HFpEF) as recommended in current ACC/AHA        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ guidelines (S9.2-4,S9.2-8).\\n\\n# Recommendation-Specific Supportive Text\\n\\n1. In adults with hypertension (SBP │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ \\u2265130 mm Hg or DBP \\u226580 mm Hg) and a high risk of CVD, a strong recommendation for BP lowering (&lt;130 mm │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Hg) is higher than that used in SPRINT.\\n# J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8\\n\\n# Whelton et al.        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ e163\\n\\n# M A Y 1 5 , 2 0 1 8 : e 1 2 7 \\u2013 2 4 8\\n\\n# 2017 High Blood Pressure Clinical Practice            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Guideline\\n\\nrisk of CVD (S8.1.2-12,S8.1.2-13). Indirect support is also provided by evidence from trials using │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ BP-lowering medications to reduce the risk of developing higher levels of BP (S8.1.2-59\\u2014S8.1.2-61) and, in │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ one case, to achieve a reduction in LV mass (S8.1.2-62). In the HOPE-3 (Heart Outcomes Prevention Evaluation-3) │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ BP Trial, there was no evidence of short-term benefit during treatment of adults (average age 66 years) with a  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ relatively low risk of CVD (3.8% CVD event rate during 5.6 years of follow-up). However, subgroup analysis      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ suggested benefit in those with an average SBP approximately &gt;140 mm Hg (and a CVD risk of 6.5% during the 5.6  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ years of follow-up) (S8.1.2-63). We acknowledge the importance of excluding white coat hypertension before      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ initiating pharmacological therapy in hypertensive patients with low ASCVD risk. This may be accomplished (as   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ described in Section 4) by HBPM or ABPM as appropriate.\\n\\n# 8.1.3. Follow-Up After Initial BP Evaluation\\n\\n#  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Recommendations for Follow-Up After Initial BP Evaluation\\n\\nReferences that support recommendations are        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ summarized in Online Data Supplement 24.\\n\\n|COR|LOE|RECOMMENDATIONS|\\n|---|---|---|\\n|I|B-R|Adults with an     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ elevated BP or stage 1 hypertension who have an estimated 10-year ASCVD risk less than 10% should be managed    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ with nonpharmacological therapy and have a repeat BP evaluation within 3 to 6 months                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (S8.1.3-1,S8.1.3-2).|\\n|I|B-R|Adults with stage 1 hypertension who have an estimated 10-year ASCVD risk of 10%  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ or higher should be managed initially with a combination of nonpharmacological and antihypertensive drug        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ therapy and have a repeat BP evaluation in 1 month (S8.1.3-1,S8.1.3-2).|\\n|I|B-R|Adults with stage 2            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ hypertension should be evaluated by or referred to a primary care provider within 1 month of the initial        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ diagnosis, have a combination of nonpharmacological and antihypertensive drug therapy (with 2 agents of         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ different classes) initiated, and have a repeat BP evaluation in 1 month (S8.1.3-1,S8.1.3-2).|\\n|I|B-R|For      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ adults with a very high average BP (e.g., SBP \\u2265180 mm Hg or DBP \\u2265110 mm Hg), evaluation followed by   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ prompt antihypertensive drug treatment is recommended (S8.1.3-1,S8.1.3-2).|\\n|IIa|C-EO|For adults with a normal │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ BP, repeat evaluation every year is reasonable.|\\n\\n# Synopsis\\n\\nAn important component of BP management in    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ hypertensive patients is follow-up. Different periods of time for follow-up are recommended depending on the    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ stage of hypertension, the presence or absence of target organ damage, treatment with antihypertensive          │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ medications, and the level of BP control. Recommendations for follow-up are summarized in Figure 4.\\n\\n#        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Recommendation-Specific Supportive Text\\n\\n1. Nonpharmacological therapy (see Section 6.2) is the preferred     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ therapy for adults with elevated BP and an appropriate first-line therapy for adults with stage 1 hypertension  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ who have an estimated 10-year ASCVD risk of &lt;10%. Adherence to and impact of non-pharmacological therapy should │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ be assessed within 3 to 6 months.\\n2. Nonpharmacological therapy can help reduce BP in patients with stage 1    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ hypertension with an estimated 10-year ASCVD risk of \\u226510% and should be used in addition to                │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ pharmacological therapy as first-line therapy in such patients (see Section 6.2).\\n3. Prompt evaluation and     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ treatment of patients with stage 2 hypertension with a combination of drug and non-pharmacological therapy are  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ important because of the elevated risk of CVD\\n\\\"first-line\\\" medication choices|\\n|ACE inhibitor intolerant|   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ |\\n|Yes|ARB *|\\n|No|ACF inhibitor|\\n\\nColors correspond to Class of Recommendation in Table 1. *CKD stage 3 or  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ higher or stage 1 or 2 with albuminuria \\u2265300 mg/d or \\u2265300 mg/g creatinine. ACE indicates              │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BP blood pressure; and CKD, chronic kidney    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ disease.\\n\\nAn ACE inhibitor (or an ARB, in case of ACE inhibitor intolerance) is a preferred drug for          │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ treatment of hypertension if albuminuria (\\u2265300 mg/day or \\u2265300 mg/g creatinine by first morning void)  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ is present, although the evidence is mixed (S9.3-10,S9.3-11) (Figure 6). In the course of reducing              │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ intraglomerular pressure and thereby reducing albuminuria, serum creatinine may increase up to 30% because of   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ concurrent reduction in GFR (S9.3-32). Further GFR decline should be investigated and may be related to other   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ factors, including volume contraction, use of nephrotoxic agents, or renovascular disease (S9.3-33). The        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ combination of an ACE inhibitor and an ARB should be avoided because of reported harms demonstrated in several  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ large cardiology trials (S9.3-34,S9.3-35) and in 1 diabetic nephropathy trial (S9.3-36). Because of the greater │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ risk of hyperkalemia and hypotension and lack of...\\n# Whelton et al.\\n\\n# J A C C V O L . 7 1 , N O . 1 9 , 2  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ 0 1 8\\n\\n# 2017 High Blood Pressure Clinical Practice Guideline\\n\\n# M A Y  1 5 , 2 0 1 8 : e 1 2 7 \\u2013 2 4  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ 8\\n\\n# 9.1. Stable Ischemic Heart Disease\\n\\n# Recommendations for Treatment of Hypertension in Patients With   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Stable Ischemic Heart Disease (SIHD)\\n\\nReferences that support recommendations are summarized in Online Data   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Supplements 30-32.\\n\\n|COR|LOE|RECOMMENDATIONS|\\n|---|---|---|\\n|SBP: B-R|I|1. In adults with SIHD and          │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ hypertension, a BP target of less than 130/80 mm Hg is recommended (S9.1-1\\u2014S9.1-5).|\\n|DBP: C-EO| |        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ |\\n|SBP: B-R|I|2. Adults with SIHD and hypertension (BP \\u2265130/80 mm Hg) should be treated with medications  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (e.g., GDMT beta blockers, ACE inhibitors, or ARBs) for compelling indications (e.g., previous MI, stable       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ angina) as first-line therapy, with the addition of other drugs (e.g., dihydropyridine CCBs, thiazide           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ diuretics, and/or mineralocorticoid receptor antagonists) as needed to further control hypertension (S9.1-6)    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (S9.1-7\\u2014S9.1-10).|\\n| |B-NR|3. In adults with SIHD with angina and persistent uncontrolled hypertension,   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ the addition of dihydropyridine CCBs to GDMT (S9.1-6) beta blockers is recommended                              │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (S9.1-8,S9.1-11,S9.1-12).|\\n| |IIa|4. In adults who have had a MI or acute coronary syndrome, it is reasonable  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ to continue GDMT (S9.1-6) beta blockers beyond 3 years as long-term therapy for hypertension                    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (S9.1-13,S9.1-14).|\\n| |IIb|5. Beta blockers and/or CCBs might be considered to control hypertension in         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ patients with CAD (without HFrEF) who had an MI more than 3 years ago and have angina.|\\n\\n#                    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Synopsis\\n\\nHypertension is a major risk factor for ischemic heart disease. Numerous RCTs have demonstrated the │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ benefits of antihypertensive drug therapy in reducing the risk of ischemic heart disease. The following         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ recommendations apply only to management of hypertension in patients with SIHD without HF. See Section 9.2 for  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ recommendations for the treatment of patients with SIHD and HF.\\n\\nFigure 5 is an algorithm on management of    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ hypertension in patients with SIHD.\\n\\n# Recommendation-Specific Supportive Text\\n\\n1. In patients with         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ increased cardiovascular risk, reduction of SBP to &lt;130/80 mm Hg has been shown to reduce CVD complications by  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ 25% and all-cause mortality by 27% (S9.1-1).\\n2. After 5 years of randomized therapy in high-CVD-risk patients, │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ ramipril produced a 22% reduction in MI, stroke, or CVD compared with placebo (S9.1-10). No added benefit on    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ CVD outcomes was seen when compared with CCBs and diuretics (S9.1-15,S9.1-16). After 4.2 years of randomized    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ therapy in patients with SIHD, perindopril reduced CVD death, MI, or cardiac arrest by 20% compared with        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ placebo (S9.1-7). Beta blockers are effective drugs for preventing angina pectoris, improving exercise time     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ until the onset of angina pectoris, reducing exercise-induced ischemic ST-segment depression, and preventing    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ coronary events (S9.1-8,S9.1-17\\u2014S9.1-22).\\n\\n# F I G U R E 5 Management of Hypertension in Patients With   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ SIHD\\n\\nHypertension With SIHD\\n\\nReduce BP to &lt;130/80 mm Hg with GDMT beta blockers, ACE inhibitor, or ARBs    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (Class I)\\n\\nBP goal not met\\n\\nAngina pectoris\\n\\nNo\\n\\nAdd dihydropyridine CCBs if needed (Class I)\\n\\nAdd    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ dihydropyridine CCBs; thiazide-type\"                                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   }                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ ]                                                                                                               │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[2m╭─\u001b[0m\u001b[2m──────────────────────────────────────────────\u001b[0m Current Messages \u001b[2m───────────────────────────────────────────────\u001b[0m\u001b[2m─╮\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mMessages before API call:\u001b[0m\u001b[2m                                                                                      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m[\u001b[0m\u001b[2m                                                                                                              \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  {\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"role\": \"system\",\u001b[0m\u001b[2m                                                                                          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"content\": \"You are a cardiology-focused AI assistant with access to three tools:\\n1) 'lookup_patient_data'\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfor querying patient records from Azure SQL.\\n2) 'search_acc_guidelines' for official ACC guidelines.\\n3) \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m'search_bing_grounding' for real-time public information.\\n\\nYou can call these tools in any order, multiple \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtimes if needed, to gather all the context.\\nStop calling tools only when you have enough information to \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mprovide a final, cohesive answer.\\nThen output your final answer to the user.\"\u001b[0m\u001b[2m                                 \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  },\u001b[0m\u001b[2m                                                                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  {\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"role\": \"user\",\u001b[0m\u001b[2m                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"content\": \"What does the ACC recommend as first-line therapy for hypertension in elderly patients?\"\u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  },\u001b[0m\u001b[2m                                                                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  {\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"role\": \"assistant\",\u001b[0m\u001b[2m                                                                                       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"content\": null,\u001b[0m\u001b[2m                                                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"tool_calls\": [\u001b[0m\u001b[2m                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m      {\u001b[0m\u001b[2m                                                                                                        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m        \"id\": \"call_LoqOLIqpc2dATUfTY5LY3UcV\",\u001b[0m\u001b[2m                                                                 \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m        \"type\": \"function\",\u001b[0m\u001b[2m                                                                                    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m        \"function\": {\u001b[0m\u001b[2m                                                                                          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m          \"name\": \"search_acc_guidelines\",\u001b[0m\u001b[2m                                                                     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m          \"arguments\": \"{\\\"query\\\":\\\"first-line therapy for hypertension in elderly patients\\\"}\"\u001b[0m\u001b[2m               \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m        }\u001b[0m\u001b[2m                                                                                                      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m      }\u001b[0m\u001b[2m                                                                                                        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    ]\u001b[0m\u001b[2m                                                                                                          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  },\u001b[0m\u001b[2m                                                                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  {\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"role\": \"tool\",\u001b[0m\u001b[2m                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"tool_call_id\": \"call_LoqOLIqpc2dATUfTY5LY3UcV\",\u001b[0m\u001b[2m                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"name\": \"search_acc_guidelines\",\u001b[0m\u001b[2m                                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"content\": \"# Whelton et al.\\n\\n# 2017 High Blood Pressure Clinical Practice Guideline\\n\\n# MAY 15, 2018: \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2me127\\u2013248\\n\\n2. The treatment of patients with hypertension without elevated risk has been systematically \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2munderstudied because lower-risk groups would require prolonged follow-up to have a sufficient number of \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mclinical events to provide useful information. Although there is clinical trial evidence that both drug and \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mnondrug therapy will interrupt the progressive course of hypertension (S8.1.5-6), there is no trial evidence \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mthat this treatment decreases CVD morbidity and mortality. The clinical trial evidence is strongest for a \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtarget BP of 140/90 mm Hg in this population. However, observational studies suggest that these individuals \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2moften have a high lifetime risk and would benefit from BP control earlier in life (S8.1.5-19, S8.1.5-20).\\n\\n# \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m8.1.6. Choice of Initial Medication\\n\\n# Recommendation for Choice of Initial Medication\\n\\nReferences that \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2msupport the recommendation are summarized in Online Data Supplement 27 and Systematic Review \u001b[0m\u001b[2m                  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mReport.\\n\\n|COR|LOE|RECOMMENDATION|\\n|---|---|---|\\n|I|ASR|For initiation of antihypertensive drug therapy, \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfirst-line agents include thiazide diuretics, CCBs, and ACE inhibitors or ARBs. (S8.1.6-1, S8.1.6-2)|\\n\\n# \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mSynopsis\\n\\nThe overwhelming majority of persons with BP sufficiently elevated to warrant pharmacological \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtherapy may be best treated initially with 2 agents (see Section 8.1.6.1). When initiation of pharmacological \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtherapy with a single medication is appropriate, primary consideration should be given to comorbid conditions \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(e.g., HF, CKD) for which specific classes of BP-lowering medication are indicated (see Section 9) (S8.1.6-1). \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mIn the largest head-to-head comparison of first-step drug therapy for hypertension (S8.1.6-3), the \u001b[0m\u001b[2m            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mthiazide-type diuretic chlorthalidone was superior to the CCB amlodipine and the ACE inhibitor lisinopril in \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mpreventing HF, a BP-related outcome of increasing importance in the growing population of older persons with \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mhypertension (S8.1.6-4\\u2014S8.1.6-7). Additionally, ACE inhibitors were less effective than thiazide diuretics\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mand CCBs in lowering BP and in prevention of stroke. For black patients, ACE inhibitors were also notably less \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2meffective than CCBs in preventing HF (S8.1.6-8) and in the prevention of stroke (S8.1.6-9) (see Section 10.1). \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mARBs may be better tolerated than ACE inhibitors in black patients, with less cough and angioedema, but \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2maccording to the limited available experience they offer no proven advantage over ACE inhibitors in preventing \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mstroke or CVD in this population, making thiazide diuretics (especially chlorthalidone) or CCBs the best \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2minitial choice for single-drug therapy. For stroke, in the general population, beta blockers were less \u001b[0m\u001b[2m        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2meffective than CCBs (36% lower risk) and thiazide diuretics (30% lower risk). CCBs have been shown to be as \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2meffective as diuretics for reducing all CVD events other than HF, and CCBs are a good alternative choice for \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2minitial therapy when thiazide diuretics are not tolerated. Alpha blockers are not used as first-line therapy \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfor hypertension because they are less effective for prevention of CVD than other first-step agents, such as \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mthiazide diuretics (S8.1.6-3, S8.1.6-10).\\n\\n# Recommendation-Specific Supportive Text\\n\\n1. The overall goal \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mof treatment should be reduction in BP, in the context of underlying CVD risk. Five drug classes have been \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mshown, in high-quality RCTs, to prevent CVD as compared with placebo (diuretics, ACE inhibitors, ARBs, CCBs, \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mand beta blockers) (S8.1.6-11, S8.1.6-12). In head-to-head comparisons of first-step therapy, different drug \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mclasses have been reported to provide somewhat divergent capacity to prevent specific CVD events. \u001b[0m\u001b[2m             \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mInterpretation of meta-analyses comparing agents from different drug classes is challenging because the \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mrelevant RCTs were conducted in different time periods, during which concurrent antihypertensive therapy was \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mless or more common, and the efficacy of agents from certain drug classes may have\\n# J A C C V O L . 71, N O .\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m1 9, 2 0 1 8\\n\\n# Whelton et al. e169\\n\\n# M A Y 1 5, 2 0 1 8 : e 1 2 7 \\u2013 2 4 8\\n\\n# 2017 High Blood \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mPressure Clinical Practice Guideline\\n\\nsignificantly better than CCBs for prevention of HF. There were some \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mother nonsignificant differences between diuretics, ACE inhibitors, ARBs, and CCBs, but the general pattern was\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfor similarity in effect. As indicated in Section 8.1.6.1, most adults with hypertension require >1 drug to \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mcontrol their BP. As recommended in Section 10.1, for black adults with hypertension (without HF or CKD), \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2minitial antihypertensive treatment should include a thiazide diuretic or CCB.\\n\\n# 8.1.6.1. Choice of Initial \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mMonotherapy Versus Initial Combination Drug \u001b[0m\u001b[2m                                                                   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mTherapy\\n\\n|COR|LOE|RECOMMENDATIONS|\\n|---|---|---|\\n|I|C-EO|Initiation of antihypertensive drug therapy with 2\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfirst-line agents of different classes, either as separate agents or in a fixed-dose combination, is \u001b[0m\u001b[2m          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mrecommended in adults with stage 2 hypertension and an average BP more than 20/10 mm Hg above their BP \u001b[0m\u001b[2m        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtarget.|\\n|IIa|C-EO|Initiation of antihypertensive drug therapy with a single antihypertensive drug is \u001b[0m\u001b[2m        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mreasonable in adults with stage 1 hypertension and BP goal <130/80 mm Hg with dosage titration and sequential \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2maddition of other agents to achieve the BP target.|\\n\\n*Fixed-dose combination antihypertensive medications are\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mlisted in Online Data Supplement D.\\n\\n# Synopsis\\n\\nSystematic review of the evidence comparing the initiation\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mof antihypertensive treatment with monotherapy and sequential (stepped-care) titration of additional agents \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mversus initiation of treatment with combination therapy (including fixed-dose combinations) did not identify \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2many RCTs meeting the systematic review questions posed in the PICOTS format (P\\u00bcpopulation, \u001b[0m\u001b[2m               \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mI\\u00bcintervention, C\\u00bccomparator, O\\u00bcoutcome, T\\u00bctiming, S\\u00bcsetting). However, in both ACCORD\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mand SPRINT, 2-drug therapy was recommended for most participants in the intensive- but not standard-therapy \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mgroups.\\n\\n# Recommendation-Specific Supportive Text\\n\\n1. Because most patients with hypertension require \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mmultiple agents for control of their BP and those with higher BPs are at greater risk, more rapid titration of \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mantihypertensive medications began to be recommended in patients with BP >20/10 mm Hg above their target, \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mbeginning with the JNC 7 report (S8.1.6.1-1). In these patients, initiation of antihypertensive therapy with 2 \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2magents is recommended. Evidence favoring this approach comes mostly from studies using fixed-dose combination \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mproducts showing greater BP lowering with fixed-dose combination agents than with single agents, as well as \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mbetter adherence to therapy (S8.1.6.1-2,S8.1.6.1-3). The safety and efficacy of this strategy have been \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mdemonstrated in adults to reduce BPs to <140/90 mm Hg though not compared with other strategies \u001b[0m\u001b[2m               \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(S8.1.6.1-4\\u2014S8.1.6.1-6). In general, this approach is reasonable in older adults, those at high CVD risk, \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mor those who have a history of hypotension or drug-associated side effects. However, caution is advised in \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2minitiating antihypertensive pharmacotherapy with 2 drugs in older patients because hypotension or orthostatic \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mhypotension may develop in some patients; BP should be carefully monitored.\\n\\n2. The stepped-care approach \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mdefined by the initiation of antihypertensive drug therapy with a single agent followed by the sequential \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtitration of the dose and addition of other agents has been the recommended treatment strategy since the first \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mreport of the National High Blood Pressure Education Program (S8.1.6.1-7). This approach is also reasonable in \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2molder adults or those at risk or who have a history of hypotension or drug-associated side effects. This \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mstrategy has been used successfully in nearly all hypertension treatment trials but has not been formally \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtested against other antihypertensive drug treatment strategies for effectiveness in achieving BP control or in\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mpreventing adverse outcomes.\\n\\n# 8.2. Achieving BP Control in Individual Patients\\n\\nRecommendations for \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mlifestyle modifications and drug selection are specified in\\n# JACC VOL. 79, NO. 17, 2022\\n\\n# Heidenreich et \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mal e329\\n\\n# MAY 3, 2022: e263 \\u2013 e421\\n\\n# 2022 AHA/ACC/HFSA Heart Failure Guideline\\n\\nExtrapolated from \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mthose for treatment of patients with hypertension in general (26). However, the optimal blood pressure goal and\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mantihypertensive regimens are not known for patients with HFpEF. RAAS antagonists including ACEi, ARB, MRA, and\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mpossibly ARNi, could be first-line agents given experience with their use in HFpEF trials (8,10,16,20,27,28). \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mBeta blockers may be used to treat hypertension in patients with a history of MI (27), symptomatic CAD, or AF \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mwith rapid ventricular response. These effects need to be balanced with the potential contribution of \u001b[0m\u001b[2m         \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mchronotropic incompetence to exercise intolerance in some patients (29).\\n\\n# 1. \u001b[0m\u001b[2m                              \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mEMPEROR-Preserved\\n\\n(Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Preserved \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mEjection Fraction) showed a significant benefit of the SGLT2i, empagliflozin, in symptomatic patients with HF \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mwith LVEF >40% and elevated natriuretic peptides (30). The 21% reduction in the primary composite endpoint of \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtime to HF hospitalization or cardiovascular death was driven mostly by a significant 29% reduction in time to \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mHF hospitalization (nonsignificant lower cardiovascular death [HR, 0.91; 95% CI, 0.76-1.0]), with no benefit on\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mall-cause mortality. Empagliflozin also resulted in a significant reduction in total HF hospitalizations, \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mdecrease in the slope of the eGFR decline, and a modest improvement in QOL at 52 weeks. Of note, the benefit \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mwas similar irrespective of the presence or absence of diabetes at baseline. Although the benefit in the \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mprimary endpoint did not have a significant interaction by LVEF subgroups (<50%, 50%\\u2013<60%, and >60%) (30),\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2min a subgroup analysis by EF, there was a signal for lower benefit on the primary composite endpoint, first and\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mrecurrent HF hospitalizations at higher LVEFs >62.5% (31).\\n\\n# 2. Atrial Fibrillation Management\\n\\nLarge, \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mrandomized clinical trial data are unavailable to specifically guide therapy in patients with HFpEF and AF. \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mCurrently, the comprehensive care of AF can be extrapolated from the clinical practice guidelines for AF, with \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mindividualization of strategies for rate or rhythm control in patients with HFpEF (see also Section 10.2, \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m\\u201cManagement of Atrial Fibrillation (AF) in HF,\\u201d for HF specific recommendations for AF). Although \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mbeta blockers and nondihydropyridine calcium channel blockers are often considered as first-line agents for \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mheart rate control in patients with HFpEF, a recent smaller open-label trial, RATE-AF in elderly patients with \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mAF and symptoms of HF (most with preserved LVEF), compared the use of the beta blocker, bisoprolol, to digoxin \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(32). At 6 months, the primary endpoint of QOL was similar between the 2 groups. However, several secondary QOL\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mendpoints, functional capacity, and reduction in NT-proBNP favored digoxin at 12 months. There was a similar \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mheart rate reduction in both groups. Of note, more adverse events such as higher rates of dizziness, lethargy, \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mand hypotension occurred with beta blockers than digoxin. The comprehensive care of AF is beyond the scope of \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mthese guidelines. AF-specific care recommendations can be found in separate ACC/AHA clinical practice \u001b[0m\u001b[2m         \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mguidelines (33,34).\\n\\n# 3. MRAs and Diastolic Function\\n\\nMRAs improve diastolic function in patients with \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mHFpEF (35). The TOPCAT trial investigated the effects of spironolactone in patients with HFpEF. The small \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mreduction (HR, 0.89) in the composite of death, aborted cardiac death, and HF hospitalization was not \u001b[0m\u001b[2m         \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mstatistically significant, although HF hospitalization was reduced (HR, 0.83); adverse effects of hyperkalemia \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mand increasing creatinine levels were more common in the treatment group (5). A post hoc analysis (6) showed \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mefficacy in the Americas (HR 0.83) but not in Russia-Georgia (HR 1.10). A sample of the Russia-Georgia \u001b[0m\u001b[2m        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mpopulation in the active treatment arm had non-detectable levels of a spironolactone metabolite. Post hoc \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2manalyses have limitations, but they suggest a possibility of benefit in appropriately selected patients with \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2msymptomatic HFpEF\\ntherapy should be assessed within 3 to 6 months.\\n2. Nonpharmacological therapy can help \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mreduce BP in patients with stage 1 hypertension with an estimated 10-year ASCVD risk of \\u226510% and should be\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mused in addition to pharmacological therapy as first-line therapy in such patients (see Section 6.2).\\n3. \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mPrompt evaluation and treatment of patients with stage 2 hypertension with a combination of drug and \u001b[0m\u001b[2m          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mnon-pharmacological therapy are important because of the elevated risk of CVD events in this subgroup, \u001b[0m\u001b[2m        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mespecially those with multiple ASCVD risk factors or target organ damage (S8.1.3-1,S8.1.3-2).\\n4. Prompt \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mmanagement of very high BP is important to reduce the risk of target organ damage (see Section 11.2). The \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mrapidity of the treatment needed is dependent on the patient\\u2019s clinical presentation (presence of new or \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mworsening target organ damage) and presence or absence of CVD complications, but treatment should be initiated \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mwithin at least 1 week.\\n# J A C C V O L . 74, N O . 1 0 , 2 0 1 9\\n\\n# 2019 ACC/AHA Guideline on the Primary \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mPrevention of Cardiovascular Disease\\n\\n1. Adults who are 40 to 75 years of age and are being evaluated for \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mcardiovascular disease prevention should undergo 10-year atherosclerotic cardiovascular disease (ASCVD) risk \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mestimation and have a clinician\\u2013patient risk discussion before starting on pharmacological therapy, such \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mas antihypertensive therapy, a statin, or aspirin. In addition, assessing for other risk-enhancing factors can \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mhelp guide decisions about preventive interventions in select individuals, as can coronary artery calcium \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mscanning.\\n2. All adults should consume a healthy diet that emphasizes the intake of vegetables, fruits, nuts, \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mwhole grains, lean vegetable or animal protein, and fish and minimizes the intake of trans fats, red meat and \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mprocessed red meats, refined carbohydrates, and sweetened beverages. For adults with overweight and obesity, \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mcounseling and caloric restriction are recommended for achieving and maintaining weight loss.\\n3. Adults should\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mengage in at least 150 minutes per week of accumulated moderate-intensity physical activity or 75 minutes per \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mweek of vigorous-intensity physical activity.\\n4. For adults with type 2 diabetes mellitus, lifestyle changes, \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2msuch as improving dietary habits and achieving exercise recommendations, are crucial. If medication is \u001b[0m\u001b[2m        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mindicated, metformin is first-line therapy, followed by consideration of a sodium-glucose cotransporter 2 \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2minhibitor or a glucagon-like peptide-1 receptor agonist.\\n5. All adults should be assessed at every healthcare \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mvisit for tobacco use, and those who use tobacco should be assisted and strongly advised to quit.\\n6. Aspirin \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mshould be used infrequently in the routine primary prevention of ASCVD because of lack of net benefit.\\n7. \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mStatin therapy is first-line treatment for primary prevention of ASCVD in patients with elevated low-density \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mlipoprotein cholesterol levels (\\u2265190 mg/dL), those with diabetes mellitus, who are 40 to 75 years of age, \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mand those determined to be at sufficient ASCVD risk after a clinician\\u2013patient risk discussion.\\n8. \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mNonpharmacological interventions are recommended for all adults with elevated blood pressure or hypertension. \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mFor those requiring pharmacological therapy, the target blood pressure should generally be <130/80 mm Hg.\\n\\n# \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mPREAMBLE\\n\\nSince 1980, the American College of Cardiology (ACC) and American Heart Association (AHA) have \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtranslated scientific evidence into clinical practice guidelines with recommendations to improve cardiovascular\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mhealth. These guidelines, which are based on systematic methods to evaluate and classify evidence, provide a \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfoundation for the delivery of quality cardiovascular care. The ACC and AHA sponsor the development and \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mpublication of clinical practice guidelines without commercial support, and members volunteer their time to the\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mwriting and review efforts.\\n\\nClinical practice guidelines provide recommendations applicable to patients with\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mor at risk of developing cardiovascular disease (CVD). The focus is on medical practice in the United States, \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mbut these guidelines are relevant to patients throughout the world. Although guidelines may be used to inform \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mregulatory or payer decisions, the goals are to improve quality of care and align with patients\\u2019 \u001b[0m\u001b[2m         \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2minterests. Guidelines are intended to define practices meeting the needs of patients in most but not all \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mcircumstances and should not replace clinical judgment.\\n\\nRecommendations for guideline-directed management \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mand therapy, which encompasses clinical evaluation, diagnostic testing, and both pharmacological and procedural\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtreatments, are effective only when adopted by both practitioners and patients. Adherence to recommendations \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mcan be enhanced by shared decision-making between clinicians and patients, with patient engagement in selecting\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2minterventions on the basis of individual values, preferences, and associated conditions and \u001b[0m\u001b[2m                   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mcomorbidities.\\n\\nThe ACC/AHA Task Force on Clinical Practice Guidelines strives to ensure that the guideline \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mwriting committee includes requisite expertise and is representative of the broader medical community by \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mselecting experts from a broad array of backgrounds, representing different geographic regions, sexes, races, \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2methnicities, intellectual perspectives/biases, and scopes of clinical practice. The ACC and AHA have rigorous \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mpolicies and methods to ensure that documents are developed without bias or improper influence. The complete \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mpolicy on relationships with industry and other entities (RWI) can be found online.\\n\\nBeginning in 2017, \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mnumerous modifications to the guidelines have been and continue to be implemented to make guidelines shorter \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mand enhance \\u201cuser friendliness.\\u201d Guidelines are written and presented in a modular knowledge chunk \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mformat, in which each chunk includes a table of recommendations, a brief synopsis, recommendation-specific \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2msupportive text and, when appropriate, flow diagrams or additional tables. Hyperlinked references are provided \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfor each modular.\\n# Whelton et al.\\n\\n# 2017 High Blood Pressure Clinical Practice Guideline\\n\\n# MAY 15, \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m2018: e127\\u2013248\\n\\n# TABLE 19\\n\\n# Intravenous Antihypertensive Drugs for Treatment of Hypertensive \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mEmergencies\\n\\n|Class|Drug(s)|Usual Dose \u001b[0m\u001b[2m                                                                      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mRange|Comments|\\n|---|---|---|---|\\n|CCB\\u2014dihydropyridines|Nicardipine|Initial 5 mg/h, increasing every 5 \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mmin by 2.5 mg/h to maximum 15 mg/h.|Contraindicated in advanced aortic stenosis; no dose adjustment needed for \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2melderly.|\\n| |Clevidipine|Initial 1\\u20132 mg/h, doubling every 90 s until BP approaches target, then \u001b[0m\u001b[2m         \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mincreasing by less than double every 5\\u201310 min; maximum dose 32 mg/h; maximum duration 72 \u001b[0m\u001b[2m                 \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mh.|Contraindicated in patients with soybean, soy product, egg, and egg product allergy and in patients with \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mdefective lipid metabolism (e.g., pathological hyperlipidemia, lipoid nephrosis or acute pancreatitis). Use \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mlow-end dose range for elderly patients.|\\n|Vasodilators\\u2014Nitric-oxide dependent|Sodium \u001b[0m\u001b[2m                   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mnitroprusside|Initial 0.3\\u20130.5 mcg/kg/min; increase in increments of 0.5 mcg/kg/min to achieve BP target; \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mmaximum dose 10 mcg/kg/min; duration of treatment as short as possible. For infusion rates \\u22654\\u201310 \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mmcg/kg/min or duration >30 min, thiosulfate can be coadministered to prevent cyanide toxicity.|Intra-arterial \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mBP monitoring recommended to prevent \\u201covershoot.\\u201d Lower dosing adjustment required for elderly. \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mTachyphylaxis common with extended use. Cyanide toxicity with prolonged use can result in irreversible \u001b[0m\u001b[2m        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mneurological changes and cardiac arrest.|\\n| |Nitroglycerin|Initial 5 mcg/min; increase in increments of 5 \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mmcg/min every 3\\u20135 min to a maximum of 20 mcg/min.|Use only in patients with acute coronary syndrome and/or\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2macute pulmonary edema. Do not use in volume-depleted patients.|\\n|Vasodilators\\u2014direct|Hydralazine|Initial \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m10 mg via slow IV infusion (maximum initial dose 20 mg); repeat every 4\\u20136 h as needed.|BP begins to \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mdecrease within 10\\u201330 min, and the fall lasts 2\\u20134 h. Unpredictability of response and prolonged \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mduration of action do not make hydralazine a desirable first-line agent for acute treatment in most \u001b[0m\u001b[2m           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mpatients.|\\n|Adrenergic blockers\\u2014beta1 receptor selective antagonist|Esmolol|Loading dose 500\\u20131000 \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mmcg/kg/min over 1 min followed by a 50-mcg/kg/min infusion. For additional dosing, the bolus dose is repeated \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mand the infusion increased in 50-mcg/kg/min increments as needed to a maximum of 200 \u001b[0m\u001b[2m                          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mmcg/kg/min.|Contraindicated in patients with concurrent beta-blocker therapy, bradycardia, or decompensated HF.\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mMonitor for bradycardia. May worsen HF. Higher doses may block beta2 receptors and impact lung function in \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mreactive airway disease.|\\n|Adrenergic blockers\\u2014combined alpha1 and nonselective beta receptor \u001b[0m\u001b[2m           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mantagonist|Labetalol|Initial 0.3\\u20131.0-mg/kg dose (maximum 20 mg) slow IV injection every 10 min or \u001b[0m\u001b[2m        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m0.4\\u20131.0-mg/kg/h IV infusion up to 3 mg/kg/h. Adjust rate up to total cumulative dose of 300 mg. This dose \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mcan be repeated every 4\\u20136 h.|Contraindicated in reactive airways disease or chronic obstructive pulmonary \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mdisease. Especially useful in hyperadrenergic syndromes. May worsen HF and should not be given in patients with\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2msecond- or third-degree heart block or bradycardia.|\\n|Adrenergic blockers\\u2014nonselective alpha receptor \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mantagonist|Phentolamine|IV bolus dose 5 mg. Additional bolus doses every 10 min as needed to lower BP to \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtarget.|Used in hypertensive emergencies induced by catecholamine excess (pheochromocytoma, interactions \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mbetween monoamine oxidase inhibitors and other drugs or food, cocaine toxicity, amphetamine overdose, or \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mclonidine withdrawal).|\\n|Dopamine-receptor1 selective agonist|Fenoldopam|Initial 0.1\\u20130.3\\n# J A C C V O L\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m. 7 1 , N O . 1 9 , 2 0 1 8\\n\\n# Whelton et al. e173\\n\\n# M A Y 1 5 , 2 0 1 8 : e 1 2 7 \\u2013 2 4 8\\n\\n# 2017 \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mHigh Blood Pressure Clinical Practice Guideline\\n\\nCompelling indications for treatment of SIHD, these drugs \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mare recommended as a first-line therapy in the treatment of hypertension when it occurs in patients with SIHD. \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mGDMT beta blockers for SIHD that are also effective in lowering BP include carvedilol, metoprolol tartrate, \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mmetoprolol succinate, nadolol, bisoprolol, propranolol, and timolol. Atenolol is not as effective as other \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mantihypertensive drugs in the treatment of hypertension (S9.1-23).\\n\\nDihydropyridine CCBs are effective \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mantianginal drugs that can lower BP and relieve angina pectoris when added to beta blockers in patients in whom\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mhypertension is present and angina pectoris persists despite beta-blocker therapy \u001b[0m\u001b[2m                             \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(S9.1-8,S9.1-17,S9.1-19\\u2014S9.1-22,S9.1-24,S9.1-25). GDMT beta blockers for SIHD that are also effective in \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mlowering BP include carvedilol, metoprolol tartrate, metoprolol succinate, nadolol, bisoprolol, propranolol, \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mand timolol.\\n\\nIn randomized long-term trials, use of beta blockers after MI reduced all-cause mortality by \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m23% (S9.1-13). Given the established efficacy of beta blockers for treating hypertension and SIHD, their use \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfor treatment continuing beyond 3 years after MI is reasonable (S9.1-6,S9.1-25).\\n\\nGDMT beta blockers and CCBs\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mare effective antihypertensive and antianginal agents. CCBs include dihydropyridine and nondihydropyridine \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2magents. CCBs can be used separately or together with beta blockers beginning 3 years after MI in patients with \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mCAD who have both hypertension and angina.\\n\\n# 9.2. Heart Failure\\n\\n# Recommendation for Prevention of HF in \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mAdults With Hypertension\\n\\nReferences that support the recommendation are summarized in Online Data Supplement\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m33.\\n\\n|COR|LOE|RECOMMENDATION|\\n|---|---|---|\\n|SBP: B-R|I|In adults at increased risk of HF, the optimal BP \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2min those with hypertension should be less than 130/80 mm Hg (S9.2-1\\u2014S9.2-3).|\\n|DBP: C-EO| | |\\n\\n# \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mSynopsis\\n\\nAntecedent hypertension is present in 75% of patients with chronic HF (S9.2-4). In the \u001b[0m\u001b[2m            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mCardiovascular Health Study (S9.2-5) and the Health, Aging and Body Composition Study (S9.2-6), 11.2% of 4408 \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mpersons (53.1% women, with a mean age of 72.8 years, living in the community, and not receiving \u001b[0m\u001b[2m               \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mantihypertensive drugs at baseline) developed HF over 10 years (S9.2-7). Compared with those with an average \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mSBP <120 mm Hg, the adjusted incidence of HF was increased 1.6, 2.2, and 2.6 times in those with average SBPs \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mbetween 120 and 139 mm Hg, between 140 and 159 mm Hg, and \\u2265160 mm Hg, respectively (S9.2-7).\\n\\nNo RCTs \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mare available that compare one BP-lowering agent to another for the management of patients with HF. The \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfollowing recommendations for treatment of hypertension in HF are based on use of drugs that lower BP and also \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mhave compelling indications for management of HF (with HFrEF or HFpEF) as recommended in current ACC/AHA \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mguidelines (S9.2-4,S9.2-8).\\n\\n# Recommendation-Specific Supportive Text\\n\\n1. In adults with hypertension (SBP\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m\\u2265130 mm Hg or DBP \\u226580 mm Hg) and a high risk of CVD, a strong recommendation for BP lowering (<130 mm\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mHg) is higher than that used in SPRINT.\\n# J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8\\n\\n# Whelton et al. \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2me163\\n\\n# M A Y 1 5 , 2 0 1 8 : e 1 2 7 \\u2013 2 4 8\\n\\n# 2017 High Blood Pressure Clinical Practice \u001b[0m\u001b[2m          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mGuideline\\n\\nrisk of CVD (S8.1.2-12,S8.1.2-13). Indirect support is also provided by evidence from trials using\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mBP-lowering medications to reduce the risk of developing higher levels of BP (S8.1.2-59\\u2014S8.1.2-61) and, in\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mone case, to achieve a reduction in LV mass (S8.1.2-62). In the HOPE-3 (Heart Outcomes Prevention Evaluation-3)\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mBP Trial, there was no evidence of short-term benefit during treatment of adults (average age 66 years) with a \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mrelatively low risk of CVD (3.8% CVD event rate during 5.6 years of follow-up). However, subgroup analysis \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2msuggested benefit in those with an average SBP approximately >140 mm Hg (and a CVD risk of 6.5% during the 5.6 \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2myears of follow-up) (S8.1.2-63). We acknowledge the importance of excluding white coat hypertension before \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2minitiating pharmacological therapy in hypertensive patients with low ASCVD risk. This may be accomplished (as \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mdescribed in Section 4) by HBPM or ABPM as appropriate.\\n\\n# 8.1.3. Follow-Up After Initial BP Evaluation\\n\\n# \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mRecommendations for Follow-Up After Initial BP Evaluation\\n\\nReferences that support recommendations are \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2msummarized in Online Data Supplement 24.\\n\\n|COR|LOE|RECOMMENDATIONS|\\n|---|---|---|\\n|I|B-R|Adults with an \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2melevated BP or stage 1 hypertension who have an estimated 10-year ASCVD risk less than 10% should be managed \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mwith nonpharmacological therapy and have a repeat BP evaluation within 3 to 6 months \u001b[0m\u001b[2m                          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(S8.1.3-1,S8.1.3-2).|\\n|I|B-R|Adults with stage 1 hypertension who have an estimated 10-year ASCVD risk of 10% \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mor higher should be managed initially with a combination of nonpharmacological and antihypertensive drug \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtherapy and have a repeat BP evaluation in 1 month (S8.1.3-1,S8.1.3-2).|\\n|I|B-R|Adults with stage 2 \u001b[0m\u001b[2m          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mhypertension should be evaluated by or referred to a primary care provider within 1 month of the initial \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mdiagnosis, have a combination of nonpharmacological and antihypertensive drug therapy (with 2 agents of \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mdifferent classes) initiated, and have a repeat BP evaluation in 1 month (S8.1.3-1,S8.1.3-2).|\\n|I|B-R|For \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2madults with a very high average BP (e.g., SBP \\u2265180 mm Hg or DBP \\u2265110 mm Hg), evaluation followed by \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mprompt antihypertensive drug treatment is recommended (S8.1.3-1,S8.1.3-2).|\\n|IIa|C-EO|For adults with a normal\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mBP, repeat evaluation every year is reasonable.|\\n\\n# Synopsis\\n\\nAn important component of BP management in \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mhypertensive patients is follow-up. Different periods of time for follow-up are recommended depending on the \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mstage of hypertension, the presence or absence of target organ damage, treatment with antihypertensive \u001b[0m\u001b[2m        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mmedications, and the level of BP control. Recommendations for follow-up are summarized in Figure 4.\\n\\n# \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mRecommendation-Specific Supportive Text\\n\\n1. Nonpharmacological therapy (see Section 6.2) is the preferred \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtherapy for adults with elevated BP and an appropriate first-line therapy for adults with stage 1 hypertension \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mwho have an estimated 10-year ASCVD risk of <10%. Adherence to and impact of non-pharmacological therapy should\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mbe assessed within 3 to 6 months.\\n2. Nonpharmacological therapy can help reduce BP in patients with stage 1 \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mhypertension with an estimated 10-year ASCVD risk of \\u226510% and should be used in addition to \u001b[0m\u001b[2m              \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mpharmacological therapy as first-line therapy in such patients (see Section 6.2).\\n3. Prompt evaluation and \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtreatment of patients with stage 2 hypertension with a combination of drug and non-pharmacological therapy are \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mimportant because of the elevated risk of CVD\\n\\\"first-line\\\" medication choices|\\n|ACE inhibitor intolerant| \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m|\\n|Yes|ARB *|\\n|No|ACF inhibitor|\\n\\nColors correspond to Class of Recommendation in Table 1. *CKD stage 3 or \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mhigher or stage 1 or 2 with albuminuria \\u2265300 mg/d or \\u2265300 mg/g creatinine. ACE indicates \u001b[0m\u001b[2m            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mangiotensin-converting enzyme; ARB, angiotensin receptor blocker; BP blood pressure; and CKD, chronic kidney \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mdisease.\\n\\nAn ACE inhibitor (or an ARB, in case of ACE inhibitor intolerance) is a preferred drug for \u001b[0m\u001b[2m        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtreatment of hypertension if albuminuria (\\u2265300 mg/day or \\u2265300 mg/g creatinine by first morning void) \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mis present, although the evidence is mixed (S9.3-10,S9.3-11) (Figure 6). In the course of reducing \u001b[0m\u001b[2m            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mintraglomerular pressure and thereby reducing albuminuria, serum creatinine may increase up to 30% because of \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mconcurrent reduction in GFR (S9.3-32). Further GFR decline should be investigated and may be related to other \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfactors, including volume contraction, use of nephrotoxic agents, or renovascular disease (S9.3-33). The \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mcombination of an ACE inhibitor and an ARB should be avoided because of reported harms demonstrated in several \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mlarge cardiology trials (S9.3-34,S9.3-35) and in 1 diabetic nephropathy trial (S9.3-36). Because of the greater\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mrisk of hyperkalemia and hypotension and lack of...\\n# Whelton et al.\\n\\n# J A C C V O L . 7 1 , N O . 1 9 , 2 \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m0 1 8\\n\\n# 2017 High Blood Pressure Clinical Practice Guideline\\n\\n# M A Y  1 5 , 2 0 1 8 : e 1 2 7 \\u2013 2 4 \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m8\\n\\n# 9.1. Stable Ischemic Heart Disease\\n\\n# Recommendations for Treatment of Hypertension in Patients With \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mStable Ischemic Heart Disease (SIHD)\\n\\nReferences that support recommendations are summarized in Online Data \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mSupplements 30-32.\\n\\n|COR|LOE|RECOMMENDATIONS|\\n|---|---|---|\\n|SBP: B-R|I|1. In adults with SIHD and \u001b[0m\u001b[2m        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mhypertension, a BP target of less than 130/80 mm Hg is recommended (S9.1-1\\u2014S9.1-5).|\\n|DBP: C-EO| | \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m|\\n|SBP: B-R|I|2. Adults with SIHD and hypertension (BP \\u2265130/80 mm Hg) should be treated with medications \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(e.g., GDMT beta blockers, ACE inhibitors, or ARBs) for compelling indications (e.g., previous MI, stable \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mangina) as first-line therapy, with the addition of other drugs (e.g., dihydropyridine CCBs, thiazide \u001b[0m\u001b[2m         \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mdiuretics, and/or mineralocorticoid receptor antagonists) as needed to further control hypertension (S9.1-6) \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(S9.1-7\\u2014S9.1-10).|\\n| |B-NR|3. In adults with SIHD with angina and persistent uncontrolled hypertension, \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mthe addition of dihydropyridine CCBs to GDMT (S9.1-6) beta blockers is recommended \u001b[0m\u001b[2m                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(S9.1-8,S9.1-11,S9.1-12).|\\n| |IIa|4. In adults who have had a MI or acute coronary syndrome, it is reasonable \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mto continue GDMT (S9.1-6) beta blockers beyond 3 years as long-term therapy for hypertension \u001b[0m\u001b[2m                  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(S9.1-13,S9.1-14).|\\n| |IIb|5. Beta blockers and/or CCBs might be considered to control hypertension in \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mpatients with CAD (without HFrEF) who had an MI more than 3 years ago and have angina.|\\n\\n# \u001b[0m\u001b[2m                  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mSynopsis\\n\\nHypertension is a major risk factor for ischemic heart disease. Numerous RCTs have demonstrated the\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mbenefits of antihypertensive drug therapy in reducing the risk of ischemic heart disease. The following \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mrecommendations apply only to management of hypertension in patients with SIHD without HF. See Section 9.2 for \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mrecommendations for the treatment of patients with SIHD and HF.\\n\\nFigure 5 is an algorithm on management of \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mhypertension in patients with SIHD.\\n\\n# Recommendation-Specific Supportive Text\\n\\n1. In patients with \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mincreased cardiovascular risk, reduction of SBP to <130/80 mm Hg has been shown to reduce CVD complications by \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m25% and all-cause mortality by 27% (S9.1-1).\\n2. After 5 years of randomized therapy in high-CVD-risk patients,\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mramipril produced a 22% reduction in MI, stroke, or CVD compared with placebo (S9.1-10). No added benefit on \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mCVD outcomes was seen when compared with CCBs and diuretics (S9.1-15,S9.1-16). After 4.2 years of randomized \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtherapy in patients with SIHD, perindopril reduced CVD death, MI, or cardiac arrest by 20% compared with \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mplacebo (S9.1-7). Beta blockers are effective drugs for preventing angina pectoris, improving exercise time \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2muntil the onset of angina pectoris, reducing exercise-induced ischemic ST-segment depression, and preventing \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mcoronary events (S9.1-8,S9.1-17\\u2014S9.1-22).\\n\\n# F I G U R E 5 Management of Hypertension in Patients With \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mSIHD\\n\\nHypertension With SIHD\\n\\nReduce BP to <130/80 mm Hg with GDMT beta blockers, ACE inhibitor, or ARBs \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(Class I)\\n\\nBP goal not met\\n\\nAngina pectoris\\n\\nNo\\n\\nAdd dihydropyridine CCBs if needed (Class I)\\n\\nAdd \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mdihydropyridine CCBs; thiazide-type\"\u001b[0m\u001b[2m                                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  }\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m]\u001b[0m\u001b[2m                                                                                                              \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╭─────────────────────────────────────────────────</span> Raw Response <span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Raw response message:                                                                                           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ ChatCompletionMessage(content='The American College of Cardiology (ACC) recommends the following first-line     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ therapies for hypertension in elderly patients:\\n\\n1. **Thiazide Diuretics**: These are often preferred due to  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ their effectiveness in reducing blood pressure (BP) and preventing heart failure (HF). Chlorthalidone, a        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ thiazide-type diuretic, has shown superior outcomes in preventing HF compared to other classes.\\n  \\n2.         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ **Calcium Channel Blockers (CCBs)**: Another effective option, particularly when thiazides are not tolerated.   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ They provide significant BP control and cardiovascular event prevention.\\n\\n3. **Angiotensin-Converting Enzyme  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (ACE) Inhibitors** or **Angiotensin Receptor Blockers (ARBs)**: These are also recommended, especially in       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ patients with specific comorbid conditions like heart failure or chronic kidney disease as they offer           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ additional therapeutic benefits.\\n\\nThe choice of initial therapy may depend on individual comorbidities and    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ tolerance, and sometimes the initiation of treatment with two agents may be needed, especially in cases of      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ stage 2 hypertension. It is essential to monitor patients closely, particularly older adults, as they might be  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ susceptible to hypotension or orthostatic changes.\\n\\nIn summary, the ACC guideline highlights thiazide         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ diuretics, CCBs, and ACE inhibitors/ARBs as critical first-line options for managing hypertension in elderly    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ patients.', refusal=None, role='assistant', audio=None, function_call=None, tool_calls=None)                    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[2m╭─\u001b[0m\u001b[2m────────────────────────────────────────────────\u001b[0m Raw Response \u001b[2m─────────────────────────────────────────────────\u001b[0m\u001b[2m─╮\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mRaw response message:\u001b[0m\u001b[2m                                                                                          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mChatCompletionMessage(content='The American College of Cardiology (ACC) recommends the following first-line \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtherapies for hypertension in elderly patients:\\n\\n1. **Thiazide Diuretics**: These are often preferred due to \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtheir effectiveness in reducing blood pressure (BP) and preventing heart failure (HF). Chlorthalidone, a \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mthiazide-type diuretic, has shown superior outcomes in preventing HF compared to other classes.\\n  \\n2. \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m**Calcium Channel Blockers (CCBs)**: Another effective option, particularly when thiazides are not tolerated. \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mThey provide significant BP control and cardiovascular event prevention.\\n\\n3. **Angiotensin-Converting Enzyme \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(ACE) Inhibitors** or **Angiotensin Receptor Blockers (ARBs)**: These are also recommended, especially in \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mpatients with specific comorbid conditions like heart failure or chronic kidney disease as they offer \u001b[0m\u001b[2m         \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2madditional therapeutic benefits.\\n\\nThe choice of initial therapy may depend on individual comorbidities and \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtolerance, and sometimes the initiation of treatment with two agents may be needed, especially in cases of \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mstage 2 hypertension. It is essential to monitor patients closely, particularly older adults, as they might be \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2msusceptible to hypotension or orthostatic changes.\\n\\nIn summary, the ACC guideline highlights thiazide \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mdiuretics, CCBs, and ACE inhibitors/ARBs as critical first-line options for managing hypertension in elderly \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mpatients.', refusal=None, role='assistant', audio=None, function_call=None, tool_calls=None)\u001b[0m\u001b[2m                   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">╭─────────────────────────────────────────────────</span><span style=\"color: #808000; text-decoration-color: #808000\"> Final Answer </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> The American College of Cardiology (ACC) recommends the following first-line therapies for hypertension in      </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> elderly patients:                                                                                               </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">                                                                                                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> 1. **Thiazide Diuretics**: These are often preferred due to their effectiveness in reducing blood pressure (BP) </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> and preventing heart failure (HF). Chlorthalidone, a thiazide-type diuretic, has shown superior outcomes in     </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> preventing HF compared to other classes.                                                                        </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">                                                                                                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> 2. **Calcium Channel Blockers (CCBs)**: Another effective option, particularly when thiazides are not           </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> tolerated. They provide significant BP control and cardiovascular event prevention.                             </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">                                                                                                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> 3. **Angiotensin-Converting Enzyme (ACE) Inhibitors** or **Angiotensin Receptor Blockers (ARBs)**: These are    </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> also recommended, especially in patients with specific comorbid conditions like heart failure or chronic kidney </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> disease as they offer additional therapeutic benefits.                                                          </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">                                                                                                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> The choice of initial therapy may depend on individual comorbidities and tolerance, and sometimes the           </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> initiation of treatment with two agents may be needed, especially in cases of stage 2 hypertension. It is       </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> essential to monitor patients closely, particularly older adults, as they might be susceptible to hypotension   </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> or orthostatic changes.                                                                                         </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">                                                                                                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> In summary, the ACC guideline highlights thiazide diuretics, CCBs, and ACE inhibitors/ARBs as critical          </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> first-line options for managing hypertension in elderly patients.                                               </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;33m╭─\u001b[0m\u001b[1;33m────────────────────────────────────────────────\u001b[0m\u001b[33m Final Answer \u001b[0m\u001b[1;33m─────────────────────────────────────────────────\u001b[0m\u001b[1;33m─╮\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mThe American College of Cardiology (ACC) recommends the following first-line therapies for hypertension in \u001b[0m\u001b[1;32m    \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32melderly patients:\u001b[0m\u001b[1;32m                                                                                              \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m                                                                                                               \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m1. **Thiazide Diuretics**: These are often preferred due to their effectiveness in reducing blood pressure (BP)\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mand preventing heart failure (HF). Chlorthalidone, a thiazide-type diuretic, has shown superior outcomes in \u001b[0m\u001b[1;32m   \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mpreventing HF compared to other classes.\u001b[0m\u001b[1;32m                                                                       \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m  \u001b[0m\u001b[1;32m                                                                                                             \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m2. **Calcium Channel Blockers (CCBs)**: Another effective option, particularly when thiazides are not \u001b[0m\u001b[1;32m         \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mtolerated. They provide significant BP control and cardiovascular event prevention.\u001b[0m\u001b[1;32m                            \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m                                                                                                               \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m3. **Angiotensin-Converting Enzyme (ACE) Inhibitors** or **Angiotensin Receptor Blockers (ARBs)**: These are \u001b[0m\u001b[1;32m  \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32malso recommended, especially in patients with specific comorbid conditions like heart failure or chronic kidney\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mdisease as they offer additional therapeutic benefits.\u001b[0m\u001b[1;32m                                                         \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m                                                                                                               \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mThe choice of initial therapy may depend on individual comorbidities and tolerance, and sometimes the \u001b[0m\u001b[1;32m         \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32minitiation of treatment with two agents may be needed, especially in cases of stage 2 hypertension. It is \u001b[0m\u001b[1;32m     \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32messential to monitor patients closely, particularly older adults, as they might be susceptible to hypotension \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mor orthostatic changes.\u001b[0m\u001b[1;32m                                                                                        \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m                                                                                                               \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mIn summary, the ACC guideline highlights thiazide diuretics, CCBs, and ACE inhibitors/ARBs as critical \u001b[0m\u001b[1;32m        \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mfirst-line options for managing hypertension in elderly patients.\u001b[0m\u001b[1;32m                                              \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "user_question_1 = \"What does the ACC recommend as first-line therapy for hypertension in elderly patients?\"\n",
    "run_multi_step_agent(user_question_1)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 82,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╭──────────────────────────────────────────────────</span> Step Start <span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">───────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">│ **Step 1**: Starting step 1                                                                                     │</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;36m╭─\u001b[0m\u001b[1;36m─────────────────────────────────────────────────\u001b[0m Step Start \u001b[1;36m──────────────────────────────────────────────────\u001b[0m\u001b[1;36m─╮\u001b[0m\n",
       "\u001b[1;36m│\u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m**Step 1**: Starting step 1\u001b[0m\u001b[1;36m                                                                                    \u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m│\u001b[0m\n",
       "\u001b[1;36m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╭───────────────────────────────────────────────</span> Current Messages <span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Messages before API call:                                                                                       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ [                                                                                                               │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   {                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"role\": \"system\",                                                                                           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"content\": \"You are a cardiology-focused AI assistant with access to three tools:\\n1) 'lookup_patient_data' │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ for querying patient records from Azure SQL.\\n2) 'search_acc_guidelines' for official ACC guidelines.\\n3)       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ 'search_bing_grounding' for real-time public information.\\n\\nYou can call these tools in any order, multiple    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ times if needed, to gather all the context.\\nStop calling tools only when you have enough information to        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ provide a final, cohesive answer.\\nThen output your final answer to the user.\"                                  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   },                                                                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   {                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"role\": \"user\",                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"content\": \"Any latest FDA approvals or clinical trial facts related to Ozempic and how it impacts          │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ cardiovascular diseases?\"                                                                                       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   }                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ ]                                                                                                               │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[2m╭─\u001b[0m\u001b[2m──────────────────────────────────────────────\u001b[0m Current Messages \u001b[2m───────────────────────────────────────────────\u001b[0m\u001b[2m─╮\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mMessages before API call:\u001b[0m\u001b[2m                                                                                      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m[\u001b[0m\u001b[2m                                                                                                              \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  {\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"role\": \"system\",\u001b[0m\u001b[2m                                                                                          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"content\": \"You are a cardiology-focused AI assistant with access to three tools:\\n1) 'lookup_patient_data'\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfor querying patient records from Azure SQL.\\n2) 'search_acc_guidelines' for official ACC guidelines.\\n3) \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m'search_bing_grounding' for real-time public information.\\n\\nYou can call these tools in any order, multiple \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtimes if needed, to gather all the context.\\nStop calling tools only when you have enough information to \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mprovide a final, cohesive answer.\\nThen output your final answer to the user.\"\u001b[0m\u001b[2m                                 \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  },\u001b[0m\u001b[2m                                                                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  {\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"role\": \"user\",\u001b[0m\u001b[2m                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"content\": \"Any latest FDA approvals or clinical trial facts related to Ozempic and how it impacts \u001b[0m\u001b[2m        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mcardiovascular diseases?\"\u001b[0m\u001b[2m                                                                                      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  }\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m]\u001b[0m\u001b[2m                                                                                                              \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╭─────────────────────────────────────────────────</span> Raw Response <span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Raw response message:                                                                                           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ ChatCompletionMessage(content=None, refusal=None, role='assistant', audio=None, function_call=None,             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ tool_calls=[ChatCompletionMessageToolCall(id='call_iAOtTON8Nhk8hU6KIbIQOeoz',                                   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ function=Function(arguments='{\"query\": \"latest FDA approvals Ozempic cardiovascular disease\"}',                 │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ name='search_bing_grounding'), type='function'),                                                                │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ ChatCompletionMessageToolCall(id='call_3jzH1RKe67FlErM2jzL3LJ3h', function=Function(arguments='{\"query\":        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ \"Ozempic clinical trials cardiovascular outcomes\"}', name='search_bing_grounding'), type='function')])          │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[2m╭─\u001b[0m\u001b[2m────────────────────────────────────────────────\u001b[0m Raw Response \u001b[2m─────────────────────────────────────────────────\u001b[0m\u001b[2m─╮\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mRaw response message:\u001b[0m\u001b[2m                                                                                          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mChatCompletionMessage(content=None, refusal=None, role='assistant', audio=None, function_call=None, \u001b[0m\u001b[2m           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtool_calls=[ChatCompletionMessageToolCall(id='call_iAOtTON8Nhk8hU6KIbIQOeoz', \u001b[0m\u001b[2m                                 \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfunction=Function(arguments='{\"query\": \"latest FDA approvals Ozempic cardiovascular disease\"}', \u001b[0m\u001b[2m               \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mname='search_bing_grounding'), type='function'), \u001b[0m\u001b[2m                                                              \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mChatCompletionMessageToolCall(id='call_3jzH1RKe67FlErM2jzL3LJ3h', function=Function(arguments='{\"query\": \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m\"Ozempic clinical trials cardiovascular outcomes\"}', name='search_bing_grounding'), type='function')])\u001b[0m\u001b[2m         \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">╭───────────────────────────────────────────────────</span> Tool Call <span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">───────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ **Step 1**: LLM calls tool search_bing_grounding                                                                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ **Arguments**:                                                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ {                                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│   \"query\": \"latest FDA approvals Ozempic cardiovascular disease\"                                                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ }                                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;34m╭─\u001b[0m\u001b[1;34m──────────────────────────────────────────────────\u001b[0m Tool Call \u001b[1;34m──────────────────────────────────────────────────\u001b[0m\u001b[1;34m─╮\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m**Step 1**: LLM calls tool \u001b[0m\u001b[1;34msearch_bing_grounding\u001b[0m\u001b[1;34m                                                               \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m                                                                                                               \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m**Arguments**:\u001b[0m\u001b[1;34m                                                                                                 \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m{\u001b[0m\u001b[1;34m                                                                                                              \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m  \"query\": \"latest FDA approvals Ozempic cardiovascular disease\"\u001b[0m\u001b[1;34m                                               \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m}\u001b[0m\u001b[1;34m                                                                                                              \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008000; text-decoration-color: #008000\">╭──────────────────────────────────────────────</span> Tool Response Added <span style=\"color: #008000; text-decoration-color: #008000\">──────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Tool output added to messages:                                                                                  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ On January 28, 2025, the FDA approved a new indication for Ozempic (semaglutide), making it the only GLP-1      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ receptor agonist approved to reduce the risk of kidney disease worsening, kidney failure (end-stage kidney      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ disease), and death due to cardiovascular disease in adults with type 2 diabetes and chronic kidney disease     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ (CKD)【0†source】【2†source】. This approval is based on the results from the FLOW phase 3b kidney outcomes     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ trial which demonstrated a statistically significant reduction in risks associated with these                   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ conditions【2†source】.                                                                                         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[32m╭─\u001b[0m\u001b[32m─────────────────────────────────────────────\u001b[0m Tool Response Added \u001b[32m─────────────────────────────────────────────\u001b[0m\u001b[32m─╮\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mTool output added to messages:\u001b[0m\u001b[32m                                                                                 \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mOn January 28, 2025, the FDA approved a new indication for Ozempic (semaglutide), making it the only GLP-1 \u001b[0m\u001b[32m    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mreceptor agonist approved to reduce the risk of kidney disease worsening, kidney failure (end-stage kidney \u001b[0m\u001b[32m    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mdisease), and death due to cardiovascular disease in adults with type 2 diabetes and chronic kidney disease \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m(CKD)【0†source】【2†source】. This approval is based on the results from the FLOW phase 3b kidney outcomes \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mtrial which demonstrated a statistically significant reduction in risks associated with these \u001b[0m\u001b[32m                 \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mconditions【2†source】.\u001b[0m\u001b[32m                                                                                        \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">╭───────────────────────────────────────────────────</span> Tool Call <span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">───────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ **Step 1**: LLM calls tool search_bing_grounding                                                                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ **Arguments**:                                                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ {                                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│   \"query\": \"Ozempic clinical trials cardiovascular outcomes\"                                                    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ }                                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;34m╭─\u001b[0m\u001b[1;34m──────────────────────────────────────────────────\u001b[0m Tool Call \u001b[1;34m──────────────────────────────────────────────────\u001b[0m\u001b[1;34m─╮\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m**Step 1**: LLM calls tool \u001b[0m\u001b[1;34msearch_bing_grounding\u001b[0m\u001b[1;34m                                                               \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m                                                                                                               \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m**Arguments**:\u001b[0m\u001b[1;34m                                                                                                 \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m{\u001b[0m\u001b[1;34m                                                                                                              \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m  \"query\": \"Ozempic clinical trials cardiovascular outcomes\"\u001b[0m\u001b[1;34m                                                   \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m}\u001b[0m\u001b[1;34m                                                                                                              \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008000; text-decoration-color: #008000\">╭──────────────────────────────────────────────</span> Tool Response Added <span style=\"color: #008000; text-decoration-color: #008000\">──────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Tool output added to messages:                                                                                  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ The SUSTAIN 6 clinical trial evaluated the cardiovascular outcomes of Ozempic (semaglutide) in patients with    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ type 2 diabetes and high cardiovascular risk. The trial showed a significant reduction in the risk of major     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ adverse cardiovascular events (MACE), which includes cardiovascular death, non-fatal myocardial infarction, and │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ non-fatal stroke, with a 26% risk reduction compared to placebo. The reduction was mainly driven by fewer       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ non-fatal myocardial infarctions and strokes【7†source】.                                                       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[32m╭─\u001b[0m\u001b[32m─────────────────────────────────────────────\u001b[0m Tool Response Added \u001b[32m─────────────────────────────────────────────\u001b[0m\u001b[32m─╮\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mTool output added to messages:\u001b[0m\u001b[32m                                                                                 \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mThe SUSTAIN 6 clinical trial evaluated the cardiovascular outcomes of Ozempic (semaglutide) in patients with \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mtype 2 diabetes and high cardiovascular risk. The trial showed a significant reduction in the risk of major \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32madverse cardiovascular events (MACE), which includes cardiovascular death, non-fatal myocardial infarction, and\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mnon-fatal stroke, with a 26% risk reduction compared to placebo. The reduction was mainly driven by fewer \u001b[0m\u001b[32m     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mnon-fatal myocardial infarctions and strokes【7†source】.\u001b[0m\u001b[32m                                                      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╭──────────────────────────────────────────────────</span> Step Start <span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">───────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">│ **Step 2**: Starting step 2                                                                                     │</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;36m╭─\u001b[0m\u001b[1;36m─────────────────────────────────────────────────\u001b[0m Step Start \u001b[1;36m──────────────────────────────────────────────────\u001b[0m\u001b[1;36m─╮\u001b[0m\n",
       "\u001b[1;36m│\u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m**Step 2**: Starting step 2\u001b[0m\u001b[1;36m                                                                                    \u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m│\u001b[0m\n",
       "\u001b[1;36m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╭───────────────────────────────────────────────</span> Current Messages <span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Messages before API call:                                                                                       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ [                                                                                                               │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   {                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"role\": \"system\",                                                                                           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"content\": \"You are a cardiology-focused AI assistant with access to three tools:\\n1) 'lookup_patient_data' │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ for querying patient records from Azure SQL.\\n2) 'search_acc_guidelines' for official ACC guidelines.\\n3)       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ 'search_bing_grounding' for real-time public information.\\n\\nYou can call these tools in any order, multiple    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ times if needed, to gather all the context.\\nStop calling tools only when you have enough information to        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ provide a final, cohesive answer.\\nThen output your final answer to the user.\"                                  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   },                                                                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   {                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"role\": \"user\",                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"content\": \"Any latest FDA approvals or clinical trial facts related to Ozempic and how it impacts          │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ cardiovascular diseases?\"                                                                                       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   },                                                                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   {                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"role\": \"assistant\",                                                                                        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"content\": null,                                                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"tool_calls\": [                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│       {                                                                                                         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│         \"id\": \"call_iAOtTON8Nhk8hU6KIbIQOeoz\",                                                                  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│         \"type\": \"function\",                                                                                     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│         \"function\": {                                                                                           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│           \"name\": \"search_bing_grounding\",                                                                      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│           \"arguments\": \"{\\\"query\\\": \\\"latest FDA approvals Ozempic cardiovascular disease\\\"}\"                   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│         }                                                                                                       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│       },                                                                                                        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│       {                                                                                                         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│         \"id\": \"call_3jzH1RKe67FlErM2jzL3LJ3h\",                                                                  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│         \"type\": \"function\",                                                                                     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│         \"function\": {                                                                                           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│           \"name\": \"search_bing_grounding\",                                                                      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│           \"arguments\": \"{\\\"query\\\": \\\"Ozempic clinical trials cardiovascular outcomes\\\"}\"                       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│         }                                                                                                       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│       }                                                                                                         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     ]                                                                                                           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   },                                                                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   {                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"role\": \"tool\",                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"tool_call_id\": \"call_iAOtTON8Nhk8hU6KIbIQOeoz\",                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"name\": \"search_bing_grounding\",                                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"content\": \"On January 28, 2025, the FDA approved a new indication for Ozempic (semaglutide), making it the │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ only GLP-1 receptor agonist approved to reduce the risk of kidney disease worsening, kidney failure (end-stage  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ kidney disease), and death due to cardiovascular disease in adults with type 2 diabetes and chronic kidney      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ disease (CKD)\\u30100\\u2020source\\u3011\\u30102\\u2020source\\u3011. This approval is based on the results from the │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ FLOW phase 3b kidney outcomes trial which demonstrated a statistically significant reduction in risks           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ associated with these conditions\\u30102\\u2020source\\u3011.\"                                                     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   },                                                                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   {                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"role\": \"tool\",                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"tool_call_id\": \"call_3jzH1RKe67FlErM2jzL3LJ3h\",                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"name\": \"search_bing_grounding\",                                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"content\": \"The SUSTAIN 6 clinical trial evaluated the cardiovascular outcomes of Ozempic (semaglutide) in  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ patients with type 2 diabetes and high cardiovascular risk. The trial showed a significant reduction in the     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ risk of major adverse cardiovascular events (MACE), which includes cardiovascular death, non-fatal myocardial   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ infarction, and non-fatal stroke, with a 26% risk reduction compared to placebo. The reduction was mainly       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ driven by fewer non-fatal myocardial infarctions and strokes\\u30107\\u2020source\\u3011.\"                         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   }                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ ]                                                                                                               │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[2m╭─\u001b[0m\u001b[2m──────────────────────────────────────────────\u001b[0m Current Messages \u001b[2m───────────────────────────────────────────────\u001b[0m\u001b[2m─╮\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mMessages before API call:\u001b[0m\u001b[2m                                                                                      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m[\u001b[0m\u001b[2m                                                                                                              \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  {\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"role\": \"system\",\u001b[0m\u001b[2m                                                                                          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"content\": \"You are a cardiology-focused AI assistant with access to three tools:\\n1) 'lookup_patient_data'\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfor querying patient records from Azure SQL.\\n2) 'search_acc_guidelines' for official ACC guidelines.\\n3) \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m'search_bing_grounding' for real-time public information.\\n\\nYou can call these tools in any order, multiple \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtimes if needed, to gather all the context.\\nStop calling tools only when you have enough information to \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mprovide a final, cohesive answer.\\nThen output your final answer to the user.\"\u001b[0m\u001b[2m                                 \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  },\u001b[0m\u001b[2m                                                                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  {\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"role\": \"user\",\u001b[0m\u001b[2m                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"content\": \"Any latest FDA approvals or clinical trial facts related to Ozempic and how it impacts \u001b[0m\u001b[2m        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mcardiovascular diseases?\"\u001b[0m\u001b[2m                                                                                      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  },\u001b[0m\u001b[2m                                                                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  {\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"role\": \"assistant\",\u001b[0m\u001b[2m                                                                                       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"content\": null,\u001b[0m\u001b[2m                                                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"tool_calls\": [\u001b[0m\u001b[2m                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m      {\u001b[0m\u001b[2m                                                                                                        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m        \"id\": \"call_iAOtTON8Nhk8hU6KIbIQOeoz\",\u001b[0m\u001b[2m                                                                 \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m        \"type\": \"function\",\u001b[0m\u001b[2m                                                                                    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m        \"function\": {\u001b[0m\u001b[2m                                                                                          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m          \"name\": \"search_bing_grounding\",\u001b[0m\u001b[2m                                                                     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m          \"arguments\": \"{\\\"query\\\": \\\"latest FDA approvals Ozempic cardiovascular disease\\\"}\"\u001b[0m\u001b[2m                  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m        }\u001b[0m\u001b[2m                                                                                                      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m      },\u001b[0m\u001b[2m                                                                                                       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m      {\u001b[0m\u001b[2m                                                                                                        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m        \"id\": \"call_3jzH1RKe67FlErM2jzL3LJ3h\",\u001b[0m\u001b[2m                                                                 \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m        \"type\": \"function\",\u001b[0m\u001b[2m                                                                                    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m        \"function\": {\u001b[0m\u001b[2m                                                                                          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m          \"name\": \"search_bing_grounding\",\u001b[0m\u001b[2m                                                                     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m          \"arguments\": \"{\\\"query\\\": \\\"Ozempic clinical trials cardiovascular outcomes\\\"}\"\u001b[0m\u001b[2m                      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m        }\u001b[0m\u001b[2m                                                                                                      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m      }\u001b[0m\u001b[2m                                                                                                        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    ]\u001b[0m\u001b[2m                                                                                                          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  },\u001b[0m\u001b[2m                                                                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  {\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"role\": \"tool\",\u001b[0m\u001b[2m                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"tool_call_id\": \"call_iAOtTON8Nhk8hU6KIbIQOeoz\",\u001b[0m\u001b[2m                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"name\": \"search_bing_grounding\",\u001b[0m\u001b[2m                                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"content\": \"On January 28, 2025, the FDA approved a new indication for Ozempic (semaglutide), making it the\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2monly GLP-1 receptor agonist approved to reduce the risk of kidney disease worsening, kidney failure (end-stage \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mkidney disease), and death due to cardiovascular disease in adults with type 2 diabetes and chronic kidney \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mdisease (CKD)\\u30100\\u2020source\\u3011\\u30102\\u2020source\\u3011. This approval is based on the results from the\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mFLOW phase 3b kidney outcomes trial which demonstrated a statistically significant reduction in risks \u001b[0m\u001b[2m         \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2massociated with these conditions\\u30102\\u2020source\\u3011.\"\u001b[0m\u001b[2m                                                    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  },\u001b[0m\u001b[2m                                                                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  {\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"role\": \"tool\",\u001b[0m\u001b[2m                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"tool_call_id\": \"call_3jzH1RKe67FlErM2jzL3LJ3h\",\u001b[0m\u001b[2m                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"name\": \"search_bing_grounding\",\u001b[0m\u001b[2m                                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"content\": \"The SUSTAIN 6 clinical trial evaluated the cardiovascular outcomes of Ozempic (semaglutide) in \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mpatients with type 2 diabetes and high cardiovascular risk. The trial showed a significant reduction in the \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mrisk of major adverse cardiovascular events (MACE), which includes cardiovascular death, non-fatal myocardial \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2minfarction, and non-fatal stroke, with a 26% risk reduction compared to placebo. The reduction was mainly \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mdriven by fewer non-fatal myocardial infarctions and strokes\\u30107\\u2020source\\u3011.\"\u001b[0m\u001b[2m                        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  }\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m]\u001b[0m\u001b[2m                                                                                                              \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╭─────────────────────────────────────────────────</span> Raw Response <span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Raw response message:                                                                                           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ ChatCompletionMessage(content='Ozempic (semaglutide) has seen significant advancements in its FDA approval and  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ clinical trial outcomes related to cardiovascular diseases:\\n\\n1. **FDA Approval**: On January 28, 2025, the    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ FDA granted a new indication for Ozempic, making it the only GLP-1 receptor agonist approved specifically to    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ reduce the risk of kidney disease worsening, kidney failure (end-stage kidney disease), and death due to        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ cardiovascular disease in adults with type 2 diabetes and chronic kidney disease (CKD). This approval was based │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ on the findings from the FLOW phase 3b kidney outcomes trial, which demonstrated a significant reduction in the │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ risks associated with these conditions.\\n\\n2. **Clinical Trials**: The SUSTAIN 6 clinical trial evaluated the   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ cardiovascular outcomes of Ozempic in patients with type 2 diabetes who are at high cardiovascular risk. The    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ results revealed a 26% reduction in the risk of major adverse cardiovascular events (MACE)—which includes       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke—when compared to a placebo. The     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ risk reduction was primarily attributed to fewer occurrences of non-fatal myocardial infarctions and strokes in │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ the Ozempic group.\\n\\nThese findings suggest that Ozempic not only aids in glycemic control but also has        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ protective benefits against cardiovascular events in diabetic patients at risk.', refusal=None,                 │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ role='assistant', audio=None, function_call=None, tool_calls=None)                                              │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[2m╭─\u001b[0m\u001b[2m────────────────────────────────────────────────\u001b[0m Raw Response \u001b[2m─────────────────────────────────────────────────\u001b[0m\u001b[2m─╮\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mRaw response message:\u001b[0m\u001b[2m                                                                                          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mChatCompletionMessage(content='Ozempic (semaglutide) has seen significant advancements in its FDA approval and \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mclinical trial outcomes related to cardiovascular diseases:\\n\\n1. **FDA Approval**: On January 28, 2025, the \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mFDA granted a new indication for Ozempic, making it the only GLP-1 receptor agonist approved specifically to \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mreduce the risk of kidney disease worsening, kidney failure (end-stage kidney disease), and death due to \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mcardiovascular disease in adults with type 2 diabetes and chronic kidney disease (CKD). This approval was based\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mon the findings from the FLOW phase 3b kidney outcomes trial, which demonstrated a significant reduction in the\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mrisks associated with these conditions.\\n\\n2. **Clinical Trials**: The SUSTAIN 6 clinical trial evaluated the \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mcardiovascular outcomes of Ozempic in patients with type 2 diabetes who are at high cardiovascular risk. The \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mresults revealed a 26% reduction in the risk of major adverse cardiovascular events (MACE)—which includes \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mcardiovascular death, non-fatal myocardial infarction, and non-fatal stroke—when compared to a placebo. The \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mrisk reduction was primarily attributed to fewer occurrences of non-fatal myocardial infarctions and strokes in\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mthe Ozempic group.\\n\\nThese findings suggest that Ozempic not only aids in glycemic control but also has \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mprotective benefits against cardiovascular events in diabetic patients at risk.', refusal=None, \u001b[0m\u001b[2m               \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mrole='assistant', audio=None, function_call=None, tool_calls=None)\u001b[0m\u001b[2m                                             \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">╭─────────────────────────────────────────────────</span><span style=\"color: #808000; text-decoration-color: #808000\"> Final Answer </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> Ozempic (semaglutide) has seen significant advancements in its FDA approval and clinical trial outcomes related </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> to cardiovascular diseases:                                                                                     </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">                                                                                                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> 1. **FDA Approval**: On January 28, 2025, the FDA granted a new indication for Ozempic, making it the only      </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> GLP-1 receptor agonist approved specifically to reduce the risk of kidney disease worsening, kidney failure     </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> (end-stage kidney disease), and death due to cardiovascular disease in adults with type 2 diabetes and chronic  </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> kidney disease (CKD). This approval was based on the findings from the FLOW phase 3b kidney outcomes trial,     </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> which demonstrated a significant reduction in the risks associated with these conditions.                       </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">                                                                                                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> 2. **Clinical Trials**: The SUSTAIN 6 clinical trial evaluated the cardiovascular outcomes of Ozempic in        </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> patients with type 2 diabetes who are at high cardiovascular risk. The results revealed a 26% reduction in the  </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> risk of major adverse cardiovascular events (MACE)—which includes cardiovascular death, non-fatal myocardial    </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> infarction, and non-fatal stroke—when compared to a placebo. The risk reduction was primarily attributed to     </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> fewer occurrences of non-fatal myocardial infarctions and strokes in the Ozempic group.                         </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">                                                                                                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> These findings suggest that Ozempic not only aids in glycemic control but also has protective benefits against  </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> cardiovascular events in diabetic patients at risk.                                                             </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;33m╭─\u001b[0m\u001b[1;33m────────────────────────────────────────────────\u001b[0m\u001b[33m Final Answer \u001b[0m\u001b[1;33m─────────────────────────────────────────────────\u001b[0m\u001b[1;33m─╮\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mOzempic (semaglutide) has seen significant advancements in its FDA approval and clinical trial outcomes related\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mto cardiovascular diseases:\u001b[0m\u001b[1;32m                                                                                    \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m                                                                                                               \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m1. **FDA Approval**: On January 28, 2025, the FDA granted a new indication for Ozempic, making it the only \u001b[0m\u001b[1;32m    \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mGLP-1 receptor agonist approved specifically to reduce the risk of kidney disease worsening, kidney failure \u001b[0m\u001b[1;32m   \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m(end-stage kidney disease), and death due to cardiovascular disease in adults with type 2 diabetes and chronic \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mkidney disease (CKD). This approval was based on the findings from the FLOW phase 3b kidney outcomes trial, \u001b[0m\u001b[1;32m   \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mwhich demonstrated a significant reduction in the risks associated with these conditions.\u001b[0m\u001b[1;32m                      \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m                                                                                                               \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m2. **Clinical Trials**: The SUSTAIN 6 clinical trial evaluated the cardiovascular outcomes of Ozempic in \u001b[0m\u001b[1;32m      \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mpatients with type 2 diabetes who are at high cardiovascular risk. The results revealed a 26% reduction in the \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mrisk of major adverse cardiovascular events (MACE)—which includes cardiovascular death, non-fatal myocardial \u001b[0m\u001b[1;32m  \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32minfarction, and non-fatal stroke—when compared to a placebo. The risk reduction was primarily attributed to \u001b[0m\u001b[1;32m   \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mfewer occurrences of non-fatal myocardial infarctions and strokes in the Ozempic group.\u001b[0m\u001b[1;32m                        \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m                                                                                                               \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mThese findings suggest that Ozempic not only aids in glycemic control but also has protective benefits against \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mcardiovascular events in diabetic patients at risk.\u001b[0m\u001b[1;32m                                                            \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "user_question_2 = \"Any latest FDA approvals or clinical trial facts related to Ozempic and how it impacts cardiovascular diseases?\"\n",
    "run_multi_step_agent(user_question_2)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 83,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╭──────────────────────────────────────────────────</span> Step Start <span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">───────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">│ **Step 1**: Starting step 1                                                                                     │</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;36m╭─\u001b[0m\u001b[1;36m─────────────────────────────────────────────────\u001b[0m Step Start \u001b[1;36m──────────────────────────────────────────────────\u001b[0m\u001b[1;36m─╮\u001b[0m\n",
       "\u001b[1;36m│\u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m**Step 1**: Starting step 1\u001b[0m\u001b[1;36m                                                                                    \u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m│\u001b[0m\n",
       "\u001b[1;36m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╭───────────────────────────────────────────────</span> Current Messages <span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Messages before API call:                                                                                       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ [                                                                                                               │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   {                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"role\": \"system\",                                                                                           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"content\": \"You are a cardiology-focused AI assistant with access to three tools:\\n1) 'lookup_patient_data' │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ for querying patient records from Azure SQL.\\n2) 'search_acc_guidelines' for official ACC guidelines.\\n3)       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ 'search_bing_grounding' for real-time public information.\\n\\nYou can call these tools in any order, multiple    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ times if needed, to gather all the context.\\nStop calling tools only when you have enough information to        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ provide a final, cohesive answer.\\nThen output your final answer to the user.\"                                  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   },                                                                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   {                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"role\": \"user\",                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"content\": \"How many patients have Hypertension and are prescribed Lisinopril?\"                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   }                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ ]                                                                                                               │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[2m╭─\u001b[0m\u001b[2m──────────────────────────────────────────────\u001b[0m Current Messages \u001b[2m───────────────────────────────────────────────\u001b[0m\u001b[2m─╮\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mMessages before API call:\u001b[0m\u001b[2m                                                                                      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m[\u001b[0m\u001b[2m                                                                                                              \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  {\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"role\": \"system\",\u001b[0m\u001b[2m                                                                                          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"content\": \"You are a cardiology-focused AI assistant with access to three tools:\\n1) 'lookup_patient_data'\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfor querying patient records from Azure SQL.\\n2) 'search_acc_guidelines' for official ACC guidelines.\\n3) \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m'search_bing_grounding' for real-time public information.\\n\\nYou can call these tools in any order, multiple \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtimes if needed, to gather all the context.\\nStop calling tools only when you have enough information to \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mprovide a final, cohesive answer.\\nThen output your final answer to the user.\"\u001b[0m\u001b[2m                                 \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  },\u001b[0m\u001b[2m                                                                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  {\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"role\": \"user\",\u001b[0m\u001b[2m                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"content\": \"How many patients have Hypertension and are prescribed Lisinopril?\"\u001b[0m\u001b[2m                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  }\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m]\u001b[0m\u001b[2m                                                                                                              \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╭─────────────────────────────────────────────────</span> Raw Response <span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Raw response message:                                                                                           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ ChatCompletionMessage(content=None, refusal=None, role='assistant', audio=None, function_call=None,             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ tool_calls=[ChatCompletionMessageToolCall(id='call_Oh3Ab9yhY2Q36sTIaJ5PWaAm',                                   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ function=Function(arguments='{\"query\":\"SELECT COUNT(*) FROM PatientMedicalData WHERE MedicalCondition LIKE      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ \\'%Hypertension%\\' AND Medications LIKE \\'%Lisinopril%\\'\"}', name='lookup_patient_data'), type='function')])    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[2m╭─\u001b[0m\u001b[2m────────────────────────────────────────────────\u001b[0m Raw Response \u001b[2m─────────────────────────────────────────────────\u001b[0m\u001b[2m─╮\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mRaw response message:\u001b[0m\u001b[2m                                                                                          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mChatCompletionMessage(content=None, refusal=None, role='assistant', audio=None, function_call=None, \u001b[0m\u001b[2m           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtool_calls=[ChatCompletionMessageToolCall(id='call_Oh3Ab9yhY2Q36sTIaJ5PWaAm', \u001b[0m\u001b[2m                                 \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfunction=Function(arguments='{\"query\":\"SELECT COUNT(*) FROM PatientMedicalData WHERE MedicalCondition LIKE \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m\\'%Hypertension%\\' AND Medications LIKE \\'%Lisinopril%\\'\"}', name='lookup_patient_data'), type='function')])\u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">╭───────────────────────────────────────────────────</span> Tool Call <span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">───────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ **Step 1**: LLM calls tool lookup_patient_data                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ **Arguments**:                                                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ {                                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│   \"query\": \"SELECT COUNT(*) FROM PatientMedicalData WHERE MedicalCondition LIKE '%Hypertension%' AND            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ Medications LIKE '%Lisinopril%'\"                                                                                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ }                                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;34m╭─\u001b[0m\u001b[1;34m──────────────────────────────────────────────────\u001b[0m Tool Call \u001b[1;34m──────────────────────────────────────────────────\u001b[0m\u001b[1;34m─╮\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m**Step 1**: LLM calls tool \u001b[0m\u001b[1;34mlookup_patient_data\u001b[0m\u001b[1;34m                                                                 \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m                                                                                                               \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m**Arguments**:\u001b[0m\u001b[1;34m                                                                                                 \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m{\u001b[0m\u001b[1;34m                                                                                                              \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m  \"query\": \"SELECT COUNT(*) FROM PatientMedicalData WHERE MedicalCondition LIKE '%Hypertension%' AND \u001b[0m\u001b[1;34m          \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34mMedications LIKE '%Lisinopril%'\"\u001b[0m\u001b[1;34m                                                                               \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m}\u001b[0m\u001b[1;34m                                                                                                              \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008000; text-decoration-color: #008000\">╭──────────────────────────────────────────────</span> Tool Response Added <span style=\"color: #008000; text-decoration-color: #008000\">──────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Tool output added to messages:                                                                                  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 1071                                                                                                            │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[32m╭─\u001b[0m\u001b[32m─────────────────────────────────────────────\u001b[0m Tool Response Added \u001b[32m─────────────────────────────────────────────\u001b[0m\u001b[32m─╮\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mTool output added to messages:\u001b[0m\u001b[32m                                                                                 \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m    \u001b[0m\u001b[32m                                                                                                           \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m1071\u001b[0m\u001b[32m                                                                                                           \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╭──────────────────────────────────────────────────</span> Step Start <span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">───────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">│ **Step 2**: Starting step 2                                                                                     │</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;36m╭─\u001b[0m\u001b[1;36m─────────────────────────────────────────────────\u001b[0m Step Start \u001b[1;36m──────────────────────────────────────────────────\u001b[0m\u001b[1;36m─╮\u001b[0m\n",
       "\u001b[1;36m│\u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m**Step 2**: Starting step 2\u001b[0m\u001b[1;36m                                                                                    \u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m│\u001b[0m\n",
       "\u001b[1;36m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╭───────────────────────────────────────────────</span> Current Messages <span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Messages before API call:                                                                                       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ [                                                                                                               │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   {                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"role\": \"system\",                                                                                           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"content\": \"You are a cardiology-focused AI assistant with access to three tools:\\n1) 'lookup_patient_data' │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ for querying patient records from Azure SQL.\\n2) 'search_acc_guidelines' for official ACC guidelines.\\n3)       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ 'search_bing_grounding' for real-time public information.\\n\\nYou can call these tools in any order, multiple    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ times if needed, to gather all the context.\\nStop calling tools only when you have enough information to        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ provide a final, cohesive answer.\\nThen output your final answer to the user.\"                                  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   },                                                                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   {                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"role\": \"user\",                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"content\": \"How many patients have Hypertension and are prescribed Lisinopril?\"                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   },                                                                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   {                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"role\": \"assistant\",                                                                                        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"content\": null,                                                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"tool_calls\": [                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│       {                                                                                                         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│         \"id\": \"call_Oh3Ab9yhY2Q36sTIaJ5PWaAm\",                                                                  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│         \"type\": \"function\",                                                                                     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│         \"function\": {                                                                                           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│           \"name\": \"lookup_patient_data\",                                                                        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│           \"arguments\": \"{\\\"query\\\":\\\"SELECT COUNT(*) FROM PatientMedicalData WHERE MedicalCondition LIKE        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ '%Hypertension%' AND Medications LIKE '%Lisinopril%'\\\"}\"                                                        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│         }                                                                                                       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│       }                                                                                                         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     ]                                                                                                           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   },                                                                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   {                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"role\": \"tool\",                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"tool_call_id\": \"call_Oh3Ab9yhY2Q36sTIaJ5PWaAm\",                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"name\": \"lookup_patient_data\",                                                                              │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"content\": \"    \\n1071\"                                                                                     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   }                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ ]                                                                                                               │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[2m╭─\u001b[0m\u001b[2m──────────────────────────────────────────────\u001b[0m Current Messages \u001b[2m───────────────────────────────────────────────\u001b[0m\u001b[2m─╮\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mMessages before API call:\u001b[0m\u001b[2m                                                                                      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m[\u001b[0m\u001b[2m                                                                                                              \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  {\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"role\": \"system\",\u001b[0m\u001b[2m                                                                                          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"content\": \"You are a cardiology-focused AI assistant with access to three tools:\\n1) 'lookup_patient_data'\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfor querying patient records from Azure SQL.\\n2) 'search_acc_guidelines' for official ACC guidelines.\\n3) \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m'search_bing_grounding' for real-time public information.\\n\\nYou can call these tools in any order, multiple \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtimes if needed, to gather all the context.\\nStop calling tools only when you have enough information to \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mprovide a final, cohesive answer.\\nThen output your final answer to the user.\"\u001b[0m\u001b[2m                                 \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  },\u001b[0m\u001b[2m                                                                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  {\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"role\": \"user\",\u001b[0m\u001b[2m                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"content\": \"How many patients have Hypertension and are prescribed Lisinopril?\"\u001b[0m\u001b[2m                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  },\u001b[0m\u001b[2m                                                                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  {\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"role\": \"assistant\",\u001b[0m\u001b[2m                                                                                       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"content\": null,\u001b[0m\u001b[2m                                                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"tool_calls\": [\u001b[0m\u001b[2m                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m      {\u001b[0m\u001b[2m                                                                                                        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m        \"id\": \"call_Oh3Ab9yhY2Q36sTIaJ5PWaAm\",\u001b[0m\u001b[2m                                                                 \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m        \"type\": \"function\",\u001b[0m\u001b[2m                                                                                    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m        \"function\": {\u001b[0m\u001b[2m                                                                                          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m          \"name\": \"lookup_patient_data\",\u001b[0m\u001b[2m                                                                       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m          \"arguments\": \"{\\\"query\\\":\\\"SELECT COUNT(*) FROM PatientMedicalData WHERE MedicalCondition LIKE \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m'%Hypertension%' AND Medications LIKE '%Lisinopril%'\\\"}\"\u001b[0m\u001b[2m                                                       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m        }\u001b[0m\u001b[2m                                                                                                      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m      }\u001b[0m\u001b[2m                                                                                                        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    ]\u001b[0m\u001b[2m                                                                                                          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  },\u001b[0m\u001b[2m                                                                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  {\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"role\": \"tool\",\u001b[0m\u001b[2m                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"tool_call_id\": \"call_Oh3Ab9yhY2Q36sTIaJ5PWaAm\",\u001b[0m\u001b[2m                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"name\": \"lookup_patient_data\",\u001b[0m\u001b[2m                                                                             \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"content\": \"    \\n1071\"\u001b[0m\u001b[2m                                                                                    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  }\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m]\u001b[0m\u001b[2m                                                                                                              \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╭─────────────────────────────────────────────────</span> Raw Response <span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Raw response message:                                                                                           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ ChatCompletionMessage(content='There are 1,071 patients who have Hypertension and are prescribed Lisinopril.',  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ refusal=None, role='assistant', audio=None, function_call=None, tool_calls=None)                                │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[2m╭─\u001b[0m\u001b[2m────────────────────────────────────────────────\u001b[0m Raw Response \u001b[2m─────────────────────────────────────────────────\u001b[0m\u001b[2m─╮\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mRaw response message:\u001b[0m\u001b[2m                                                                                          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mChatCompletionMessage(content='There are 1,071 patients who have Hypertension and are prescribed Lisinopril.', \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mrefusal=None, role='assistant', audio=None, function_call=None, tool_calls=None)\u001b[0m\u001b[2m                               \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">╭─────────────────────────────────────────────────</span><span style=\"color: #808000; text-decoration-color: #808000\"> Final Answer </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> There are 1,071 patients who have Hypertension and are prescribed Lisinopril.                                   </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;33m╭─\u001b[0m\u001b[1;33m────────────────────────────────────────────────\u001b[0m\u001b[33m Final Answer \u001b[0m\u001b[1;33m─────────────────────────────────────────────────\u001b[0m\u001b[1;33m─╮\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mThere are 1,071 patients who have Hypertension and are prescribed Lisinopril.\u001b[0m\u001b[1;32m                                  \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "user_question_3 = \"How many patients have Hypertension and are prescribed Lisinopril?\"\n",
    "# The agent should generate a valid SQL query, for example:\n",
    "## Note, the answer will depend on the actual data in the database (it should return 1071!)\n",
    "run_multi_step_agent(user_question_3)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 84,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╭──────────────────────────────────────────────────</span> Step Start <span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">───────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">│ **Step 1**: Starting step 1                                                                                     │</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;36m╭─\u001b[0m\u001b[1;36m─────────────────────────────────────────────────\u001b[0m Step Start \u001b[1;36m──────────────────────────────────────────────────\u001b[0m\u001b[1;36m─╮\u001b[0m\n",
       "\u001b[1;36m│\u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m**Step 1**: Starting step 1\u001b[0m\u001b[1;36m                                                                                    \u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m│\u001b[0m\n",
       "\u001b[1;36m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╭───────────────────────────────────────────────</span> Current Messages <span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Messages before API call:                                                                                       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ [                                                                                                               │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   {                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"role\": \"system\",                                                                                           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"content\": \"You are a cardiology-focused AI assistant with access to three tools:\\n1) 'lookup_patient_data' │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ for querying patient records from Azure SQL.\\n2) 'search_acc_guidelines' for official ACC guidelines.\\n3)       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ 'search_bing_grounding' for real-time public information.\\n\\nYou can call these tools in any order, multiple    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ times if needed, to gather all the context.\\nStop calling tools only when you have enough information to        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ provide a final, cohesive answer.\\nThen output your final answer to the user.\"                                  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   },                                                                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   {                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"role\": \"user\",                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"content\": \"I have a 79-year-old patient named Gloria Paul with hyperlipidemia. She's on Atorvastatin. Can  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ you confirm her medical details from the database, check the ACC guidelines for hyperlipidemia, and see if      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ there are any new medication updates from the FDA as of Feb 2025? Then give me a summary.\"                      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   }                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ ]                                                                                                               │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[2m╭─\u001b[0m\u001b[2m──────────────────────────────────────────────\u001b[0m Current Messages \u001b[2m───────────────────────────────────────────────\u001b[0m\u001b[2m─╮\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mMessages before API call:\u001b[0m\u001b[2m                                                                                      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m[\u001b[0m\u001b[2m                                                                                                              \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  {\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"role\": \"system\",\u001b[0m\u001b[2m                                                                                          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"content\": \"You are a cardiology-focused AI assistant with access to three tools:\\n1) 'lookup_patient_data'\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfor querying patient records from Azure SQL.\\n2) 'search_acc_guidelines' for official ACC guidelines.\\n3) \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m'search_bing_grounding' for real-time public information.\\n\\nYou can call these tools in any order, multiple \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtimes if needed, to gather all the context.\\nStop calling tools only when you have enough information to \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mprovide a final, cohesive answer.\\nThen output your final answer to the user.\"\u001b[0m\u001b[2m                                 \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  },\u001b[0m\u001b[2m                                                                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  {\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"role\": \"user\",\u001b[0m\u001b[2m                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"content\": \"I have a 79-year-old patient named Gloria Paul with hyperlipidemia. She's on Atorvastatin. Can \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2myou confirm her medical details from the database, check the ACC guidelines for hyperlipidemia, and see if \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mthere are any new medication updates from the FDA as of Feb 2025? Then give me a summary.\"\u001b[0m\u001b[2m                     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  }\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m]\u001b[0m\u001b[2m                                                                                                              \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╭─────────────────────────────────────────────────</span> Raw Response <span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Raw response message:                                                                                           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ ChatCompletionMessage(content=None, refusal=None, role='assistant', audio=None, function_call=None,             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ tool_calls=[ChatCompletionMessageToolCall(id='call_wDYynvTCJlXDSeGHihDW3rof',                                   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ function=Function(arguments='{\"query\": \"SELECT * FROM PatientMedicalData WHERE FirstName=\\'Gloria\\' AND         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ LastName=\\'Paul\\'\"}', name='lookup_patient_data'), type='function'),                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ ChatCompletionMessageToolCall(id='call_AcZAtI7rblAPdmxzoC6nxGgg', function=Function(arguments='{\"query\":        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ \"hyperlipidemia\"}', name='search_acc_guidelines'), type='function'),                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ ChatCompletionMessageToolCall(id='call_Wj83hyOr277uKGy1oSceoOi9', function=Function(arguments='{\"query\": \"FDA   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ new hyperlipidemia drugs February 2025\"}', name='search_bing_grounding'), type='function')])                    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[2m╭─\u001b[0m\u001b[2m────────────────────────────────────────────────\u001b[0m Raw Response \u001b[2m─────────────────────────────────────────────────\u001b[0m\u001b[2m─╮\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mRaw response message:\u001b[0m\u001b[2m                                                                                          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mChatCompletionMessage(content=None, refusal=None, role='assistant', audio=None, function_call=None, \u001b[0m\u001b[2m           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtool_calls=[ChatCompletionMessageToolCall(id='call_wDYynvTCJlXDSeGHihDW3rof', \u001b[0m\u001b[2m                                 \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfunction=Function(arguments='{\"query\": \"SELECT * FROM PatientMedicalData WHERE FirstName=\\'Gloria\\' AND \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mLastName=\\'Paul\\'\"}', name='lookup_patient_data'), type='function'), \u001b[0m\u001b[2m                                          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mChatCompletionMessageToolCall(id='call_AcZAtI7rblAPdmxzoC6nxGgg', function=Function(arguments='{\"query\": \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m\"hyperlipidemia\"}', name='search_acc_guidelines'), type='function'), \u001b[0m\u001b[2m                                          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mChatCompletionMessageToolCall(id='call_Wj83hyOr277uKGy1oSceoOi9', function=Function(arguments='{\"query\": \"FDA \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mnew hyperlipidemia drugs February 2025\"}', name='search_bing_grounding'), type='function')])\u001b[0m\u001b[2m                   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">╭───────────────────────────────────────────────────</span> Tool Call <span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">───────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ **Step 1**: LLM calls tool lookup_patient_data                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ **Arguments**:                                                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ {                                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│   \"query\": \"SELECT * FROM PatientMedicalData WHERE FirstName='Gloria' AND LastName='Paul'\"                      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ }                                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;34m╭─\u001b[0m\u001b[1;34m──────────────────────────────────────────────────\u001b[0m Tool Call \u001b[1;34m──────────────────────────────────────────────────\u001b[0m\u001b[1;34m─╮\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m**Step 1**: LLM calls tool \u001b[0m\u001b[1;34mlookup_patient_data\u001b[0m\u001b[1;34m                                                                 \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m                                                                                                               \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m**Arguments**:\u001b[0m\u001b[1;34m                                                                                                 \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m{\u001b[0m\u001b[1;34m                                                                                                              \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m  \"query\": \"SELECT * FROM PatientMedicalData WHERE FirstName='Gloria' AND LastName='Paul'\"\u001b[0m\u001b[1;34m                     \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m}\u001b[0m\u001b[1;34m                                                                                                              \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008000; text-decoration-color: #008000\">╭──────────────────────────────────────────────</span> Tool Response Added <span style=\"color: #008000; text-decoration-color: #008000\">──────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Tool output added to messages:                                                                                  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│  PatientID FirstName LastName DateOfBirth Gender ContactNumber        EmailAddress                              │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Address        City PostalCode Country MedicalCondition  Medications Allergies BloodType LastVisitDate          │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ SmokingStatus AlcoholConsumption ExerciseFrequency            Occupation  Height_cm  Weight_kg BloodPressure    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ HeartRate_bpm  Temperature_C                                                                                    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Notes                                                                                                           │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│          1    Gloria     Paul  1944-07-15  Other  428-674-1336 keymary@example.com 62908 Fuentes                │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Cove\\nLewisberg, MN 13491 Buchananton      59963   India   Hyperlipidemia Atorvastatin      None        O+      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 2024-03-26  Never Smoker      Light drinker  1-2 times a week Administrator, sports      176.2       77.7       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 120/79 mmHg             90           37.6 Affect idea turn either see six. Suggest cultural change nice travel  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ year parent. Happen energy level anyone position. Few available thought world development.                      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[32m╭─\u001b[0m\u001b[32m─────────────────────────────────────────────\u001b[0m Tool Response Added \u001b[32m─────────────────────────────────────────────\u001b[0m\u001b[32m─╮\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mTool output added to messages:\u001b[0m\u001b[32m                                                                                 \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m PatientID FirstName LastName DateOfBirth Gender ContactNumber        EmailAddress                             \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mAddress        City PostalCode Country MedicalCondition  Medications Allergies BloodType LastVisitDate \u001b[0m\u001b[32m        \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mSmokingStatus AlcoholConsumption ExerciseFrequency            Occupation  Height_cm  Weight_kg BloodPressure  \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mHeartRate_bpm  Temperature_C                                                                                   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mNotes\u001b[0m\u001b[32m                                                                                                          \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m         1    Gloria     Paul  1944-07-15  Other  428-674-1336 keymary@example.com 62908 Fuentes \u001b[0m\u001b[32m              \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mCove\\nLewisberg, MN 13491 Buchananton      59963   India   Hyperlipidemia Atorvastatin      None        O+    \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m2024-03-26  Never Smoker      Light drinker  1-2 times a week Administrator, sports      176.2       77.7   \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m120/79 mmHg             90           37.6 Affect idea turn either see six. Suggest cultural change nice travel \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32myear parent. Happen energy level anyone position. Few available thought world development.\u001b[0m\u001b[32m                     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">╭───────────────────────────────────────────────────</span> Tool Call <span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">───────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ **Step 1**: LLM calls tool search_acc_guidelines                                                                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ **Arguments**:                                                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ {                                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│   \"query\": \"hyperlipidemia\"                                                                                     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ }                                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;34m╭─\u001b[0m\u001b[1;34m──────────────────────────────────────────────────\u001b[0m Tool Call \u001b[1;34m──────────────────────────────────────────────────\u001b[0m\u001b[1;34m─╮\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m**Step 1**: LLM calls tool \u001b[0m\u001b[1;34msearch_acc_guidelines\u001b[0m\u001b[1;34m                                                               \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m                                                                                                               \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m**Arguments**:\u001b[0m\u001b[1;34m                                                                                                 \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m{\u001b[0m\u001b[1;34m                                                                                                              \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m  \"query\": \"hyperlipidemia\"\u001b[0m\u001b[1;34m                                                                                    \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m}\u001b[0m\u001b[1;34m                                                                                                              \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">╭─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│ Tool Invoked: ACC Guidelines Search                                                                             │</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│ Query: hyperlipidemia                                                                                           │</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;33m╭─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╮\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;33m \u001b[0m\u001b[1;33mTool Invoked: ACC Guidelines Search\u001b[0m\u001b[1;33m                                                                            \u001b[0m\u001b[1;33m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;33m \u001b[0m\u001b[1;33mQuery: hyperlipidemia\u001b[0m\u001b[1;33m                                                                                          \u001b[0m\u001b[1;33m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008000; text-decoration-color: #008000\">╭──────────────────────────────────────────────</span> Tool Response Added <span style=\"color: #008000; text-decoration-color: #008000\">──────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Tool output added to messages:                                                                                  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ received service or treatment for the specific condition. Detailed information on the identification of chronic │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ conditions is available from the CMS Chronic Conditions Data Warehouse (13).                                    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # Table 1                                                                                                       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Table 1 shows the 10 most common comorbidities for each index cardiovascular condition for beneficiaries ‡65    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ years of age in 2012 (13). The numbers of Medicare beneficiaries with the 4 index cardiovascular conditions     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ were 8,678,060 with ischemic heart disease, 4,366,489 with heart failure, 2,556,839 with atrial fibrillation,   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ and 1,145,719 with stroke. Two conditions that are major cardiovascular risk factors—hypertension and           │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ hyperlipidemia—constitute the most frequent dyad. Hypertension, hyperlipidemia, and ischemic heart disease were │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ the 3 most prevalent comorbidities for patients with heart failure, atrial fibrillation, and stroke, whereas    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ hypertension, hyperlipidemia, and diabetes mellitus were the most prevalent comorbidities in those with         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ ischemic heart disease; however, arthritis, anemia, chronic obstructive pulmonary disease, and Alzheimer’s      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ disease also appeared.                                                                                          │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # Table 2                                                                                                       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Table 2 lists the top 5 most prevalent dyad and triad comorbidities for beneficiaries ‡65 years of age with at  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ least 2 (for dyads) or 3 (for triads) chronic conditions. Combinations of high cholesterol, high blood          │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ pressure, and ischemic heart disease were most frequently represented in the dyads and triads, with diabetes    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ mellitus and arthritis completing the remaining prevalent combinations (14).                                    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ than in former smokers, and there was a significant relationship between the severity of carotid stenosis and   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ pack-years of exposure to tobacco (239). The RRs of finding 60% carotid stenosis were 1.5 and 3.9 among         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ cigarette smokers with cerebral ischemia in the NOMASS and the BCID (Berlin Cerebral Ischemia Databank)         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ studies, respectively (258).                                                                                    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # 6.3. Control of Hyperlipidemia                                                                                │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # 6.3.1. Recommendations for Control of Hyperlipidemia                                                          │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ CLASS I                                                                                                         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 1. Treatment with a statin medication is recommended for all patients with extracranial carotid or vertebral    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ atherosclerosis to reduce low-density lipoprotein (LDL) cholesterol below 100 mg/dL (111,259,260). (Level of    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Evidence: B)                                                                                                    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ CLASS IIa                                                                                                       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 1. Treatment with a statin medication is reasonable for all patients with extracranial carotid or vertebral     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ atherosclerosis who sustain ischemic stroke to reduce LDL-cholesterol to a level near or below 70 mg/dL (259).  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ (Level of Evidence: B)                                                                                          │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 2. If treatment with a statin (including trials of higher-dose statins and higher-potency statins) does not     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ achieve the goal selected for a patient, intensifying LDL-lowering drug therapy with an additional drug from    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ among those with evidence of improving outcomes (i.e., bile acid sequestrants or niacin) can be effective       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ (261–264). (Level of Evidence: B)                                                                               │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 3. For patients who do not tolerate statins, LDL-lowering therapy with bile acid sequestrants and/or niacin is  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ reasonable (261,263,265). (Level of Evidence: B)                                                                │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ The relationship between cholesterol and ischemic stroke is not as evident as that between cholesterol and MI,  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ and findings from population-based studies are inconsistent. In the MR FIT (Multiple Risk Factor Intervention   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Trial), comprising more than 350,000 men, the RR of death increased progressively with serum cholesterol,       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ exceeding 2.5 in those with the highest levels (266). An analysis of 45 prospective observational cohorts       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ involving approximately 450,000 individuals, however, found no association of hypercholesterolemia with stroke  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ (267). In the ARIC study, the relationships between lipid values and incident ischemic.                         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # J A C C V O L . 73, N O . 2 4 , 2 0 1 9                                                                       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # Grundy et al. e313                                                                                            │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # J U N E 25, 2 0 1 9 : e 2 8 5 - 3 5 0                                                                         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # 2018 Cholesterol Clinical Practice Guideline                                                                  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ As discussed in these guidelines (Section 4.2.) FH often goes undiagnosed. Young adults with primary elevations │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ of LDL-C ≥ 190 mg/dl have a long-term ASCVD burden (S4.4.4.2-3), and statin therapy is recommended. In adults   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ with hypercholesterolemia, cascade screening often identifies other family members with elevated LDL-C (Section │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 4.2.).                                                                                                          │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ However, even moderate hypercholesterolemia can accelerate development of atherosclerosis (S4.4.4.2-4).         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Secondary causes of elevated cholesterol—hypothyroidism (TSH), obstructive liver disease (liver panel), renal   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ disease and nephrosis (creatinine and urine analysis) as well as dietary and medication history—should be       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ addressed appropriately (S4.4.4.2-5). Elevations of LDL-C persisting after excluding secondary causes suggests  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ genetic forms of hypercholesterolemia. Young adults who experience prolonged exposure to hyperlipidemia prior   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ to age 55 are shown to have significantly increased risk of coronary heart disease (S4.4.4.2-6). Intensive      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ lifestyle change has the potential to reduce the hyperlipidemia and associated ASCVD risk factor burden.        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ A smaller group, but even at higher risk, are young adults with persistent, moderate hypercholesterolemia       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ (LDL-C 160-189 mg/dL), especially when risk-enhancing factors, such as a family history of premature ASCVD, are │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ present. Since there is increased probability of genetic FH in this LDL-C range, clinical judgment would        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ suggest that these high risk young adults will benefit from long-term statin therapy (S4.4.4.2-7) (Section      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 4.2.). Indeed, it has been shown that those with higher LDL-C can gain as much or more benefit from cholesterol │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ reduction as do those with lower pretreatment LDL-C but at higher risk (S4.4.4.2-8, S4.4.4.2-9).                │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ In young adults without phenotypically severe hypercholesterolemia, risk assessment should begin by estimation  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ of lifetime risk (S4.4.4.2-10). The pooled cohort equations (PCE) can be used to estimate lifetime risk         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ starting at age 21 years (see Section 4.4.2.). This information can inform a focused risk discussion designed   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ to improve high-risk lifestyle behaviors including tobacco use, sedentary lifestyle and/or poor diet            │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ (S4.4.4.2-11, S4.4.4.2-12). When young adults with hypercholesterolemia or multiple risk factors are            │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ identified, lifestyle intervention is indicated. To date, no long-term RCTs with cholesterol-lowering drugs     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ have been carried out in those 20 to 39 years age. However, a primary prevention RCT in those younger           │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ individuals at low to moderate short-term risk, but at high lifetime risk has been proposed (S4.4.4.2-13).      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ One approach to identifying young adults who could benefit from statins or drug combination would be to detect  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ significant coronary atherosclerosis with coronary artery calcium (CAC) scores. Its use for this purpose has    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ been suggested (S4.4.4.2-14). But again, absence of RCT data precludes guideline recommendations at this time.  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # 4.4.4.3. Children and Adolescents                                                                             │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # Recommendations for Children and Adolescents                                                                  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Referenced studies that support recommendations are summarized in Online Data Supplements 18 to 21.             │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |COR|LOE|RECOMMENDATIONS|                                                                                       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |---|---|---|                                                                                                   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |I|A|In children and adolescents with lipid disorders related to obesity, it is recommended to intensify        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ lifestyle therapy, including moderate caloric restriction and regular aerobic physical activity                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ (S4.4.4.3-1—S4.4.4.3-4).|                                                                                       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |I|B-NR|In children and adolescents with lipid abnormalities, lifestyle counseling is beneficial for lowering   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ LDL-C (S4.4.4.3-1—S4.4.4.3-3,                                                                                   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ The diagnosis is made by the presence of any 3 of the following 5 risk factors: elevated waist circumference,   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ elevated serum triglycerides, reduced HDL-C, elevated blood pressure, and elevated fasting glucose (Table S2 in │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ the Web Supplement). Metabolic syndrome is closely linked to excess weight and particularly to abdominal        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ obesity (S3.1.2-4). Therefore, the prevalence of metabolic syndrome has risen sharply among both adults and     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ children as levels of overweight and obesity have risen. Metabolic syndrome is now found in approximately       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ one-third of the adults in the United States (S3.1.2-5) and is likely under-recognized because of insufficient  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ rates of screening. The prevalence of metabolic syndrome increases with age and very commonly occurs in         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ patients with type 2 diabetes mellitus. See Table S2 in the Web Supplement.                                     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # 3.2. Lipid-Lowering Drugs                                                                                     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Among lipid-lowering drugs, statins are the cornerstone of therapy, in addition to healthy lifestyle            │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ interventions. Other LDL-lowering drugs include ezetimibe, bile acid sequestrants, and PCSK9 inhibitors.        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Triglyceride-lowering drugs are fibrates and niacin; they have a mild LDL-lowering action, but RCTs do not      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ support their use as add-on drugs to statin therapy (S3.2-1). Characteristics of LDL-lowering drugs are         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ summarized in Table S3 in the Web Supplement.                                                                   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # 3.2.1. Statin Therapy                                                                                         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ The intensity of statin therapy is divided into 3 categories: high-intensity, moderate-intensity, and           │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ low-intensity (S3.2.1-1). High-intensity statin therapy typically lowers LDL-C levels by ≥50%,                  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ moderate-intensity statin therapy by 30% to 49%, and low-intensity statin therapy by &lt;30% (Table 3). Of course, │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ the magnitude of LDL-C lowering will vary in clinical practice (S3.2.1-2). Certain Asian populations may have a │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ greater response to certain statins (S3.2.1-18). Pharmacokinetic profiles among statins are heterogeneous       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ (Table S4 in the Web Supplement). Statin safety has been extensively evaluated (S3.2.1-19). Statin-associated   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ side effects are discussed in Section 5. Common medications that may potentially interact with statins are      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ listed in Table S5 in the Web Supplement. More information on statin drug–drug interactions can be obtained     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ from the ACC LDL-C Manager (S3.2.1-20).                                                                         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # 3.2.2. Nonstatin Therapies                                                                                    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Ezetimibe is the most commonly used nonstatin agent. It lowers LDL-C levels by 13% to 20% and has a low         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ incidence of side effects (S3.2.2-1, S3.2.2-2). Bile acid sequestrants reduce LDL-C levels by 15% to 30%        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ depending on the dose. Bile acid sequestrants are not absorbed and do not cause systemic side effects, but they │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ are associated with gastrointestinal complaints (e.g., constipation) and can cause severe hypertriglyceridemia  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ when fasting triglycerides are ≥300 mg/dL (≥3.4 mmol/L). PCSK9 inhibitors are powerful LDL-lowering drugs.      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # J A C C V O L . 6 4 , N O . 1 7 , 2 0 1 4                                                                     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # O C T O B E R 2 8 , 2 0 1 4 : 1 8 5 1 – 6                                                                     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # AHA/ACC/HHS Strategies on Comorbidities                                                                       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # T A B L E 1 The 10 Most Common Comorbidities for 4 Index Cardiovascular Conditions: 2012 Data for Medicare    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Beneficiaries $65 Years of Age (13)                                                                             │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |Comorbidity|Ischemic Heart Disease* (N = 8,678,060)|HF* (N = 4,366,489)|AF* (N = 2,556,839)|Stroke* (N =       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 1,145,719)|                                                                                                     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |---|---|---|---|---|                                                                                           │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |Hypertension|1 (81.3)|1 (85.6)|1 (84.5)|1 (89.0)|                                                              │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |Hyperlipidemia|2 (69.1)|3 (62.6)|2 (64.4)|2 (69.9)|                                                            │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |Diabetes mellitus|3 (41.7)|5 (47.1)|7 (37.1)|6 (41.5)|                                                         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |Arthritis|4 (40.6)|6 (45.6)|6 (41.7)|5 (44.2)|                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |Anemia|5 (38.7)|4 (51.2)|5 (43.0)|4 (46.8)|                                                                    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |HF|6 (36.3)|Index|4 (50.9)|7 (37.2)|                                                                           │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |Ischemic heart disease|Index|2 (72.1)|3 (63.5)|3 (58.1)|                                                       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |Chronic kidney disease|7 (30.2)|7 (44.8)|8 (34.4)|8 (35.2)|                                                    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |Cataract|8 (21.6)|†|10 (22.6)|†|                                                                               │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |COPD|9 (21.0)|8 (30.9)|9 (23.8)|†|                                                                             │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |AF|10 (18.7)|9 (28.8)|Index|†|                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |Alzheimer’s disease/dementia|†|10 (26.3)|†|9 (33.8)|                                                           │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |Depression|†|†|†|10 (29.7)|                                                                                    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |Stroke|†|†|†|Index|                                                                                            │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ *Data shown as rank and percentage of persons with index condition who also had a comorbidity. The percentage   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ is included parenthetically when applicable. †Comorbidity was not in the top 10 for this index condition (13).  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ AF indicates atrial fibrillation; COPD, chronic obstructive pulmonary disease; and HF, heart failure.           │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # IMPLICATIONS AND FUTURE DIRECTIONS IN THE DEVELOPMENT OF CPGs                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Two general, but important, points emerge from the CMS data. First, a beneficiary with cardiovascular disease   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ but without at least 1 comorbid chronic condition is the exception rather than the rule. Second, whereas common │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ risk factors such as hypertension and hyperlipidemia are associated with the index cardiovascular conditions,   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ the index conditions are associated with a constellation of comorbidities, the pathophysiology of which may be  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ distinct from the index condition and for which prevalence increases with age or other factors.                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Organizations that develop CPGs must now consider comorbidities during the development process for              │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ disease-specific CPGs. For high-prevalence index conditions, few CPGs address comorbidities (15), and even      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ fewer provide guidance for patients with specific combinations of diseases. Managing patients with multiple     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ conditions is more complex than managing patients with a single disease, and the presence of multiple           │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ conditions increases challenges for healthcare providers and patients. Comorbidities may constitute barriers to │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ adherence to CPGs, and caring for patients with multiple comorbidities can affect patient safety if             │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ recommendations for diagnosis and treatment in one CPG conflict with those for another condition (16). The      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ complexity of various regimens for multiple comorbidities adds to the difficulty in patient management and      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ assessment of clinical outcomes (17). Furthermore, limited attention has been given to the physical, cognitive, │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ social, psychological, and financial implications of managing comorbidities. Involving patients in the CPG      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ development process, which the AHA/ACC recently initiated, is critically important to fully appreciate patient  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ perspectives (18,19).                                                                                           │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Currently, there are important challenges in addressing common comorbidities in the development and             │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ implementation                                                                                                  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # J A C C V O L . 73, N O . 24, 2019                                                                            │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # Grundy et al. e315                                                                                            │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # J U N E 25, 2019: e 285 - 350                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # 2018 Cholesterol Clinical Practice Guideline                                                                  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # T A B L E 9 Normal and Abnormal Lipid Values in Childhood*                                                    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ | |Acceptable, mg/dL|Borderline, mg/dL|Abnormal, mg/dL|                                                         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |---|---|---|---|                                                                                               │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |TC|&amp;lt;170 (&amp;lt;4.3 mmol/L)|170-199 (4.3-5.1 mmol/L)|$200 ($5.1 mmol/L)|                                       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |Triglycerides (0-9 y)|&amp;lt;75 (&amp;lt;0.8 mmol/L)|75-99 (0.8-1.1 mmol/L)|$100 ($1.1 mmol/L)|                       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |Triglycerides (10-19 y)|&amp;lt;90 (&amp;lt;1.0 mmol/L)|90-129 (1.0-1.5 mmol/L)|$130 ($1.4 mmol/L)|                    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |HDL-C|&amp;gt;45 (&amp;gt;1.2 mmol/L)|40-45 (1.0-1.2 mmol/L)|&amp;lt;40 (&amp;lt;1.0 mmol/L)|                                  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |LDL-C|&amp;lt;110 (&amp;lt;2.8 mmol/L)|110-129 (2.8-3.3 mmol/L)|$130 ($3.4 mmol/L)|                                    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |Non–HDL-C|&amp;lt;120 (&amp;lt;3.1 mmol/L)|120-144 (3.1-3.7 mmol/L)|$145 ($3.7 mmol/L)|                                │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Values given are in mg/dL. To convert to SI units, divide the results for TC, LDL-C, HDL-C, and non–HDL-C by    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 38.6; for triglycerides, divide by 88.6.                                                                        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ *Values for plasma lipid and lipoprotein levels are from the NCEP Expert Panel on Cholesterol Levels in         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Children. Non–HDL-C values from the Bogalusa Heart Study are equivalent to the NCEP Pediatric Panel cutpoints   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ for LDL-C.                                                                                                      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ †The cutpoints for high and borderline high represent approximately the 95th and 75th percentiles,              │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ respectively. Low cutpoints for HDL-C represent approximately the 10th percentile.                              │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ HDL-C indicates high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; NCEP,         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ National Cholesterol Education Program; SI, Système international d’unités (International System of Units); and │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ TC, total cholesterol.                                                                                          │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Hypercholesterolemia show reasonable LDL-C lowering with no significant adverse effects (S4.4.4.3-13).          │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Nonsystemic bile acid sequestrants can be useful for LDL-C lowering, but tolerability is an issue               │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ (S4.4.4.3-13—S4.4.4.3-16).                                                                                      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 4. Lipid testing during childhood can identify the severe hypercholesterolemia phenotype (S4.4.4.3-35). Severe  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ hypercholesterolemia, which includes FH, can be identified in children and adolescents with an LDL-C level $190 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ mg/dL ($4.9 mmol/L). Moreover, children and adolescents with LDL-C $160 mg/dL ($4.1 mmol/L) and a family        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ history of early atherosclerosis or similarly elevated cholesterol in 1 parent likely are those with FH and     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ related genetic disorders associated with accelerated ASCVD (S4.4.4.3-17—S4.4.4.3-21).                          │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Subclinical atherosclerosis data suggest divergence between affected and unaffected children and adolescents    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ beginning at age 10 years (S4.4.4.3-28), which supports screening by this age, although this topic is still     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ considered controversial (S4.4.4.3-36). Screening is advised beginning at age 2 years if a family history is    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ suggestive of either early CVD or significant primary hypercholesterolemia. Identification of a child with      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ severe hypercholesterolemia should prompt screening of extended family members (e.g., reverse-cascade           │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ screening), according to studies outside the United States demonstrating efficacy of this approach              │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ (S4.4.4.3-37). Screening for severe                                                                             │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # J A C C V O L . 7 7 , N O . 4 , 2 0 2 1                                                                       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease                                           │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ capacity or an abnormal blood pressure response. Recording aortic valve hemodynamics with exercise is of        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ limited value and does not show additive value for predicting clinical outcome when baseline measures of        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ hemodynamic severity and functional status are considered. In addition, recording hemodynamics with exercise is │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ challenging, and simpler parameters are adequate in most patients (2–4,6–11).                                   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ As reported in several prospective and retrospective studies, the risk of exercise testing is low in            │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ asymptomatic patients with AS. However, exercise testing is avoided in symptomatic patients with AS because of  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ a high risk of complications, including syncope, ventricular tachycardia, and death. In a prospective survey of │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 20 medical centers in Sweden that included 50,000 exercise tests done over an 18-month period, the complication │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ rate was 18.4 per 10,000 tests; morbidity rate, 5.2 per 10,000 tests; and mortality rate, 0.4 per 10,000 tests. │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Although the number of patients with AS was not reported, 12 of the 92 complications occurred in patients with  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ AS: 8 had a decline in blood pressure during exercise, 1 had asystole, and 3 had ventricular tachycardia        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ (2,4,5,7–10,12).                                                                                                │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # 3.2.2. Medical Therapy                                                                                        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # Recommendations for Medical Therapy of AS                                                                     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Referenced studies that support the recommendations are summarized in Online Data Supplement 5.                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |COR|LOE|RECOMMENDATIONS|                                                                                       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |---|---|---|                                                                                                   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |1|B-NR|In patients at risk of developing AS (Stage A) and in patients with asymptomatic AS (Stages B and C),   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ hypertension should be treated according to standard GDMT, started at a low dose, and gradually titrated upward │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ as needed, with appropriate clinical monitoring (1–3).|                                                         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |1|A|In all patients with calcific AS, statin therapy is indicated for primary and secondary prevention of      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ atherosclerosis on the basis of standard risk scores (4–6).|                                                    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |2b|B-NR|In patients who have undergone TAVI, renin–angiotensin system blocker therapy (ACE inhibitor or ARB)   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ may be considered to reduce the long-term risk of all-cause mortality (7,8).|                                   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |3: No Benefit|A|In patients with calcific AS (Stages B and C), statin therapy is not indicated for prevention  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ of hemodynamic progression of AS (4–6).|                                                                        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # Synopsis                                                                                                      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Medical treatment of hypertension and hyperlipidemia according to GDMT is appropriate for patients with AS. ACE │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ inhibitor or ARB treatment may reduce the mortality rate in patients with AS who underwent TAVI.                │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # Recommendation-Specific Supportive Text                                                                       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 1. Hypertension is common in patients with AS, may be a risk factor for AS, and adds to the total pressure      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ overload on the LV in combination with valve obstruction. Concern that antihypertensive medications might       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ result in a decrease in cardiac output has not been corroborated in studies of medical therapy, including 2     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ small RCTs, likely because AS does not result in “fixed” valve obstruction until late in the disease process.   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ In 1616 patients with asymptomatic AS in the SEAS (Simvastatin Ezetimibe in Aortic Stenosis) study,             │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ hypertension (n=1340) was associated with a 56% higher rate of ischemic cardiovascular events and a 2-fold      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ higher mortality rate (both P&lt;0.01) than those seen in normotensive patients with AS, although no impact on     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ mortality was observed.                                                                                         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 2. Concurrent CAD is common in patients with AS, and all patients should be screened and treated for            │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ hypercholesterolemia, with GDMT used for primary and secondary prevention of CAD. In RCTs of statin therapy for │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ mild to moderate AS, although aortic valve event rates...                                                       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # e300 Grundy et al.                                                                                            │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # J A C C V O L . 7 3 , N O . 2 4 , 2 0 1 9                                                                     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # 2018 Cholesterol Clinical Practice Guideline                                                                  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # J U N E 2 5 , 2 0 1 9 : e 2 8 5 - 3 5 0                                                                       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ LDL-C is inadequately controlled with drug therapy, LDL apheresis is an option. Referral to a lipid specialist  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ may be indicated.                                                                                               │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # Recommendation-Specific Supportive Text                                                                       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 1. Patients with primary severe hypercholesterolemia (LDL-C levels ≥190 mg/dL [≥4.9 mmol/L]) have a high-risk   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ of ASCVD (S4.2-2, S4.2-4, S4.2-18) and premature and recurrent coronary events (S4.2-3). Although there have    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ been no randomized, placebo-controlled trials of statin therapy done exclusively in subjects with LDL-C levels  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ ≥190 mg/dL (≥4.9 mmol/L), a placebo-controlled primary prevention study performed in men with a mean baseline   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ LDL-C level of 192.17 mg/dL (4.90.4 mmol/L) demonstrated a reduced incidence of MI and cardiovascular death in  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ those receiving pravastatin 40 mg daily (S4.2-5). These findings were extended in a post hoc analysis of 2,560  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ exclusively primary-prevention subjects in that RCT and in a 20-year observational post-trial long-term         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ follow-up study (S4.2-19). In addition, retrospective cohort studies have demonstrated that statin therapy      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ reduces risk of incident MI (S4.2-6) and of CHD and all-cause death (S4.2-1) in patients with phenotypic or     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ genetically confirmed FH. Because moderate- or high-intensity statins have been shown to reduce ASCVD risk in   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ both primary- and secondary-prevention trials and because high-intensity statins provide greater ASCVD risk     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ reduction than moderate-intensity statins or placebo (S4.2-7), maximally tolerated statin therapy should be     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ administered to patients with primary severe hypercholesterolemia.                                              │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 2. A large placebo-controlled RCT examined the effect of simvastatin 80 mg daily, with or without ezetimibe 10  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ mg daily, on carotid intima-media thickness and plasma lipoproteins over 2 years. Mean LDL-C reduction was      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ greater in the combined-therapy group, but there was no difference in carotid intima-media thickness between    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ the 2 groups. The study was not powered to examine the risk of ASCVD events (S4.2-10). However, a very large    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ placebo-controlled RCT examining ASCVD outcomes in post-ACS patients, performed over a period of 7 years,       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ showed that the addition of ezetimibe 10 mg to simvastatin 40 mg daily resulted in greater ASCVD risk reduction │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ than that produced by statin monotherapy (S4.2-8). Secondary-prevention patients with certain ASCVD risk        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ indicators exhibit greater ASCVD risk reduction from ezetimibe therapy than do patients without these           │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ characteristics (S4.2-20). Patients with severe hypercholesterolemia who are adherent to statins, achieve &lt;50%  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ reduction in LDL-C levels with maximally tolerated statin therapy, and have an LDL-C level ≥100 mg/dL (≥2.6     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ mmol/L) are likely to derive additional ASCVD risk reduction from ezetimibe add-on therapy through additional   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ LDL-C lowering (S4.2-9).                                                                                        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 3. When administered to patients with severe hypercholesterolemia who are taking maximally tolerated statins    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ with or without ezetimibe, bile acid sequestrants have demonstrated LDL-C-lowering efficacy (S4.2-11, S4.2-12). │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ However, the clinical utility of bile acid sequestrants is limited by the absence of ASCVD outcomes data when   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ used in combination with statins, as well as by the issues of twice-daily dosing, high pill burden, the absence │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ of well-tolerated generic formulations, drug interactions, and the potential for triglyceride elevation.        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Nonetheless, in patients with very severe hypercholesterolemia, adding sequestrants to otherwise maximal        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ cholesterol-lowering therapy in patients who are not eligible for a PCSK9 inhibitor may be considered.          │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 4. PCSK9 inhibitors are promising drugs for treatment of FH                                                     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ prevention of cardiovascular disease: an opportunity to harmonize guidelines. JAMA Cardiol. 2017;2:1175–6.      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ S4.4.4.2-10. Berry JD, Dyer A, Cai X, et al. Lifetime risks of cardiovascular disease. N Engl J Med. 2012;      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 366:321–9.                                                                                                      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ S4.4.4.2-11. Lehr AL, Driver SL, Stone NJ. The ABCDs of lifestyle counseling. JAMA Cardiol. 2016;1:505–6.       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ S4.4.4.2-12. Omura JD, Watson KB, Loustalot F, et al. Primary care providers’ awareness of physical             │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ activity-related intensive behavioral counseling services for cardiovascular disease prevention. Am J Health    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Promot. 2018. 890117118784226.                                                                                  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # 4.4.4.3. Children and Adolescents                                                                             │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ S4.4.4.3-1. Iannuzzi A, Licenziati MR, Vacca M, et al. Comparison of two diets of varying glycemic index on     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ carotid subclinical atherosclerosis in obese children. Heart Vessels. 2009;24:419–24.                           │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ S4.4.4.3-2. Murphy EC, Carson L, Neal W, et al. Effects of an exercise intervention using Dance Dance           │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Revolution on endothelial function and other risk factors in overweight children. Int J Pediatr Obes.           │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 2009;4:205–14.                                                                                                  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ S4.4.4.3-3. Pratt RE, Kavey RE, Quinzi D. Combined dyslipidemia in obese children: response to a focused        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ lifestyle approach. J Clin Lipidol. 2014;8:181–6.                                                               │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ S4.4.4.3-4. de Ferranti SD, Milliren CE, Denhoff ER, et al. Providing food to treat adolescents at risk for     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ cardiovascular disease. Obesity (Silver Spring). 2015; 23:2109–17.                                              │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ S4.4.4.3-5. Niinikoski H, Lagstrom H, Jokinen E, et al. Impact of repeated dietary counseling between infancy   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ and 14 years of age on dietary intakes and serum lipids and lipoproteins: the STRIP study. Circulation. 2007;   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 116:1032–40.                                                                                                    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ S4.4.4.3-6. Obarzanek E, Kimm SY, Barton BA, et al. Long-term safety and efficacy of a cholesterol-lowering     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ diet in children with elevated low-density lipoprotein cholesterol: seven-year results of the Dietary           │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Intervention Study in Children (DISC). Pediatrics. 2001;107:256–64.                                             │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ S4.4.4.3-7. Dorgan JF, Liu L, Barton BA, et al. Adolescent diet and metabolic syndrome in young women: results  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ of the Dietary Intervention Study in Children (DISC) follow-up study. J Clin Endocrinol Metab.                  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 2011;96:E1999–2008.                                                                                             │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ S4.4.4.3-8. Wong H, Chahal N, Manlhiot C, et al. Flaxseed in pediatric hyperlipidemia: a placebo-controlled,    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ blinded, randomized clinical trial of dietary flaxseed supplementation for children and adolescents with        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ hypercholesterolemia. JAMA Pediatr. 2013;167:708–13.                                                            │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ S4.4.4.3-9. Zachariah JP, Chan J, Mendelson MM, et al. Adolescent dyslipidemia and standardized lifestyle       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ modification: benchmarking real-world practice. J Am Coll Cardiol. 2016;68:2122–3.                              │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ S4.4.4.3-10. Torvik K, Narverud I, Ottestad I, et al. Dietary counseling is associated with an improved lipid   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ profile in children with familial hypercholesterolemia. Atherosclerosis. 2016;252:21–7.                         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ S4.4.4.3-11. Koletzko B, Kupke I, Wendel U. Treatment of hypercholesterolemia in children and adolescents. Acta │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Paediatr. 1992;81:682–5.                                                                                        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ S4.4.4.3-12. Tershakovec AM, Shannon BM, Achterberg CL, et al. One-year follow-up of nutrition education for    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ hypercholesterolemic children.                                                                                  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # Grundy et al.                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # J A C C V O L . 7 3 , N O . 2 4 , 2 0 1 9                                                                     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # 2018 Cholesterol Clinical Practice Guideline                                                                  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # J U N E 2 5 , 2 0 1 9 : e 2 8 5 - 3 5 0                                                                       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # Table 3 High-, Moderate-, and Low-Intensity Statin Therapy*                                                   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |High Intensity| | |Moderate Intensity|Low Intensity|                                                           │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |---|---|---|---|---|                                                                                           │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |LDL-C lowering†|≥50%| |30%–49%|&amp;lt;30%|                                                                        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |Statins|Atorvastatin (40 mg‡) 80 mg Rosuvastatin 20 mg (40 mg)|Atorvastatin 10 mg (20 mg) Rosuvastatin (5 mg)  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 10 mg Simvastatin 20–40 mg§ Pravastatin 40 mg (80 mg) Lovastatin 40 mg (80 mg) Fluvastatin XL 80 mg Fluvastatin │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 40 mg BID Pitavastatin 1–4 mg|Simvastatin 10 mg Pravastatin 10–20 mg Lovastatin 20 mg Fluvastatin 20–40 mg| |   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Percent LDL-C reductions with the primary statin medications used in clinical practice (atorvastatin,           │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ rosuvastatin, simvastatin) were estimated using the median reduction in LDL-C from the VOYAGER database         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ (S3.2.1-2). Reductions in LDL-C for other statin medications (fluvastatin, lovastatin, pitavastatin,            │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ pravastatin) were identified according to FDA-approved product labeling in adults with hyperlipidemia, primary  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ hypercholesterolemia, and mixed dyslipidemia (S3.2.1-4). Boldface type indicates specific statins and doses     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ that were evaluated in RCTs (S3.2.1-3, S3.2.1-5—S3.2.1-16), and the Cholesterol Treatment Trialists’ 2010       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ meta-analysis (S3.2.1-17). All these RCTs demonstrated a reduction in major cardiovascular events.              │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ *Percent reductions are estimates from data across large populations. Individual responses to statin therapy    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ varied in the RCTs and should be expected to vary in clinical practice (S3.2.1-2).                              │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ †LDL-C lowering that should occur with the dosage listed below each intensity.                                  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ ‡Evidence from 1 RCT only: down titration if unable to tolerate atorvastatin 80 mg in the IDEAL (Incremental    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Decrease through Aggressive Lipid Lowering) study (S3.2.1-3).                                                   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ §Although simvastatin 80 mg was evaluated in RCTs, initiation of simvastatin 80 mg or titration to 80 mg is not │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ recommended by the FDA because of the increased risk of myopathy, including rhabdomyolysis.                     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ BID indicates twice daily; FDA, U.S. Food and Drug Administration; LDL-C, low-density lipoprotein cholesterol;  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ RCT, randomized controlled trial; VOYAGER, an individual patient data meta-analysis of statin therapy in        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ at-risk groups: effects of rosuvastatin, atorvastatin, and simvastatin; and XL, extended release.               │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # 3.1.2. Lifestyle Therapies and Metabolic Syndrome                                                             │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Lifestyle therapies are particularly indicated for the metabolic syndrome, which is a cluster of risk factors   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ associated with an increased risk of ASCVD, diabetes mellitus, and all-cause death (S3.1.2-1, S3.1.2-2).        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Metabolic syndrome is a risk-enhancing factor for ASCVD. The most widely used clinical definition of metabolic  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ syndrome is that proposed by an international consortium of cardiovascular and diabetes organizations           │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ (S3.1.2-3). The diagnosis is made by the presence of any 3 of the following 5 risk factors: elevated waist      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ circumference, elevated serum triglycerides, reduced HDL-C, elevated blood pressure, and elevated fasting       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ glucose (Table S2 in the Web Supplement). Metabolic syndrome is closely linked to excess weight and             │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ particularly to abdominal obesity (S3.1.2-4). Therefore, the prevalence of metabolic syndrome has risen sharply │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ among both adults and children as levels of overweight and obesity have risen. Metabolic                        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[32m╭─\u001b[0m\u001b[32m─────────────────────────────────────────────\u001b[0m Tool Response Added \u001b[32m─────────────────────────────────────────────\u001b[0m\u001b[32m─╮\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mTool output added to messages:\u001b[0m\u001b[32m                                                                                 \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mreceived service or treatment for the specific condition. Detailed information on the identification of chronic\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mconditions is available from the CMS Chronic Conditions Data Warehouse (13).\u001b[0m\u001b[32m                                   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# Table 1\u001b[0m\u001b[32m                                                                                                      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mTable 1 shows the 10 most common comorbidities for each index cardiovascular condition for beneficiaries ‡65 \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32myears of age in 2012 (13). The numbers of Medicare beneficiaries with the 4 index cardiovascular conditions \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mwere 8,678,060 with ischemic heart disease, 4,366,489 with heart failure, 2,556,839 with atrial fibrillation, \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mand 1,145,719 with stroke. Two conditions that are major cardiovascular risk factors—hypertension and \u001b[0m\u001b[32m         \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mhyperlipidemia—constitute the most frequent dyad. Hypertension, hyperlipidemia, and ischemic heart disease were\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mthe 3 most prevalent comorbidities for patients with heart failure, atrial fibrillation, and stroke, whereas \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mhypertension, hyperlipidemia, and diabetes mellitus were the most prevalent comorbidities in those with \u001b[0m\u001b[32m       \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mischemic heart disease; however, arthritis, anemia, chronic obstructive pulmonary disease, and Alzheimer’s \u001b[0m\u001b[32m    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mdisease also appeared.\u001b[0m\u001b[32m                                                                                         \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# Table 2\u001b[0m\u001b[32m                                                                                                      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mTable 2 lists the top 5 most prevalent dyad and triad comorbidities for beneficiaries ‡65 years of age with at \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mleast 2 (for dyads) or 3 (for triads) chronic conditions. Combinations of high cholesterol, high blood \u001b[0m\u001b[32m        \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mpressure, and ischemic heart disease were most frequently represented in the dyads and triads, with diabetes \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mmellitus and arthritis completing the remaining prevalent combinations (14).\u001b[0m\u001b[32m                                   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mthan in former smokers, and there was a significant relationship between the severity of carotid stenosis and \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mpack-years of exposure to tobacco (239). The RRs of finding 60% carotid stenosis were 1.5 and 3.9 among \u001b[0m\u001b[32m       \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mcigarette smokers with cerebral ischemia in the NOMASS and the BCID (Berlin Cerebral Ischemia Databank) \u001b[0m\u001b[32m       \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mstudies, respectively (258).\u001b[0m\u001b[32m                                                                                   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# 6.3. Control of Hyperlipidemia\u001b[0m\u001b[32m                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# 6.3.1. Recommendations for Control of Hyperlipidemia\u001b[0m\u001b[32m                                                         \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mCLASS I\u001b[0m\u001b[32m                                                                                                        \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m1. Treatment with a statin medication is recommended for all patients with extracranial carotid or vertebral \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32matherosclerosis to reduce low-density lipoprotein (LDL) cholesterol below 100 mg/dL (111,259,260). (Level of \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mEvidence: B)\u001b[0m\u001b[32m                                                                                                   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mCLASS IIa\u001b[0m\u001b[32m                                                                                                      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m1. Treatment with a statin medication is reasonable for all patients with extracranial carotid or vertebral \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32matherosclerosis who sustain ischemic stroke to reduce LDL-cholesterol to a level near or below 70 mg/dL (259). \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m(Level of Evidence: B)\u001b[0m\u001b[32m                                                                                         \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m2. If treatment with a statin (including trials of higher-dose statins and higher-potency statins) does not \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32machieve the goal selected for a patient, intensifying LDL-lowering drug therapy with an additional drug from \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mamong those with evidence of improving outcomes (i.e., bile acid sequestrants or niacin) can be effective \u001b[0m\u001b[32m     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m(261–264). (Level of Evidence: B)\u001b[0m\u001b[32m                                                                              \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m3. For patients who do not tolerate statins, LDL-lowering therapy with bile acid sequestrants and/or niacin is \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mreasonable (261,263,265). (Level of Evidence: B)\u001b[0m\u001b[32m                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mThe relationship between cholesterol and ischemic stroke is not as evident as that between cholesterol and MI, \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mand findings from population-based studies are inconsistent. In the MR FIT (Multiple Risk Factor Intervention \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mTrial), comprising more than 350,000 men, the RR of death increased progressively with serum cholesterol, \u001b[0m\u001b[32m     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mexceeding 2.5 in those with the highest levels (266). An analysis of 45 prospective observational cohorts \u001b[0m\u001b[32m     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32minvolving approximately 450,000 individuals, however, found no association of hypercholesterolemia with stroke \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m(267). In the ARIC study, the relationships between lipid values and incident ischemic.\u001b[0m\u001b[32m                        \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# J A C C V O L . 73, N O . 2 4 , 2 0 1 9\u001b[0m\u001b[32m                                                                      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# Grundy et al. e313\u001b[0m\u001b[32m                                                                                           \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# J U N E 25, 2 0 1 9 : e 2 8 5 - 3 5 0\u001b[0m\u001b[32m                                                                        \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# 2018 Cholesterol Clinical Practice Guideline\u001b[0m\u001b[32m                                                                 \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mAs discussed in these guidelines (Section 4.2.) FH often goes undiagnosed. Young adults with primary elevations\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mof LDL-C ≥ 190 mg/dl have a long-term ASCVD burden (S4.4.4.2-3), and statin therapy is recommended. In adults \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mwith hypercholesterolemia, cascade screening often identifies other family members with elevated LDL-C (Section\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m4.2.).\u001b[0m\u001b[32m                                                                                                         \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mHowever, even moderate hypercholesterolemia can accelerate development of atherosclerosis (S4.4.4.2-4). \u001b[0m\u001b[32m       \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mSecondary causes of elevated cholesterol—hypothyroidism (TSH), obstructive liver disease (liver panel), renal \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mdisease and nephrosis (creatinine and urine analysis) as well as dietary and medication history—should be \u001b[0m\u001b[32m     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32maddressed appropriately (S4.4.4.2-5). Elevations of LDL-C persisting after excluding secondary causes suggests \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mgenetic forms of hypercholesterolemia. Young adults who experience prolonged exposure to hyperlipidemia prior \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mto age 55 are shown to have significantly increased risk of coronary heart disease (S4.4.4.2-6). Intensive \u001b[0m\u001b[32m    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mlifestyle change has the potential to reduce the hyperlipidemia and associated ASCVD risk factor burden.\u001b[0m\u001b[32m       \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mA smaller group, but even at higher risk, are young adults with persistent, moderate hypercholesterolemia \u001b[0m\u001b[32m     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m(LDL-C 160-189 mg/dL), especially when risk-enhancing factors, such as a family history of premature ASCVD, are\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mpresent. Since there is increased probability of genetic FH in this LDL-C range, clinical judgment would \u001b[0m\u001b[32m      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32msuggest that these high risk young adults will benefit from long-term statin therapy (S4.4.4.2-7) (Section \u001b[0m\u001b[32m    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m4.2.). Indeed, it has been shown that those with higher LDL-C can gain as much or more benefit from cholesterol\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mreduction as do those with lower pretreatment LDL-C but at higher risk (S4.4.4.2-8, S4.4.4.2-9).\u001b[0m\u001b[32m               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mIn young adults without phenotypically severe hypercholesterolemia, risk assessment should begin by estimation \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mof lifetime risk (S4.4.4.2-10). The pooled cohort equations (PCE) can be used to estimate lifetime risk \u001b[0m\u001b[32m       \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mstarting at age 21 years (see Section 4.4.2.). This information can inform a focused risk discussion designed \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mto improve high-risk lifestyle behaviors including tobacco use, sedentary lifestyle and/or poor diet \u001b[0m\u001b[32m          \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m(S4.4.4.2-11, S4.4.4.2-12). When young adults with hypercholesterolemia or multiple risk factors are \u001b[0m\u001b[32m          \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32midentified, lifestyle intervention is indicated. To date, no long-term RCTs with cholesterol-lowering drugs \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mhave been carried out in those 20 to 39 years age. However, a primary prevention RCT in those younger \u001b[0m\u001b[32m         \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mindividuals at low to moderate short-term risk, but at high lifetime risk has been proposed (S4.4.4.2-13).\u001b[0m\u001b[32m     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mOne approach to identifying young adults who could benefit from statins or drug combination would be to detect \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32msignificant coronary atherosclerosis with coronary artery calcium (CAC) scores. Its use for this purpose has \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mbeen suggested (S4.4.4.2-14). But again, absence of RCT data precludes guideline recommendations at this time.\u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# 4.4.4.3. Children and Adolescents\u001b[0m\u001b[32m                                                                            \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# Recommendations for Children and Adolescents\u001b[0m\u001b[32m                                                                 \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mReferenced studies that support recommendations are summarized in Online Data Supplements 18 to 21.\u001b[0m\u001b[32m            \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|COR|LOE|RECOMMENDATIONS|\u001b[0m\u001b[32m                                                                                      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|---|---|---|\u001b[0m\u001b[32m                                                                                                  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|I|A|In children and adolescents with lipid disorders related to obesity, it is recommended to intensify \u001b[0m\u001b[32m      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mlifestyle therapy, including moderate caloric restriction and regular aerobic physical activity \u001b[0m\u001b[32m               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m(S4.4.4.3-1—S4.4.4.3-4).|\u001b[0m\u001b[32m                                                                                      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|I|B-NR|In children and adolescents with lipid abnormalities, lifestyle counseling is beneficial for lowering \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mLDL-C (S4.4.4.3-1—S4.4.4.3-3,\u001b[0m\u001b[32m                                                                                  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mThe diagnosis is made by the presence of any 3 of the following 5 risk factors: elevated waist circumference, \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32melevated serum triglycerides, reduced HDL-C, elevated blood pressure, and elevated fasting glucose (Table S2 in\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mthe Web Supplement). Metabolic syndrome is closely linked to excess weight and particularly to abdominal \u001b[0m\u001b[32m      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mobesity (S3.1.2-4). Therefore, the prevalence of metabolic syndrome has risen sharply among both adults and \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mchildren as levels of overweight and obesity have risen. Metabolic syndrome is now found in approximately \u001b[0m\u001b[32m     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mone-third of the adults in the United States (S3.1.2-5) and is likely under-recognized because of insufficient \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mrates of screening. The prevalence of metabolic syndrome increases with age and very commonly occurs in \u001b[0m\u001b[32m       \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mpatients with type 2 diabetes mellitus. See Table S2 in the Web Supplement.\u001b[0m\u001b[32m                                    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# 3.2. Lipid-Lowering Drugs\u001b[0m\u001b[32m                                                                                    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mAmong lipid-lowering drugs, statins are the cornerstone of therapy, in addition to healthy lifestyle \u001b[0m\u001b[32m          \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32minterventions. Other LDL-lowering drugs include ezetimibe, bile acid sequestrants, and PCSK9 inhibitors. \u001b[0m\u001b[32m      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mTriglyceride-lowering drugs are fibrates and niacin; they have a mild LDL-lowering action, but RCTs do not \u001b[0m\u001b[32m    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32msupport their use as add-on drugs to statin therapy (S3.2-1). Characteristics of LDL-lowering drugs are \u001b[0m\u001b[32m       \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32msummarized in Table S3 in the Web Supplement.\u001b[0m\u001b[32m                                                                  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# 3.2.1. Statin Therapy\u001b[0m\u001b[32m                                                                                        \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mThe intensity of statin therapy is divided into 3 categories: high-intensity, moderate-intensity, and \u001b[0m\u001b[32m         \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mlow-intensity (S3.2.1-1). High-intensity statin therapy typically lowers LDL-C levels by ≥50%, \u001b[0m\u001b[32m                \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mmoderate-intensity statin therapy by 30% to 49%, and low-intensity statin therapy by <30% (Table 3). Of course,\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mthe magnitude of LDL-C lowering will vary in clinical practice (S3.2.1-2). Certain Asian populations may have a\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mgreater response to certain statins (S3.2.1-18). Pharmacokinetic profiles among statins are heterogeneous \u001b[0m\u001b[32m     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m(Table S4 in the Web Supplement). Statin safety has been extensively evaluated (S3.2.1-19). Statin-associated \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mside effects are discussed in Section 5. Common medications that may potentially interact with statins are \u001b[0m\u001b[32m    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mlisted in Table S5 in the Web Supplement. More information on statin drug–drug interactions can be obtained \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mfrom the ACC LDL-C Manager (S3.2.1-20).\u001b[0m\u001b[32m                                                                        \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# 3.2.2. Nonstatin Therapies\u001b[0m\u001b[32m                                                                                   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mEzetimibe is the most commonly used nonstatin agent. It lowers LDL-C levels by 13% to 20% and has a low \u001b[0m\u001b[32m       \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mincidence of side effects (S3.2.2-1, S3.2.2-2). Bile acid sequestrants reduce LDL-C levels by 15% to 30% \u001b[0m\u001b[32m      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mdepending on the dose. Bile acid sequestrants are not absorbed and do not cause systemic side effects, but they\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mare associated with gastrointestinal complaints (e.g., constipation) and can cause severe hypertriglyceridemia \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mwhen fasting triglycerides are ≥300 mg/dL (≥3.4 mmol/L). PCSK9 inhibitors are powerful LDL-lowering drugs.\u001b[0m\u001b[32m     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# J A C C V O L . 6 4 , N O . 1 7 , 2 0 1 4\u001b[0m\u001b[32m                                                                    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# O C T O B E R 2 8 , 2 0 1 4 : 1 8 5 1 – 6\u001b[0m\u001b[32m                                                                    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# AHA/ACC/HHS Strategies on Comorbidities\u001b[0m\u001b[32m                                                                      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# T A B L E 1 The 10 Most Common Comorbidities for 4 Index Cardiovascular Conditions: 2012 Data for Medicare \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mBeneficiaries $65 Years of Age (13)\u001b[0m\u001b[32m                                                                            \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|Comorbidity|Ischemic Heart Disease* (N = 8,678,060)|HF* (N = 4,366,489)|AF* (N = 2,556,839)|Stroke* (N = \u001b[0m\u001b[32m     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m1,145,719)|\u001b[0m\u001b[32m                                                                                                    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|---|---|---|---|---|\u001b[0m\u001b[32m                                                                                          \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|Hypertension|1 (81.3)|1 (85.6)|1 (84.5)|1 (89.0)|\u001b[0m\u001b[32m                                                             \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|Hyperlipidemia|2 (69.1)|3 (62.6)|2 (64.4)|2 (69.9)|\u001b[0m\u001b[32m                                                           \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|Diabetes mellitus|3 (41.7)|5 (47.1)|7 (37.1)|6 (41.5)|\u001b[0m\u001b[32m                                                        \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|Arthritis|4 (40.6)|6 (45.6)|6 (41.7)|5 (44.2)|\u001b[0m\u001b[32m                                                                \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|Anemia|5 (38.7)|4 (51.2)|5 (43.0)|4 (46.8)|\u001b[0m\u001b[32m                                                                   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|HF|6 (36.3)|Index|4 (50.9)|7 (37.2)|\u001b[0m\u001b[32m                                                                          \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|Ischemic heart disease|Index|2 (72.1)|3 (63.5)|3 (58.1)|\u001b[0m\u001b[32m                                                      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|Chronic kidney disease|7 (30.2)|7 (44.8)|8 (34.4)|8 (35.2)|\u001b[0m\u001b[32m                                                   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|Cataract|8 (21.6)|†|10 (22.6)|†|\u001b[0m\u001b[32m                                                                              \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|COPD|9 (21.0)|8 (30.9)|9 (23.8)|†|\u001b[0m\u001b[32m                                                                            \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|AF|10 (18.7)|9 (28.8)|Index|†|\u001b[0m\u001b[32m                                                                                \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|Alzheimer’s disease/dementia|†|10 (26.3)|†|9 (33.8)|\u001b[0m\u001b[32m                                                          \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|Depression|†|†|†|10 (29.7)|\u001b[0m\u001b[32m                                                                                   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|Stroke|†|†|†|Index|\u001b[0m\u001b[32m                                                                                           \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m*Data shown as rank and percentage of persons with index condition who also had a comorbidity. The percentage \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mis included parenthetically when applicable. †Comorbidity was not in the top 10 for this index condition (13).\u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mAF indicates atrial fibrillation; COPD, chronic obstructive pulmonary disease; and HF, heart failure.\u001b[0m\u001b[32m          \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# IMPLICATIONS AND FUTURE DIRECTIONS IN THE DEVELOPMENT OF CPGs\u001b[0m\u001b[32m                                                \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mTwo general, but important, points emerge from the CMS data. First, a beneficiary with cardiovascular disease \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mbut without at least 1 comorbid chronic condition is the exception rather than the rule. Second, whereas common\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mrisk factors such as hypertension and hyperlipidemia are associated with the index cardiovascular conditions, \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mthe index conditions are associated with a constellation of comorbidities, the pathophysiology of which may be \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mdistinct from the index condition and for which prevalence increases with age or other factors.\u001b[0m\u001b[32m                \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mOrganizations that develop CPGs must now consider comorbidities during the development process for \u001b[0m\u001b[32m            \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mdisease-specific CPGs. For high-prevalence index conditions, few CPGs address comorbidities (15), and even \u001b[0m\u001b[32m    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mfewer provide guidance for patients with specific combinations of diseases. Managing patients with multiple \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mconditions is more complex than managing patients with a single disease, and the presence of multiple \u001b[0m\u001b[32m         \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mconditions increases challenges for healthcare providers and patients. Comorbidities may constitute barriers to\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32madherence to CPGs, and caring for patients with multiple comorbidities can affect patient safety if \u001b[0m\u001b[32m           \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mrecommendations for diagnosis and treatment in one CPG conflict with those for another condition (16). The \u001b[0m\u001b[32m    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mcomplexity of various regimens for multiple comorbidities adds to the difficulty in patient management and \u001b[0m\u001b[32m    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32massessment of clinical outcomes (17). Furthermore, limited attention has been given to the physical, cognitive,\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32msocial, psychological, and financial implications of managing comorbidities. Involving patients in the CPG \u001b[0m\u001b[32m    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mdevelopment process, which the AHA/ACC recently initiated, is critically important to fully appreciate patient \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mperspectives (18,19).\u001b[0m\u001b[32m                                                                                          \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mCurrently, there are important challenges in addressing common comorbidities in the development and \u001b[0m\u001b[32m           \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mimplementation\u001b[0m\u001b[32m                                                                                                 \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# J A C C V O L . 73, N O . 24, 2019\u001b[0m\u001b[32m                                                                           \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# Grundy et al. e315\u001b[0m\u001b[32m                                                                                           \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# J U N E 25, 2019: e 285 - 350\u001b[0m\u001b[32m                                                                                \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# 2018 Cholesterol Clinical Practice Guideline\u001b[0m\u001b[32m                                                                 \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# T A B L E 9 Normal and Abnormal Lipid Values in Childhood*\u001b[0m\u001b[32m                                                   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m| |Acceptable, mg/dL|Borderline, mg/dL|Abnormal, mg/dL|\u001b[0m\u001b[32m                                                        \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|---|---|---|---|\u001b[0m\u001b[32m                                                                                              \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|TC|&lt;170 (&lt;4.3 mmol/L)|170-199 (4.3-5.1 mmol/L)|$200 ($5.1 mmol/L)|\u001b[0m\u001b[32m                                      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|Triglycerides (0-9 y)|&lt;75 (&lt;0.8 mmol/L)|75-99 (0.8-1.1 mmol/L)|$100 ($1.1 mmol/L)|\u001b[0m\u001b[32m                      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|Triglycerides (10-19 y)|&lt;90 (&lt;1.0 mmol/L)|90-129 (1.0-1.5 mmol/L)|$130 ($1.4 mmol/L)|\u001b[0m\u001b[32m                   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|HDL-C|&gt;45 (&gt;1.2 mmol/L)|40-45 (1.0-1.2 mmol/L)|&lt;40 (&lt;1.0 mmol/L)|\u001b[0m\u001b[32m                                 \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|LDL-C|&lt;110 (&lt;2.8 mmol/L)|110-129 (2.8-3.3 mmol/L)|$130 ($3.4 mmol/L)|\u001b[0m\u001b[32m                                   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|Non–HDL-C|&lt;120 (&lt;3.1 mmol/L)|120-144 (3.1-3.7 mmol/L)|$145 ($3.7 mmol/L)|\u001b[0m\u001b[32m                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mValues given are in mg/dL. To convert to SI units, divide the results for TC, LDL-C, HDL-C, and non–HDL-C by \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m38.6; for triglycerides, divide by 88.6.\u001b[0m\u001b[32m                                                                       \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m*Values for plasma lipid and lipoprotein levels are from the NCEP Expert Panel on Cholesterol Levels in \u001b[0m\u001b[32m       \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mChildren. Non–HDL-C values from the Bogalusa Heart Study are equivalent to the NCEP Pediatric Panel cutpoints \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mfor LDL-C.\u001b[0m\u001b[32m                                                                                                     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m†The cutpoints for high and borderline high represent approximately the 95th and 75th percentiles, \u001b[0m\u001b[32m            \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mrespectively. Low cutpoints for HDL-C represent approximately the 10th percentile.\u001b[0m\u001b[32m                             \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mHDL-C indicates high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; NCEP, \u001b[0m\u001b[32m       \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mNational Cholesterol Education Program; SI, Système international d’unités (International System of Units); and\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mTC, total cholesterol.\u001b[0m\u001b[32m                                                                                         \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mHypercholesterolemia show reasonable LDL-C lowering with no significant adverse effects (S4.4.4.3-13). \u001b[0m\u001b[32m        \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mNonsystemic bile acid sequestrants can be useful for LDL-C lowering, but tolerability is an issue \u001b[0m\u001b[32m             \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m(S4.4.4.3-13—S4.4.4.3-16).\u001b[0m\u001b[32m                                                                                     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m4. Lipid testing during childhood can identify the severe hypercholesterolemia phenotype (S4.4.4.3-35). Severe \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mhypercholesterolemia, which includes FH, can be identified in children and adolescents with an LDL-C level $190\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mmg/dL ($4.9 mmol/L). Moreover, children and adolescents with LDL-C $160 mg/dL ($4.1 mmol/L) and a family \u001b[0m\u001b[32m      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mhistory of early atherosclerosis or similarly elevated cholesterol in 1 parent likely are those with FH and \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mrelated genetic disorders associated with accelerated ASCVD (S4.4.4.3-17—S4.4.4.3-21).\u001b[0m\u001b[32m                         \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mSubclinical atherosclerosis data suggest divergence between affected and unaffected children and adolescents \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mbeginning at age 10 years (S4.4.4.3-28), which supports screening by this age, although this topic is still \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mconsidered controversial (S4.4.4.3-36). Screening is advised beginning at age 2 years if a family history is \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32msuggestive of either early CVD or significant primary hypercholesterolemia. Identification of a child with \u001b[0m\u001b[32m    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32msevere hypercholesterolemia should prompt screening of extended family members (e.g., reverse-cascade \u001b[0m\u001b[32m         \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mscreening), according to studies outside the United States demonstrating efficacy of this approach \u001b[0m\u001b[32m            \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m(S4.4.4.3-37). Screening for severe\u001b[0m\u001b[32m                                                                            \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# J A C C V O L . 7 7 , N O . 4 , 2 0 2 1\u001b[0m\u001b[32m                                                                      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease\u001b[0m\u001b[32m                                          \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mcapacity or an abnormal blood pressure response. Recording aortic valve hemodynamics with exercise is of \u001b[0m\u001b[32m      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mlimited value and does not show additive value for predicting clinical outcome when baseline measures of \u001b[0m\u001b[32m      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mhemodynamic severity and functional status are considered. In addition, recording hemodynamics with exercise is\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mchallenging, and simpler parameters are adequate in most patients (2–4,6–11).\u001b[0m\u001b[32m                                  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mAs reported in several prospective and retrospective studies, the risk of exercise testing is low in \u001b[0m\u001b[32m          \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32masymptomatic patients with AS. However, exercise testing is avoided in symptomatic patients with AS because of \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32ma high risk of complications, including syncope, ventricular tachycardia, and death. In a prospective survey of\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m20 medical centers in Sweden that included 50,000 exercise tests done over an 18-month period, the complication\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mrate was 18.4 per 10,000 tests; morbidity rate, 5.2 per 10,000 tests; and mortality rate, 0.4 per 10,000 tests.\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mAlthough the number of patients with AS was not reported, 12 of the 92 complications occurred in patients with \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mAS: 8 had a decline in blood pressure during exercise, 1 had asystole, and 3 had ventricular tachycardia \u001b[0m\u001b[32m      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m(2,4,5,7–10,12).\u001b[0m\u001b[32m                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# 3.2.2. Medical Therapy\u001b[0m\u001b[32m                                                                                       \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# Recommendations for Medical Therapy of AS\u001b[0m\u001b[32m                                                                    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mReferenced studies that support the recommendations are summarized in Online Data Supplement 5.\u001b[0m\u001b[32m                \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|COR|LOE|RECOMMENDATIONS|\u001b[0m\u001b[32m                                                                                      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|---|---|---|\u001b[0m\u001b[32m                                                                                                  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|1|B-NR|In patients at risk of developing AS (Stage A) and in patients with asymptomatic AS (Stages B and C), \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mhypertension should be treated according to standard GDMT, started at a low dose, and gradually titrated upward\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mas needed, with appropriate clinical monitoring (1–3).|\u001b[0m\u001b[32m                                                        \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|1|A|In all patients with calcific AS, statin therapy is indicated for primary and secondary prevention of \u001b[0m\u001b[32m    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32matherosclerosis on the basis of standard risk scores (4–6).|\u001b[0m\u001b[32m                                                   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|2b|B-NR|In patients who have undergone TAVI, renin–angiotensin system blocker therapy (ACE inhibitor or ARB) \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mmay be considered to reduce the long-term risk of all-cause mortality (7,8).|\u001b[0m\u001b[32m                                  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|3: No Benefit|A|In patients with calcific AS (Stages B and C), statin therapy is not indicated for prevention \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mof hemodynamic progression of AS (4–6).|\u001b[0m\u001b[32m                                                                       \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# Synopsis\u001b[0m\u001b[32m                                                                                                     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mMedical treatment of hypertension and hyperlipidemia according to GDMT is appropriate for patients with AS. ACE\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32minhibitor or ARB treatment may reduce the mortality rate in patients with AS who underwent TAVI.\u001b[0m\u001b[32m               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# Recommendation-Specific Supportive Text\u001b[0m\u001b[32m                                                                      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m1. Hypertension is common in patients with AS, may be a risk factor for AS, and adds to the total pressure \u001b[0m\u001b[32m    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32moverload on the LV in combination with valve obstruction. Concern that antihypertensive medications might \u001b[0m\u001b[32m     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mresult in a decrease in cardiac output has not been corroborated in studies of medical therapy, including 2 \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32msmall RCTs, likely because AS does not result in “fixed” valve obstruction until late in the disease process. \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mIn 1616 patients with asymptomatic AS in the SEAS (Simvastatin Ezetimibe in Aortic Stenosis) study, \u001b[0m\u001b[32m           \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mhypertension (n=1340) was associated with a 56% higher rate of ischemic cardiovascular events and a 2-fold \u001b[0m\u001b[32m    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mhigher mortality rate (both P<0.01) than those seen in normotensive patients with AS, although no impact on \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mmortality was observed.\u001b[0m\u001b[32m                                                                                        \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m2. Concurrent CAD is common in patients with AS, and all patients should be screened and treated for \u001b[0m\u001b[32m          \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mhypercholesterolemia, with GDMT used for primary and secondary prevention of CAD. In RCTs of statin therapy for\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mmild to moderate AS, although aortic valve event rates...\u001b[0m\u001b[32m                                                      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# e300 Grundy et al.\u001b[0m\u001b[32m                                                                                           \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# J A C C V O L . 7 3 , N O . 2 4 , 2 0 1 9\u001b[0m\u001b[32m                                                                    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# 2018 Cholesterol Clinical Practice Guideline\u001b[0m\u001b[32m                                                                 \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# J U N E 2 5 , 2 0 1 9 : e 2 8 5 - 3 5 0\u001b[0m\u001b[32m                                                                      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mLDL-C is inadequately controlled with drug therapy, LDL apheresis is an option. Referral to a lipid specialist \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mmay be indicated.\u001b[0m\u001b[32m                                                                                              \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# Recommendation-Specific Supportive Text\u001b[0m\u001b[32m                                                                      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m1. Patients with primary severe hypercholesterolemia (LDL-C levels ≥190 mg/dL [≥4.9 mmol/L]) have a high-risk \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mof ASCVD (S4.2-2, S4.2-4, S4.2-18) and premature and recurrent coronary events (S4.2-3). Although there have \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mbeen no randomized, placebo-controlled trials of statin therapy done exclusively in subjects with LDL-C levels \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m≥190 mg/dL (≥4.9 mmol/L), a placebo-controlled primary prevention study performed in men with a mean baseline \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mLDL-C level of 192.17 mg/dL (4.90.4 mmol/L) demonstrated a reduced incidence of MI and cardiovascular death in \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mthose receiving pravastatin 40 mg daily (S4.2-5). These findings were extended in a post hoc analysis of 2,560 \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mexclusively primary-prevention subjects in that RCT and in a 20-year observational post-trial long-term \u001b[0m\u001b[32m       \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mfollow-up study (S4.2-19). In addition, retrospective cohort studies have demonstrated that statin therapy \u001b[0m\u001b[32m    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mreduces risk of incident MI (S4.2-6) and of CHD and all-cause death (S4.2-1) in patients with phenotypic or \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mgenetically confirmed FH. Because moderate- or high-intensity statins have been shown to reduce ASCVD risk in \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mboth primary- and secondary-prevention trials and because high-intensity statins provide greater ASCVD risk \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mreduction than moderate-intensity statins or placebo (S4.2-7), maximally tolerated statin therapy should be \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32madministered to patients with primary severe hypercholesterolemia.\u001b[0m\u001b[32m                                             \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m2. A large placebo-controlled RCT examined the effect of simvastatin 80 mg daily, with or without ezetimibe 10 \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mmg daily, on carotid intima-media thickness and plasma lipoproteins over 2 years. Mean LDL-C reduction was \u001b[0m\u001b[32m    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mgreater in the combined-therapy group, but there was no difference in carotid intima-media thickness between \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mthe 2 groups. The study was not powered to examine the risk of ASCVD events (S4.2-10). However, a very large \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mplacebo-controlled RCT examining ASCVD outcomes in post-ACS patients, performed over a period of 7 years, \u001b[0m\u001b[32m     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mshowed that the addition of ezetimibe 10 mg to simvastatin 40 mg daily resulted in greater ASCVD risk reduction\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mthan that produced by statin monotherapy (S4.2-8). Secondary-prevention patients with certain ASCVD risk \u001b[0m\u001b[32m      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mindicators exhibit greater ASCVD risk reduction from ezetimibe therapy than do patients without these \u001b[0m\u001b[32m         \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mcharacteristics (S4.2-20). Patients with severe hypercholesterolemia who are adherent to statins, achieve <50% \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mreduction in LDL-C levels with maximally tolerated statin therapy, and have an LDL-C level ≥100 mg/dL (≥2.6 \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mmmol/L) are likely to derive additional ASCVD risk reduction from ezetimibe add-on therapy through additional \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mLDL-C lowering (S4.2-9).\u001b[0m\u001b[32m                                                                                       \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m3. When administered to patients with severe hypercholesterolemia who are taking maximally tolerated statins \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mwith or without ezetimibe, bile acid sequestrants have demonstrated LDL-C-lowering efficacy (S4.2-11, S4.2-12).\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mHowever, the clinical utility of bile acid sequestrants is limited by the absence of ASCVD outcomes data when \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mused in combination with statins, as well as by the issues of twice-daily dosing, high pill burden, the absence\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mof well-tolerated generic formulations, drug interactions, and the potential for triglyceride elevation. \u001b[0m\u001b[32m      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mNonetheless, in patients with very severe hypercholesterolemia, adding sequestrants to otherwise maximal \u001b[0m\u001b[32m      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mcholesterol-lowering therapy in patients who are not eligible for a PCSK9 inhibitor may be considered.\u001b[0m\u001b[32m         \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m4. PCSK9 inhibitors are promising drugs for treatment of FH\u001b[0m\u001b[32m                                                    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mprevention of cardiovascular disease: an opportunity to harmonize guidelines. JAMA Cardiol. 2017;2:1175–6.\u001b[0m\u001b[32m     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mS4.4.4.2-10. Berry JD, Dyer A, Cai X, et al. Lifetime risks of cardiovascular disease. N Engl J Med. 2012; \u001b[0m\u001b[32m    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m366:321–9.\u001b[0m\u001b[32m                                                                                                     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mS4.4.4.2-11. Lehr AL, Driver SL, Stone NJ. The ABCDs of lifestyle counseling. JAMA Cardiol. 2016;1:505–6.\u001b[0m\u001b[32m      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mS4.4.4.2-12. Omura JD, Watson KB, Loustalot F, et al. Primary care providers’ awareness of physical \u001b[0m\u001b[32m           \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mactivity-related intensive behavioral counseling services for cardiovascular disease prevention. Am J Health \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mPromot. 2018. 890117118784226.\u001b[0m\u001b[32m                                                                                 \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# 4.4.4.3. Children and Adolescents\u001b[0m\u001b[32m                                                                            \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mS4.4.4.3-1. Iannuzzi A, Licenziati MR, Vacca M, et al. Comparison of two diets of varying glycemic index on \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mcarotid subclinical atherosclerosis in obese children. Heart Vessels. 2009;24:419–24.\u001b[0m\u001b[32m                          \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mS4.4.4.3-2. Murphy EC, Carson L, Neal W, et al. Effects of an exercise intervention using Dance Dance \u001b[0m\u001b[32m         \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mRevolution on endothelial function and other risk factors in overweight children. Int J Pediatr Obes. \u001b[0m\u001b[32m         \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m2009;4:205–14.\u001b[0m\u001b[32m                                                                                                 \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mS4.4.4.3-3. Pratt RE, Kavey RE, Quinzi D. Combined dyslipidemia in obese children: response to a focused \u001b[0m\u001b[32m      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mlifestyle approach. J Clin Lipidol. 2014;8:181–6.\u001b[0m\u001b[32m                                                              \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mS4.4.4.3-4. de Ferranti SD, Milliren CE, Denhoff ER, et al. Providing food to treat adolescents at risk for \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mcardiovascular disease. Obesity (Silver Spring). 2015; 23:2109–17.\u001b[0m\u001b[32m                                             \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mS4.4.4.3-5. Niinikoski H, Lagstrom H, Jokinen E, et al. Impact of repeated dietary counseling between infancy \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mand 14 years of age on dietary intakes and serum lipids and lipoproteins: the STRIP study. Circulation. 2007; \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m116:1032–40.\u001b[0m\u001b[32m                                                                                                   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mS4.4.4.3-6. Obarzanek E, Kimm SY, Barton BA, et al. Long-term safety and efficacy of a cholesterol-lowering \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mdiet in children with elevated low-density lipoprotein cholesterol: seven-year results of the Dietary \u001b[0m\u001b[32m         \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mIntervention Study in Children (DISC). Pediatrics. 2001;107:256–64.\u001b[0m\u001b[32m                                            \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mS4.4.4.3-7. Dorgan JF, Liu L, Barton BA, et al. Adolescent diet and metabolic syndrome in young women: results \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mof the Dietary Intervention Study in Children (DISC) follow-up study. J Clin Endocrinol Metab. \u001b[0m\u001b[32m                \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m2011;96:E1999–2008.\u001b[0m\u001b[32m                                                                                            \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mS4.4.4.3-8. Wong H, Chahal N, Manlhiot C, et al. Flaxseed in pediatric hyperlipidemia: a placebo-controlled, \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mblinded, randomized clinical trial of dietary flaxseed supplementation for children and adolescents with \u001b[0m\u001b[32m      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mhypercholesterolemia. JAMA Pediatr. 2013;167:708–13.\u001b[0m\u001b[32m                                                           \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mS4.4.4.3-9. Zachariah JP, Chan J, Mendelson MM, et al. Adolescent dyslipidemia and standardized lifestyle \u001b[0m\u001b[32m     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mmodification: benchmarking real-world practice. J Am Coll Cardiol. 2016;68:2122–3.\u001b[0m\u001b[32m                             \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mS4.4.4.3-10. Torvik K, Narverud I, Ottestad I, et al. Dietary counseling is associated with an improved lipid \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mprofile in children with familial hypercholesterolemia. Atherosclerosis. 2016;252:21–7.\u001b[0m\u001b[32m                        \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mS4.4.4.3-11. Koletzko B, Kupke I, Wendel U. Treatment of hypercholesterolemia in children and adolescents. Acta\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mPaediatr. 1992;81:682–5.\u001b[0m\u001b[32m                                                                                       \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mS4.4.4.3-12. Tershakovec AM, Shannon BM, Achterberg CL, et al. One-year follow-up of nutrition education for \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mhypercholesterolemic children.\u001b[0m\u001b[32m                                                                                 \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# Grundy et al.\u001b[0m\u001b[32m                                                                                                \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# J A C C V O L . 7 3 , N O . 2 4 , 2 0 1 9\u001b[0m\u001b[32m                                                                    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# 2018 Cholesterol Clinical Practice Guideline\u001b[0m\u001b[32m                                                                 \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# J U N E 2 5 , 2 0 1 9 : e 2 8 5 - 3 5 0\u001b[0m\u001b[32m                                                                      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# Table 3 High-, Moderate-, and Low-Intensity Statin Therapy*\u001b[0m\u001b[32m                                                  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|High Intensity| | |Moderate Intensity|Low Intensity|\u001b[0m\u001b[32m                                                          \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|---|---|---|---|---|\u001b[0m\u001b[32m                                                                                          \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|LDL-C lowering†|≥50%| |30%–49%|&lt;30%|\u001b[0m\u001b[32m                                                                       \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|Statins|Atorvastatin (40 mg‡) 80 mg Rosuvastatin 20 mg (40 mg)|Atorvastatin 10 mg (20 mg) Rosuvastatin (5 mg) \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m10 mg Simvastatin 20–40 mg§ Pravastatin 40 mg (80 mg) Lovastatin 40 mg (80 mg) Fluvastatin XL 80 mg Fluvastatin\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m40 mg BID Pitavastatin 1–4 mg|Simvastatin 10 mg Pravastatin 10–20 mg Lovastatin 20 mg Fluvastatin 20–40 mg| |\u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mPercent LDL-C reductions with the primary statin medications used in clinical practice (atorvastatin, \u001b[0m\u001b[32m         \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mrosuvastatin, simvastatin) were estimated using the median reduction in LDL-C from the VOYAGER database \u001b[0m\u001b[32m       \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m(S3.2.1-2). Reductions in LDL-C for other statin medications (fluvastatin, lovastatin, pitavastatin, \u001b[0m\u001b[32m          \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mpravastatin) were identified according to FDA-approved product labeling in adults with hyperlipidemia, primary \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mhypercholesterolemia, and mixed dyslipidemia (S3.2.1-4). Boldface type indicates specific statins and doses \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mthat were evaluated in RCTs (S3.2.1-3, S3.2.1-5—S3.2.1-16), and the Cholesterol Treatment Trialists’ 2010 \u001b[0m\u001b[32m     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mmeta-analysis (S3.2.1-17). All these RCTs demonstrated a reduction in major cardiovascular events.\u001b[0m\u001b[32m             \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m*Percent reductions are estimates from data across large populations. Individual responses to statin therapy \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mvaried in the RCTs and should be expected to vary in clinical practice (S3.2.1-2).\u001b[0m\u001b[32m                             \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m†LDL-C lowering that should occur with the dosage listed below each intensity.\u001b[0m\u001b[32m                                 \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m‡Evidence from 1 RCT only: down titration if unable to tolerate atorvastatin 80 mg in the IDEAL (Incremental \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mDecrease through Aggressive Lipid Lowering) study (S3.2.1-3).\u001b[0m\u001b[32m                                                  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m§Although simvastatin 80 mg was evaluated in RCTs, initiation of simvastatin 80 mg or titration to 80 mg is not\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mrecommended by the FDA because of the increased risk of myopathy, including rhabdomyolysis.\u001b[0m\u001b[32m                    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mBID indicates twice daily; FDA, U.S. Food and Drug Administration; LDL-C, low-density lipoprotein cholesterol; \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mRCT, randomized controlled trial; VOYAGER, an individual patient data meta-analysis of statin therapy in \u001b[0m\u001b[32m      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mat-risk groups: effects of rosuvastatin, atorvastatin, and simvastatin; and XL, extended release.\u001b[0m\u001b[32m              \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# 3.1.2. Lifestyle Therapies and Metabolic Syndrome\u001b[0m\u001b[32m                                                            \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mLifestyle therapies are particularly indicated for the metabolic syndrome, which is a cluster of risk factors \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32massociated with an increased risk of ASCVD, diabetes mellitus, and all-cause death (S3.1.2-1, S3.1.2-2). \u001b[0m\u001b[32m      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mMetabolic syndrome is a risk-enhancing factor for ASCVD. The most widely used clinical definition of metabolic \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32msyndrome is that proposed by an international consortium of cardiovascular and diabetes organizations \u001b[0m\u001b[32m         \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m(S3.1.2-3). The diagnosis is made by the presence of any 3 of the following 5 risk factors: elevated waist \u001b[0m\u001b[32m    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mcircumference, elevated serum triglycerides, reduced HDL-C, elevated blood pressure, and elevated fasting \u001b[0m\u001b[32m     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mglucose (Table S2 in the Web Supplement). Metabolic syndrome is closely linked to excess weight and \u001b[0m\u001b[32m           \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mparticularly to abdominal obesity (S3.1.2-4). Therefore, the prevalence of metabolic syndrome has risen sharply\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mamong both adults and children as levels of overweight and obesity have risen. Metabolic\u001b[0m\u001b[32m                       \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">╭───────────────────────────────────────────────────</span> Tool Call <span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">───────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ **Step 1**: LLM calls tool search_bing_grounding                                                                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ **Arguments**:                                                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ {                                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│   \"query\": \"FDA new hyperlipidemia drugs February 2025\"                                                         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ }                                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;34m╭─\u001b[0m\u001b[1;34m──────────────────────────────────────────────────\u001b[0m Tool Call \u001b[1;34m──────────────────────────────────────────────────\u001b[0m\u001b[1;34m─╮\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m**Step 1**: LLM calls tool \u001b[0m\u001b[1;34msearch_bing_grounding\u001b[0m\u001b[1;34m                                                               \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m                                                                                                               \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m**Arguments**:\u001b[0m\u001b[1;34m                                                                                                 \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m{\u001b[0m\u001b[1;34m                                                                                                              \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m  \"query\": \"FDA new hyperlipidemia drugs February 2025\"\u001b[0m\u001b[1;34m                                                        \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m}\u001b[0m\u001b[1;34m                                                                                                              \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008000; text-decoration-color: #008000\">╭──────────────────────────────────────────────</span> Tool Response Added <span style=\"color: #008000; text-decoration-color: #008000\">──────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Tool output added to messages:                                                                                  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ In February 2025, the FDA accepted the Biologics License Application for Lerodalcibep, a novel third-generation │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ PCSK9 inhibitor developed by LIB Therapeutics. This drug aims to reduce low-density lipoprotein cholesterol     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ (LDL-C) for patients with atherosclerotic cardiovascular disease (ASCVD) and primary hyperlipidemia.            │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Lerodalcibep is designed to be a more convenient, once-monthly, subcutaneous injection that does not require    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ refrigeration. The FDA's action date for the review is set for December 12, 2025【0†source】【1†source】.       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[32m╭─\u001b[0m\u001b[32m─────────────────────────────────────────────\u001b[0m Tool Response Added \u001b[32m─────────────────────────────────────────────\u001b[0m\u001b[32m─╮\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mTool output added to messages:\u001b[0m\u001b[32m                                                                                 \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mIn February 2025, the FDA accepted the Biologics License Application for Lerodalcibep, a novel third-generation\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mPCSK9 inhibitor developed by LIB Therapeutics. This drug aims to reduce low-density lipoprotein cholesterol \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m(LDL-C) for patients with atherosclerotic cardiovascular disease (ASCVD) and primary hyperlipidemia. \u001b[0m\u001b[32m          \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mLerodalcibep is designed to be a more convenient, once-monthly, subcutaneous injection that does not require \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mrefrigeration. The FDA's action date for the review is set for December 12, 2025【0†source】【1†source】.\u001b[0m\u001b[32m      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╭──────────────────────────────────────────────────</span> Step Start <span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">───────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">│ **Step 2**: Starting step 2                                                                                     │</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;36m╭─\u001b[0m\u001b[1;36m─────────────────────────────────────────────────\u001b[0m Step Start \u001b[1;36m──────────────────────────────────────────────────\u001b[0m\u001b[1;36m─╮\u001b[0m\n",
       "\u001b[1;36m│\u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m**Step 2**: Starting step 2\u001b[0m\u001b[1;36m                                                                                    \u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m│\u001b[0m\n",
       "\u001b[1;36m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╭───────────────────────────────────────────────</span> Current Messages <span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Messages before API call:                                                                                       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ [                                                                                                               │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   {                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"role\": \"system\",                                                                                           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"content\": \"You are a cardiology-focused AI assistant with access to three tools:\\n1) 'lookup_patient_data' │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ for querying patient records from Azure SQL.\\n2) 'search_acc_guidelines' for official ACC guidelines.\\n3)       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ 'search_bing_grounding' for real-time public information.\\n\\nYou can call these tools in any order, multiple    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ times if needed, to gather all the context.\\nStop calling tools only when you have enough information to        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ provide a final, cohesive answer.\\nThen output your final answer to the user.\"                                  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   },                                                                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   {                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"role\": \"user\",                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"content\": \"I have a 79-year-old patient named Gloria Paul with hyperlipidemia. She's on Atorvastatin. Can  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ you confirm her medical details from the database, check the ACC guidelines for hyperlipidemia, and see if      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ there are any new medication updates from the FDA as of Feb 2025? Then give me a summary.\"                      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   },                                                                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   {                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"role\": \"assistant\",                                                                                        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"content\": null,                                                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"tool_calls\": [                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│       {                                                                                                         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│         \"id\": \"call_wDYynvTCJlXDSeGHihDW3rof\",                                                                  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│         \"type\": \"function\",                                                                                     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│         \"function\": {                                                                                           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│           \"name\": \"lookup_patient_data\",                                                                        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│           \"arguments\": \"{\\\"query\\\": \\\"SELECT * FROM PatientMedicalData WHERE FirstName='Gloria' AND             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ LastName='Paul'\\\"}\"                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│         }                                                                                                       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│       },                                                                                                        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│       {                                                                                                         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│         \"id\": \"call_AcZAtI7rblAPdmxzoC6nxGgg\",                                                                  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│         \"type\": \"function\",                                                                                     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│         \"function\": {                                                                                           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│           \"name\": \"search_acc_guidelines\",                                                                      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│           \"arguments\": \"{\\\"query\\\": \\\"hyperlipidemia\\\"}\"                                                        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│         }                                                                                                       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│       },                                                                                                        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│       {                                                                                                         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│         \"id\": \"call_Wj83hyOr277uKGy1oSceoOi9\",                                                                  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│         \"type\": \"function\",                                                                                     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│         \"function\": {                                                                                           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│           \"name\": \"search_bing_grounding\",                                                                      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│           \"arguments\": \"{\\\"query\\\": \\\"FDA new hyperlipidemia drugs February 2025\\\"}\"                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│         }                                                                                                       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│       }                                                                                                         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     ]                                                                                                           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   },                                                                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   {                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"role\": \"tool\",                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"tool_call_id\": \"call_wDYynvTCJlXDSeGHihDW3rof\",                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"name\": \"lookup_patient_data\",                                                                              │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"content\": \" PatientID FirstName LastName DateOfBirth Gender ContactNumber        EmailAddress              │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Address        City PostalCode Country MedicalCondition  Medications Allergies BloodType LastVisitDate          │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ SmokingStatus AlcoholConsumption ExerciseFrequency            Occupation  Height_cm  Weight_kg BloodPressure    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ HeartRate_bpm  Temperature_C                                                                                    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Notes\\n         1    Gloria     Paul  1944-07-15  Other  428-674-1336 keymary@example.com 62908 Fuentes         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Cove\\\\nLewisberg, MN 13491 Buchananton      59963   India   Hyperlipidemia Atorvastatin      None        O+     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ 2024-03-26  Never Smoker      Light drinker  1-2 times a week Administrator, sports      176.2       77.7       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ 120/79 mmHg             90           37.6 Affect idea turn either see six. Suggest cultural change nice travel  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ year parent. Happen energy level anyone position. Few available thought world development.\"                     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   },                                                                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   {                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"role\": \"tool\",                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"tool_call_id\": \"call_AcZAtI7rblAPdmxzoC6nxGgg\",                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"name\": \"search_acc_guidelines\",                                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"content\": \"received service or treatment for the specific condition. Detailed information on the           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ identification of chronic conditions is available from the CMS Chronic Conditions Data Warehouse (13).\\n\\n#     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Table 1\\n\\nTable 1 shows the 10 most common comorbidities for each index cardiovascular condition for           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ beneficiaries \\u202165 years of age in 2012 (13). The numbers of Medicare beneficiaries with the 4 index        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ cardiovascular conditions were 8,678,060 with ischemic heart disease, 4,366,489 with heart failure, 2,556,839   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ with atrial fibrillation, and 1,145,719 with stroke. Two conditions that are major cardiovascular risk          │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ factors\\u2014hypertension and hyperlipidemia\\u2014constitute the most frequent dyad. Hypertension,              │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ hyperlipidemia, and ischemic heart disease were the 3 most prevalent comorbidities for patients with heart      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ failure, atrial fibrillation, and stroke, whereas hypertension, hyperlipidemia, and diabetes mellitus were the  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ most prevalent comorbidities in those with ischemic heart disease; however, arthritis, anemia, chronic          │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ obstructive pulmonary disease, and Alzheimer\\u2019s disease also appeared.\\n\\n# Table 2\\n\\nTable 2 lists the    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ top 5 most prevalent dyad and triad comorbidities for beneficiaries \\u202165 years of age with at least 2 (for  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ dyads) or 3 (for triads) chronic conditions. Combinations of high cholesterol, high blood pressure, and         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ ischemic heart disease were most frequently represented in the dyads and triads, with diabetes mellitus and     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ arthritis completing the remaining prevalent combinations (14).\\nthan in former smokers, and there was a        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ significant relationship between the severity of carotid stenosis and pack-years of exposure to tobacco (239).  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ The RRs of finding 60% carotid stenosis were 1.5 and 3.9 among cigarette smokers with cerebral ischemia in the  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ NOMASS and the BCID (Berlin Cerebral Ischemia Databank) studies, respectively (258).\\n\\n# 6.3. Control of       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Hyperlipidemia\\n\\n# 6.3.1. Recommendations for Control of Hyperlipidemia\\n\\nCLASS I\\n\\n1. Treatment with a      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ statin medication is recommended for all patients with extracranial carotid or vertebral atherosclerosis to     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ reduce low-density lipoprotein (LDL) cholesterol below 100 mg/dL (111,259,260). (Level of Evidence: B)\\n\\nCLASS │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ IIa\\n\\n1. Treatment with a statin medication is reasonable for all patients with extracranial carotid or        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ vertebral atherosclerosis who sustain ischemic stroke to reduce LDL-cholesterol to a level near or below 70     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ mg/dL (259). (Level of Evidence: B)\\n2. If treatment with a statin (including trials of higher-dose statins and │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ higher-potency statins) does not achieve the goal selected for a patient, intensifying LDL-lowering drug        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ therapy with an additional drug from among those with evidence of improving outcomes (i.e., bile acid           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ sequestrants or niacin) can be effective (261\\u2013264). (Level of Evidence: B)\\n3. For patients who do not     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ tolerate statins, LDL-lowering therapy with bile acid sequestrants and/or niacin is reasonable (261,263,265).   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (Level of Evidence: B)\\n\\nThe relationship between cholesterol and ischemic stroke is not as evident as that    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ between cholesterol and MI, and findings from population-based studies are inconsistent. In the MR FIT          │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (Multiple Risk Factor Intervention Trial), comprising more than 350,000 men, the RR of death increased          │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ progressively with serum cholesterol, exceeding 2.5 in those with the highest levels (266). An analysis of 45   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ prospective observational cohorts involving approximately 450,000 individuals, however, found no association of │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ hypercholesterolemia with stroke (267). In the ARIC study, the relationships between lipid values and incident  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ ischemic.\\n# J A C C V O L . 73, N O . 2 4 , 2 0 1 9\\n\\n# Grundy et al. e313\\n\\n# J U N E 25, 2 0 1 9 : e 2 8 5 │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ - 3 5 0\\n\\n# 2018 Cholesterol Clinical Practice Guideline\\n\\nAs discussed in these guidelines (Section 4.2.) FH │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ often goes undiagnosed. Young adults with primary elevations of LDL-C \\u2265 190 mg/dl have a long-term ASCVD   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ burden (S4.4.4.2-3), and statin therapy is recommended. In adults with hypercholesterolemia, cascade screening  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ often identifies other family members with elevated LDL-C (Section 4.2.).\\n\\nHowever, even moderate             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ hypercholesterolemia can accelerate development of atherosclerosis (S4.4.4.2-4). Secondary causes of elevated   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ cholesterol\\u2014hypothyroidism (TSH), obstructive liver disease (liver panel), renal disease and nephrosis     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (creatinine and urine analysis) as well as dietary and medication history\\u2014should be addressed              │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ appropriately (S4.4.4.2-5). Elevations of LDL-C persisting after excluding secondary causes suggests genetic    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ forms of hypercholesterolemia. Young adults who experience prolonged exposure to hyperlipidemia prior to age 55 │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ are shown to have significantly increased risk of coronary heart disease (S4.4.4.2-6). Intensive lifestyle      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ change has the potential to reduce the hyperlipidemia and associated ASCVD risk factor burden.\\n\\nA smaller     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ group, but even at higher risk, are young adults with persistent, moderate hypercholesterolemia (LDL-C 160-189  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ mg/dL), especially when risk-enhancing factors, such as a family history of premature ASCVD, are present. Since │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ there is increased probability of genetic FH in this LDL-C range, clinical judgment would suggest that these    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ high risk young adults will benefit from long-term statin therapy (S4.4.4.2-7) (Section 4.2.). Indeed, it has   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ been shown that those with higher LDL-C can gain as much or more benefit from cholesterol reduction as do those │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ with lower pretreatment LDL-C but at higher risk (S4.4.4.2-8, S4.4.4.2-9).\\n\\nIn young adults without           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ phenotypically severe hypercholesterolemia, risk assessment should begin by estimation of lifetime risk         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (S4.4.4.2-10). The pooled cohort equations (PCE) can be used to estimate lifetime risk starting at age 21 years │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (see Section 4.4.2.). This information can inform a focused risk discussion designed to improve high-risk       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ lifestyle behaviors including tobacco use, sedentary lifestyle and/or poor diet (S4.4.4.2-11, S4.4.4.2-12).     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ When young adults with hypercholesterolemia or multiple risk factors are identified, lifestyle intervention is  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ indicated. To date, no long-term RCTs with cholesterol-lowering drugs have been carried out in those 20 to 39   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ years age. However, a primary prevention RCT in those younger individuals at low to moderate short-term risk,   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ but at high lifetime risk has been proposed (S4.4.4.2-13).\\n\\nOne approach to identifying young adults who      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ could benefit from statins or drug combination would be to detect significant coronary atherosclerosis with     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ coronary artery calcium (CAC) scores. Its use for this purpose has been suggested (S4.4.4.2-14). But again,     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ absence of RCT data precludes guideline recommendations at this time.\\n\\n# 4.4.4.3. Children and                │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Adolescents\\n\\n# Recommendations for Children and Adolescents\\n\\nReferenced studies that support                │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ recommendations are summarized in Online Data Supplements 18 to                                                 │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ 21.\\n\\n|COR|LOE|RECOMMENDATIONS|\\n|---|---|---|\\n|I|A|In children and adolescents with lipid disorders related  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ to obesity, it is recommended to intensify lifestyle therapy, including moderate caloric restriction and        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ regular aerobic physical activity (S4.4.4.3-1\\u2014S4.4.4.3-4).|\\n|I|B-NR|In children and adolescents with      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ lipid abnormalities, lifestyle counseling is beneficial for lowering LDL-C (S4.4.4.3-1\\u2014S4.4.4.3-3,\\nThe    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ diagnosis is made by the presence of any 3 of the following 5 risk factors: elevated waist circumference,       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ elevated serum triglycerides, reduced HDL-C, elevated blood pressure, and elevated fasting glucose (Table S2 in │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ the Web Supplement). Metabolic syndrome is closely linked to excess weight and particularly to abdominal        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ obesity (S3.1.2-4). Therefore, the prevalence of metabolic syndrome has risen sharply among both adults and     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ children as levels of overweight and obesity have risen. Metabolic syndrome is now found in approximately       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ one-third of the adults in the United States (S3.1.2-5) and is likely under-recognized because of insufficient  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ rates of screening. The prevalence of metabolic syndrome increases with age and very commonly occurs in         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ patients with type 2 diabetes mellitus. See Table S2 in the Web Supplement.\\n\\n# 3.2. Lipid-Lowering            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Drugs\\n\\nAmong lipid-lowering drugs, statins are the cornerstone of therapy, in addition to healthy lifestyle   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ interventions. Other LDL-lowering drugs include ezetimibe, bile acid sequestrants, and PCSK9 inhibitors.        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Triglyceride-lowering drugs are fibrates and niacin; they have a mild LDL-lowering action, but RCTs do not      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ support their use as add-on drugs to statin therapy (S3.2-1). Characteristics of LDL-lowering drugs are         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ summarized in Table S3 in the Web Supplement.\\n\\n# 3.2.1. Statin Therapy\\n\\nThe intensity of statin therapy is  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ divided into 3 categories: high-intensity, moderate-intensity, and low-intensity (S3.2.1-1). High-intensity     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ statin therapy typically lowers LDL-C levels by \\u226550%, moderate-intensity statin therapy by 30% to 49%, and │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ low-intensity statin therapy by &lt;30% (Table 3). Of course, the magnitude of LDL-C lowering will vary in         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ clinical practice (S3.2.1-2). Certain Asian populations may have a greater response to certain statins          │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (S3.2.1-18). Pharmacokinetic profiles among statins are heterogeneous (Table S4 in the Web Supplement). Statin  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ safety has been extensively evaluated (S3.2.1-19). Statin-associated side effects are discussed in Section 5.   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Common medications that may potentially interact with statins are listed in Table S5 in the Web Supplement.     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ More information on statin drug\\u2013drug interactions can be obtained from the ACC LDL-C Manager               │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (S3.2.1-20).\\n\\n# 3.2.2. Nonstatin Therapies\\n\\nEzetimibe is the most commonly used nonstatin agent. It lowers  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ LDL-C levels by 13% to 20% and has a low incidence of side effects (S3.2.2-1, S3.2.2-2). Bile acid sequestrants │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ reduce LDL-C levels by 15% to 30% depending on the dose. Bile acid sequestrants are not absorbed and do not     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ cause systemic side effects, but they are associated with gastrointestinal complaints (e.g., constipation) and  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ can cause severe hypertriglyceridemia when fasting triglycerides are \\u2265300 mg/dL (\\u22653.4 mmol/L). PCSK9  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ inhibitors are powerful LDL-lowering drugs.\\n# J A C C V O L . 6 4 , N O . 1 7 , 2 0 1 4\\n\\n# O C T O B E R 2 8 │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ , 2 0 1 4 : 1 8 5 1 \\u2013 6\\n\\n# AHA/ACC/HHS Strategies on Comorbidities\\n\\n# T A B L E 1 The 10 Most Common   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Comorbidities for 4 Index Cardiovascular Conditions: 2012 Data for Medicare Beneficiaries $65 Years of Age      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (13)\\n\\n|Comorbidity|Ischemic Heart Disease* (N = 8,678,060)|HF* (N = 4,366,489)|AF* (N = 2,556,839)|Stroke* (N │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ = 1,145,719)|\\n|---|---|---|---|---|\\n|Hypertension|1 (81.3)|1 (85.6)|1 (84.5)|1 (89.0)|\\n|Hyperlipidemia|2     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (69.1)|3 (62.6)|2 (64.4)|2 (69.9)|\\n|Diabetes mellitus|3 (41.7)|5 (47.1)|7 (37.1)|6 (41.5)|\\n|Arthritis|4       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (40.6)|6 (45.6)|6 (41.7)|5 (44.2)|\\n|Anemia|5 (38.7)|4 (51.2)|5 (43.0)|4 (46.8)|\\n|HF|6 (36.3)|Index|4 (50.9)|7 │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (37.2)|\\n|Ischemic heart disease|Index|2 (72.1)|3 (63.5)|3 (58.1)|\\n|Chronic kidney disease|7 (30.2)|7 (44.8)|8 │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (34.4)|8 (35.2)|\\n|Cataract|8 (21.6)|\\u2020|10 (22.6)|\\u2020|\\n|COPD|9 (21.0)|8 (30.9)|9 (23.8)|\\u2020|\\n|AF|10 │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (18.7)|9 (28.8)|Index|\\u2020|\\n|Alzheimer\\u2019s disease/dementia|\\u2020|10 (26.3)|\\u2020|9                     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (33.8)|\\n|Depression|\\u2020|\\u2020|\\u2020|10 (29.7)|\\n|Stroke|\\u2020|\\u2020|\\u2020|Index|\\n\\n*Data shown as     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ rank and percentage of persons with index condition who also had a comorbidity. The percentage is included      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ parenthetically when applicable. \\u2020Comorbidity was not in the top 10 for this index condition (13).\\n\\nAF   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ indicates atrial fibrillation; COPD, chronic obstructive pulmonary disease; and HF, heart failure.\\n\\n#         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ IMPLICATIONS AND FUTURE DIRECTIONS IN THE DEVELOPMENT OF CPGs\\n\\nTwo general, but important, points emerge from │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ the CMS data. First, a beneficiary with cardiovascular disease but without at least 1 comorbid chronic          │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ condition is the exception rather than the rule. Second, whereas common risk factors such as hypertension and   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ hyperlipidemia are associated with the index cardiovascular conditions, the index conditions are associated     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ with a constellation of comorbidities, the pathophysiology of which may be distinct from the index condition    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ and for which prevalence increases with age or other factors.\\n\\nOrganizations that develop CPGs must now       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ consider comorbidities during the development process for disease-specific CPGs. For high-prevalence index      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ conditions, few CPGs address comorbidities (15), and even fewer provide guidance for patients with specific     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ combinations of diseases. Managing patients with multiple conditions is more complex than managing patients     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ with a single disease, and the presence of multiple conditions increases challenges for healthcare providers    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ and patients. Comorbidities may constitute barriers to adherence to CPGs, and caring for patients with multiple │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ comorbidities can affect patient safety if recommendations for diagnosis and treatment in one CPG conflict with │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ those for another condition (16). The complexity of various regimens for multiple comorbidities adds to the     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ difficulty in patient management and assessment of clinical outcomes (17). Furthermore, limited attention has   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ been given to the physical, cognitive, social, psychological, and financial implications of managing            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ comorbidities. Involving patients in the CPG development process, which the AHA/ACC recently initiated, is      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ critically important to fully appreciate patient perspectives (18,19).\\n\\nCurrently, there are important        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ challenges in addressing common comorbidities in the development and implementation\\n# J A C C V O L . 73, N O  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ . 24, 2019\\n\\n# Grundy et al. e315\\n\\n# J U N E 25, 2019: e 285 - 350\\n\\n# 2018 Cholesterol Clinical Practice   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Guideline\\n\\n# T A B L E 9 Normal and Abnormal Lipid Values in Childhood*\\n\\n| |Acceptable, mg/dL|Borderline,   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ mg/dL|Abnormal, mg/dL|\\n|---|---|---|---|\\n|TC|&amp;lt;170 (&amp;lt;4.3 mmol/L)|170-199 (4.3-5.1 mmol/L)|$200 ($5.1     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ mmol/L)|\\n|Triglycerides (0-9 y)|&amp;lt;75 (&amp;lt;0.8 mmol/L)|75-99 (0.8-1.1 mmol/L)|$100 ($1.1                      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ mmol/L)|\\n|Triglycerides (10-19 y)|&amp;lt;90 (&amp;lt;1.0 mmol/L)|90-129 (1.0-1.5 mmol/L)|$130 ($1.4                   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ mmol/L)|\\n|HDL-C|&amp;gt;45 (&amp;gt;1.2 mmol/L)|40-45 (1.0-1.2 mmol/L)|&amp;lt;40 (&amp;lt;1.0 mmol/L)|\\n|LDL-C|&amp;lt;110        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (&amp;lt;2.8 mmol/L)|110-129 (2.8-3.3 mmol/L)|$130 ($3.4 mmol/L)|\\n|Non\\u2013HDL-C|&amp;lt;120 (&amp;lt;3.1 mmol/L)|120-144 │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (3.1-3.7 mmol/L)|$145 ($3.7 mmol/L)|\\n\\nValues given are in mg/dL. To convert to SI units, divide the results   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ for TC, LDL-C, HDL-C, and non\\u2013HDL-C by 38.6; for triglycerides, divide by 88.6.\\n\\n*Values for plasma      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ lipid and lipoprotein levels are from the NCEP Expert Panel on Cholesterol Levels in Children. Non\\u2013HDL-C   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ values from the Bogalusa Heart Study are equivalent to the NCEP Pediatric Panel cutpoints for                   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ LDL-C.\\n\\n\\u2020The cutpoints for high and borderline high represent approximately the 95th and 75th            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ percentiles, respectively. Low cutpoints for HDL-C represent approximately the 10th percentile.\\n\\nHDL-C        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ indicates high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; NCEP, National      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Cholesterol Education Program; SI, Syst\\u00e8me international d\\u2019unit\\u00e9s (International System of       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Units); and TC, total cholesterol.\\n\\nHypercholesterolemia show reasonable LDL-C lowering with no significant   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ adverse effects (S4.4.4.3-13). Nonsystemic bile acid sequestrants can be useful for LDL-C lowering, but         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ tolerability is an issue (S4.4.4.3-13\\u2014S4.4.4.3-16).\\n\\n4. Lipid testing during childhood can identify the  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ severe hypercholesterolemia phenotype (S4.4.4.3-35). Severe hypercholesterolemia, which includes FH, can be     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ identified in children and adolescents with an LDL-C level $190 mg/dL ($4.9 mmol/L). Moreover, children and     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ adolescents with LDL-C $160 mg/dL ($4.1 mmol/L) and a family history of early atherosclerosis or similarly      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ elevated cholesterol in 1 parent likely are those with FH and related genetic disorders associated with         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ accelerated ASCVD (S4.4.4.3-17\\u2014S4.4.4.3-21).\\n\\nSubclinical atherosclerosis data suggest divergence        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ between affected and unaffected children and adolescents beginning at age 10 years (S4.4.4.3-28), which         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ supports screening by this age, although this topic is still considered controversial (S4.4.4.3-36). Screening  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ is advised beginning at age 2 years if a family history is suggestive of either early CVD or significant        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ primary hypercholesterolemia. Identification of a child with severe hypercholesterolemia should prompt          │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ screening of extended family members (e.g., reverse-cascade screening), according to studies outside the United │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ States demonstrating efficacy of this approach (S4.4.4.3-37). Screening for severe\\n# J A C C V O L . 7 7 , N O │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ . 4 , 2 0 2 1\\n\\n# 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease\\n\\ncapacity or an        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ abnormal blood pressure response. Recording aortic valve hemodynamics with exercise is of limited value and     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ does not show additive value for predicting clinical outcome when baseline measures of hemodynamic severity and │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ functional status are considered. In addition, recording hemodynamics with exercise is challenging, and simpler │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ parameters are adequate in most patients (2\\u20134,6\\u201311).\\n\\nAs reported in several prospective and        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ retrospective studies, the risk of exercise testing is low in asymptomatic patients with AS. However, exercise  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ testing is avoided in symptomatic patients with AS because of a high risk of complications, including syncope,  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ ventricular tachycardia, and death. In a prospective survey of 20 medical centers in Sweden that included       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ 50,000 exercise tests done over an 18-month period, the complication rate was 18.4 per 10,000 tests; morbidity  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ rate, 5.2 per 10,000 tests; and mortality rate, 0.4 per 10,000 tests. Although the number of patients with AS   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ was not reported, 12 of the 92 complications occurred in patients with AS: 8 had a decline in blood pressure    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ during exercise, 1 had asystole, and 3 had ventricular tachycardia (2,4,5,7\\u201310,12).\\n\\n# 3.2.2. Medical    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Therapy\\n\\n# Recommendations for Medical Therapy of AS\\n\\nReferenced studies that support the recommendations   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ are summarized in Online Data Supplement 5.\\n\\n|COR|LOE|RECOMMENDATIONS|\\n|---|---|---|\\n|1|B-NR|In patients at │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ risk of developing AS (Stage A) and in patients with asymptomatic AS (Stages B and C), hypertension should be   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ treated according to standard GDMT, started at a low dose, and gradually titrated upward as needed, with        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ appropriate clinical monitoring (1\\u20133).|\\n|1|A|In all patients with calcific AS, statin therapy is          │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ indicated for primary and secondary prevention of atherosclerosis on the basis of standard risk scores          │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (4\\u20136).|\\n|2b|B-NR|In patients who have undergone TAVI, renin\\u2013angiotensin system blocker therapy (ACE  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ inhibitor or ARB) may be considered to reduce the long-term risk of all-cause mortality (7,8).|\\n|3: No         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Benefit|A|In patients with calcific AS (Stages B and C), statin therapy is not indicated for prevention of      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ hemodynamic progression of AS (4\\u20136).|\\n\\n# Synopsis\\n\\nMedical treatment of hypertension and               │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ hyperlipidemia according to GDMT is appropriate for patients with AS. ACE inhibitor or ARB treatment may reduce │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ the mortality rate in patients with AS who underwent TAVI.\\n\\n# Recommendation-Specific Supportive Text\\n\\n1.   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Hypertension is common in patients with AS, may be a risk factor for AS, and adds to the total pressure         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ overload on the LV in combination with valve obstruction. Concern that antihypertensive medications might       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ result in a decrease in cardiac output has not been corroborated in studies of medical therapy, including 2     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ small RCTs, likely because AS does not result in \\u201cfixed\\u201d valve obstruction until late in the disease  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ process. In 1616 patients with asymptomatic AS in the SEAS (Simvastatin Ezetimibe in Aortic Stenosis) study,    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ hypertension (n=1340) was associated with a 56% higher rate of ischemic cardiovascular events and a 2-fold      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ higher mortality rate (both P&lt;0.01) than those seen in normotensive patients with AS, although no impact on     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ mortality was observed.\\n\\n2. Concurrent CAD is common in patients with AS, and all patients should be screened │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ and treated for hypercholesterolemia, with GDMT used for primary and secondary prevention of CAD. In RCTs of    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ statin therapy for mild to moderate AS, although aortic valve event rates...\\n# e300 Grundy et al.\\n\\n# J A C C │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ V O L . 7 3 , N O . 2 4 , 2 0 1 9\\n\\n# 2018 Cholesterol Clinical Practice Guideline\\n\\n# J U N E 2 5 , 2 0 1 9  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ : e 2 8 5 - 3 5 0\\n\\nLDL-C is inadequately controlled with drug therapy, LDL apheresis is an option. Referral   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ to a lipid specialist may be indicated.\\n\\n# Recommendation-Specific Supportive Text\\n\\n1. Patients with        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ primary severe hypercholesterolemia (LDL-C levels \\u2265190 mg/dL [\\u22654.9 mmol/L]) have a high-risk of ASCVD │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (S4.2-2, S4.2-4, S4.2-18) and premature and recurrent coronary events (S4.2-3). Although there have been no     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ randomized, placebo-controlled trials of statin therapy done exclusively in subjects with LDL-C levels          │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ \\u2265190 mg/dL (\\u22654.9 mmol/L), a placebo-controlled primary prevention study performed in men with a mean  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ baseline LDL-C level of 192.17 mg/dL (4.90.4 mmol/L) demonstrated a reduced incidence of MI and cardiovascular  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ death in those receiving pravastatin 40 mg daily (S4.2-5). These findings were extended in a post hoc analysis  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ of 2,560 exclusively primary-prevention subjects in that RCT and in a 20-year observational post-trial          │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ long-term follow-up study (S4.2-19). In addition, retrospective cohort studies have demonstrated that statin    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ therapy reduces risk of incident MI (S4.2-6) and of CHD and all-cause death (S4.2-1) in patients with           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ phenotypic or genetically confirmed FH. Because moderate- or high-intensity statins have been shown to reduce   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ ASCVD risk in both primary- and secondary-prevention trials and because high-intensity statins provide greater  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ ASCVD risk reduction than moderate-intensity statins or placebo (S4.2-7), maximally tolerated statin therapy    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ should be administered to patients with primary severe hypercholesterolemia.\\n2. A large placebo-controlled RCT │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ examined the effect of simvastatin 80 mg daily, with or without ezetimibe 10 mg daily, on carotid intima-media  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ thickness and plasma lipoproteins over 2 years. Mean LDL-C reduction was greater in the combined-therapy group, │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ but there was no difference in carotid intima-media thickness between the 2 groups. The study was not powered   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ to examine the risk of ASCVD events (S4.2-10). However, a very large placebo-controlled RCT examining ASCVD     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ outcomes in post-ACS patients, performed over a period of 7 years, showed that the addition of ezetimibe 10 mg  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ to simvastatin 40 mg daily resulted in greater ASCVD risk reduction than that produced by statin monotherapy    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (S4.2-8). Secondary-prevention patients with certain ASCVD risk indicators exhibit greater ASCVD risk reduction │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ from ezetimibe therapy than do patients without these characteristics (S4.2-20). Patients with severe           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ hypercholesterolemia who are adherent to statins, achieve &lt;50% reduction in LDL-C levels with maximally         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ tolerated statin therapy, and have an LDL-C level \\u2265100 mg/dL (\\u22652.6 mmol/L) are likely to derive       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ additional ASCVD risk reduction from ezetimibe add-on therapy through additional LDL-C lowering (S4.2-9).\\n3.   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ When administered to patients with severe hypercholesterolemia who are taking maximally tolerated statins with  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ or without ezetimibe, bile acid sequestrants have demonstrated LDL-C-lowering efficacy (S4.2-11, S4.2-12).      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ However, the clinical utility of bile acid sequestrants is limited by the absence of ASCVD outcomes data when   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ used in combination with statins, as well as by the issues of twice-daily dosing, high pill burden, the absence │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ of well-tolerated generic formulations, drug interactions, and the potential for triglyceride elevation.        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Nonetheless, in patients with very severe hypercholesterolemia, adding sequestrants to otherwise maximal        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ cholesterol-lowering therapy in patients who are not eligible for a PCSK9 inhibitor may be considered.\\n4.      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ PCSK9 inhibitors are promising drugs for treatment of FH\\nprevention of cardiovascular disease: an opportunity  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ to harmonize guidelines. JAMA Cardiol. 2017;2:1175\\u20136.\\n\\nS4.4.4.2-10. Berry JD, Dyer A, Cai X, et al.      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Lifetime risks of cardiovascular disease. N Engl J Med. 2012; 366:321\\u20139.\\n\\nS4.4.4.2-11. Lehr AL, Driver   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ SL, Stone NJ. The ABCDs of lifestyle counseling. JAMA Cardiol. 2016;1:505\\u20136.\\n\\nS4.4.4.2-12. Omura JD,     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Watson KB, Loustalot F, et al. Primary care providers\\u2019 awareness of physical activity-related intensive    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ behavioral counseling services for cardiovascular disease prevention. Am J Health Promot. 2018.                 │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ 890117118784226.\\n\\n# 4.4.4.3. Children and Adolescents\\n\\nS4.4.4.3-1. Iannuzzi A, Licenziati MR, Vacca M, et   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ al. Comparison of two diets of varying glycemic index on carotid subclinical atherosclerosis in obese children. │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Heart Vessels. 2009;24:419\\u201324.\\n\\nS4.4.4.3-2. Murphy EC, Carson L, Neal W, et al. Effects of an exercise   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ intervention using Dance Dance Revolution on endothelial function and other risk factors in overweight          │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ children. Int J Pediatr Obes. 2009;4:205\\u201314.\\n\\nS4.4.4.3-3. Pratt RE, Kavey RE, Quinzi D. Combined         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ dyslipidemia in obese children: response to a focused lifestyle approach. J Clin Lipidol.                       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ 2014;8:181\\u20136.\\n\\nS4.4.4.3-4. de Ferranti SD, Milliren CE, Denhoff ER, et al. Providing food to treat       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ adolescents at risk for cardiovascular disease. Obesity (Silver Spring). 2015; 23:2109\\u201317.\\n\\nS4.4.4.3-5.  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Niinikoski H, Lagstrom H, Jokinen E, et al. Impact of repeated dietary counseling between infancy and 14 years  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ of age on dietary intakes and serum lipids and lipoproteins: the STRIP study. Circulation. 2007;                │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ 116:1032\\u201340.\\n\\nS4.4.4.3-6. Obarzanek E, Kimm SY, Barton BA, et al. Long-term safety and efficacy of a     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ cholesterol-lowering diet in children with elevated low-density lipoprotein cholesterol: seven-year results of  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ the Dietary Intervention Study in Children (DISC). Pediatrics. 2001;107:256\\u201364.\\n\\nS4.4.4.3-7. Dorgan JF,  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Liu L, Barton BA, et al. Adolescent diet and metabolic syndrome in young women: results of the Dietary          │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Intervention Study in Children (DISC) follow-up study. J Clin Endocrinol Metab.                                 │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ 2011;96:E1999\\u20132008.\\n\\nS4.4.4.3-8. Wong H, Chahal N, Manlhiot C, et al. Flaxseed in pediatric              │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ hyperlipidemia: a placebo-controlled, blinded, randomized clinical trial of dietary flaxseed supplementation    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ for children and adolescents with hypercholesterolemia. JAMA Pediatr. 2013;167:708\\u201313.\\n\\nS4.4.4.3-9.      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Zachariah JP, Chan J, Mendelson MM, et al. Adolescent dyslipidemia and standardized lifestyle modification:     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ benchmarking real-world practice. J Am Coll Cardiol. 2016;68:2122\\u20133.\\n\\nS4.4.4.3-10. Torvik K, Narverud I, │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Ottestad I, et al. Dietary counseling is associated with an improved lipid profile in children with familial    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ hypercholesterolemia. Atherosclerosis. 2016;252:21\\u20137.\\n\\nS4.4.4.3-11. Koletzko B, Kupke I, Wendel U.       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Treatment of hypercholesterolemia in children and adolescents. Acta Paediatr.                                   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ 1992;81:682\\u20135.\\n\\nS4.4.4.3-12. Tershakovec AM, Shannon BM, Achterberg CL, et al. One-year follow-up of     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ nutrition education for hypercholesterolemic children.\\n# Grundy et al.\\n\\n# J A C C V O L . 7 3 , N O . 2 4 ,  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ 2 0 1 9\\n\\n# 2018 Cholesterol Clinical Practice Guideline\\n\\n# J U N E 2 5 , 2 0 1 9 : e 2 8 5 - 3 5 0\\n\\n#     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Table 3 High-, Moderate-, and Low-Intensity Statin Therapy*\\n\\n|High Intensity| | |Moderate Intensity|Low       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Intensity|\\n|---|---|---|---|---|\\n|LDL-C lowering\\u2020|\\u226550%|                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ |30%\\u201349%|&amp;lt;30%|\\n|Statins|Atorvastatin (40 mg\\u2021) 80 mg Rosuvastatin 20 mg (40 mg)|Atorvastatin 10 mg │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (20 mg) Rosuvastatin (5 mg) 10 mg Simvastatin 20\\u201340 mg\\u00a7 Pravastatin 40 mg (80 mg) Lovastatin 40 mg    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (80 mg) Fluvastatin XL 80 mg Fluvastatin 40 mg BID Pitavastatin 1\\u20134 mg|Simvastatin 10 mg Pravastatin       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ 10\\u201320 mg Lovastatin 20 mg Fluvastatin 20\\u201340 mg| |\\n\\nPercent LDL-C reductions with the primary statin │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ medications used in clinical practice (atorvastatin, rosuvastatin, simvastatin) were estimated using the median │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ reduction in LDL-C from the VOYAGER database (S3.2.1-2). Reductions in LDL-C for other statin medications       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (fluvastatin, lovastatin, pitavastatin, pravastatin) were identified according to FDA-approved product labeling │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ in adults with hyperlipidemia, primary hypercholesterolemia, and mixed dyslipidemia (S3.2.1-4). Boldface type   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ indicates specific statins and doses that were evaluated in RCTs (S3.2.1-3, S3.2.1-5\\u2014S3.2.1-16), and the   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Cholesterol Treatment Trialists\\u2019 2010 meta-analysis (S3.2.1-17). All these RCTs demonstrated a reduction   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ in major cardiovascular events.\\n\\n*Percent reductions are estimates from data across large populations.        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Individual responses to statin therapy varied in the RCTs and should be expected to vary in clinical practice   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (S3.2.1-2).\\n\\n\\u2020LDL-C lowering that should occur with the dosage listed below each                         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ intensity.\\n\\n\\u2021Evidence from 1 RCT only: down titration if unable to tolerate atorvastatin 80 mg in the    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ IDEAL (Incremental Decrease through Aggressive Lipid Lowering) study (S3.2.1-3).\\n\\n\\u00a7Although simvastatin  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ 80 mg was evaluated in RCTs, initiation of simvastatin 80 mg or titration to 80 mg is not recommended by the    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ FDA because of the increased risk of myopathy, including rhabdomyolysis.\\n\\nBID indicates twice daily; FDA,     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ U.S. Food and Drug Administration; LDL-C, low-density lipoprotein cholesterol; RCT, randomized controlled       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ trial; VOYAGER, an individual patient data meta-analysis of statin therapy in at-risk groups: effects of        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ rosuvastatin, atorvastatin, and simvastatin; and XL, extended release.\\n\\n# 3.1.2. Lifestyle Therapies and      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Metabolic Syndrome\\n\\nLifestyle therapies are particularly indicated for the metabolic syndrome, which is a     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ cluster of risk factors associated with an increased risk of ASCVD, diabetes mellitus, and all-cause death      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (S3.1.2-1, S3.1.2-2). Metabolic syndrome is a risk-enhancing factor for ASCVD. The most widely used clinical    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ definition of metabolic syndrome is that proposed by an international consortium of cardiovascular and diabetes │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ organizations (S3.1.2-3). The diagnosis is made by the presence of any 3 of the following 5 risk factors:       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ elevated waist circumference, elevated serum triglycerides, reduced HDL-C, elevated blood pressure, and         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ elevated fasting glucose (Table S2 in the Web Supplement). Metabolic syndrome is closely linked to excess       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ weight and particularly to abdominal obesity (S3.1.2-4). Therefore, the prevalence of metabolic syndrome has    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ risen sharply among both adults and children as levels of overweight and obesity have risen. Metabolic\"         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   },                                                                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   {                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"role\": \"tool\",                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"tool_call_id\": \"call_Wj83hyOr277uKGy1oSceoOi9\",                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"name\": \"search_bing_grounding\",                                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"content\": \"In February 2025, the FDA accepted the Biologics License Application for Lerodalcibep, a novel  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ third-generation PCSK9 inhibitor developed by LIB Therapeutics. This drug aims to reduce low-density            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ lipoprotein cholesterol (LDL-C) for patients with atherosclerotic cardiovascular disease (ASCVD) and primary    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ hyperlipidemia. Lerodalcibep is designed to be a more convenient, once-monthly, subcutaneous injection that     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ does not require refrigeration. The FDA's action date for the review is set for December 12,                    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ 2025\\u30100\\u2020source\\u3011\\u30101\\u2020source\\u3011.\"                                                        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   }                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ ]                                                                                                               │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[2m╭─\u001b[0m\u001b[2m──────────────────────────────────────────────\u001b[0m Current Messages \u001b[2m───────────────────────────────────────────────\u001b[0m\u001b[2m─╮\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mMessages before API call:\u001b[0m\u001b[2m                                                                                      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m[\u001b[0m\u001b[2m                                                                                                              \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  {\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"role\": \"system\",\u001b[0m\u001b[2m                                                                                          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"content\": \"You are a cardiology-focused AI assistant with access to three tools:\\n1) 'lookup_patient_data'\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfor querying patient records from Azure SQL.\\n2) 'search_acc_guidelines' for official ACC guidelines.\\n3) \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m'search_bing_grounding' for real-time public information.\\n\\nYou can call these tools in any order, multiple \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtimes if needed, to gather all the context.\\nStop calling tools only when you have enough information to \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mprovide a final, cohesive answer.\\nThen output your final answer to the user.\"\u001b[0m\u001b[2m                                 \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  },\u001b[0m\u001b[2m                                                                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  {\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"role\": \"user\",\u001b[0m\u001b[2m                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"content\": \"I have a 79-year-old patient named Gloria Paul with hyperlipidemia. She's on Atorvastatin. Can \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2myou confirm her medical details from the database, check the ACC guidelines for hyperlipidemia, and see if \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mthere are any new medication updates from the FDA as of Feb 2025? Then give me a summary.\"\u001b[0m\u001b[2m                     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  },\u001b[0m\u001b[2m                                                                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  {\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"role\": \"assistant\",\u001b[0m\u001b[2m                                                                                       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"content\": null,\u001b[0m\u001b[2m                                                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"tool_calls\": [\u001b[0m\u001b[2m                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m      {\u001b[0m\u001b[2m                                                                                                        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m        \"id\": \"call_wDYynvTCJlXDSeGHihDW3rof\",\u001b[0m\u001b[2m                                                                 \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m        \"type\": \"function\",\u001b[0m\u001b[2m                                                                                    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m        \"function\": {\u001b[0m\u001b[2m                                                                                          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m          \"name\": \"lookup_patient_data\",\u001b[0m\u001b[2m                                                                       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m          \"arguments\": \"{\\\"query\\\": \\\"SELECT * FROM PatientMedicalData WHERE FirstName='Gloria' AND \u001b[0m\u001b[2m           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mLastName='Paul'\\\"}\"\u001b[0m\u001b[2m                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m        }\u001b[0m\u001b[2m                                                                                                      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m      },\u001b[0m\u001b[2m                                                                                                       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m      {\u001b[0m\u001b[2m                                                                                                        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m        \"id\": \"call_AcZAtI7rblAPdmxzoC6nxGgg\",\u001b[0m\u001b[2m                                                                 \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m        \"type\": \"function\",\u001b[0m\u001b[2m                                                                                    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m        \"function\": {\u001b[0m\u001b[2m                                                                                          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m          \"name\": \"search_acc_guidelines\",\u001b[0m\u001b[2m                                                                     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m          \"arguments\": \"{\\\"query\\\": \\\"hyperlipidemia\\\"}\"\u001b[0m\u001b[2m                                                       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m        }\u001b[0m\u001b[2m                                                                                                      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m      },\u001b[0m\u001b[2m                                                                                                       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m      {\u001b[0m\u001b[2m                                                                                                        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m        \"id\": \"call_Wj83hyOr277uKGy1oSceoOi9\",\u001b[0m\u001b[2m                                                                 \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m        \"type\": \"function\",\u001b[0m\u001b[2m                                                                                    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m        \"function\": {\u001b[0m\u001b[2m                                                                                          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m          \"name\": \"search_bing_grounding\",\u001b[0m\u001b[2m                                                                     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m          \"arguments\": \"{\\\"query\\\": \\\"FDA new hyperlipidemia drugs February 2025\\\"}\"\u001b[0m\u001b[2m                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m        }\u001b[0m\u001b[2m                                                                                                      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m      }\u001b[0m\u001b[2m                                                                                                        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    ]\u001b[0m\u001b[2m                                                                                                          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  },\u001b[0m\u001b[2m                                                                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  {\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"role\": \"tool\",\u001b[0m\u001b[2m                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"tool_call_id\": \"call_wDYynvTCJlXDSeGHihDW3rof\",\u001b[0m\u001b[2m                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"name\": \"lookup_patient_data\",\u001b[0m\u001b[2m                                                                             \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"content\": \" PatientID FirstName LastName DateOfBirth Gender ContactNumber        EmailAddress             \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mAddress        City PostalCode Country MedicalCondition  Medications Allergies BloodType LastVisitDate \u001b[0m\u001b[2m        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mSmokingStatus AlcoholConsumption ExerciseFrequency            Occupation  Height_cm  Weight_kg BloodPressure  \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mHeartRate_bpm  Temperature_C                                                                                   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mNotes\\n         1    Gloria     Paul  1944-07-15  Other  428-674-1336 keymary@example.com 62908 Fuentes \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mCove\\\\nLewisberg, MN 13491 Buchananton      59963   India   Hyperlipidemia Atorvastatin      None        O+    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m2024-03-26  Never Smoker      Light drinker  1-2 times a week Administrator, sports      176.2       77.7   \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m120/79 mmHg             90           37.6 Affect idea turn either see six. Suggest cultural change nice travel \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2myear parent. Happen energy level anyone position. Few available thought world development.\"\u001b[0m\u001b[2m                    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  },\u001b[0m\u001b[2m                                                                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  {\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"role\": \"tool\",\u001b[0m\u001b[2m                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"tool_call_id\": \"call_AcZAtI7rblAPdmxzoC6nxGgg\",\u001b[0m\u001b[2m                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"name\": \"search_acc_guidelines\",\u001b[0m\u001b[2m                                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"content\": \"received service or treatment for the specific condition. Detailed information on the \u001b[0m\u001b[2m         \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2midentification of chronic conditions is available from the CMS Chronic Conditions Data Warehouse (13).\\n\\n# \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mTable 1\\n\\nTable 1 shows the 10 most common comorbidities for each index cardiovascular condition for \u001b[0m\u001b[2m         \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mbeneficiaries \\u202165 years of age in 2012 (13). The numbers of Medicare beneficiaries with the 4 index \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mcardiovascular conditions were 8,678,060 with ischemic heart disease, 4,366,489 with heart failure, 2,556,839 \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mwith atrial fibrillation, and 1,145,719 with stroke. Two conditions that are major cardiovascular risk \u001b[0m\u001b[2m        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfactors\\u2014hypertension and hyperlipidemia\\u2014constitute the most frequent dyad. Hypertension, \u001b[0m\u001b[2m            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mhyperlipidemia, and ischemic heart disease were the 3 most prevalent comorbidities for patients with heart \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfailure, atrial fibrillation, and stroke, whereas hypertension, hyperlipidemia, and diabetes mellitus were the \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mmost prevalent comorbidities in those with ischemic heart disease; however, arthritis, anemia, chronic \u001b[0m\u001b[2m        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mobstructive pulmonary disease, and Alzheimer\\u2019s disease also appeared.\\n\\n# Table 2\\n\\nTable 2 lists the \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtop 5 most prevalent dyad and triad comorbidities for beneficiaries \\u202165 years of age with at least 2 (for \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mdyads) or 3 (for triads) chronic conditions. Combinations of high cholesterol, high blood pressure, and \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mischemic heart disease were most frequently represented in the dyads and triads, with diabetes mellitus and \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2marthritis completing the remaining prevalent combinations (14).\\nthan in former smokers, and there was a \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2msignificant relationship between the severity of carotid stenosis and pack-years of exposure to tobacco (239). \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mThe RRs of finding 60% carotid stenosis were 1.5 and 3.9 among cigarette smokers with cerebral ischemia in the \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mNOMASS and the BCID (Berlin Cerebral Ischemia Databank) studies, respectively (258).\\n\\n# 6.3. Control of \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mHyperlipidemia\\n\\n# 6.3.1. Recommendations for Control of Hyperlipidemia\\n\\nCLASS I\\n\\n1. Treatment with a \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mstatin medication is recommended for all patients with extracranial carotid or vertebral atherosclerosis to \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mreduce low-density lipoprotein (LDL) cholesterol below 100 mg/dL (111,259,260). (Level of Evidence: B)\\n\\nCLASS\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mIIa\\n\\n1. Treatment with a statin medication is reasonable for all patients with extracranial carotid or \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mvertebral atherosclerosis who sustain ischemic stroke to reduce LDL-cholesterol to a level near or below 70 \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mmg/dL (259). (Level of Evidence: B)\\n2. If treatment with a statin (including trials of higher-dose statins and\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mhigher-potency statins) does not achieve the goal selected for a patient, intensifying LDL-lowering drug \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtherapy with an additional drug from among those with evidence of improving outcomes (i.e., bile acid \u001b[0m\u001b[2m         \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2msequestrants or niacin) can be effective (261\\u2013264). (Level of Evidence: B)\\n3. For patients who do not \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtolerate statins, LDL-lowering therapy with bile acid sequestrants and/or niacin is reasonable (261,263,265). \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(Level of Evidence: B)\\n\\nThe relationship between cholesterol and ischemic stroke is not as evident as that \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mbetween cholesterol and MI, and findings from population-based studies are inconsistent. In the MR FIT \u001b[0m\u001b[2m        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(Multiple Risk Factor Intervention Trial), comprising more than 350,000 men, the RR of death increased \u001b[0m\u001b[2m        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mprogressively with serum cholesterol, exceeding 2.5 in those with the highest levels (266). An analysis of 45 \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mprospective observational cohorts involving approximately 450,000 individuals, however, found no association of\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mhypercholesterolemia with stroke (267). In the ARIC study, the relationships between lipid values and incident \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mischemic.\\n# J A C C V O L . 73, N O . 2 4 , 2 0 1 9\\n\\n# Grundy et al. e313\\n\\n# J U N E 25, 2 0 1 9 : e 2 8 5\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m- 3 5 0\\n\\n# 2018 Cholesterol Clinical Practice Guideline\\n\\nAs discussed in these guidelines (Section 4.2.) FH\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2moften goes undiagnosed. Young adults with primary elevations of LDL-C \\u2265 190 mg/dl have a long-term ASCVD \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mburden (S4.4.4.2-3), and statin therapy is recommended. In adults with hypercholesterolemia, cascade screening \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2moften identifies other family members with elevated LDL-C (Section 4.2.).\\n\\nHowever, even moderate \u001b[0m\u001b[2m           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mhypercholesterolemia can accelerate development of atherosclerosis (S4.4.4.2-4). Secondary causes of elevated \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mcholesterol\\u2014hypothyroidism (TSH), obstructive liver disease (liver panel), renal disease and nephrosis \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(creatinine and urine analysis) as well as dietary and medication history\\u2014should be addressed \u001b[0m\u001b[2m            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mappropriately (S4.4.4.2-5). Elevations of LDL-C persisting after excluding secondary causes suggests genetic \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mforms of hypercholesterolemia. Young adults who experience prolonged exposure to hyperlipidemia prior to age 55\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mare shown to have significantly increased risk of coronary heart disease (S4.4.4.2-6). Intensive lifestyle \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mchange has the potential to reduce the hyperlipidemia and associated ASCVD risk factor burden.\\n\\nA smaller \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mgroup, but even at higher risk, are young adults with persistent, moderate hypercholesterolemia (LDL-C 160-189 \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mmg/dL), especially when risk-enhancing factors, such as a family history of premature ASCVD, are present. Since\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mthere is increased probability of genetic FH in this LDL-C range, clinical judgment would suggest that these \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mhigh risk young adults will benefit from long-term statin therapy (S4.4.4.2-7) (Section 4.2.). Indeed, it has \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mbeen shown that those with higher LDL-C can gain as much or more benefit from cholesterol reduction as do those\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mwith lower pretreatment LDL-C but at higher risk (S4.4.4.2-8, S4.4.4.2-9).\\n\\nIn young adults without \u001b[0m\u001b[2m         \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mphenotypically severe hypercholesterolemia, risk assessment should begin by estimation of lifetime risk \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(S4.4.4.2-10). The pooled cohort equations (PCE) can be used to estimate lifetime risk starting at age 21 years\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(see Section 4.4.2.). This information can inform a focused risk discussion designed to improve high-risk \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mlifestyle behaviors including tobacco use, sedentary lifestyle and/or poor diet (S4.4.4.2-11, S4.4.4.2-12). \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mWhen young adults with hypercholesterolemia or multiple risk factors are identified, lifestyle intervention is \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mindicated. To date, no long-term RCTs with cholesterol-lowering drugs have been carried out in those 20 to 39 \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2myears age. However, a primary prevention RCT in those younger individuals at low to moderate short-term risk, \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mbut at high lifetime risk has been proposed (S4.4.4.2-13).\\n\\nOne approach to identifying young adults who \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mcould benefit from statins or drug combination would be to detect significant coronary atherosclerosis with \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mcoronary artery calcium (CAC) scores. Its use for this purpose has been suggested (S4.4.4.2-14). But again, \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mabsence of RCT data precludes guideline recommendations at this time.\\n\\n# 4.4.4.3. Children and \u001b[0m\u001b[2m              \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mAdolescents\\n\\n# Recommendations for Children and Adolescents\\n\\nReferenced studies that support \u001b[0m\u001b[2m              \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mrecommendations are summarized in Online Data Supplements 18 to \u001b[0m\u001b[2m                                               \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m21.\\n\\n|COR|LOE|RECOMMENDATIONS|\\n|---|---|---|\\n|I|A|In children and adolescents with lipid disorders related \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mto obesity, it is recommended to intensify lifestyle therapy, including moderate caloric restriction and \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mregular aerobic physical activity (S4.4.4.3-1\\u2014S4.4.4.3-4).|\\n|I|B-NR|In children and adolescents with \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mlipid abnormalities, lifestyle counseling is beneficial for lowering LDL-C (S4.4.4.3-1\\u2014S4.4.4.3-3,\\nThe \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mdiagnosis is made by the presence of any 3 of the following 5 risk factors: elevated waist circumference, \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2melevated serum triglycerides, reduced HDL-C, elevated blood pressure, and elevated fasting glucose (Table S2 in\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mthe Web Supplement). Metabolic syndrome is closely linked to excess weight and particularly to abdominal \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mobesity (S3.1.2-4). Therefore, the prevalence of metabolic syndrome has risen sharply among both adults and \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mchildren as levels of overweight and obesity have risen. Metabolic syndrome is now found in approximately \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mone-third of the adults in the United States (S3.1.2-5) and is likely under-recognized because of insufficient \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mrates of screening. The prevalence of metabolic syndrome increases with age and very commonly occurs in \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mpatients with type 2 diabetes mellitus. See Table S2 in the Web Supplement.\\n\\n# 3.2. Lipid-Lowering \u001b[0m\u001b[2m          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mDrugs\\n\\nAmong lipid-lowering drugs, statins are the cornerstone of therapy, in addition to healthy lifestyle \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2minterventions. Other LDL-lowering drugs include ezetimibe, bile acid sequestrants, and PCSK9 inhibitors. \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mTriglyceride-lowering drugs are fibrates and niacin; they have a mild LDL-lowering action, but RCTs do not \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2msupport their use as add-on drugs to statin therapy (S3.2-1). Characteristics of LDL-lowering drugs are \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2msummarized in Table S3 in the Web Supplement.\\n\\n# 3.2.1. Statin Therapy\\n\\nThe intensity of statin therapy is \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mdivided into 3 categories: high-intensity, moderate-intensity, and low-intensity (S3.2.1-1). High-intensity \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mstatin therapy typically lowers LDL-C levels by \\u226550%, moderate-intensity statin therapy by 30% to 49%, and\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mlow-intensity statin therapy by <30% (Table 3). Of course, the magnitude of LDL-C lowering will vary in \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mclinical practice (S3.2.1-2). Certain Asian populations may have a greater response to certain statins \u001b[0m\u001b[2m        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(S3.2.1-18). Pharmacokinetic profiles among statins are heterogeneous (Table S4 in the Web Supplement). Statin \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2msafety has been extensively evaluated (S3.2.1-19). Statin-associated side effects are discussed in Section 5. \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mCommon medications that may potentially interact with statins are listed in Table S5 in the Web Supplement. \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mMore information on statin drug\\u2013drug interactions can be obtained from the ACC LDL-C Manager \u001b[0m\u001b[2m             \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(S3.2.1-20).\\n\\n# 3.2.2. Nonstatin Therapies\\n\\nEzetimibe is the most commonly used nonstatin agent. It lowers \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mLDL-C levels by 13% to 20% and has a low incidence of side effects (S3.2.2-1, S3.2.2-2). Bile acid sequestrants\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mreduce LDL-C levels by 15% to 30% depending on the dose. Bile acid sequestrants are not absorbed and do not \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mcause systemic side effects, but they are associated with gastrointestinal complaints (e.g., constipation) and \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mcan cause severe hypertriglyceridemia when fasting triglycerides are \\u2265300 mg/dL (\\u22653.4 mmol/L). PCSK9 \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2minhibitors are powerful LDL-lowering drugs.\\n# J A C C V O L . 6 4 , N O . 1 7 , 2 0 1 4\\n\\n# O C T O B E R 2 8\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m, 2 0 1 4 : 1 8 5 1 \\u2013 6\\n\\n# AHA/ACC/HHS Strategies on Comorbidities\\n\\n# T A B L E 1 The 10 Most Common \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mComorbidities for 4 Index Cardiovascular Conditions: 2012 Data for Medicare Beneficiaries $65 Years of Age \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(13)\\n\\n|Comorbidity|Ischemic Heart Disease* (N = 8,678,060)|HF* (N = 4,366,489)|AF* (N = 2,556,839)|Stroke* (N\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m= 1,145,719)|\\n|---|---|---|---|---|\\n|Hypertension|1 (81.3)|1 (85.6)|1 (84.5)|1 (89.0)|\\n|Hyperlipidemia|2 \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(69.1)|3 (62.6)|2 (64.4)|2 (69.9)|\\n|Diabetes mellitus|3 (41.7)|5 (47.1)|7 (37.1)|6 (41.5)|\\n|Arthritis|4 \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(40.6)|6 (45.6)|6 (41.7)|5 (44.2)|\\n|Anemia|5 (38.7)|4 (51.2)|5 (43.0)|4 (46.8)|\\n|HF|6 (36.3)|Index|4 (50.9)|7\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(37.2)|\\n|Ischemic heart disease|Index|2 (72.1)|3 (63.5)|3 (58.1)|\\n|Chronic kidney disease|7 (30.2)|7 (44.8)|8\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(34.4)|8 (35.2)|\\n|Cataract|8 (21.6)|\\u2020|10 (22.6)|\\u2020|\\n|COPD|9 (21.0)|8 (30.9)|9 (23.8)|\\u2020|\\n|AF|10\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(18.7)|9 (28.8)|Index|\\u2020|\\n|Alzheimer\\u2019s disease/dementia|\\u2020|10 (26.3)|\\u2020|9 \u001b[0m\u001b[2m                   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(33.8)|\\n|Depression|\\u2020|\\u2020|\\u2020|10 (29.7)|\\n|Stroke|\\u2020|\\u2020|\\u2020|Index|\\n\\n*Data shown as \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mrank and percentage of persons with index condition who also had a comorbidity. The percentage is included \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mparenthetically when applicable. \\u2020Comorbidity was not in the top 10 for this index condition (13).\\n\\nAF \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mindicates atrial fibrillation; COPD, chronic obstructive pulmonary disease; and HF, heart failure.\\n\\n# \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mIMPLICATIONS AND FUTURE DIRECTIONS IN THE DEVELOPMENT OF CPGs\\n\\nTwo general, but important, points emerge from\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mthe CMS data. First, a beneficiary with cardiovascular disease but without at least 1 comorbid chronic \u001b[0m\u001b[2m        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mcondition is the exception rather than the rule. Second, whereas common risk factors such as hypertension and \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mhyperlipidemia are associated with the index cardiovascular conditions, the index conditions are associated \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mwith a constellation of comorbidities, the pathophysiology of which may be distinct from the index condition \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mand for which prevalence increases with age or other factors.\\n\\nOrganizations that develop CPGs must now \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mconsider comorbidities during the development process for disease-specific CPGs. For high-prevalence index \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mconditions, few CPGs address comorbidities (15), and even fewer provide guidance for patients with specific \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mcombinations of diseases. Managing patients with multiple conditions is more complex than managing patients \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mwith a single disease, and the presence of multiple conditions increases challenges for healthcare providers \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mand patients. Comorbidities may constitute barriers to adherence to CPGs, and caring for patients with multiple\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mcomorbidities can affect patient safety if recommendations for diagnosis and treatment in one CPG conflict with\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mthose for another condition (16). The complexity of various regimens for multiple comorbidities adds to the \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mdifficulty in patient management and assessment of clinical outcomes (17). Furthermore, limited attention has \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mbeen given to the physical, cognitive, social, psychological, and financial implications of managing \u001b[0m\u001b[2m          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mcomorbidities. Involving patients in the CPG development process, which the AHA/ACC recently initiated, is \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mcritically important to fully appreciate patient perspectives (18,19).\\n\\nCurrently, there are important \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mchallenges in addressing common comorbidities in the development and implementation\\n# J A C C V O L . 73, N O \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m. 24, 2019\\n\\n# Grundy et al. e315\\n\\n# J U N E 25, 2019: e 285 - 350\\n\\n# 2018 Cholesterol Clinical Practice \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mGuideline\\n\\n# T A B L E 9 Normal and Abnormal Lipid Values in Childhood*\\n\\n| |Acceptable, mg/dL|Borderline, \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mmg/dL|Abnormal, mg/dL|\\n|---|---|---|---|\\n|TC|&lt;170 (&lt;4.3 mmol/L)|170-199 (4.3-5.1 mmol/L)|$200 ($5.1 \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mmmol/L)|\\n|Triglycerides (0-9 y)|&lt;75 (&lt;0.8 mmol/L)|75-99 (0.8-1.1 mmol/L)|$100 ($1.1 \u001b[0m\u001b[2m                    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mmmol/L)|\\n|Triglycerides (10-19 y)|&lt;90 (&lt;1.0 mmol/L)|90-129 (1.0-1.5 mmol/L)|$130 ($1.4 \u001b[0m\u001b[2m                 \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mmmol/L)|\\n|HDL-C|&gt;45 (&gt;1.2 mmol/L)|40-45 (1.0-1.2 mmol/L)|&lt;40 (&lt;1.0 mmol/L)|\\n|LDL-C|&lt;110 \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(&lt;2.8 mmol/L)|110-129 (2.8-3.3 mmol/L)|$130 ($3.4 mmol/L)|\\n|Non\\u2013HDL-C|&lt;120 (&lt;3.1 mmol/L)|120-144\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(3.1-3.7 mmol/L)|$145 ($3.7 mmol/L)|\\n\\nValues given are in mg/dL. To convert to SI units, divide the results \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfor TC, LDL-C, HDL-C, and non\\u2013HDL-C by 38.6; for triglycerides, divide by 88.6.\\n\\n*Values for plasma \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mlipid and lipoprotein levels are from the NCEP Expert Panel on Cholesterol Levels in Children. Non\\u2013HDL-C \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mvalues from the Bogalusa Heart Study are equivalent to the NCEP Pediatric Panel cutpoints for \u001b[0m\u001b[2m                 \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mLDL-C.\\n\\n\\u2020The cutpoints for high and borderline high represent approximately the 95th and 75th \u001b[0m\u001b[2m          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mpercentiles, respectively. Low cutpoints for HDL-C represent approximately the 10th percentile.\\n\\nHDL-C \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mindicates high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; NCEP, National \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mCholesterol Education Program; SI, Syst\\u00e8me international d\\u2019unit\\u00e9s (International System of \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mUnits); and TC, total cholesterol.\\n\\nHypercholesterolemia show reasonable LDL-C lowering with no significant \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2madverse effects (S4.4.4.3-13). Nonsystemic bile acid sequestrants can be useful for LDL-C lowering, but \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtolerability is an issue (S4.4.4.3-13\\u2014S4.4.4.3-16).\\n\\n4. Lipid testing during childhood can identify the \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2msevere hypercholesterolemia phenotype (S4.4.4.3-35). Severe hypercholesterolemia, which includes FH, can be \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2midentified in children and adolescents with an LDL-C level $190 mg/dL ($4.9 mmol/L). Moreover, children and \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2madolescents with LDL-C $160 mg/dL ($4.1 mmol/L) and a family history of early atherosclerosis or similarly \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2melevated cholesterol in 1 parent likely are those with FH and related genetic disorders associated with \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2maccelerated ASCVD (S4.4.4.3-17\\u2014S4.4.4.3-21).\\n\\nSubclinical atherosclerosis data suggest divergence \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mbetween affected and unaffected children and adolescents beginning at age 10 years (S4.4.4.3-28), which \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2msupports screening by this age, although this topic is still considered controversial (S4.4.4.3-36). Screening \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mis advised beginning at age 2 years if a family history is suggestive of either early CVD or significant \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mprimary hypercholesterolemia. Identification of a child with severe hypercholesterolemia should prompt \u001b[0m\u001b[2m        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mscreening of extended family members (e.g., reverse-cascade screening), according to studies outside the United\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mStates demonstrating efficacy of this approach (S4.4.4.3-37). Screening for severe\\n# J A C C V O L . 7 7 , N O\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m. 4 , 2 0 2 1\\n\\n# 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease\\n\\ncapacity or an \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mabnormal blood pressure response. Recording aortic valve hemodynamics with exercise is of limited value and \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mdoes not show additive value for predicting clinical outcome when baseline measures of hemodynamic severity and\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfunctional status are considered. In addition, recording hemodynamics with exercise is challenging, and simpler\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mparameters are adequate in most patients (2\\u20134,6\\u201311).\\n\\nAs reported in several prospective and \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mretrospective studies, the risk of exercise testing is low in asymptomatic patients with AS. However, exercise \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtesting is avoided in symptomatic patients with AS because of a high risk of complications, including syncope, \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mventricular tachycardia, and death. In a prospective survey of 20 medical centers in Sweden that included \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m50,000 exercise tests done over an 18-month period, the complication rate was 18.4 per 10,000 tests; morbidity \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mrate, 5.2 per 10,000 tests; and mortality rate, 0.4 per 10,000 tests. Although the number of patients with AS \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mwas not reported, 12 of the 92 complications occurred in patients with AS: 8 had a decline in blood pressure \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mduring exercise, 1 had asystole, and 3 had ventricular tachycardia (2,4,5,7\\u201310,12).\\n\\n# 3.2.2. Medical \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mTherapy\\n\\n# Recommendations for Medical Therapy of AS\\n\\nReferenced studies that support the recommendations \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mare summarized in Online Data Supplement 5.\\n\\n|COR|LOE|RECOMMENDATIONS|\\n|---|---|---|\\n|1|B-NR|In patients at\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mrisk of developing AS (Stage A) and in patients with asymptomatic AS (Stages B and C), hypertension should be \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtreated according to standard GDMT, started at a low dose, and gradually titrated upward as needed, with \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mappropriate clinical monitoring (1\\u20133).|\\n|1|A|In all patients with calcific AS, statin therapy is \u001b[0m\u001b[2m        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mindicated for primary and secondary prevention of atherosclerosis on the basis of standard risk scores \u001b[0m\u001b[2m        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(4\\u20136).|\\n|2b|B-NR|In patients who have undergone TAVI, renin\\u2013angiotensin system blocker therapy (ACE \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2minhibitor or ARB) may be considered to reduce the long-term risk of all-cause mortality (7,8).|\\n|3: No \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mBenefit|A|In patients with calcific AS (Stages B and C), statin therapy is not indicated for prevention of \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mhemodynamic progression of AS (4\\u20136).|\\n\\n# Synopsis\\n\\nMedical treatment of hypertension and \u001b[0m\u001b[2m             \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mhyperlipidemia according to GDMT is appropriate for patients with AS. ACE inhibitor or ARB treatment may reduce\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mthe mortality rate in patients with AS who underwent TAVI.\\n\\n# Recommendation-Specific Supportive Text\\n\\n1. \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mHypertension is common in patients with AS, may be a risk factor for AS, and adds to the total pressure \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2moverload on the LV in combination with valve obstruction. Concern that antihypertensive medications might \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mresult in a decrease in cardiac output has not been corroborated in studies of medical therapy, including 2 \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2msmall RCTs, likely because AS does not result in \\u201cfixed\\u201d valve obstruction until late in the disease \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mprocess. In 1616 patients with asymptomatic AS in the SEAS (Simvastatin Ezetimibe in Aortic Stenosis) study, \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mhypertension (n=1340) was associated with a 56% higher rate of ischemic cardiovascular events and a 2-fold \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mhigher mortality rate (both P<0.01) than those seen in normotensive patients with AS, although no impact on \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mmortality was observed.\\n\\n2. Concurrent CAD is common in patients with AS, and all patients should be screened\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mand treated for hypercholesterolemia, with GDMT used for primary and secondary prevention of CAD. In RCTs of \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mstatin therapy for mild to moderate AS, although aortic valve event rates...\\n# e300 Grundy et al.\\n\\n# J A C C\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mV O L . 7 3 , N O . 2 4 , 2 0 1 9\\n\\n# 2018 Cholesterol Clinical Practice Guideline\\n\\n# J U N E 2 5 , 2 0 1 9 \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m: e 2 8 5 - 3 5 0\\n\\nLDL-C is inadequately controlled with drug therapy, LDL apheresis is an option. Referral \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mto a lipid specialist may be indicated.\\n\\n# Recommendation-Specific Supportive Text\\n\\n1. Patients with \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mprimary severe hypercholesterolemia (LDL-C levels \\u2265190 mg/dL [\\u22654.9 mmol/L]) have a high-risk of ASCVD\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(S4.2-2, S4.2-4, S4.2-18) and premature and recurrent coronary events (S4.2-3). Although there have been no \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mrandomized, placebo-controlled trials of statin therapy done exclusively in subjects with LDL-C levels \u001b[0m\u001b[2m        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m\\u2265190 mg/dL (\\u22654.9 mmol/L), a placebo-controlled primary prevention study performed in men with a mean \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mbaseline LDL-C level of 192.17 mg/dL (4.90.4 mmol/L) demonstrated a reduced incidence of MI and cardiovascular \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mdeath in those receiving pravastatin 40 mg daily (S4.2-5). These findings were extended in a post hoc analysis \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mof 2,560 exclusively primary-prevention subjects in that RCT and in a 20-year observational post-trial \u001b[0m\u001b[2m        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mlong-term follow-up study (S4.2-19). In addition, retrospective cohort studies have demonstrated that statin \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtherapy reduces risk of incident MI (S4.2-6) and of CHD and all-cause death (S4.2-1) in patients with \u001b[0m\u001b[2m         \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mphenotypic or genetically confirmed FH. Because moderate- or high-intensity statins have been shown to reduce \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mASCVD risk in both primary- and secondary-prevention trials and because high-intensity statins provide greater \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mASCVD risk reduction than moderate-intensity statins or placebo (S4.2-7), maximally tolerated statin therapy \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mshould be administered to patients with primary severe hypercholesterolemia.\\n2. A large placebo-controlled RCT\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mexamined the effect of simvastatin 80 mg daily, with or without ezetimibe 10 mg daily, on carotid intima-media \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mthickness and plasma lipoproteins over 2 years. Mean LDL-C reduction was greater in the combined-therapy group,\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mbut there was no difference in carotid intima-media thickness between the 2 groups. The study was not powered \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mto examine the risk of ASCVD events (S4.2-10). However, a very large placebo-controlled RCT examining ASCVD \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2moutcomes in post-ACS patients, performed over a period of 7 years, showed that the addition of ezetimibe 10 mg \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mto simvastatin 40 mg daily resulted in greater ASCVD risk reduction than that produced by statin monotherapy \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(S4.2-8). Secondary-prevention patients with certain ASCVD risk indicators exhibit greater ASCVD risk reduction\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfrom ezetimibe therapy than do patients without these characteristics (S4.2-20). Patients with severe \u001b[0m\u001b[2m         \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mhypercholesterolemia who are adherent to statins, achieve <50% reduction in LDL-C levels with maximally \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtolerated statin therapy, and have an LDL-C level \\u2265100 mg/dL (\\u22652.6 mmol/L) are likely to derive \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2madditional ASCVD risk reduction from ezetimibe add-on therapy through additional LDL-C lowering (S4.2-9).\\n3. \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mWhen administered to patients with severe hypercholesterolemia who are taking maximally tolerated statins with \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mor without ezetimibe, bile acid sequestrants have demonstrated LDL-C-lowering efficacy (S4.2-11, S4.2-12). \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mHowever, the clinical utility of bile acid sequestrants is limited by the absence of ASCVD outcomes data when \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mused in combination with statins, as well as by the issues of twice-daily dosing, high pill burden, the absence\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mof well-tolerated generic formulations, drug interactions, and the potential for triglyceride elevation. \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mNonetheless, in patients with very severe hypercholesterolemia, adding sequestrants to otherwise maximal \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mcholesterol-lowering therapy in patients who are not eligible for a PCSK9 inhibitor may be considered.\\n4. \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mPCSK9 inhibitors are promising drugs for treatment of FH\\nprevention of cardiovascular disease: an opportunity \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mto harmonize guidelines. JAMA Cardiol. 2017;2:1175\\u20136.\\n\\nS4.4.4.2-10. Berry JD, Dyer A, Cai X, et al. \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mLifetime risks of cardiovascular disease. N Engl J Med. 2012; 366:321\\u20139.\\n\\nS4.4.4.2-11. Lehr AL, Driver \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mSL, Stone NJ. The ABCDs of lifestyle counseling. JAMA Cardiol. 2016;1:505\\u20136.\\n\\nS4.4.4.2-12. Omura JD, \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mWatson KB, Loustalot F, et al. Primary care providers\\u2019 awareness of physical activity-related intensive \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mbehavioral counseling services for cardiovascular disease prevention. Am J Health Promot. 2018. \u001b[0m\u001b[2m               \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m890117118784226.\\n\\n# 4.4.4.3. Children and Adolescents\\n\\nS4.4.4.3-1. Iannuzzi A, Licenziati MR, Vacca M, et \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mal. Comparison of two diets of varying glycemic index on carotid subclinical atherosclerosis in obese children.\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mHeart Vessels. 2009;24:419\\u201324.\\n\\nS4.4.4.3-2. Murphy EC, Carson L, Neal W, et al. Effects of an exercise \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mintervention using Dance Dance Revolution on endothelial function and other risk factors in overweight \u001b[0m\u001b[2m        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mchildren. Int J Pediatr Obes. 2009;4:205\\u201314.\\n\\nS4.4.4.3-3. Pratt RE, Kavey RE, Quinzi D. Combined \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mdyslipidemia in obese children: response to a focused lifestyle approach. J Clin Lipidol. \u001b[0m\u001b[2m                     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m2014;8:181\\u20136.\\n\\nS4.4.4.3-4. de Ferranti SD, Milliren CE, Denhoff ER, et al. Providing food to treat \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2madolescents at risk for cardiovascular disease. Obesity (Silver Spring). 2015; 23:2109\\u201317.\\n\\nS4.4.4.3-5. \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mNiinikoski H, Lagstrom H, Jokinen E, et al. Impact of repeated dietary counseling between infancy and 14 years \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mof age on dietary intakes and serum lipids and lipoproteins: the STRIP study. Circulation. 2007; \u001b[0m\u001b[2m              \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m116:1032\\u201340.\\n\\nS4.4.4.3-6. Obarzanek E, Kimm SY, Barton BA, et al. Long-term safety and efficacy of a \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mcholesterol-lowering diet in children with elevated low-density lipoprotein cholesterol: seven-year results of \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mthe Dietary Intervention Study in Children (DISC). Pediatrics. 2001;107:256\\u201364.\\n\\nS4.4.4.3-7. Dorgan JF, \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mLiu L, Barton BA, et al. Adolescent diet and metabolic syndrome in young women: results of the Dietary \u001b[0m\u001b[2m        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mIntervention Study in Children (DISC) follow-up study. J Clin Endocrinol Metab. \u001b[0m\u001b[2m                               \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m2011;96:E1999\\u20132008.\\n\\nS4.4.4.3-8. Wong H, Chahal N, Manlhiot C, et al. Flaxseed in pediatric \u001b[0m\u001b[2m            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mhyperlipidemia: a placebo-controlled, blinded, randomized clinical trial of dietary flaxseed supplementation \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfor children and adolescents with hypercholesterolemia. JAMA Pediatr. 2013;167:708\\u201313.\\n\\nS4.4.4.3-9. \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mZachariah JP, Chan J, Mendelson MM, et al. Adolescent dyslipidemia and standardized lifestyle modification: \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mbenchmarking real-world practice. J Am Coll Cardiol. 2016;68:2122\\u20133.\\n\\nS4.4.4.3-10. Torvik K, Narverud I,\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mOttestad I, et al. Dietary counseling is associated with an improved lipid profile in children with familial \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mhypercholesterolemia. Atherosclerosis. 2016;252:21\\u20137.\\n\\nS4.4.4.3-11. Koletzko B, Kupke I, Wendel U. \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mTreatment of hypercholesterolemia in children and adolescents. Acta Paediatr. \u001b[0m\u001b[2m                                 \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m1992;81:682\\u20135.\\n\\nS4.4.4.3-12. Tershakovec AM, Shannon BM, Achterberg CL, et al. One-year follow-up of \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mnutrition education for hypercholesterolemic children.\\n# Grundy et al.\\n\\n# J A C C V O L . 7 3 , N O . 2 4 , \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m2 0 1 9\\n\\n# 2018 Cholesterol Clinical Practice Guideline\\n\\n# J U N E 2 5 , 2 0 1 9 : e 2 8 5 - 3 5 0\\n\\n# \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mTable 3 High-, Moderate-, and Low-Intensity Statin Therapy*\\n\\n|High Intensity| | |Moderate Intensity|Low \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mIntensity|\\n|---|---|---|---|---|\\n|LDL-C lowering\\u2020|\\u226550%| \u001b[0m\u001b[2m                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m|30%\\u201349%|&lt;30%|\\n|Statins|Atorvastatin (40 mg\\u2021) 80 mg Rosuvastatin 20 mg (40 mg)|Atorvastatin 10 mg\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(20 mg) Rosuvastatin (5 mg) 10 mg Simvastatin 20\\u201340 mg\\u00a7 Pravastatin 40 mg (80 mg) Lovastatin 40 mg \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(80 mg) Fluvastatin XL 80 mg Fluvastatin 40 mg BID Pitavastatin 1\\u20134 mg|Simvastatin 10 mg Pravastatin \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m10\\u201320 mg Lovastatin 20 mg Fluvastatin 20\\u201340 mg| |\\n\\nPercent LDL-C reductions with the primary statin\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mmedications used in clinical practice (atorvastatin, rosuvastatin, simvastatin) were estimated using the median\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mreduction in LDL-C from the VOYAGER database (S3.2.1-2). Reductions in LDL-C for other statin medications \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(fluvastatin, lovastatin, pitavastatin, pravastatin) were identified according to FDA-approved product labeling\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2min adults with hyperlipidemia, primary hypercholesterolemia, and mixed dyslipidemia (S3.2.1-4). Boldface type \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mindicates specific statins and doses that were evaluated in RCTs (S3.2.1-3, S3.2.1-5\\u2014S3.2.1-16), and the \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mCholesterol Treatment Trialists\\u2019 2010 meta-analysis (S3.2.1-17). All these RCTs demonstrated a reduction \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2min major cardiovascular events.\\n\\n*Percent reductions are estimates from data across large populations. \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mIndividual responses to statin therapy varied in the RCTs and should be expected to vary in clinical practice \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(S3.2.1-2).\\n\\n\\u2020LDL-C lowering that should occur with the dosage listed below each \u001b[0m\u001b[2m                       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mintensity.\\n\\n\\u2021Evidence from 1 RCT only: down titration if unable to tolerate atorvastatin 80 mg in the \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mIDEAL (Incremental Decrease through Aggressive Lipid Lowering) study (S3.2.1-3).\\n\\n\\u00a7Although simvastatin \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m80 mg was evaluated in RCTs, initiation of simvastatin 80 mg or titration to 80 mg is not recommended by the \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mFDA because of the increased risk of myopathy, including rhabdomyolysis.\\n\\nBID indicates twice daily; FDA, \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mU.S. Food and Drug Administration; LDL-C, low-density lipoprotein cholesterol; RCT, randomized controlled \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtrial; VOYAGER, an individual patient data meta-analysis of statin therapy in at-risk groups: effects of \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mrosuvastatin, atorvastatin, and simvastatin; and XL, extended release.\\n\\n# 3.1.2. Lifestyle Therapies and \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mMetabolic Syndrome\\n\\nLifestyle therapies are particularly indicated for the metabolic syndrome, which is a \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mcluster of risk factors associated with an increased risk of ASCVD, diabetes mellitus, and all-cause death \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(S3.1.2-1, S3.1.2-2). Metabolic syndrome is a risk-enhancing factor for ASCVD. The most widely used clinical \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mdefinition of metabolic syndrome is that proposed by an international consortium of cardiovascular and diabetes\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2morganizations (S3.1.2-3). The diagnosis is made by the presence of any 3 of the following 5 risk factors: \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2melevated waist circumference, elevated serum triglycerides, reduced HDL-C, elevated blood pressure, and \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2melevated fasting glucose (Table S2 in the Web Supplement). Metabolic syndrome is closely linked to excess \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mweight and particularly to abdominal obesity (S3.1.2-4). Therefore, the prevalence of metabolic syndrome has \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mrisen sharply among both adults and children as levels of overweight and obesity have risen. Metabolic\"\u001b[0m\u001b[2m        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  },\u001b[0m\u001b[2m                                                                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  {\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"role\": \"tool\",\u001b[0m\u001b[2m                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"tool_call_id\": \"call_Wj83hyOr277uKGy1oSceoOi9\",\u001b[0m\u001b[2m                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"name\": \"search_bing_grounding\",\u001b[0m\u001b[2m                                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"content\": \"In February 2025, the FDA accepted the Biologics License Application for Lerodalcibep, a novel \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mthird-generation PCSK9 inhibitor developed by LIB Therapeutics. This drug aims to reduce low-density \u001b[0m\u001b[2m          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mlipoprotein cholesterol (LDL-C) for patients with atherosclerotic cardiovascular disease (ASCVD) and primary \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mhyperlipidemia. Lerodalcibep is designed to be a more convenient, once-monthly, subcutaneous injection that \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mdoes not require refrigeration. The FDA's action date for the review is set for December 12, \u001b[0m\u001b[2m                  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m2025\\u30100\\u2020source\\u3011\\u30101\\u2020source\\u3011.\"\u001b[0m\u001b[2m                                                       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  }\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m]\u001b[0m\u001b[2m                                                                                                              \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╭─────────────────────────────────────────────────</span> Raw Response <span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Raw response message:                                                                                           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ ChatCompletionMessage(content=\"### Patient Summary\\n- **Name:** Gloria Paul\\n- **Date of Birth:** July 15, 1944 │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (Age: 79)\\n- **Gender:** Other\\n- **Medical Condition:** Hyperlipidemia\\n- **Medications:** Atorvastatin\\n-     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ **Allergies:** None\\n- **Blood Type:** O+\\n- **Last Visit Date:** March 26, 2024\\n- **Smoking Status:** Never   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Smoker\\n- **Alcohol Consumption:** Light drinker (1-2 times a week)\\n- **Exercise Frequency:** Light\\n-         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ **Occupation:** Administrator, sports\\n- **Height:** 176.2 cm\\n- **Weight:** 77.7 kg\\n- **Blood Pressure:**     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ 120/79 mmHg\\n- **Heart Rate:** 90 bpm\\n- **Notes:** Descriptions of personal insights and lifestyle changes are │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ noted.\\n\\n### ACC Guidelines for Hyperlipidemia\\n1. **Statin Therapy:**\\n   - **Class I**: Treatment with       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ statin medication is recommended for patients with significant atherosclerotic diseases to reduce LDL           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ cholesterol levels below 100 mg/dL.\\n   - **Class IIa**: It is reasonable to aim for LDL cholesterol levels     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ near or below 70 mg/dL in patients who have had ischemic stroke.\\n   - If LDL targets are not achieved with     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ statins, intensifying therapy with additional medications may be appropriate.\\n\\n2. **Lifestyle                 │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Modifications**: Intensifying lifestyle changes, including diet and exercise, is essential for managing         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ hyperlipidemia.\\n\\n3. **Comorbidities**: Special attention should be given to hypertension and diabetes as they │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ frequently co-occur with hyperlipidemia, which complicates clinical management.\\n\\n### New Medication Updates   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (As of February 2025)\\n- The **FDA accepted the Biologics License Application for Lerodalcibep**, a novel PCSK9 │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ inhibitor designed for patients with atherosclerotic cardiovascular disease (ASCVD) and primary hyperlipidemia. │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ \\n- **Features**: Lerodalcibep is a once-monthly subcutaneous injection that does not require refrigeration,    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ making it a potentially more convenient treatment option.\\n- The FDA's review action date for this medication   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ is December 12, 2025.\\n\\n### Summary\\nGloria Paul is a 79-year-old woman effectively managed on atorvastatin    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ for hyperlipidemia, meeting current ACC guidelines emphasizing the use of statins to achieve lower LDL          │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ cholesterol targets while recommending lifestyle modifications. Notably, the recent approval process for a new  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ drug, Lerodalcibep, may offer further treatment options for patients with similar conditions. Always ensure     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ adherence to guidelines when managing complex medical cases, especially in elderly patients.\", refusal=None,    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ role='assistant', audio=None, function_call=None, tool_calls=None)                                              │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[2m╭─\u001b[0m\u001b[2m────────────────────────────────────────────────\u001b[0m Raw Response \u001b[2m─────────────────────────────────────────────────\u001b[0m\u001b[2m─╮\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mRaw response message:\u001b[0m\u001b[2m                                                                                          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mChatCompletionMessage(content=\"### Patient Summary\\n- **Name:** Gloria Paul\\n- **Date of Birth:** July 15, 1944\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(Age: 79)\\n- **Gender:** Other\\n- **Medical Condition:** Hyperlipidemia\\n- **Medications:** Atorvastatin\\n- \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m**Allergies:** None\\n- **Blood Type:** O+\\n- **Last Visit Date:** March 26, 2024\\n- **Smoking Status:** Never \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mSmoker\\n- **Alcohol Consumption:** Light drinker (1-2 times a week)\\n- **Exercise Frequency:** Light\\n- \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m**Occupation:** Administrator, sports\\n- **Height:** 176.2 cm\\n- **Weight:** 77.7 kg\\n- **Blood Pressure:** \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m120/79 mmHg\\n- **Heart Rate:** 90 bpm\\n- **Notes:** Descriptions of personal insights and lifestyle changes are\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mnoted.\\n\\n### ACC Guidelines for Hyperlipidemia\\n1. **Statin Therapy:**\\n   - **Class I**: Treatment with \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mstatin medication is recommended for patients with significant atherosclerotic diseases to reduce LDL \u001b[0m\u001b[2m         \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mcholesterol levels below 100 mg/dL.\\n   - **Class IIa**: It is reasonable to aim for LDL cholesterol levels \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mnear or below 70 mg/dL in patients who have had ischemic stroke.\\n   - If LDL targets are not achieved with \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mstatins, intensifying therapy with additional medications may be appropriate.\\n\\n2. **Lifestyle \u001b[0m\u001b[2m               \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mModifications**: Intensifying lifestyle changes, including diet and exercise, is essential for managing \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mhyperlipidemia.\\n\\n3. **Comorbidities**: Special attention should be given to hypertension and diabetes as they\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfrequently co-occur with hyperlipidemia, which complicates clinical management.\\n\\n### New Medication Updates \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(As of February 2025)\\n- The **FDA accepted the Biologics License Application for Lerodalcibep**, a novel PCSK9\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2minhibitor designed for patients with atherosclerotic cardiovascular disease (ASCVD) and primary hyperlipidemia.\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m\\n- **Features**: Lerodalcibep is a once-monthly subcutaneous injection that does not require refrigeration, \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mmaking it a potentially more convenient treatment option.\\n- The FDA's review action date for this medication \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mis December 12, 2025.\\n\\n### Summary\\nGloria Paul is a 79-year-old woman effectively managed on atorvastatin \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfor hyperlipidemia, meeting current ACC guidelines emphasizing the use of statins to achieve lower LDL \u001b[0m\u001b[2m        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mcholesterol targets while recommending lifestyle modifications. Notably, the recent approval process for a new \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mdrug, Lerodalcibep, may offer further treatment options for patients with similar conditions. Always ensure \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2madherence to guidelines when managing complex medical cases, especially in elderly patients.\", refusal=None, \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mrole='assistant', audio=None, function_call=None, tool_calls=None)\u001b[0m\u001b[2m                                             \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">╭─────────────────────────────────────────────────</span><span style=\"color: #808000; text-decoration-color: #808000\"> Final Answer </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> ### Patient Summary                                                                                             </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Name:** Gloria Paul                                                                                         </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Date of Birth:** July 15, 1944 (Age: 79)                                                                    </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Gender:** Other                                                                                             </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Medical Condition:** Hyperlipidemia                                                                         </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Medications:** Atorvastatin                                                                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Allergies:** None                                                                                           </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Blood Type:** O+                                                                                            </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Last Visit Date:** March 26, 2024                                                                           </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Smoking Status:** Never Smoker                                                                              </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Alcohol Consumption:** Light drinker (1-2 times a week)                                                     </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Exercise Frequency:** Light                                                                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Occupation:** Administrator, sports                                                                         </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Height:** 176.2 cm                                                                                          </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Weight:** 77.7 kg                                                                                           </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Blood Pressure:** 120/79 mmHg                                                                               </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Heart Rate:** 90 bpm                                                                                        </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Notes:** Descriptions of personal insights and lifestyle changes are noted.                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">                                                                                                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> ### ACC Guidelines for Hyperlipidemia                                                                           </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> 1. **Statin Therapy:**                                                                                          </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">    - **Class I**: Treatment with statin medication is recommended for patients with significant atherosclerotic </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> diseases to reduce LDL cholesterol levels below 100 mg/dL.                                                      </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">    - **Class IIa**: It is reasonable to aim for LDL cholesterol levels near or below 70 mg/dL in patients who   </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> have had ischemic stroke.                                                                                       </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">    - If LDL targets are not achieved with statins, intensifying therapy with additional medications may be      </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> appropriate.                                                                                                    </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">                                                                                                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> 2. **Lifestyle Modifications**: Intensifying lifestyle changes, including diet and exercise, is essential for   </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> managing hyperlipidemia.                                                                                        </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">                                                                                                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> 3. **Comorbidities**: Special attention should be given to hypertension and diabetes as they frequently         </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> co-occur with hyperlipidemia, which complicates clinical management.                                            </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">                                                                                                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> ### New Medication Updates (As of February 2025)                                                                </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - The **FDA accepted the Biologics License Application for Lerodalcibep**, a novel PCSK9 inhibitor designed for </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> patients with atherosclerotic cardiovascular disease (ASCVD) and primary hyperlipidemia.                        </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Features**: Lerodalcibep is a once-monthly subcutaneous injection that does not require refrigeration,      </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> making it a potentially more convenient treatment option.                                                       </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - The FDA's review action date for this medication is December 12, 2025.                                        </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">                                                                                                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> ### Summary                                                                                                     </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> Gloria Paul is a 79-year-old woman effectively managed on atorvastatin for hyperlipidemia, meeting current ACC  </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> guidelines emphasizing the use of statins to achieve lower LDL cholesterol targets while recommending lifestyle </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> modifications. Notably, the recent approval process for a new drug, Lerodalcibep, may offer further treatment   </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> options for patients with similar conditions. Always ensure adherence to guidelines when managing complex       </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> medical cases, especially in elderly patients.                                                                  </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;33m╭─\u001b[0m\u001b[1;33m────────────────────────────────────────────────\u001b[0m\u001b[33m Final Answer \u001b[0m\u001b[1;33m─────────────────────────────────────────────────\u001b[0m\u001b[1;33m─╮\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m### Patient Summary\u001b[0m\u001b[1;32m                                                                                            \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Name:** Gloria Paul\u001b[0m\u001b[1;32m                                                                                        \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Date of Birth:** July 15, 1944 (Age: 79)\u001b[0m\u001b[1;32m                                                                   \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Gender:** Other\u001b[0m\u001b[1;32m                                                                                            \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Medical Condition:** Hyperlipidemia\u001b[0m\u001b[1;32m                                                                        \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Medications:** Atorvastatin\u001b[0m\u001b[1;32m                                                                                \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Allergies:** None\u001b[0m\u001b[1;32m                                                                                          \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Blood Type:** O+\u001b[0m\u001b[1;32m                                                                                           \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Last Visit Date:** March 26, 2024\u001b[0m\u001b[1;32m                                                                          \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Smoking Status:** Never Smoker\u001b[0m\u001b[1;32m                                                                             \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Alcohol Consumption:** Light drinker (1-2 times a week)\u001b[0m\u001b[1;32m                                                    \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Exercise Frequency:** Light\u001b[0m\u001b[1;32m                                                                                \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Occupation:** Administrator, sports\u001b[0m\u001b[1;32m                                                                        \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Height:** 176.2 cm\u001b[0m\u001b[1;32m                                                                                         \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Weight:** 77.7 kg\u001b[0m\u001b[1;32m                                                                                          \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Blood Pressure:** 120/79 mmHg\u001b[0m\u001b[1;32m                                                                              \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Heart Rate:** 90 bpm\u001b[0m\u001b[1;32m                                                                                       \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Notes:** Descriptions of personal insights and lifestyle changes are noted.\u001b[0m\u001b[1;32m                                \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m                                                                                                               \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m### ACC Guidelines for Hyperlipidemia\u001b[0m\u001b[1;32m                                                                          \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m1. **Statin Therapy:**\u001b[0m\u001b[1;32m                                                                                         \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m   - **Class I**: Treatment with statin medication is recommended for patients with significant atherosclerotic\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mdiseases to reduce LDL cholesterol levels below 100 mg/dL.\u001b[0m\u001b[1;32m                                                     \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m   - **Class IIa**: It is reasonable to aim for LDL cholesterol levels near or below 70 mg/dL in patients who \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mhave had ischemic stroke.\u001b[0m\u001b[1;32m                                                                                      \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m   - If LDL targets are not achieved with statins, intensifying therapy with additional medications may be \u001b[0m\u001b[1;32m    \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mappropriate.\u001b[0m\u001b[1;32m                                                                                                   \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m                                                                                                               \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m2. **Lifestyle Modifications**: Intensifying lifestyle changes, including diet and exercise, is essential for \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mmanaging hyperlipidemia.\u001b[0m\u001b[1;32m                                                                                       \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m                                                                                                               \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m3. **Comorbidities**: Special attention should be given to hypertension and diabetes as they frequently \u001b[0m\u001b[1;32m       \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mco-occur with hyperlipidemia, which complicates clinical management.\u001b[0m\u001b[1;32m                                           \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m                                                                                                               \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m### New Medication Updates (As of February 2025)\u001b[0m\u001b[1;32m                                                               \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- The **FDA accepted the Biologics License Application for Lerodalcibep**, a novel PCSK9 inhibitor designed for\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mpatients with atherosclerotic cardiovascular disease (ASCVD) and primary hyperlipidemia. \u001b[0m\u001b[1;32m                      \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Features**: Lerodalcibep is a once-monthly subcutaneous injection that does not require refrigeration, \u001b[0m\u001b[1;32m    \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mmaking it a potentially more convenient treatment option.\u001b[0m\u001b[1;32m                                                      \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- The FDA's review action date for this medication is December 12, 2025.\u001b[0m\u001b[1;32m                                       \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m                                                                                                               \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m### Summary\u001b[0m\u001b[1;32m                                                                                                    \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mGloria Paul is a 79-year-old woman effectively managed on atorvastatin for hyperlipidemia, meeting current ACC \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mguidelines emphasizing the use of statins to achieve lower LDL cholesterol targets while recommending lifestyle\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mmodifications. Notably, the recent approval process for a new drug, Lerodalcibep, may offer further treatment \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32moptions for patients with similar conditions. Always ensure adherence to guidelines when managing complex \u001b[0m\u001b[1;32m     \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mmedical cases, especially in elderly patients.\u001b[0m\u001b[1;32m                                                                 \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "run_multi_step_agent(\"I have a 79-year-old patient named Gloria Paul with hyperlipidemia. She's on Atorvastatin. Can you confirm her medical details from the database, check the ACC guidelines for hyperlipidemia, and see if there are any new medication updates from the FDA as of Feb 2025? Then give me a summary.\")"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": ".venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.13.2"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
